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Abstract
Targeted therapies, including anti-endocrine agents and inhibitors of growth factor receptors 
and tyrosine kinases have significantly changed the treatment of breast cancer. However, 
clinical resistance to agents like tamoxifen poses a major problem. We therefore aimed to 
identify the molecular mechanisms behind drug resistance in breast cancer in order to reverse 
them.
Here we provide an in-depth characterisation of acquired resistance to tamoxifen, fulvestrant 
and lapatinib using novel breast cancer cell line models (MCF7-TR, T47D-FR and SKBR3- 
LapR, respectively). We utilised methods such as cell viability assays. Western blotting. Real 
time quantitative polymerase chain reaction, Annexin V-FITC with propidium iodide assay, 
and confocol microscopy .Mefloquine (2 fxM) or LY294002 (lOpM) (autophagy inhibitors) 
were used to asses the role of autophagy in mediating drug resistance. Mechanisms of 
lapatinib-resistance were assessed by micro-RNA array.
Oestrogen receptor-alpha (ERa) was significantly down-regulated in the drug-resistant 
sublines and p27^^^ trans-activation reduced, whilst HERl/2/3, PI3K, Akt and ERK were 
significantly up-regulated. Treatment with the dual HER 1/2 inhibitor lapatinib indicated the 
presence of collateral sensitivity in both MCF7-TR and T47D-FR cells through reduced 
HERl and HER2 signalling, re-induction of p27^^^ and reactivation of ERa. These data 
provided important evidence of the crosstalk between ERa and HER1/HER2 signalling 
pathways. Lapatinib stimulated cell death in tamoxifen- and fulvestrant-resistant cells when 
used as monotherapy and a synergistic reduction in cell viability was observed when used 
concomitantly with tamoxifen.
II
Analysis of cell death pathways implied that apoptosis was impaired due to loss of caspase 
activity and that autophagy was activated as a survival mechanism. Both MCF7-TR and 
T47D-FR cells were substantially sensitized to tamoxifen treatment when mefloquine or 
LY294002 were co-administered. MiR-205 wasup-regulated, indicating inhibition of 
epithelial-mesenchymal-transition, together with an apparent hyperactivation of the MET- 
receptor in lapatinib-resistant SKBR3 cells.
Overall, our findings highlight the highly plastic and heterogeneous nature of endocrine- 
resistant breast cancer and demonstrate that drug combination regimens targeting different 
signalling and cell death pathways significantly could improve therapeutic outcome.
Ill
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1 Introduction
1.1. Overview of cancer
In 1985 it was proposed that cancer is a distinct type of disease in which not one but 
numerous mutations are required to elicit disease in the majority of cases (Knudson, 1985). 
Each mutation causes a change to the cellular phenotype and often drives a wave of cellular 
multiplication that is correlated with gradual increases in tumour size, proliferation, and the 
occurrence of malignancy. It has been documented that three to six mutations seem to be 
required to complete this process (Vogelstein and Kinzler, 1993).
It is now generally accepted that that cancer is a multi-step process, in which numerous 
genomic alterations accumulate and progressively drive changes from normal cells to 
malignant cells (Lemmon and Schlessinger, 2010; Witsch et al., 2010). Since the recognition 
of its progressive nature, cancer has been officially defined as a group of diseases, in which 
normal, healthy cells in the body undergo several stages that eventually change them to 
abnormal, cancerous cells. Cancerous cells are characterised by unregulated cell growth, 
allowing cells to escape from thenormal controls that prevent excessive growth and 
proliferation, which leads to the formation of tumours. Tumours are complex tissues made up 
of multiple distinct cell types that share heterotypic interactions with one another (Hanahan 
and Weinberg, 2000). Tumours can be divided into two main types: benign and malignant. 
Benign tumours are limited to within a well-defined capsule, while malignant tumours are 
invasive; i.e. they have the ability to spread from the origin (primary site) to other sites in the 
body (secondary sites).While cancer is heterogeneous in nature, several hallmarks common to 
all or most tumours can be used to define it. These hallmarks are described in the section 
below.
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1.1.1. Hallmarks of cancer
In the year 2000, Hanahan and Weinberg defined six hallmarks which are characteristic of 
most cancer cells and in 2011, they sought to refine and extend the concept of cancer 
hallmarks, which has provided a useful conceptual framework for further understanding the 
complex biology of cancer(Hanahan and Weinberg, 2000, 2011). Based on their review based 
on research of others, they proposed that the fundamental trait of cancer cells involved their 
ability to sustain chronic proliferation even without growth factor signalling, whereas normal 
cells rely on this signalling and carefully control the production and release of growth signals 
(Cheng et al., 2008). The second hallmark is evasion of growth inhibitory effects in 
comparison with normal cells that respond to inhibitory signals to maintain homeostatic 
regulation (Wertz and Dixit, 2010). The third hallmark is the ability of cancerous cells to 
evade programmed cell death. Paradoxically, apoptosis is an essential process by which 
normal cells die to facilitate cell turn-over and the replacement of worn out or damaged cells 
(Adams and Cory, 2007). Thus, avoidance of apoptosis only facilitates the accumulation of 
mutations that contribute to a malignant phenotype.
The fourth hallmark is unlimited replication. Upon cell replication, the protective ends of 
chromosomes (the telomeres) usually shorten. These act as a cellular time-keeper, limiting 
the number of divisions a cell can undergo before its chromosomes become unstable and the 
cell enters a senescent state (Dahse et al., 1997). Cancer cells become immortalised when 
telomeres are maintained via increased telomerase activity (an enzyme that lengthens 
telomeres). However, this immortality comes at the cost of accumulating damaging 
mutations, explaining the association of short telomere length with aggressive disease 
(Artandi and DePinho, 2010). Impaired telomerase function may accelerate the generation of 
tumour promoting mutations and genome instability, yet telomere stabilisation after up-
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regulation of telomerase in later tumour development contributes to uncontrolled cell 
divisionsduring neoplastic growth (Bacchetti, 1996).
The fifth hallmark is the formation of new blood vessels; the process known as angiogenesis, 
which is needed for tumour survival and expansion. Lastly, invasion and metastasis are 
essential hallmarks of carcinogenesis. Whereas normal cells maintain their location in the 
body and do not migrate, malignant cells can spread from their site of origin to invade a 
secondary site (Baeriswyl and Christofori, 2009). Evasion of immune system defences, or 
utilisation of host defences for promotion are also considered an important characteristic of 
cancer cells. During the past decade, much evidence has indicated the mechanisms 
underlying the dynamic interplay between immune cells and cancer progression (de Visser 
and Coussens, 2006). The weight of the data suggests that the outcome of an immune 
response toward a tumour is largely determined by the type of immune response elicited. For 
example, tumour-directed immune responses involving catalytic CD8+ T cells, T-helper 
(Thl) cells, and natural killer (NK) cells appear to protect against tumour development and 
progression (Youinou et al., 2007). Conversely, immune responses involving B cells and 
activation of humoral immunity appear to increase promotion of tumour development and 
progression. It has also been shown that CD4+ T cells are indirectly involved in enhancing 
breast cancer progression (Adams and Cory, 2007).
Since this thesis will focus solely on breast cancer, the following sections are breast-cancer 
specific.
1.2. Breast cancer demographics
Breast cancer is the most conunonly diagnosed malignancy and one of the major causes of 
mortality among women worldwide. It is diagnosed in about 1 million women every
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year,causing the death of over 400,000 (Kasler et ah, 2009). Breast cancer in men is much 
less common than in women, affecting one in every 100,000 men in the UK (Cancer 
Research UK, 2014), while 1 in 8 women(=12,500 in 100,000) in the UK develop breast 
cancer in their lifetime (Breast Cancer Facts, 2014). In 2013, breast cancer was the most 
diagnosed cancer in the UK, with 232,340 new cases of breast cancer expected in that year. 
Breast cancer was also listed as the fourth highest cause of death (National Cancer Institute, 
2013). For this reason, it is one of the most investigated diseases.
Though breast cancer survival rates have been improving for forty years(Cancer Research 
UK, 2013), the disease remains a major global health-burden. International comparisons of 
disease incidence by geographical location and other demographic characteristics, such as 
age, reproductive history, socio-economic status and lifestyle among others, can provide 
important clues to the underlying causes of disease (Nabavizadeh et al., 2011). In Western 
industrialised countries, the incidence of breast cancer is rising. In these countries, the life- 
timerisk of breast cancer development is around 10% for women and with approximately 
30% of these cases leading to death, it is generally agreed that certain aspects of lifestyle 
favour the development of breast cancer growth. Some of the most influential factors 
affecting breast cancer incidence are discussed in more detail in the following sections.
1.3. Breast cancer aetiology
1.3.1. Age and Gender
Age is one of the most well-established risk-factors of breast cancer which explains why 
incidence rates in developing countries are positively correlated to life expectancy estimates 
(Nkondjock and Ghadirian, 2004). In the UK, 81% of breast cancer cases occur in women 
aged 50 years and over, with nearly half (48%) of these cases diagnosed in the 50-69 years
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age group (Cancer Research UK, 2014). In North America and Northern Europe, breast 
cancer incidence rates begin increasing in the early reproductive years and continue climbing 
into the late seventies, whereas rates plateau following menopause in Japan and less 
developed countries (Hulka and Moorman, 2001).
1.3.2. Nutrition and lifestyle choices: Weight, obesity and physical activity
Being overweight or obese has been found to increase breast cancer risk, especially for 
women after menopause (American Cancer Society, 2013). A study by Lawrie and colleagues 
reported that hormone replacement therapy does not increase the risk of breast cancer in 
obese, postmenopausal women (Risk ratio (RR), 1.02 for BM I25 kg/m2), though it is a 
significant risk for breast cancer in normal-weight women (RR, 1.73). This suggests that the 
excess oestrogen secreted from adipose tissue is the main contributing factor for increased 
breast cancer risk in obese patients (Lawrie et al., 2011). It is known that obesity in women 
increases the risk of breast cancer by the action of aromatase on androgens to produce excess 
oestrogen (Doisneau-Sixou et al., 2003). Evidence is also growing that physical activity can 
reduce breast cancer risk, although estimates of the amount of activity required are not as 
clear. In a recent study, it has been shown that both exercise and occupational activity are 
associated with lower breast cancer risk, but exercise in addition to an active occupation did 
not confer any further advantage (Pronk et al., 2011). This finding concurs with current 
health promotion campaigns promoting active lifestyles in the developed world.
1.3.3. Alcohol consumption
The intake of alcohol is clearly linked to an increased risk of developing breast cancer and of 
cancer recurrence in previously treated women(Testino et al., 2014). Alcohol consumption 
increases breast cancer risk in a dose-dependent manner; the risk increases by 10% for each
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alcoholic drink consumed daily, with a drink defined as 354.8ml of beer or 147.8ml of wine 
(Simonsson et al., 2014). Recent in vitro data have also indicated that alcohol plays an 
important role in a dose-dependent mannerin cancer metastasis (Land et al., 2014). Thus, 
alcohol has a role in the incidence, recurrence, and prognosis of breast cancer in women.
The correlation between alcohol consumption and increased risk for breast cancer has been a 
consistent finding in the most of epidemiological studies during the past two decades 
(Singletary and Gapstur, 2001).Increased oestrogen and androgen levels in women 
consuming alcohol appear to be important mechanisms behind the association. Other 
plausible mechanisms involve enhanced mammary gland susceptibility to carcinogenesis, 
increased DNA damage, and greater metastatic potential of breast cancer cells (Boffetta and 
Hashibe, 2006).
1.3.4. Tobacco smoking:
There is very limited evidence that smoking may be linked to breast cancer in women who 
started smoking before the age of 20 or before the birth of their first child. One study by 
Baptista et al (2006) supports the hypothesis that passive and active tobacco smoking are 
associated with more than a doubling of pre-menopausal risk of breast cancer, whereas 
postmenopausal risk estimates were not as high (Baptista et al., 2006). Smoking and tobacco 
smoke are decidedly carcinogenic to humans. Epidemiological studies of smoking and breast 
cancer report that chemical carcinogens in tobacco smoke can cause mammary tumours in 
animals (Li et al., 2002). Metabolites of tobacco smoke have been found in the breast fluid or 
tissue of smokers (Palmer and Rosenberg, 1993). Thus, it is biologically plausible that 
exposure to tobacco smoke is associated with breast cancer (Terry and Rohan, 2002)
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1.3.5. Genetics and Mutations
Up to 10% of breast cancer in Western countries is due to genetic predisposition, generally 
inherited as an autosomal dominant trait with limited penetrance. It is not yet known how 
many breast cancer-associated genes there may be, but women with germline BRCA-1 and 
BRCA-2 (BRCA-1/2) mutations have an estimated risk of breast cancer exceeding 80%, once 
the carrier reaches the age of 70 (Ford et al., 1995). In comparison, men carrying the mutated 
genes have a 6% risk at the same age (Miki et al., 1994). The BRCA-1 gene encodes the 
breast cancer type 1 susceptibility protein, involved in pathways for cell-cycle progression, 
gene transcription and DNA repair (Manoukian et al., 2011)Although more than 600 
mutations have been identified in this gene, only a few of them occur regularly in un-related 
families and are responsible for the majority of inherited breast cancers (Dufloth et al., 2005). 
The normal gene product of BCRA2 has no recognisable protein motifs comparable to 
BCRAl protein, but the two proteins do share a number of functional similarities(Thorlacius 
et al., 1997). Similarity between the regulatory functions of these proteins helps to explain 
their roles in breast cancer development when mutated. Other mutations also pre-dispose to 
breast cancer, such as mutations in the oestrogen receptor {ER), human epidermal growth 
factor receptor {HER2) and in tumour suppressor genes such as p53. Mutations in oncogenes 
and tumour suppressor genes are discussed in section 1.5.1.
1.3.6. Reproductive history and hormonal influences
Reproductive factors that increase risk include a long menstrual history, nulliparity, recent 
use of postmenopausal hormone therapy (PMHT) or oral contraceptives, and late age at 
primipara(Hulka and Moorman, 2001) Women who have early menarche or late menopause 
have a higher risk of developing breast cancer, due to longer exposure to endogenous 
oestrogen (Nkondjock and Ghadirian, 2004). Similarly, the risk of breast cancer in women
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who have their first child after the age of 30 is twice that of those who have a child at 20 
(Helewa et ah, 2002). It is well known that use of oral contraceptives increases breast cancer 
incidence by increasing circulating levels of endogenous oestrogen (Gierisch et al., 2013) 
Moreover, there is now evidence to suggest that longer-term use of oral contraceptivescan 
boost 17a-oestradiol levels after cessation of the contraceptive pill (Gierisch et al., 2013)
1.4. Classification of breast cancer
Breast cancer is not a single entity, but rather a heterogenous group of several subtypes of 
diseases that show substantial variation in their molecular and clinical characteristics. This 
heterogeneity reveals significant challenges not only in the management of breast cancer, but 
also in the studying the biology of diseases (Dawson et al., 2013). Pérou et al (2000) 
demonstrated that the phenotypic diversity of breast tumours was correlated with 
corresponding gene expression diversity (Pérou et al., 2000).
The classification of breast cancer divides into categories according to different schemes, 
each based on different criteria and assisting a different purpose. Recently, huge progress has 
been made in understanding the complexity and the genomic diversity of breast cancer 
biology and its classification. This progress will facilitate the personalised best treatment 
approaches that are more targeted and effective and also associated with less toxic effects.
1.4.1. Histopathological classification of breast cancer
The classification of breast cancer involves the assessment of histological criteria comprising 
of both a morphological basis and immunohistochemical (IHC) analyses. Over the past 
decade, the major classifications of breast cancer have involved histological parameters i.e. 
the grade of the tumour, the stage of the tumour, axillary lymph node involvement, 
proteins/receptors and more latterly the expression of certain genes. These classifications
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have been shown to correlate with clinical outcome and afford the basis for prognostic 
evaluation (Elston et ah, 1999). IHC parameters involve determination the expression of 
oestrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor 
receptor 2 (HER2) status in conjunction with histopathological assessment.
1.4.2. Histopathological subtypes and tumour grade
1.4.21. Breast physiology and tissue development
Breast tissues are made up of fat, connective tissues, and a network of ducts (tiny tubes) that 
spread from the lobes (milk-producing glands) towards the nipple, as shown in figure 1-1. 
The breast tissue under the skin, leads into the armpit (axilla) where there are several lymph 
glands, also named as lymph nodes. The lymph glands are considered part of the natural 
drainage system in the body known as the lymphatic system. The lymphatic system consists 
of a network of lymph glands, connected throughout the body via tiny tubes called lymph 
vessels.
Lobes <■
Milk ducts ^
Fatty tissue ^
Figure 1-1 Physiology of the breast.Taken from (Cancer Research UK, 2013)
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Breast tissue does not develop fully before puberty. The first phase of breast development 
begins at the fetal stage and the second growth phase starts during puberty. In the second 
growth phase, immature ducts elongate into the surrounding connective tissue to form 
approximately 20 lobuli, this phase also involves multiplication of the ductal cells, which 
cause an expansion of the connective tissue in the breast. Then, for a period of up to 45 years, 
the ductal tissue goes through regular monthly cycles of proliferation and apoptosis before 
the cessation growth phase takes place. During cessation, ovulation and oestrogen production 
stop, which induces menopause (Schulz, 2007).
I.4.2.2. Types of breast cancer
Commonly, there are two types of breast cancer: invasive and non-invasive (also known as 
pre-invasive breast cancer). Non-invasive breast cancer includes ductal carcinoma in-situ 
(DCIS) or lobular carcinoma in-situ (LCIS). Both are tumours characterised by the existence 
of malignant cells in the breast ducts or lobules respectively, but with no evidence of invasion 
or spreading to the surrounding tissues. This condition is most frequently diagnosed by either 
detection as a palpable lump by physical examination or through screening mammography 
(as shown in figure l-2)(Brighton and Wood, 2005).
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Normal Benign cyst C ancer
Figurel-2Mammography images of a) a normal breast, c) a benign cyst, and c) a 
malignant tumour .Taken from(National Cancer Institute, 2014).
Invasive breast cancer involves the presence of malignant tumour that has breached the 
basement membrane that normally surrounds the epithelial cells within normal breast ducts or 
lobules. Clinically, the most common type of invasive breast cancer is invasive ductal 
carcinoma (IDC), which is responsible for approximately 80% to 85% of all clinical cases. In 
IDC, cancerous cell growth starts in a milk duct of the breast, penetrates through the wall of 
the duct, and grows into the fatty tissue of the breast. At this point, it may be able to spread to 
other parts of the body through the lymphatic system and bloodstream. Invasive lobular 
carcinoma (ILC) starts in the milk-producing glands (lobules) and can metastasize to other 
parts of the body. About 15% to 20% of invasive breast cancer is ILC (American Cancer 
Society, 2013). The World and Health Organisation (WHO) defined IDC-NOS as a breast 
tumour that fails to show sufficient morphological characteristics to be classified into one of 
the histological special types Approximately 25% of breast cancers are recognised as special 
types based on histological architectural patterns and cytological features such as lobular, 
tubular, medullary, and metaplastic carcinomas (Weigelt et al., 2008;World Health 
Organization, 2013).
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Although tumour type provides useful prognostic information, the majority of breast 
carcinomas have no special type of characteristics such as IDC-NOS. To date, those special 
types are relatively uncommon. As a consequence, the role of histological typing in clinical 
management analysis is limited (Pereira et al., 1995).
It is essential to consider the lymph node status, as it is one of the most important predictors 
of breast cancer recurrence and survival. Gathering data from the Surveillance,
Epidemiology, and End Results (SEER) Program in the US clearly shows that women with 
cancer-free lymph nodes known as lymph node negative have a better survival than women 
with cancerous nodes, known as lymph node positive. As the number of cancerous nodes 
increases, survival decreases and this is associated with poor prognosis (Breast Cancer 
Research Studies, 2014).
In addition to histological tumour type, tumour grade is the other important tumour 
characteristic that can be assessed by histopathological analysis based on the degree of 
differentiation of the tumour tissue. Tumour grading is considered a semi-quantitative 
evaluation of morphological characteristics and is a relatively simple and low cost method. 
The Nottingham Grading System (NGS) is the grading system recommended by a variety of 
professional bodies internationally. The WHO, the American Joint Committee on Cancer 
(AJCC), the European Union (EU), and the Royal College of Pathologists (RCP), agreed that 
tumour grade is based on assessment of three morphological features: (a) degree of tubule or 
gland formation, (b) nuclear pleomorphism, and (c) proliferative activity also known as 
mitotic index (Elston and Ellis, 1991;Rakha et al., 2010).
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1.4.3. Oestrogen receptor (ER), progesterone receptor (PR) and Human 
epidermal growth factor receptor (HER2)
Hormone receptor-positive breast cancers account for around 75-80% of all cases of breast 
cancer (Konecny et al., 2003).It is well established that oestrogen receptor (ER) and 
progesterone receptor (PR) expression should be measured by standardised IHC assays on 
every primary invasive breast cancer and on metastatic lesions, as expression levels influence 
treatment planning. In pre- and post-menopausal patients, steroid hormone receptor status 
must be tested routinely to guide the selection of patients for hormonal based therapies (anti- 
endocrine therapy) in both primary and metastatic disease settings (Cummings, 2002). These 
treatments include tamoxifen, ovarian ablation (surgical or chemical), aromatase inhibitors 
(anastrazole, letrozole, exemestane), and irreversible ER inhibitors (eg, fulvestrant).
Anti-Endocrine treatments are used for prevention of new cancers and of recurrent distant 
métastasés. ER content is associated with a favourable prognosis, and is highly predictive of 
benefit from adjuvant endocrine hormonal therapeutic agents. However, ER negativity is 
associated with a worse outcome especially in patients with DCIS (Emster et al., 1996).
HER2 is amplified and overexpressed in approximately 15% to 30% of newly diagnosed 
breast cancers and is associated with more aggressive behaviour (Wolff et al., 2007). Several 
potential clinical applications have been proposed for determination of HER2 status in 
patients with invasive carcinoma , including: 1- identification of prognosis in untreated 
patients; 2- prediction of resistance to anti-endocrine therapies such as tamoxifen; 3- 
prediction of resistance to certain chemotherapeutic agents such as cyclophosphamide, 
methotrexate, and fluorouracil (CMF)-like regimens; 4- prediction of benefits from using 
paclitaxel and determination of the sensitivity from using anti-HER2 therapies, in particular 
trastuzumab and lapatinib (Harris et al., 2007).
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1.4.4. Molecular classification of breast cancer
Microarray-based technology has been used to detect the expression of many different genes 
involved in breast cancer and encourages researchers to start moving towards a 
comprehensive molecular profile of breast cancer. These efforts have led to the identification 
of clinically relevant molecular subtypes and have offered early insights into the molecular 
heterogeneity of breast cancer disease (Sorlie et al., 2003). Five distinct intrinsic subtypes of 
breast tumours have arisen that are based solely on gene expression. These are : 1- luminal 
A, 2- luminal B, 3- HER2 overexpressing, 4- basal-like , 5- normal breast tissue-like (Hu et 
al., 2006).
More recently, molecular intrinsic subtyping has been refined in a PAM50 assay by 
measuring the expression profile of 50 key genes. The PAM50 test is the first clinical 
iteration of the gene expression signature, which has already been extensively validated in the 
research setting(Nielsen et al., 2010). A large homogeneously treated cohort of breast cancer 
patients is used to compare gene expression results with high-quality clinical and central IHC 
findings. It has been shown the PAM50 approach is superior as a prognostic test and is 
specifically able to identify an ultralow-risk group who may not need chemotherapy 
treatments based on these outcomes (Nielsen et al., 2010).In recent studies, gene expression 
has evolved a further sub-classification of breast cancer tumours by identification of a new 
molecular subtype referred to as claudin-low or mesenchymal-like. This subtype is 
characteristically negative for ER, PR and HER2 and is therefore known as “triple negative” 
breast cancer (Prat et al., 2010). Triple negative breast cancer accounts for 10-15% of breast 
cancer and carries a poor prognosis. These tumours represent a key clinical entity given their 
lack of treatments options (Dawson et al., 2009).
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In parallel with the identification of the intrinsic subtype classifications, gene expression 
profiling has also been used by several groups to determine distinct prognostic signatures. 
Two distinct prognostic signatures have been approved and used clinically. These are 
Mammaprint, which is described as a microarray-based assay of the 70-gene breast cancer 
signature (Wittner et al., 2008) and OncotypeDX, which is a PCR-based assay of a panel of 
21 genes (Paik et al., 2004). These signatures are now being tested randomised clinical trials 
(Cardoso et al., 2008). Recently, Haibe-Kains and colleagues (2012) proposed a three gene 
model known as SCMGENE, which classifies tumours by a quantitative measurement of the 
ESRl, ERBB2 and AURKA genes (Haibe-Kains et al., 2012).
1.4.5. Tumour markers in breast cancer
The American Society of Clinical Oncology (ASCO) first published evidence-based clinical 
practice guidelines for the use of tumour markers in breast cancer in 1996. An Update 
Committee of the original Expert Panel, then update these guidelines to reflect newly 
identified tumour markers for breast cancer. The last update of the guideline related tumour 
markers was published in 2007, when the scope of the guideline was expanded to include a 
broader range of breast tumour markers (Harris et al., 2007). The tumour markers most 
frequently used as indicators for breast cancer are discussed in the following sections.
I.4.5.I. CA 15-3 and CA 27.29 as markers for breast cancer
CA 15-3 and CA 27.29 are well-characterized assays that allow the detection of circulating 
MUC-1 antigen in peripheral blood. Several studies have supported the prognostic relevance 
of this circulating marker in early-stage breast cancer (Gion et al., 2002;Martin et al., 2006). 
Several well-designed studies have shown that an increase in CA 15-3 or CA 27.29 after
16
Chapter 1 Introduction
primary and or adjuvant therapy can predict recurrence an average of 5 to 6 months before 
other symptoms may occur (Ebeling et ah, 2002;MoIina et ah, 2003).
1.4.5 2. Carcinoembryonic antigen as a marker for breast cancer
Carcinoembryonic antigen (CEA) is not recommended for screening, diagnosis, staging, or 
routine surveillance of breast cancer patients after primary therapy. Present data are 
insufficient to recommend use of CEA alonefor monitoring. However, it has been established 
that CEA can be used in conjunction with diagnostic imaging, history, and physical 
examination (Harris et ah, 2007;Veronesi et ah, 1982).
I.4.5.3. ER, PR, and HER2 as markers for breast cancer
The standard evaluation of breast cancer for clinical purposes involves the measurement of 
ER and PR expression status in conjunction with histopathological assessment. For more than 
three decades, ER has been the most vital biomarker measured for the management of 
hormone receptor-positive breast cancers (Konecny et ah, 2003). Clinically, progesterone 
receptor (PR) is also measured for the management of breast cancer (Harris et ah, 2007). 
Initial reports, which have been validated through the years, recommended that breast cancer 
patients with ER-positive/PR-negative tumours have a worse prognosis compared with 
patients who have solely PR positive tumours (Clark et ah, 1983). It has been suggested that 
PR would be an important predictive factor for benefit from anti-oestrogen therapeutic agents 
(Hammond et ah, 2010). In 2007, the ASCO conference presented HER2 as an additional 
predictive tumour marker in breast cancer to be used routinely(Harris et ah, 2007). HER2 is 
amplified and overexpressed in approximately 15% to 30% of newly diagnosed breast 
cancers and is associated with more aggressive behaviour (Wolff et ah, 2007).
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I.4.5.4. p53 as a marker for breast cancer
A study by Thor et al., in 1992 was the first study to report the p53 mutation as an 
independent prognostic marker of survival in breast cancer. These results were obtained by 
using two distinct tumour banks inclusive of sporadic as well as hereditary breast carcinomas 
(Thor et al., 1992). A number of studies have revealed that high tissue p53 protein levels 
measured by IHC, or mutations or deletions in the p53 gene measured by single-strand 
conformational polymorphism (SSCP) gel electrophoresis, manual sequencing, or allele- 
specific polymerase chain reaction (PCR) appear to be predictors of poor outcome in breast 
cancer patients (Pharoah et al., 1999). Recently, a study from Norway investigated nearly 
2,000 women with newly diagnosed breast cancer and suggested that p53 gene abnormalities, 
as determined by sequencing, are associated with worse prognosis. Importantly, subset 
analysis suggested that p53 mutations/deletions were particularly prognostic in node­
negative, ER-positive patients (Olivier et al., 2006), although treatment was not described, 
treatment-related prognosis was discussed and out forward as a mechanism. Consequently, 
p53 status could be used to determine which patients would benefit from the addition of 
chemotherapy to endocrine therapy (Harris et al., 2007).
1.4.5 5. Cyclin E as a marker for breast cancer
Cyclin E is a protein that is expressed in the late G1 phase of the cell cycle. Association of 
cyclin E with CDK2 stimulates kinase activity and promotes transition of cells to the S phase, 
ensuring subsequent cell division by phosphorylating the RB protein that then releases bound 
E2F transcription factors and promotes DNA synthesis.Elevated levels of cyclin E have been 
observed in a number of different cancers (Hwang and Clurman, 2005). In addition, it has 
been established that cyclin E protein, and particularly its low molecular weight 
(LMW)fragments, are markers of poor prognosis in breast cancer (Wingate et al., 2005).
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1.4.5.6. Proteomic analysis for breast cancer
The emerging field of proteomics is complex. In theory, different clinical diseases, including 
cancer, might be represented by distinct protein expression patterns, or signatures. These 
signatures might consist of completely different proteins, of various mixtures of peptide 
fragments, or of modifications of proteins or peptides, such as glycosylation, cysteinylation, 
lipidation, and glutathionylation, each of which might be cancer-specific. Therefore, one 
might be able to exploit these differences, either in tissue, in the circulation, or in secreted 
fluids, for diagnostic purposes. For proteomic pattern analysis, computer-based algorithms 
have been developed to distinguish breast cancer from benign disease and to identify 
individuals at high risk of relapse based on the pattern of peptide peaks (Grassl et al., 2006).
1.4.6. Breast cancer staging
Clinically, it is very important to consider staging of the breast cancer tumour as it applies in 
conjunction with the histopathology classification scheme as a determinant in breast cancer 
prognosis (Schulz, 2007). The accepted clinical method for breast cancer staging is the 
tumour lymph node métastasés (TNM) classification system. Breast cancer staging takes into 
account various factors such as the size of the tumour, either a breast lump or the area of 
cancer cells that are found on a scan or mammogram; whether cancer cells have spread into 
the nearby lymph glands (lymph nodes); and whether the tumour has metastasized(Cancer 
Research UK, 2013). Table 1 below shows a description of breast cancer staging system
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Table 1-lDescription of the breast cancer staging system (incidence and survival rates 
taken from Cancer Research UK).
0 Ductal carcinoma in situ
I Tumour is smaller than 2cm and has not 
spread
41% 99.1%
IIA The tumour is largerthan 2cm but not larger 
than 5cm and there is no cancer in the lymph 
nodes
45% 87.6%
IIB The tumour is larger than 2cm but not larger 
than 5cm and there is no cancer in the lymph 
nodes
IIIA The tumour is 2- 5cm and involvement of 4 
or more auxiliary nodes.
9% 55.1%
IIIB Tumour has spread to chest wall or skin and 
may have spread to more than 10 auxiliary 
lymph nodes
m e The tumour has spread to the chest wall. It 
has also spread to 10 or more lymph nodes 
in the armpit
IV The cancer has spread (metastasized) to 
other parts of the body such as the bones, 
lungs, liver or brain
5% 14.7%
1.5. Molecular mechanisms of breast cancer
Breast carcinogenesis is a complex and multi-step disease characterised by genetic alterations 
that affect multitudes of cellular pathways and signalling mechanisms. Although recent 
research has emphasised the heterogeneity of the disease, much of its biology remains poorly 
elucidated. Some of the documented mechanisms are outlined below.
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1.5.1. Oncogenes and tumour suppressor genes
Cancer arises from mutations in genes that contribute to growth, differentiation, and death.
In order for a normal cell to transform into a cancer cell, genes that are responsible for cell 
growth regulation and differentiation must be altered (Croce, 2008). There are two broad 
categories of genes that lead to carcinogenesis; these are oncogenes and tumour suppressor 
genes. Oncogenes refer to the genes whose alterations lead to gain of functional effects, 
whereas alterations of tumour suppressor genes cause loss of functional influences. The 
effects of both alterations are very complex because of the numerous changes that occur in a 
typical breast cancer case (Osborne et al., 2004).
15.1.1. Oncogenes
Cells normally undergo a programmed form of death (apoptosis), when they become worn- 
out or damaged. Activated oncogenes can cause those cells to survive and proliferate 
instead(Osbome et al., 2004). Most oncogenes require an additional step, such as mutations 
in another gene, or environmental factors, such as radiation or infection, to cause cancer. It is 
important to note that almost all known oncogenes are altered forms of normal genes. There 
are various ways in which oncogene may be activated (Croce, 2008). A common mechanism 
is through chromosomal translocation, which is the exchange of one part of a chromosome 
for another part of a different chromosome, resulting in changes of the base sequence of DNA 
but also drastic changes in gene regulation e.g. BCR/Abl (Kakizuka et al., 1991). An 
important translocation is that associated with the Philadelphia chromosome. Phi, which is 
present in all cases of chronic myeloid leukaemia (CML) (Soupir et al., 2007).
Another mechanism of oncogene-activation occurs through gene amplification. Examples of 
such are those oncogenes associated with the HER family, such as HERl in glioblastomas 
and breast carcinoma and gene amplification of HER2 that contributes to breast cancer in
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about 20% of breast cancer cases (Pauletti et al., 2000). A further mechanism of activation is 
the occurrence of point mutations in intracellular signal transducers such as the Ras oncogene 
(Baines et al., 2011). The oncogenic activation of Ras is reported in about 30% of human 
tumours, which are seen commonly in lung, colorectal, and pancreatic cancer, but is not 
common in breast cancer (Femandez-Medarde and Santos, 2011).There are several hundred 
oncogenes that have been identified in human cancer, some of which are shown in table 1-2, 
but relatively very few have been reported to be crucial in breast cancer progression.
Table 1-2 Oncogenes of major importance.
Ras Lung, Pancreatic, Colon, Bladder, Thyroid
HER2/ERBB2, Kit Breast, Ovary
HERl/EGFR Breast, Glioblastoma
Akt, Raf Gastric
Bcl-2 Follicular lymphoma
Myc Leukaemia
The HER2 oncogene
HER2 is a human epidermal growth factor receptor (EGFR) also known as ERBB2 or neu 
(Marshall, 1995). The structure of HER2 is totally different from other EGFR receptors, as it 
has no ligand of its own and acts by forming heterodimerswith any of the other three 
receptors (EGFR (HERl), HER3 and HER4). This makes HER2 a preferred dimérisation 
partner for the other activated HER receptors as shown in figure 1-3 (Howe and Brown,
2011). The first step in the growth factor receptor signal transduction pathway, which is the 
binding of epidermal growth factor (EGF) to its receptor, causes a conformational change that 
reveals an extracellular receptor dimérisation domain (Camarena et al., 2010), thatstimulates
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its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of 
intracellular kinase domains of HER2 occurs. This autophosphorylation triggers downstream 
activation and signalling by several other proteins that associate with the phosphorylated 
tyrosines through their own phosphotyrosine-binding SH2 domains (Ueda et al., 2006). These 
downstream signalling proteins initiate several signal transduction cascades, principally the 
Ras, Raf, MARK, MEK and phosphatidylinositol 3-kinase (P13K) pathways, leading to DNA 
synthesis, cell proliferation, and progression(Hynes and Lane, 2005).
Key
EGFR (H E R l)
HER2
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Phosphate
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Figure 1-3HER2 receptor and downstream signalling pathways.HER2 is an orphan receptor 
with no known ligands, but HER2 is the preferred dimerization partner for all the other HER 
receptors. The formation of receptor heterodimers and the activation of the intrinsic kinase 
domainresults in phosphorylation of specific tyrosine residues within the cytoplasmic tail. This 
initiates several signal transduction cascades, principally the Ras, Raf, MARK, ERK pathways and the
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phosphatidylinositol 3-kinase (P13K), Akt and mTOR pathways, leading to the activation of gene 
transcription, cell proliferation and progression.
The HER2/neu proto-oncogene is amplified in 20% to 25% of human primary breast cancers 
and this alteration is associated with poor clinical prognosis of breast cancer(Baselga, 
2010;Slamon et al., 1987). It has been shown in several studies that HER2 is linked with 
increased proliferation, decreased apoptosis, metastasis, and development of resistance to 
chemotherapy and radiotherapy (Repetto et al., 2005). Thus, small molecule inhibitors that 
inhibit HER2 would be therapeutically advantageous in the treatment of breast cancers 
(Zlobec et al., 2007).
Other HER family members
Other HER family genes, include the one encoding the EGFR also known as HERl. HERl is 
overexpressed very commonly in head and neck cancer and lung cancer but to a lesser extent 
in breast cancer. However, it has been reported that HERl is associated with worse clinical 
outcome in breast cancer patients (Srirajaskanthan et al., 2010). The most striking finding 
was that HER2 can heterodimerise with HERl and initiate signal transduction and eventually 
stimulate breast tumour growth. Consequently, there is a huge interest in targeting the HERl 
receptor in the treatment of breast cancer (Mendelsohn and Baselga, 2003).
Downstream signal transduction modulators
One of the fundamental features of cells is their ability to proliferate. This process known as 
cell division must be carefully regulated and DNA replication must be coordinated precisely 
to maintain the integrity and stability of the genome. Unregulated cell growth is considered a 
quintessential characteristic of cancer. In normal cells, cell division is only initiated in 
response to signals external to the cell. External growth signals such as those from the EGF
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family stimulate cell growth by transmitting the signal to protein receptors. This leads to 
downstream events occurring within the nucleus, to regulate gene expression and ultimately 
produce proteins. Growth factor-mediated signal transduction facilitates different kinases that 
act as master switches and can control several pathways. These include PI3K, mammalian 
target of rapamycin (mTOR), and signal transduction and activator of transcription (STAT3) 
signalling, which form a complex signalling network. This network was found to be 
important for breast cancer cell survival and proliferation and may have implications for the 
development of agents that target breast cancer cell populations (Zhou et al., 2007).
Other downstream centrally acting proteins belong to the Ras gene family. The RAS proteins 
are star players in regulating cell growth because of their role in signal transduction 
pathways. The three members of the RAS family (N-RAS, H-RAS, and K-RAS) are all GTP- 
binding proteins. When bound to GDP they are inactive and when bound to GTP they are 
active. Active RAS proteins act as pivotal factors for the integration of a growth factor signal 
through the cytoplasm and into nucleus. The consequence of mutations is a loss of GTPase 
activity of the RAS protein, which is normally required to return active RAS-GTP to inactive 
RAS-GDP. Mutations in the Ras gene have been identified in specific cancer types such as 
bladder carcinoma, colorectal cancer, and lung cancer but Ras mutations are generally rare in 
breast cancer (Bos, 1988).
RAS-GTP binds to and contributes to the activation of the serine/threonine kinase, Raf,The 
recruitment of Raf to the cell membrane is necessary for its activation by RAS-GTP. 
Activated Raf is a signal transducer that transfers the signal away from the membrane by 
phosphorylating and thus activating mitogen-activated protein kinase (MAPK). Oncogenic 
activation of Rafis a common occurrence in melanomas (Abel et al., 2013).
25
Chapter 1 Introduction
The C~myc oncogene
The protein product of the c-myc oncogene acts as a transcription factor; it binds to DNA and 
regulates the expression of genes involved in growth, differentiation and death. Oncogenic 
activation of c-myc occurs through gene amplification has been reported in neuroblastoma 
and small cell lung cancer (Rapp et al., 2009). However, increased oncogenic activity of the 
c-myc gene is observed in Burkitt’s lymphoma (Li et al., 2003) .The c-myc oncogene is 
amplified or overexpressed in 15%-25% of breast tumours (Nass and Dickson, 1997;Slamon 
et al., 1987). It is frequently activated in invasive breast ductal carcinoma in situ and has been 
associated with high metastatic levels and poorer disease outcomes (Aulmann et al., 2002).
The cell cycle and oncogenes involved in cell-cycle modulation
All proliferating cells go through a series of four carefully controlled distinct phases of cell 
division: G l, S phase, G2 and M phase. Cells first enter the first gap or G1 phase where they 
prepare for DNA synthesis. After passing the restriction point and the end of Gl phase, the 
cells enter the S phase where DNA synthesis takes place. G2 is the second gap phase, where 
cells prepare to divide (Kibria et al., 2008). Combined, G l, S, and G2 phase make up the 
process called interphase. M phase is the stage in which mitosis occurs and involves 
cytokinesis to partition the cell into two daughter cells. In addition to this replicative cycle, 
some cells may enter GO phase, where they remain quiescent, which is referred as a 
quiescence state; where the cell is neither dividing nor preparing to divide (Maddika et al., 
2007).
Progression through the cell cycle is regulated and coordinated by a set of cell-cycle regulator 
molecules. These consist of a group of regulatory subunits called the cyclins and a group of 
catalytic kinase subunits known as cyclin-dependent kinases (CDKs) (Li and Brooks, 1999). 
Cyclins were termed because the cyclical changes in their concentrations that occur over a
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series of cell divisions. Contrary to this, the concentration of CDKs does not fluctuate during 
the cell division (Bravo and Macdonald-Bravo, 1987). CDKs are a group of regulatory 
proteins that are serine/threonine kinases. These kinases sequentially regulate progression 
through the phases of the cell cycle. Therefore, the regulation of CDK activity is crucial for 
precise cell division (Barbacid et al., 2005).
It has been documented that there are different mechanisms responsible for CDK regulation, 
such as association with cyclins and association with CDK inhibitors (CDKIs) (Harper et al., 
1993). There are several known CDKs in human cells that act together with specific cyclins 
to form complexes. The pairing of cyclins with the CDKs is highly specific. Upon binding of 
a cyclin to its CDK partner, the cyclin induces a conformational change in the catalytic 
subunit of the CDK that reveals its active site and therefore controls its activity (Ely et al., 
2005). Different cyclin-CDK complexes are present at specific points in the cell cycle and 
have specific roles at that point. For example, CDK4 and CDK6 pair with D-cyclins that are 
involved within the Gl phase, while CDKl pairs with cyclin B, which is involved at G2/M 
transition phase (Senderowicz and Sausville, 2000).
Cell cycle checkpoints are described as a control mechanism that ensure thefidelity of cell 
cycle and function as sensor mechanisms in order to induce cellular response to DNA 
damage. Functioning of these checkpoints enable DNA repair or activation of cell death 
mechanism (apoptosis) in case of damage that cannot be repaired, and are thus important in 
carcinogenesis and for maintaining the integrity of the genome. These checkpoints verify 
whether the processes at each phase of the cell cycle have been accurately completed before 
progression into the next phase.
It is now apparent that the great majority of cancers possess deregulation in the control of the 
cell cycle, particularly through loss of control of checkpoints, permitting them to
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continuously cycle (Barton et al., 2006). For example, loss of the G l checkpoint at which 
cells are able to commit to further DNA replication, can lead to genomic instability. This may 
occur in numerous ways, but an important example is the inactivation of the p53 gene. In 
normal biological systems, p53 is described as a brake on the cell cycle (Amundson et al., 
1998). P53 is directly phosphorylated by ataxi-telangiectasia mutated (ATM) upon DNA 
damage and can be additionally phosphorylated by Chk2/Chkl. Phosphorylation results in 
accumulation, stabilisation, and increased transcriptional activity of p53, which activates p21 
Cipl that causes Gl arrest by inhibition of CDK2-cyclinE activity. Arrest at Gl prevents the 
cell passing through the Gl-S transition (Curtin, 2012;Foster et al., 2010). Mutation of 
p53causes a disruption of normal Gl/S checkpoint functionof the cell cycle control which 
leads to the inhibition of the apoptosis , and promote cancer cell growth and proliferation 
(Amaral et al., 2010).
Another important pathway involved in the Gl checkpoint that is deregulated in cancer is the 
retinoblastoma (RB) RB/CDK4/cyclin D pathway (Muller and Helin, 2000). The 
phosphorylation of the pRB by CDKs is a key player of cell cycle progression from the Gl 
phase of the cell cycle. In Gl phase, the pRB is hypo-phosphorylated to permit binding to the 
transcription factor, E2F. However, at the end of Gl phase, various CDKs (CDK4, 6 and 2) 
in association with their cyclin partners, add additional phosphate groups to pRB, thereby 
releasing E2F. This ultimately leads to transcription of genes required for the S phase. 
Deregulation may occur through mutation or loss of the p l6  INK4a CDKl (Besson and 
Yong, 2001), which normally inhibits CDK4/cyclin D. It has been reported that the p l6  
deletion is found in 55% of glioma and mesothelioma and that mutation of p 16 is observed in 
40% of pancreatic and breast carcinomas (Bartsch et al., 2002). Experimental evidence shows 
that mRNA expression levels of cyclin D are up-regulated in 50% of breast tumours (Kenny 
et al., 1999). It has been found that the induction of hyperplasia and adenocarcinoma of the
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breast occurs because both ER and EGFR oncogenes exert their oncogenic effect by 
transcriptional activation of cyclin D. However, the exact mechanism by which cyclin D 
exerts its mitogenic effects is not fully understood but may be due to cyclin-D enhancing, 
ER-mediated transcriptional activity by binding to the hormone binding domain of ER and 
enhancing protein interactions with ER’s co-activators (Roy and Thompson, 2006).
Many investigators address the relevance of cyclin E alterations in breast cancer. In normal 
cells, cyclin E is regulated tightly and is expressed only when needed and is degraded 
thereafter (Barton et al., 2006). It has also been demonstrated that over-expression and 
alterations of the cyclin E oncogene are found in 20%-30% of ER-negative breast tumours 
that have a high proliferative index and correlate with remarkably poor outcomes (Keyomarsi 
et al., 2002). In vitro, it has been observed that amplification of the cyclin E gene in breast 
cancer cell lines can result in as much as 64-fold overexpression at the mRNA level 
compared with that constitutively expressed throughout all phases of the cell cycle 
(Weinstein et al., 1997).
The G2 checkpoint is located at the end of G2 phase, with the purpose of blocking entry into 
M-phase in cells that have suffered from DNA damage or have not correctly completed S 
phase (Stark and Taylor, 2004). One molecular target of the G2/M checkpoint involves an 
activating phosphatase, known as Cdc25, which under favorable conditions regulates CDK 
activity by removing the inhibitory phosphates present within the Mitosis Promoting Factor 
(MPF;term for the cyclin B/CDKl complex). Cdc25 proteins are encoded by a multigene 
family, comprising of Cdc25A, Cdc25B, and Cdc25C. Specific Cdc25s (B and C) are 
significantly important in the G2-M transition (Boutros et al., 2007). In the instance of DNA 
damage, the cell cycle is arrested via inactivation of the Cdc25 phosphatases. In human cells, 
it has been detected that overexpression the Cdc25B gene was observed in 32% of human
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breast cancers tested along with an association with poor prognosis (Galaktionov et al.,
1995).
In addition, topo-isomerase II (T0P2A) plays a role in of the G2 checkpoint by releasing 
torsional stress, which leads to the breakage of DNA double strands and allows DNA 
unwinding. This is considered a key mechanism of the G2 checkpoint. It is a well-established 
that the T0P2A oncogene is considered a surrogate marker of cell proliferation and its 
expression has been associated with high tumour grade of breast cancer (Romero et al.,
2011), Interestingly, the T0P2A gene itself is frequently found co-amplified with HER2- 
amplified human breast carcinomas (Jarvinen et al., 2000).
The mitotic checkpoint also named as the spindle assembly checkpoint and the metaphase 
checkpoint occurs at the point in metaphase to ensure correct chromosomal segregation 
during mitosis and the generation of two genetically identical nuclei (Zhou et al., 2002). 
Evidence suggests that mutation in genes that code for components involved in the metaphase 
checkpoint are not common and have not implicated in human cancer cell progression (Erson 
and Petty, 2004).
1.5.12. Tumour suppressor genes
Tumour suppressor genes are defined as those genes, whose products protect a cell from 
cancer and for which loss of function causes the enhancement of malignancy and cancer 
progression (Buchholz et al., 1999). There are several tumour suppressor genes now known, 
as shown in table 1-3 Although inherited abnormalities of tumour suppressor genes account 
for a minority of breast cancer cases(Osbome et al., 2004), a few of the more well-known 
ones are discussed below.
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Table l-3Common tumour suppressor genes.
RB Retinoblastoma
P53 Many types of cancer
PTEN Breast cancer
BRCA-1 Breast cancer
BRCA-2 Breast cancer
p53 Tumour suppressor gene
The p53 gene was the first tumour suppressor gene to be identified more than two decades 
ago and since its discovery (Donehower and Lozano, 2009), p53 has become the most 
studied. It has been found that the p53 pathway is frequently altered in most human cancers, 
with deletion and point mutations observed in about one-fourth of all sporadic breast cancers 
(Zhivotovsky and Orrenius, 2003).
p53 functions as a tumour suppressive mechanism and thus has been named the guardian of 
the genome. The p53 gene is located on chromosome 17p and codes a 393-kDa protein that 
has multiple functions and is regulated via phosphorylation at different sites. In the normal 
state, the level of p53 is low in a cell due to its short half-life, which is approximately 10-20 
minutes and is insufficient for activity. The short half-life of p53 comes from its post- 
translational modification and subsequent degradation through the mouse double minute 2 
(MDM2) ligase which exists as a complex with p53 (Malkin et al., 1990). Under normal
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conditions, p53 acts as a regulating mechanism for cell division and in response to stress 
signals such as DNA damage, the cellular content of p53 is increased, allowing it to directly 
interact with DNA to enhance the transcriptional activity of a number of genes. Target genes 
include OKI p21^^^  ^that acts by inhibiting the formation of several cyclin-CDK complexes. 
This causes cell cycle arrest so that there is a chance to repair the damage before the next 
round of replication. Thus, the damaged DNA will be prevented from being passed on to 
daughter cells and the genotype is maintained (Mashimo et al., 1998). Mutations of p53 are 
estimated in over 50% of human cancers and approximately 20%-30% of breast cancer cases; 
these defects lead to the promotion of tumour progression and increased genomic instability 
(Hollstein et al., 1991).
Crawford et al (1982) found circulating antibodies to human p53 protein in 9% of breast 
cancer patients, particularly those with visceral métastasés (Crawford et al., 1982). 
Overexpression of p53 has been strongly correlated with node-negative breast cancer among 
patients, and mutation of p53 linked with a 33% risk of disease relapse (loakim-Liossi et al., 
2001;Thor et al., 1992). Patients with germline p55mutations (Li-Fraumeni syndrome) also 
predispose to breast cancer (Malkin et al., 1990). Recent evidence suggests a relationship 
between BRCA-1 and p53 in hereditary breast cancer (Li, 1990).
p2?Kipl
p27^'^^belongs to the Cip/Kipfamily of CDKIs. First isolated in 1993, was found to act
as a negative regulator of the cell cycle. Due to its function, p27^'^4s referred to as a cell 
cycle inhibitor protein because its major function is to stop or slow cell cycle division and 
cause G l cell-cycle arrest (Russo et al., 1996). p27^'^4s able to bind several different classes 
of cyclin and CDK molecules. Several roles of p27^'^^have been proposed, such as 
modulating drug resistance, cell differentiation, and protection from inflammation
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(Ophascharoensuk et al., 1998;Schmidt et al., 2001). Down-regulation of p27^'^^has been 
documented in a variety of breast cancer cell lines. However mutation in p27 '^^  ^is very rare 
and occurs only in 1% of malignant tumours (Spirin et al., 1996). Expression of p27^*^^has 
prognostic value in lung and colon cancer (Loda et al., 1997). In breast cancer, decreased 
expression ofp27 '^^^is linked with increase in both the overall cancer cell survival rate and 
cell progression. It is possible that p27^'^4s a more reliable predictor of outcome than 
identification of p53 alteration in breast carcinoma (Catzavelos et al., 1997). The expression 
of p27^^Hs associated with a better outcome in patients with breast carcinomas who undergo 
potential curative surgery. Loss ofp27^^^expression correlates with a poor outcome due to the 
role in modulating cell-cell adhesion, thus enhancement of metastatic breast cancer spread 
when this adhesion is lost (Tan et al., 1997).
Skp2
S-phase kinase-associated protein (Skp2) functions as phosphorylation-dependent 
ubiquitinase. This protein is an essential element of the cyclin A-CDK2 S-phase kinase 
complex. Skp2preferably recognizes phosphorylated p27^^^\ predominantly in S phase and 
interacts with pl9  (Castagnino et al., 2013). It has been reported by Signoretti and co-workers 
that Skp2 has an oncogenic role in stimulating growth of breast carcinomas. Using microarray 
hybridisation of RNA from 89 breast carcinomas, they found that Skp2 is overexpressed in 
both ER-positive and -negative breast cancer cells and suggested that Skp2 is a therapeutic 
target for the inhibition of breast cancer cell growth (Signoretti et al., 2002).
BRCA-1
Based on linkage analysis of families with breast cancer, the locus of an associated gene at 
17q21 was reported in 1990 and the gene discovered now known as BRCA-1 was 
consequently identified in 1992 (Margaritte et al., 1992). It has been estimated that roughly
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0.12% of the general population carries a mutation in BRCA-1. BRCA-1 is a human 
suppressor gene responsible for the repair of DNA damage. BRCA-1 mutations have been 
proposed to account for more than 5% of all breast cancer cases, and are especially common 
in women below the age of 40 years. This estimation is increased to over 90% in families that 
have a history of four or more cases of breast cancer (Ford et al., 1995). The risk of breast 
cancer incidence in patients that carry the BRCA-1 mutation is estimated to be 49% to 73% 
by age 50 years and is increased to 71% to 89% by the age of 70 years. The lifetime risk of 
ovarian cancer is 20% to 30%, and the risk of colorectal and prostate cancer might also be 
increased.
BRCA-1 has been found to interact with BRCA-associated ring domain protein (BARDl), 
which is known to have a suppressor function of its own. Following genotoxic exposure, 
BRCA-1 protein along with BARDl have been seen to localise at the area of damaged DNA, 
enhance the role of transcription factors and repair the DNA double strand (Scully et al.,
1997). Mutated BRCA-1 is the most frequently associated cause of familial breast cancer, 
whereas BRCA-Rs rarely found to be mutated in sporadic breast tumours. Over 200 
individual BRCA-1 mutations have been found, such as deletions, insertions and substitutions 
that occur throughout the length of the gene. Approximately 80% of these mutations yield 
abnormal truncation of the BRCA-1 protein (Couch et al., 1997). It has been found that 
BRCAl mutation is less likely to be associated with ER-positive breast cancer, but may be 
associated with amplification of the C-myc-gene(Chen et al., 2011).
BRCA-2
After it was discovered that BRCA-1 accounted for only a minor number of inherited cases of 
breast cancer, later research led to the discovery of a gene localised to 13ql2-ql3, named 
BRCA-2 (Wooster et al., 1994). BRCA-2 shares similar features with BRCA-1 although they
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have different structures. BRCA-2 protein binds to Rad51 and its paralogues, which is 
required for sister chromatid template proofreading in DNA repair. It has been shown that 
mutations in BRCA-2 gene are associated with a high risk of breast and ovarian cancer 
(Hedenfalk et al., 2001). To date, over 100 BRCA-2 mutations have been identified that lead 
to premature truncation of the protein (Sorlie et al., 2003). It is important to note that 
mutations in BRCA-2 are not associated with a high tumour grade as BRCA-1 mutations are, 
and have no observable of lymphocytic infiltrate. Gene expression profiling reveals a 
significant difference between BRCA-1 and BRCA-2-related tumours. As such, the BRCA-2 
mutation confers increased risk of different cancers such as melanoma, gastric cancer, and 
biliary carcinoma. Assessment tests should be provided to patients with family histories 
suggesting BRCA-1/2 mutations. Genetic assays to test specific mutations in patients are 
commercially available but their usage is limited due to controversy, suggesting that these 
tests should not be applied to the population at large. Testing should involve genetic 
counselling and when mutation carriers are identified, it is appropriate to offer and discuss 
prophylactic options such as surgery and the testing of other family members.
Taking together, mutations in the BRCA-1/2 genes are found in most families with a positive 
history of breast cancer, especially in early-onset groups (Petrucelli et al., 2010). Patients in 
the 35-45 year age group, who are diagnosed with breast cancer, only have a 2.4-4.9% 
incidence of these mutations (Nkondjock and Ghadirian, 2004).
PTEN
Phosphatase and tensin homolog (PTEN) is a protein that is encoded by the PTENgcnc. 
Mutations of this gene are involved in breast tumourigenesis and tumour progression (Mills 
et al., 2001). PTENwas the first phosphatase to be identified as a tumour suppressor gene 
with different functions, including regulation of the cell cycle and apoptosis (Goberdhan and
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Wilson, 2003). PTEN also acts as a negative regulator of the survival signalling molecule 
Akt(Nelen et al., 1997;Stambolic et al., 1998). One study reported that PTEN appears to 
suppress the growth of breast cancer cells (MCF-7) by down-regulation of PI3K signalling, 
which leads to the abolishment of the cell cycle and induction of the cell death (Weng et al., 
1999).
CHK2
Cell-cycle-checkpoint kinase 2 (CHEK2), previously known as CHK2 (Bell et al., 1999), is 
one of the key mediators of cellular responses to DNA damage (Bartek et al., 2001). CHEK2 
is counted as a part of the p53 pathway and modulates the function of p53 via 
phosphorylating it in the case of DNA insult, causing a cell cycle arrest at G1. In addition, 
CHEK2 regulates the function of the BRCA-1 protein after DNA damage has occurred (Lee 
et al., 2000). CHEK2 is regulated upstream in the p53 pathway by ataxi-telangiectasia 
mutated (ATM) protein, which activates CHEK2 by phosphorylation in response to double­
strand DNA breaks. Loss of both alleles of the ATM gene causes ataxia-telangiectasia 
syndrome, which is characterised by progressive cerebellum degeneration, blood vessel 
fragility and immunological defects (Khanna and Jackson, 2001). Some estimates have 
indicated that carriers of the mutation are at an up to a twelve-fold higher risk of breast 
cancer (Shiloh, 2003). This confirms that CHEK2 is a functional component of networks that 
control the cell cycle and that it has a vital role in DNA repair. Most importantly, it is a 
susceptibility gene in hereditary cancer syndromes (Kastan and Lim, 2000).
In addition, it has been found that CHEK2 undergoes somatic mutations in a number of 
cancer types, including lung, ovarian, and lymphoid tumours, and sarcomas (Hofmann et al.,
2001). A rare germline missense variant of CHEK2 has been reported in families with multi­
cancer Li-Fraumeni syndrome (Vahteristo et al., 2001). Interestingly, the same recurrent
36
Chapter 1 Introduction
protein-truncating mutation -llOOdelC in exon 10, which abolishes the kinase function of 
CHEK2 has been reported both among families with Li-Fraumeni syndrome in the United 
States and among Finnish families with a cancer phenotype that is suggestive of breast 
cancer (Wu et al., 2001).
Retinoblastoma (RB)
The retinoblastoma protein (RB) is a tumour suppressorprotein; its main function is to 
prevent the cell from replicating damaged DNA by inhibiting cell cycle progression through 
the Gl into S phase. This happens by RB binding to and thereby inhibiting transcription 
factors of the E2F family (Mao et al., 2007). Mutations affecting the RB gene predispose to 
inherited retinoblastomasbut also other malignancies such as breast cancer. However, 
information about the potential role of RB mutations in breast cancer is very limited and 
poorly understood (Berge et al., 2011;Borg et al., 1992). Nevertheless, some studies have 
reported that loss of RB expression occurs in up to 30% of breast cancer cases, and it has 
been associated with a greater likelihood of disease progression and metastasis (Andersen et 
al., 1992;Lee et al., 1987). In a recent study. Berge and colleagues first reported point 
mutations affecting RB in advanced primary breast cancer tissue (Berge et al.,
2010).Moreover, patients who carried RBmutations were resistant towards anthracycline and/ 
ormitomycin-based chemotherapy (Berge et al., 2011).
1.6. Cell death and cancer
Cell death is a fundamental process of life. Thus, not surprisingly several different types of 
cell death exist, which can be classified according to both morphological appearance and 
biochemical features. These types include apoptosis, necrosis and autophagy (Chaabane et
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al., 2013). The morphological appearance and distinct biochemical features that characterise 
these three types of cell death are shown in table 1-4.
Table l-4Features that characterise the four main types of cell death
Apoptosis Blebbing,
membrane
integrity
maintained
Formation of 
apoptotic bodies
Chromatin 
condensation, 
DNA laddering, 
nuclear 
fragmentation
Caspase-
dependent
Autophagy Blebbing Increased number 
of autophagic 
vesicles.
Partial chromatin 
condensation, no 
DNA laddering
Non-caspase
dependent
Necrosis Loss of membrane 
integrity (swelling 
& rupture)
Swelling of 
cellular organelles
Random DNA 
Degradation
None
identified
The field of cell death research has continued its expansion; significant progress has been 
made and recognised cell death modalities have been described as detailed in the following 
sections.
1.6.1. Apoptosis and Cancer
Between 1962 and 1965, histological investigations of ischaemic liver injury were 
implemented to distinguish between two types of cell death: classical necrosis, and a another 
unknown process that involves the conversion of scattered cells into small round masses of 
cytoplasm that often comprise specks of condensed nuclear chromatin. Enzyme 
histochemistry also showed a rupture of lysosomes in this latter cell death type. Electron
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microscopy further displayed that the small round bodies were caused by cellular 
condensation and budding and that they were bounded by membranes and contained intact 
organelles. It was also noticed that these bodies were phagocytosed and digested by resident 
tissue cells, including epithelial cells (Kerr, 1965). Continuing work was done in 
collaboration with Jeffrey Searle and the process was found to happen spontaneously in 
different malignant tumours and to be enhanced in squamous cell carcinomas of skin in 
responding to radiotherapy (Kerr, 1969). During 1971-1972, this distinct phenomenon that 
sub-serves a broad spectrum of homoeostatic functions was coined apoptosis (Kerr et al., 
1972).
Apoptosis is a programmed cell death pathway, recognised as an orchestrated, highly 
regulated process of cell death, whereby aged, damaged, or unnecessary cells are removed. 
Apoptosis also plays a role in development morphogenesis and in tumour suppression (Kerr, 
2002). Apoptosis is considered a main tumour suppression mechanism in our bodies because 
it removes cells that have extensive DNA damage and potentially lead to cancer. Apoptosis is 
characterised by cell shrinkage, membrane blebbing, chromatin condensation, precise 
fragmentation, and apoptotic body formation, all of which contribute to the neat disposal of 
the cellular contents (Mooney et al., 2002).
As mentioned previously, Hanahan and Weinberg defined six hallmarks of cancer, with one 
of the proposed mechanisms being resistance to cell death (Hanahan and Weinberg, 2011). 
The concept of apoptosis acting as a barrier to cancer development was first raised in 1972 
when Kerr, Wyllie, and Currie described massive apoptosis in the cells populating rapidly 
growing, hormone-dependent tumours following hormone withdrawal (Kerr et al., 1972). 
Research has revealed impairment of apoptosis is a critical step in tumour growth, 
malignancy, and drug resistance (Adams and Cory, 2007).
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One of the most important advances in Cancer Research in recent years is the recognition that 
cell death, mostly by apoptosis, is critically involved in the regulation of tumour formation 
and crucially determines treatment response (Hajji and Joseph, 2010). Most anticancer 
strategies such as cytotoxic and hormonal treatments, as well as radiotherapy that are 
currently used in clinical oncology ultimately kill cancer cells by causing irreparable cellular 
damage that triggers apoptosis. Consequently, the efficacy of cancer treatments depends on 
the cell’s ability to respond to the damage by activation apoptotic machinery (Okada and 
Mak, 2004).
Caspases a group of cysteine-dependent aspartate-specific proteases that play an essential 
role in apoptosis (Thomberry et al., 1992), are key players in the process of apoptosis and 
help to break down cellular components for the complete disposal that is characteristic of 
apoptosis (Stegh and Peter, 2001). Approximately fourteen types of caspases have 
beenidentified in mammals, but not all are involved in apoptotic cell death mechanisms 
(Cohen, 1997).Caspases can be categorised into three groups based on their functional 
activity:
(1) Initiator /apical caspases involved in apoptosis include caspase-2, -8, -9 and -10. These 
cleave inactive pro-forms of effector caspases and thereby activate them.
(2) Effector/executioner caspases of apoptotic cell death include caspases 3, 6 and 7. These in 
turn cleave other substrates within the cell, in order to trigger the apoptotic process.
(3) Caspases involved in cytokine activation include caspase-1, -4, -5, -11, -13 and -14 (Fan 
et al., 2005).
It has been documented that not all caspases are fully elucidated respective to their functions. 
These belong to a group of enzymes known as cysteine proteases and exist within the cell
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asinactive pro-caspases or zymogens. These zymogens can be cleaved to form active 
enzymes that initiate apoptotic activity (Zheng et al., 2000).
In the literature, two distinct molecular signalling pathways that lead to apoptotic cell death 
have been identified: the extrinsic, or extracellular activated pathway, and the intrinsic also 
named the mitochondria-mediated pathway. Both pathways involve an activation of caspase 
cascades as shown in figure l-4(Srinivasula et al., 1996).
Intrinsic pathw ay Extrinsic pathway
Growth factor 
deprivation, UV, 
stress, viruses
Death ligands (FasL, TNF)
BID cleavage
Death receptors (Fas, TNFR)
Caspase 8
BAX/BAK
Mitochondria
ProcaspaseS
Apoptosome Caspase cascade
A p af-1  ^ Cytochrome c
Apoptosis
Figure l-4Schematic representation of the two apoptotic pathways.Apoptosis can be
induced by cell surface receptors such as Fas and tumour necrosis factor-receptor 1 (TNRFl) 
(extrinsic pathway) or via various cellular insults (intrinsic pathway). The intrinsic pathway is 
initiated by BH3-only protein-induction or post-translational activation, which results in the
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inactivation of some Bcl-2 family members. This relieves the inhibition of Bax and Bak, which in turn 
promote apoptosis by stimulating cytochrome c release. Some BH3-only proteins can also directly 
activate Bax and/or Bak (dotted line). Cytochrome c release leads to the activation of Apaf-1 to form 
an apoptosome and activates caspase-9 to initiate the caspase cascade. Caspases in turn activate 
degradative machinery, orchestrating the destruction of the cell. The extrinsic pathway can bypass the 
mitochondria and activate caspase-8 directly, causing apoptosis via the caspase cascade. BID can 
coordinate the two pathways via modulation of Bcl-2 and Bax and/or Bak.
The extrinsic pathway begins outside the cell and it is controlled by a number of death 
receptors and their ligands. Ligands such as Fas or tumour necrosis factor (TNF) act through 
induction of signalling transduction in order to activate apoptotic cascades (Ricci and Zong, 
2006). When a ligand binds to its death receptor, the adaptor protein F ADD recruits pro- 
caspase-8 and -10, forming the death inducing signalling complex (DISC), and activates these 
two caspases (Suliman et al., 2001). Consequently, caspase-8 and -10 result in activation of 
downstream executioner caspases leading to induction of apoptosis (Nagata, 1997).
Mutations in death receptor genes, such as those encoding the Fas receptor occur in some 
cancers. Fas ligand and receptor are induced by UV light. Signalling through Fas receptors 
induces the development of sunburn in response to UV and is considered an important 
defence against skin cancers (Guzman et al., 2003). It has been reported that mutations in Fas 
receptors cause melanomas and squamous cell carcinomas and down-regulation of the Fas 
receptor has been found in many breast cancer cells. Caspase-8 is the first caspase activated 
by death receptors and maintains the initiation of the caspase cascade. Loss of caspase-8 
expression observed in neuroblastomas and small-cell carcinomas are due to both epigenetic 
and mutational alterations (Simstein et al., 2003). One of the mechanisms through which 
tumour cells are believed to acquire resistance to apoptosis is by overexpression of inhibitor 
of apoptosis proteins (lAPs). lAPs are a group of structurally related proteins that were 
initially identified in baculoviruses. Mammalian lAPs suppress apoptosis either by binding 
and inhibiting caspases or through caspase-independent mechanisms. This family of proteins
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has become increasingly prominent in the field of cancer biology. To date, overexpression of 
several lAPs has been detected in various cancers such as breast cancer (Nachmias et al., 
2004).
A huge body of evidence supports that mitochondria are at the core of the intrinsic pathway 
along with a number of apoptotic regulators that inhibit or activate apoptosis (Adrain and 
Martin, 2001). This pathway does not depend on external factors, but stimuli from inside the 
cell, such as DNA damage or oxidative stress (Saelens et al., 2004).
When under stress, mitochondria start to release cytochrome C from the inter-membrane 
space into the cytoplasm. Consequently, cytochrome C binds to and activates oligomerisation 
of Apaf-1 in the presence of dATP, which assemble together in a wheel structure with pro- 
caspase-9 to build the apoptosome complex sometimes referred to as the “wheel of death” 
(Logue and Martin, 2008). Different investigations using knockout mice have explored the 
important role of caspase-9 and Apaf-1 in activating downstream caspases in the intrinsic 
pathway (Logue and Martin, 2008). The apoptosome activates caspase-9, followed by 
activation of the executioners caspases (3 and -7), resulting in activation of a downstream 
caspase cascade (Lindsten et al., 2000). Despite this, caspase-7 shows no involvement in 
activation of downstream caspases. Caspase-3 drives the activation of caspase cascades by 
proteolysis and leads to activation of caspase-2 and 6 (Acehan et al., 2002).
According to a number of studies, the Bcl-2 family proteins function as powerful and 
significantly important regulators of intrinsic apoptotic pathways (Lindsten et al., 2000;Ricci 
and Zong, 2006). Accumulated evidence shows that the Bcl-2 family proteins consist of two 
members: some promote apoptosis, known as proapoptotic proteins and others inhibit 
apoptotic cell death and are named as antiapoptotic (Logue and Martin, 2008). The 
antiapoptotic subfamily members are Bcl-2, Bcl-xL, Bcl-w, Bcl-b, Mcl-l, and A 1 (Willis et
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al., 2005). The proapoptotic proteins include Bax, Bak and Bok, which have domains 
homologous to the BHl-3 domains, and the pro-apoptotic BH3-only proteins. Bid, Bim, Bad, 
Bik and PUMA (Wei et al., 2001). These proteins function as antagonists/agonists that 
determine the response of the cell to apoptotic death signals and they mostly function in the 
external mitochondrial membrane (Du et al., 2000). Bcl-2 anti-apoptotic proteins inhibit 
Apaf-1 mediated activation of caspase-9 (Coultas and Strasser, 2003). In addition, Bax/Bok 
proteins promote cytochrome C release from the mitochondria, whereas Bcl-2 proteins 
prevent this (Wang, 2001). Therefore, it has been suggested that these proteins control 
mitochondrial membrane integrity (Lindsten et al., 2000).
Alterations of the intrinsic pathway of apoptosis during carcinogenesis are much more 
common than alterations in the extrinsic pathway (Wallace-Brodeur and Lowe, 1999). The 
major contributor to alternations in the intrinsic pathway occurs through mutations that affect 
the p53 pathway. Mutations in the p53 gene are the most frequent mutations in cancer cells 
and its pathway is altered in most human cancers (Vousden and Lu, 2002).
Bcl-2, the first member of the Bcl-2 family of proteins was initially identified from a 
chromosomal translocation in B-cell lymphomas, hence the name Bel. Over-expression of the 
anti-apoptotic protein Bcl-2 leads to insufficient apoptotic turnover and accumulation of B- 
cells (Reed, 2006). This translocation is not only found in most cases of follicular B-cell 
lymphomas but also in other types of cancer such as breast, gastric, lung and prostate. 
Aberrant expression of most of the genes in the Bcl-2 family is linked to carcinogenesis 
(Hamilton and Piccart, 2000).
Members of Bcl-2 pro-apoptotic members act as tumour suppressor genes. Mutations in 
genes that code for pro-apoptotic proteins, such as deletion in the Bak and Bid genes, are
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characteristic of some tumours. Bax is mutated in over 50% of different classes of colon 
tumours (Reed, 2006).
Molecules involved in events downstream of the release of the mitochondrial apoptotic 
factors also play a role in tumourigenesis. The gene encoding Apaf-1, and the co-activator of 
caspase-9 is mutated and transcriptionally repressed in metastatic breast cancer (Mashima 
and Tsuruo, 2005).
1.6.2. Autophagy and Cancer
Autophagy is a conserved evolutionary process that can enable cells to maintain homeostasis 
(Cook et al., 2011). Autophagy (from the Greek, “auto” oneself, “phagy” to eat) means self­
eating, leading to the cellular degradative pathway that involves the delivery of cytoplasmic 
cargo to the lysosome. Three different forms of autophagy have been identified: chaperone- 
mediated autophagy, microautophagy, and macroautophagy. These types are differentiated 
with respect to the physiological function and the mode of cargo delivery to the lysosome 
(Klionsky, 2007). This study will focus on macroautophay (herein referred to simply as 
autophagy).
Autophagy is a lysosomal degradation pathway that is essential for survival, differentiation, 
development, and homeostasis and is established as a major regulated catabolic mechanism 
(White and DiPaola, 2009). Autophagy is also stress-responsive, making it important for the 
removal of damaged proteins and organelles. It serves to maintain cellular metabolism 
through recycling of cellular components in situations when the availability of external 
nutrient sources are limited (Mathew et al., 2007). In contrast to autophagic cell death as a 
tumour suppression mechanism, autophagy is a reversible process that can contribute both to 
tumour cell death and survival, depending on the environmental stimuli (Levine and 
Kroemer, 2008). It is notable that the importance of autophagy as a homeostatic and survival-
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promoting mechanism is understood by the association of autophagy defects in the aetiology 
of many pathological disorders, including neurodegenerative diseases, cardiomyopathy, 
Crohn’s disease, steatosis, infection, and cancer (Levine and Kroemer, 2008). One of the 
most remarkable feats within tumour cells is the activation of autophagy in response to stress 
including starvation, hypoxia, and factor deprivation, as a survival strategy. Progressive 
autophagy and selective cellular self-consumption is an effective survival mechanism, 
particularly when apoptosis is defective, which allows cells to become smaller and remain in 
a dormant state in the presence of stress. These apparently dormant tumour cells represent the 
minimal cells capable of recovery (MCCR), which retain the capacity to return to normal size 
and resume cell proliferation once the stressor is removed (White and DiPaola, 2009).
Although decades of research has unravelled the pathways that regulate apoptosis and 
allowed the development of novel diagnostic and therapeutic modalities in cancer treatment, 
only recently has the regulation and significance of tumour cell autophagy become the focus 
of investigations. Autophagy plays a dual role in cancer cell survival and death(Liu et al.,
2011). The autophagic cell death pathway is important in restricting cellular transformation 
and regulating protein degradation (Yang et al., 2011). Defects in protein degradation are 
often associated with cancer and several oncogenes and tumour-suppressor genes have 
collectively been shown to influence the autophagic pathway (Okada and Mak, 2004). Hence, 
mechanisms that inhibit this pathway may lead to tumour progression. Inhibition of 
autophagy disrupts the natural turnover of proteins that function as active regulators of cell 
growth. Thus, inhibition of autophagy promotes cell survival and stimulates cell growth in 
response to mitogenic signals(Kondo et al., 2005;Sridhar et al., 2012). The role of autophagy 
in cancer development is discussed in detail in chapter 5.
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1.6.3. Necrosis and Cancer
While apoptosis is a well-defined process at the molecular level, necrosis lacks a molecular 
signature and has been referred to as uncontrolled cell death (Ricci and Zong, 2006). Necrosis 
plays a role in a number of disease processes including vascular-occlusive disease, 
neurodegenerative diseases, infection, inflammatory diseases, exposures to toxins, trauma 
that causes a failure in normal cellular mechanisms, and cancer (Majno and Joris, 1995). Cell 
suicide by necrosis is referred to as unscheduled cell death and is signalled by irreversible 
changes in the nucleus and the cytoplasm. The fundamental features of necrosisinclude 
cellular energy depletion, damage to membrane lipids, and loss of function of homeostatic 
ion pumps/channels.
Unlike apoptosis, in which the Bcl-2 family of proteins and caspases play key roles, necrosis 
is induced by inhibition of cellular energy production, imbalance of intracellular calcium 
flux, generation of ROS, and activation of non-apoptotic proteases. These events often 
potentiate each other and synergize to cause necrosis (Marzo et al., 1998). For example, the 
imbalance in intracellular calcium flux and ROS production can lead to the stimulation of 
non-apoptotic proteases. Increased production of ROS causes oxidative stress that damages 
intracellular molecules and organelles resulting in necrosis (Ricci and Zong, 2006). ROS also 
cause DNA strand cleavage and oxidation of purines, as well as lipid oxidation, resulting in 
loss of membrane integrity that may lead to the influx of calcium, or leak of non-caspase 
proteases, causing necrosis (Mamett, 2000).
Although decades of research clarified the mechanisms that regulate apoptosis and allowed 
the development of novel therapeutic strategy to target cancer, only recently the significance 
of necrosis in cancer has become an area of research interest(Verdine and Walensky, 2007). 
Necrosis is considered a non-apoptotic, but discreteprocess with its own regulatory networks
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occurring as a consequence of cancer therapy (Amaravadi and Thompson, 2007). While 
apoptosis is basically an immunosuppressive process, it has been revealed that therapy 
induced necrotic cell death initiates an immune response to tumour cells. Whether the 
inflammation correlates with necrosis leads to further tumour growth is still under 
debate(Amaravadi and Thompson, 2007).
1.6.4. Interplay between cell death mechanisms
Understanding the relationship between necrosis, autophagy, and apoptosis is currently 
undergoingcritical analysis(Amaravadi and Thompson, 2007). The extensive characterisation 
of apoptosis has permitted the development of targeted therapies designed to induce apoptotic 
cell death. However, in most cancer types, there are a wide variety of genetic defects that can 
cause suppression of apoptosis and consequently allow cancer cells to survive (Verdine and 
Walensky, 2007).In cases where cells are genetically deficient in apoptotic machinery, 
autophagy was activated and protected the cell from death (Lum et al., 2005). It has also been 
revealed that autophagy can often be observed in cells undergoing necrosis. These outcomes 
propose that necrosis, autophagy and apoptosis can coexist within the same tumour (Verdine 
and Walensky, 2007).
1.7. Oestrogen signalling
The association between the risk of breast cancer and persistently elevated oestrogen levels 
has been conducted consistently in many subsequent studies (Yager and Davidson, 2006).A 
group of cancers are associated with a common mechanism of carcinogenesis that involves 
endogenous hormones as initiators. These hormone-related cancers include breast, ovarian, 
endometrium, testis, prostate, and thyroid cancer. This thesis specifically focusses on breast 
cancer as an example for hormonal carcinogenesis. The hormone oestrogen appears to play a
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central role in the stimulation and proliferation of breast epithelial cells, and has been 
implicated in the pathogenesis of breast cancer (Lee et al, 2008).
Oestrogen and oestrogen receptors (ERs) are key players in proliferation and differentiation 
of breast epithelial cells and also have a central role in female physiology, behaviour and 
reproduction (Riggins et al., 2007). Oestrogens are cyclopentanophenanthrene compounds 
whose synthesis begins with cholesterol, like other sex and adrenal hormones. In addition, 
androgens either androstenedione or testosterone are converted to oestrogens by the 
aromatase enzyme (Geisler et al., 1996). The three major naturally occurring oestrogens in 
the body are estrone (El), 17B-oestradioI (E2), and estriol (E3) (Ascenzi et al., 2006). The 
most abundant oestrogen in humans is 178-estradiol (E2), commonly referred to as oestrogen 
in this thesis, and has a potency approximately 80 times that ofoestriol (Coldham and James, 
1990). The principal site of oestrogen secretion changes with increasing age; the ovaries are 
the main source in premenopausal women, whereas adipose tissue (fat) is the main source in 
postmenopausal women (Howell et al., 2004). The steroid structure of oestrogen allows it to 
diffuse passively through the cytoplasm and then to the nucleus where it binds to its nuclear 
receptor. The widespread role for oestrogen in human physiology is also implicated with 
numerous pathological diseases such as osteoporosis, neurodegenerative and cardiovascular 
diseases, insulin resistance, lupus erythematosus, endometriosis, and obesity.
I
1.7.1. Oestrogen Receptor Subtypes
The effects of oestrogen are mediated through ERs, the interaction of which forms the basis 
for therapeutic intervention. ER belongs to a superfamily of nuclear receptors that includes 
other steroid hormone receptors. It is a ligand-regulated transcription factor that transduces 
hormonal signalling into a variety of physiological responses in different organs in the body 
(Ascenzi et al., 2006). In the late 1950s, Jensen and Jacobsen demonstrated the existence of a
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receptor molecule that could bind 17p-oestradiol (Dahlman-Wright et ah, 2006). It was 
believed that this was a single receptor and named ERa, until Kuiper et ah, in 1996 were able 
to clone another ER and named it ERp (Kuiper et ah, 1996).
Today, the two oestrogen receptors are still designated as ERa and ER8. The two structurally 
related proteins are products of two separate distinct genes (encoded by ESRl and ESR2, 
respectively). These genes are differentially expressed in different tissues. For instance ERa 
is responsible for oestrogen-induced mitogenic signalling in epithelial cells in the breast, 
uterine and ovarian tissues (Ali and Coombes, 2000), while ERB is more highly expressed in 
prostate, bone, lungs, and in various parts of the central and peripheral nervous system (Zilli 
et ah, 2009).
Clinical and experimental evidence has confirmed both ER isoforms are expressed at similar 
low levels in normal breast tissue (McDonnell and Norris, 2002). Whereas it has been found 
that ERa is stronger transcriptional activator than ERp and plays a crucial role in breast 
malignancies, it has also been observed that ERa is the only ER that detected by 
immunohistochemical analysis of breast cancer biopsies. At least 70% of breast cancer 
tumours are ER-positive and express mainly ERa (Fu et ah, 2011).
ERa and p proteins share common regions, designated as A/B, C, D, E, and F. These regions 
participate in the formation of independent but interacting functional domains (Ascenzi et ah, 
2006) as shown in figure 1-5. This illustrates the well-defined domain organisation of the two 
receptors, representing a significant overall sequence homology in the specific domains, as 
well as a high degree of similarity at the amino acid level. The transcriptional activity of ER 
is mediated by the two distinct activation function domains: AF-1 and AF-2. The N-terminal 
A/B domain includes the activation function 1 (AF-1), which is the region responsible for the 
constitutive and ligand-independent transcriptional activity of ER. The C domain, also known
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as DNA-binding domain (DBD), is responsible for receptor dimerization by binding to the 
oestrogen response element. The D domain is a flexible hinge region with a nuclear 
localisation signal that connects the C and E domains. The E domain is a ligand binding 
domain (LED) that contains the AF-2, which is responsible for the ligand-dependent activity 
of ER. The F domain is located at the extreme carboxy-terminus of the ERbut its role is not 
fully established. However, it does have a specific and complex modulatory function that 
affects the transcriptional activity of the liganded ER in cells (Skafar and Zhao, 2008;Zilli et 
ah, 2009).
ERa and (3 share a high degree of homology in their DBD and LED (figure 1-5). In contrast, 
the N-terminal A/B domain and the C-terminal F domain are the most variable regions (Hall 
and McDonnell, 1999). This variation might contribute to ER subtype actions on target genes. 
For instance, ER(3 displayed a weak AFl activity and demonstrated a different response to 
agonist and antagonist ligands compared with the ERa activation status (Schwartz et al.,
2002). These differences could have distinct functions in terms of gene regulation and the 
biological response to the different target tissues (Pearce and Jordan, 2004).
LBDDBD
AF-1 AF-2
A /BERa N — — C
A/BN —ERp
Figure l-5Schematic diagram of the structure of two human nuclear oestrogen 
receptors:ERa and ERp.Both receptors consist a well-defined functional domains, including the 
A/Bdomain at the N-terminus contains the ligand-independent transcriptional activation function 1 
(AFl), the C domain represents the DNA-binding domain (DBD) and contains anuclear localization 
signal (NFS), the D domain corresponds to the hinge region, the E domain harbors the ligand-binding
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domain and the ligand-dependent transcriptional activation function 2 (AF2) and the F domain at the 
C-terminus.
ER mediates its physiological effects on normal and cancerous breast tissue, either by ligand- 
activated transcriptional regulation known as genomic action (also known as nuclear-initiated 
steroid signalling (NISS)) or by acting as a component of membrane and cytoplasmic 
signalling cascades (non-genomic actions) also called as membrane-initiated steroid 
signalling (MISS). These mechanisms are explained further below (Zilli et ah, 2009).
l.T.l.l.Genomic ER signalling
Oestrogen influences the physiology of many target tissues and the long-term effects of 
oestrogen are mediated predominantly via ERs functioning as DNA-binding transcription 
factors. ERs regulate gene expression by both direct (classical) and indirect (non-classical) 
binding of an ER to DNA (Zilli et al., 2009). These pathways are both referred to as genomic 
or NISS pathways. In genomic signalling, ER functions as a ligand-dependent transcription 
factor and promotes expression of a variety of genes (Schiff et al., 2004).
Classical Genomic Mechanism
In the absence of oestrogen, ERs exists in the cell nucleus as inactive monomeric molecules 
bound to heat-shock proteins (Cheung and Smith, 2000). Oestrogen binds to the LBD of the 
receptor and undergoes a series of modifications including conformational changes, 
phosphorylation, dissociation from the chaperone proteins and homo- or hetero-dimerisation 
(Ring and Dowsett, 2004). The ER dimer binds to the oestrogen response element (ERE), 
which is located in the promoter region of the gene. Receptor dimerization also facilitates the 
binding of coregulatory proteins (CoA), which strongly enhance the transcriptional activity of
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genes involved in cell proliferation and survival and protein production (A scenzi et al., 2006). 
The binding m echanism  is shown in figure 1-6.
Key
ER Oestrogen receptor 
E Oestrogen
ERE Oestrogen Receptor Element 
CoA Coactivator
Protein
CoA
^  Transcription >  mRNA
ERE
GenePromoter
Figure l-6Theclassical genomic pathway of oestrogen action.Nuclear genomic (NISS) ER 
activity. ER, in its classic action, directly binds to DNA sequences called estrogen response elements 
(EREs) residing in the promoter region of target genes, and by recruiting coregulatory proteins 
regulates gene transcription. Estrogen (E)-bound ER generally recruits coactivators (CoA) to induce 
gene transcription.
Non-Classical Genomic Mechanism
Classical genom ic action is directly related to the ability o f ER  to regulate the expression o f 
genes containing the ERE sequence in their prom oter. In addition, ER can influence the 
transcriptional activity o f genes lacking E R E sequences, by what is know n as the non- 
elassieal m echanism . This does not require direct binding o f ER to DNA, m eaning that the 
non-elassieal pathw ay ean be activated in genes lacking an ERE (Renoir e t al., 2013)
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The prom oter elem ents involved in this m echanism  include activating pro tein  (AP-1) sites, 
cyclic A M P response elem ents (GRES) and S p l sites, which directly bind Jun/Fos, c- 
Jun/A TF-2, and S p l, respectively. F R  interacts with these transcription factors, it stabilises 
their direct binding to D N A  and thus stim ulates transcription activity (M aor et ah, 2006) as 
shown in figure 1-7.
ER Oestrogen receptor 
E Oestrogen 
CoA Coactivator
CoA Protein
A
CoA
Transcription mRNAJun ( Jun
AP-1
GenePromoter
Figure l-7The Non-classical genomic pathway of oestrogen action.ER, in its non-classic 
action, FR regulates gene transcription via protein-protein interaction (e.g., with the Fos/Jun family 
members) at DNA sites responsive to other transcription factors such as AP-1.
V ia both classical and non-classical pathw ays, oestrogen is able to stim ulate gene 
transcription and regulate cell proliferation and survival only if  A F l and /or AF2 are 
activated. A ctivation is based both on the cellular environm ent and the specific prom oter 
type. E ither A F l or AF2 can be dom inant, but generally the activation function occurs by the 
synergistic activity o f both. However, A F2 activation is totally ligand-dependent. The binding 
of oestrogen to FR  induces a rearrangem ent o f the F E D  helices 3, 5, and 12, with the creation
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of a hydrophobic cleft, where specifieally orientated helix 12 seals the hormone inside and 
uncovers the AF2 region. This region serves as a binding surfaee for proteins containing a- 
helical leucine-rich peptide motifs or NR boxes, which act as coactivators or corepressors of 
ER (coheetively named coregulatory proteins) (MeKenna et al., 1999).
The most studied coaetivators are members of the p i60 family of nuclear-receptor 
coaetivators, including: nuclear-receptor coactivator 1 (NCoAl), also known as steroid 
reeeptor eoaetivator 1 (SRC-1); NCoA2, also known as SRC-2, or translation initiation factor 
2 (TIF2); and NCoA3, also known as amplified in breast cancer 1 (AIBl), or SRC-3 (Leo and 
Chen, 2000). Binding of these molecules to AF2 enhances transeriptional activity of FR by 
forming large complexes that recruit histone-acetyltransferase (HAT), an enzyme causing the 
chromatin decondensation required for gene transcription.
In contrast to AF2 function, AFl is ligand-independent and activated by phosphorylation at 
serine residues following the aetivation of kinase pathways such as p42/p44 mitogen- 
activated protein kinase (MARK), phosphatidylinositol 3 kinase(PI3K), and Akt. Growth 
factor receptors such as epidermal growth factor receptor (FGFR), insulin-like growth factor- 
1 receptor (IGFR), and human epidermal growth faetor receptor type 2 (HFR2) have been 
implicated in triggering these pathways (Ring and Dowsett, 2004). The mechanism 
underlying the ability of oestrogen to induce AFl activity is not well understood at this point. 
It is, however, important to note that in the absence of oestrogen, minimal phosphorylation is 
responsible for constitutive AFl activity and that growth factor signalling pathways can 
directly activate FR and subsequent transeription (Frasor et al., 2003).
1.7.1.2.Nongenomic ER action
In contrast to the genomic pathway, FR functions can be initiated independently of gene 
transeription. This is known as non-genomic mechanism of action or membrane-initiated
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steroid signalling (MISS) pathway, which occurs rapidly in the cell (in seconds to minutes). 
This rapid mechanism of action is mediated by membrane-associated ER via a population of 
ERs that exists within caveolin rafts and a variety of proximal signalling molecules, ineluding 
G-proteins, Sre and Ras, and B-Raf. Activation of these ERs results in signal cascades from 
G-protein activation. Similar to many other G-protein coupled receptors, G-protein activation 
by ER leads to the cell-speeifie stimulation of phospholipase C, protein kinase C, PI3K, Akt 
and ERK (Razandi et al., 2003). The activation of these kinases has the ability to aetivate 
growth faetor receptors sueh as EGFR(HERl), HFR2 and IGFRl, which may in turn, 
phosphorylate FR and its coregulators, resulting in the activation of nuclear FR-driven 
transcription (Santeusanio et al., 2000) as shown in figure 1-8.
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Figure l-8The Non-genomic pathway of oestrogen action.Upon stimulation by growth 
factors, ERa is able to initiate cytoplasmic signalling cascades, such as the MAPK and PI3K 
pathways. ERa is phosphorylatcd in the non-genomic pathway by a growth factor receptor (GFR) in a 
ligand-independent manner and can promote unregulated gene transcription.
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Altogether, these observations suggest that the genomic and non- genomic activities of ER 
are complementary and also synergistic. Therefore, the ER and GFR pathways have been 
established as a bidirectional functional activation leading to amplification of the growth 
signal (Shou et ah, 2004).
The cross-talk between ER andgrowth factor signalling is explained further in chapter 2 as a 
potential mechanism of resistance to anti- endocrine therapy.
1.8. Management and treatment of breast cancer
Breast cancer management has become progressively complex and involves a comprehensive 
assessment of multiple tasks such as simple extirpation of the primary tumour, breast 
imaging, advanced pathology, and a variety of therapies, both local and systemic. This has 
reallocated breast cancer management into a multidisciplinary science (Veronesi et al., 2002). 
Several of the most common management and treatment strategies are discussed in the 
following sections.
1.8.1. Surgery and Radiotherapy
Surgery is considered the main and essential standard treatment. Surgical procedures on the 
breast are performed based on the breast surgery guidelines prior to the use of systemic 
chemotherapeutic agents (Kaufmann et al., 2007).Different factors must be taken into account 
that influences the success of breast cancer surgery. These factors include tumour size, 
lymphatic invasion, nodal status, and spread of microcalcifications (Chen et al., 2005).
Treatment of patients with early stage breast cancer involves either breast-conserving surgery 
(BCS) or mastectomy, which is the total removal of the breast (removing the breast tissue, 
nipple-areola complex and skin).Mastectomy is one type of surgical management for
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metastatic breast cancer. Lumpectomy is a common procedure designed to remove a discrete 
lump(Ballard and Momoh, 2014).Another option in surgical treatment is 
subcutaneousmastectomy, which is the removal of breast tissues only, sparing the nipple- 
areola complex,skin and nodes (Arrington et al., 2014). Surgical intervention has the potential 
to impact a patient's quality of life (QOL) across several domains and therefore options 
should be considered carefully. For instance, body image is one domain related to QOL that 
can be influenced by the type of surgical procedure that a breast cancer patient receives 
(Collins et al., 2011).
Surgical procedures are often followed by some combination of radiation, chemotherapy, 
and/or anti-endocrine therapy. Post-surgical treatment with radiotherapy is highly 
recommended for the majority of breast cancers. Early trials clearly demonstrated that 
radiotherapy reduced the risk of relapse, with a relative risk reduction that is now known to 
be about 70% (Cuzick, 2005;Veronesi et al., 2001).
1.8.2. Chemotherapy
Chemotherapy by itself can be classified as neo-adjuvant chemotherapy (chemotherapy prior 
to operation) or adjuvant (chemotherapy after operation). Neo-adjuvant chemotherapy may 
be applied in situations where the breast tumour is large or locally advanced, in order to cause 
shrinkage and subsequently make it easier to remove surgically. On the other hand, adjuvant 
chemotherapy is given to reduce the risk of relapse and increase the likelihood of overall 
survival. Breast cancer patients may receive a combination of these treatments depending on 
the type of breast cancer, the size of the breast tumour, the stage and grade of the cancer cells 
(Lee et al., 2014).
Chemotherapeutic agents are grouped according to mechanism of action, but all act by 
chemically inhibiting the growth and survival of cells, with a more potent effect on those that
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are cancerous. The types of chemotherapeutic agents in use are discussed in the following 
sections; an overview of their structures is given in Figure 1-9.
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a) Cyclophosphamide b) Capecitabine
c) Methotrexate d) Doxorubicin
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e) Paclitaxel f) Docetaxel
Figure l-9Structures of commonly used chemotherapeutic agents.
I.8.2.I. Alkylating agents and platinum-based drugs
Alkylating agents and platinum-based drugs are highly reactive compounds that act via a 
similar mechanism. Alkylating agents have the ability to impair cell function by forming 
covalent bonds with an alkyl group of a base, causing cross-linking and abnormal base
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pairing of DNA strands. This ultimately leads to the inhibition of transcription and replication 
and eventually causes cellular death, especially in those cells that undergo rapid cell division, 
such as cancerous cells.
Cyclophosphamide has been the most widely used of the alkylating agents because of its 
efficacy against a variety of tumours (Peters et al., 1988;Steams et al., 2004). The drug 
requires metabolic activation in the liver to produce 4-hydroxycyclophosphamide; the main 
active metabolite of cyclophosphamide. This metabolite spontaneously establishes an 
equilibrium with its tautomer, the amino-aldehyde aldophosphamide (Mahoney et al., 2003). 
Most of the aldophosphamide is oxidised by the enzyme aldehyde dehydrogenase (ALDH) to 
produce the inactive metabolite carboxyphosphamide. The aldophosphamide that escapes 
enzymatic oxidation by ALDH then undergoes an enzyme-independent elimination reaction 
to yield phosphoramide mustard as a main metabolite and acrolein as a by-product. It is this 
by-product that has been associated with bladder toxicity (Hensley et al., 1999).
Phosphoramide mustard is generally considered to be the active alkylating agent responsible 
for the cross-linking of DNA by altering the conformation of the double helix, preventing 
separation of the DNA strands, and interfering with DNA replication. Thus, phosphoramide 
mustard is the metabolite responsible for the biological and clinical effects of 
cyclophosphamide (Mahoney et al., 2003).
The most common side effects of cyclophosphamide in human recipients are 
myelosuppression, predominantly leukopenia; nausea and vomiting; skin and nail 
pigmentation; hair loss (alopecia); and loss of fertility. Haemorrhagic cystitis is a long-term 
complication of cyclophosphamide treatment due to the effects of acrolein on the bladder 
(Steams et al., 2004).
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Cisplatin and carboplatin are the main examples of platinum-based compounds commonly 
used in cancer treatment. These agents have the ability to form covalent bonds with DNA via 
the platinum atom and are active during all stages of the cell cycle, leading to the inhibition 
of DNA synthesis and the impairment of transcription and replication (Kelland, 2007).
Cisplatin was first used clinically in 1970 for the treatment of metastatic breast cancer (MBC) 
in patients who were refractive to other forms of chemotherapy (Henderson, 1983). Since 
then, several studies have indicated a significant clinical response to cisplatin in patients with 
MBC who have no previous exposure to chemotherapy (Steams et al., 2004). Moreover, 
many studies have shown the synergistic effects of cisplatin when used in combination with 
other pharmacological anti-cancer agents, especially those diagnosed with MBC(Raymond et 
al., 2002;Shamseddine et al., 1999). The combination of cisplatin and paclitaxel treatment is 
marginally effective for the treatment of MBC patients, as demonstrated by Comella et al., 
who administered the dmgs in a conventional weekly scheme to 43 patients. An overall 
response rate of 52% in the evaluable patients who had not previously been treated with 
chemotherapy was encountered in this study (Comella et al., 2000). Numerous preclinical 
studies have also reported a synergistic interaction between the humanized monoclonal 
antibody, trastizumab and cisplatin in human breast cancer cells over-expressing the HBR2 
gene product (Gravalos et al., 201 l;Stemmler et al., 2005).
Dose limiting nephrotoxicity is the main problem associated with the clinical use of cisplatin, 
and carboplatin has since been identified as a less toxic platinum-based altemative (Arany 
and Safirstein, 2003). Clinical studies evaluating the synergistic activity of carboplatin in 
combination with docetaxel and trastuzumab are currently under investigation(Perez,
2004).The preliminary outcomes are very promising for women with MBC and in those who 
over-express HER2 (Pegram et al., 2004;Perez, 2004).
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I.8.2.2. Anti-metabolites
Anti-metabolites and nucleotide analogues are compounds that are structurally similar to 
intracellular molecules that are essential for cell function and replication, respectively. These 
compounds are therefore able to mimic metabolic pathways and disrupt nucleic acid function. 
Common examples of this drug class include methotrexate and 5-fluorouracil (5-FU); these 
are both described in more detail below.
Methotrexate is a competitive inhibitor of the enzyme dihydrofolate reductase (DHFR); the 
enzyme responsible for the generation of tetrahydrofolate, which is required for purine and 
pyrimidine synthesis. Consequently, inhibition of this enzyme leads to depletion of 
chemically reduced folate and cessation of nucleotide and protein synthesis (Uga et al.,
2006). Methotrexate has also been widely used to treat certain types of cancer such as breast, 
skin, head and neck, or lung. It may also be used for other indications such as severe psoriasis 
and rheumatoid arthritis (Dabkowska and Dabkowski, 2001) Clinically, the most widely used 
and oldest regimen in the management of breast cancer is to administer cyclophosphamide, 
methotrexate, and 5-FU in combination (Harbeck et al., 2010;Steams et al., 2004)
5-FU, a pyrimidine analogue, is a commonly used chemotherapeutic agent with activity 
against a variety of solid tumours. These include tumours of the head and neck, breast, 
pancreas, liver, and genitourinary and gastrointestinal systems (Steams et al., 2004). 5-FU is 
a uracil derivative that acts principally as a thymidylate synthase (TS) inhibitor, interrupting 
the synthesis of the pyrimidine thymidine. Thymidine is one of the four essential nucleotides 
required for DNA replication, and its deficiency induces cell death.
5-FU is usually given intravenously (IV), but the oral pro-dmg of 5-FU known as 
capecitabine is broadly used in patients with MBC who are resistant to anthracyclines and 
taxanes. The combination of capecitabine and ixabepilone demonstrates superior survival
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efficacy than capecitabine alone when used to treat tumours refractory to anthracyclines and 
taxanes (Sparano et al., 2010). Ixapebilone is in the epothilone class of chemotherapeutic 
agents, exerts cytotoxic affects by microtubule destabilization block mitosis and cell 
proliferation by targeting the dynamics of the cytoskeleton. (Puhalla and Brufsky, 
2008).Clinical trials have demonstrated that the usefulness of this combination treatment is 
limited due to the occurrence of multiple common side effects. These include 
myelosuppression, particularly leukopenia; nausea and vomiting; sensory peripheral 
disturbances; muscle pain (myalgia); and pigmentation of the nails when used at higher doses 
(Roche et al., 2011)
I.8.2.3. Anthracycline antibiotics
The history of anthracycline antibiotics (doxorubicin and daunorubicin) can be traced back 
over 30 years. Doxorubicin and daunorubicin are among the most widely used 
chemotherapeutic agents in current clinical practice(Wojtacki et al., 2000). They are 
especially active against several types of cancer including Hodgkin's disease, leukaemia, 
non-Hodgkin's lymphoma, neuroblastoma, sarcomas of the bone and soft tissues, as well as 
carcinoma of the breast, lung, ovary, stomach and thyroid (Hamilton and Hortobagyi, 2005). 
More specifically, doxorubicin is currently used principally for the treatment of the solid 
tumours, especially breast and lung cancer (Henderson et al., 2003).
An important advance in understanding the mechanism of anti-tumour activity was the 
finding that doxorubicin forms a complex with DNA by intercalating between base pairs.
This interaction leads to the formation of free radicals and the subsequent inhibition of 
topoisomerase 11. This enzyme, associated with the nuclear matrix, plays a critical role in 
releasing torsional stress during DNA replication, by trapping single-strand and double-strand 
DNA intermediates. Inhibition of this function results in cell cycle arrest and ultimately, cell
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death (Jackson, 2003). Doxorubicin diffuses across cell membranes and accumulates in most 
cell types and therefore results in widespread cell damage. The major limiting factor in the 
clinical use of doxorubicin is cardiac toxicity, but the development of analogues such as 
epirubicin is being investigated in order to lessen the risk of cardiac toxicity (Piccart et al.,
2001).
Adjuvant chemotherapy with anthracyclines has been shown to be superior in the treatment 
of early stage breast cancer compared with non-anthracyclin-based adjuvant chemotherapy 
regimens(Giordano et al., 2012). Clinical investigators have demonstrated that the added 
benefit of adjuvant treatment with anthracyclines is mainly confined to women with over­
expression or amplification of HER2 in breast tumours (Press et al., 2008)
An increasing number of clinical trials investigating the efficacy of adjuvant anthracycline- 
based regimens compared with the classical combinatorial regimens of cyclophosphamide, 
methotrexate and 5-FU for the treatment of node-positive breast cancer are in 
progress(Ferreira Filho et al., 2002). The results show that adjuvant therapy with 
anthracyclines is more efficient at improving disease-free and overall survival rates 
(Hamilton and Hortobagyi, 2005). This finding has been mainly observed in pre-menopausal 
women with node-positive breast cancer. A study by Piccart and colleagues aimed to 
compare a high-dose epirubicin-cyclophosphamide regimen (HEC) with a moderate-dose 
epirubicin-cyclophosphamide regimen (EC) in the adjuvant therapy of node-positive breast 
cancer, in pre- and post-menopausal subgroups. The study showed a statistically significant 
difference in favour of the HEC regimen over the EC regimen, with regard to improvement of 
survival (Piccart et al., 2001)
65
Chapter 1 Introduction
I.8.2.4. Microtubule inhibitors
Taxanes are an important new class of anticancer agent that exert cytotoxic effects on 
microtubules by a unique mechanism of action. Paclitaxel was discovered as a part of a 
National Cancer Institute progranune in which extracts of thousands of plants were screened 
for anticancer activity (Steams et al., 2004). A natural product was isolated from the bark of 
the Pacific Yew known as Taxus brevifolia(CTagg, 1998), and paclitaxel was named as the 
active constituent of the extract. In addition, later work found that the precursor of paclitaxel 
could be isolated from other members of Yew species, such as Taxus baccata. The isolation 
of such precursors means that it is likely to be possible to produce sufficient quantities to 
meet the commercial demand (Roy and Thompson, 2006).
Paclitaxel was approved in the US by the food and dmg administration (FDA) for the 
treatment of several malignancies, such as ovarian cancer in 1992, and advanced breast 
cancer in 1994 (Braakhuis et al., 1994). Paclitaxel displays a high affinity for binding to 13- 
tubulin subunits in a mitotic spindle position during mitosis. It works by stabilising 
microtubules against depolarization and enhancing microtubule assembly (McGrogan et al., 
2008). This results in inhibition of cellular proliferation by inducing a sustained mitotic block 
at the metaphase-anaphase boundary. A number of studies have suggested that using a 
combination of paclitaxel and doxombicin is significantly better than using single-agent 
chemotherapy with either with doxombicin or paclitaxel alone (Sledge et al., 2003).
Docetaxel is a semi-synthetic analogue of paclitaxel, which is clinically established as a 
potent anti-microtubule formation agent (Gligorov and Lotz, 2004) It has been shown to be 
effective against a range of tumours, such as advanced breast cancer, head and neck tumours, 
and ovarian tumours refractory to conventional chemotherapy. Four separate studies have 
indicated that the combination of docetaxel plus anthracycline produces a higher response 
compared with single-agent anthracycline. In addition, clinical data has shown that docetaxel
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plus capecitabine has an advantage in MBC pre-treated with anthracycline regimens(Gelmon 
et al., 2006;Leonard et al., 2006;Mandelblat et al., 2006;Saeki and Takashima, 2004).
1.8.3. Hormonal treatments (Anti-endocrine therapy)
1.8.3.1.The concept of anti- endocrine therapy for breast cancer
The revolution of anti-endocrine therapy in the treatment of breast cancer was first 
acknowledged over a century ago when surgeon Sir George Beatson preformed an 
oophorectomy on a patient with advanced breast cancer and showed improvement and 
dramatic cure after bilateral oophorectomy (Beatson, 1896). His discovery suggested a new 
method for breast cancer treatment and since then he has been called the father of 
anti-endocrine ablation in breast cancer management. At that time, he had no knowledge of 
the ER, but simply noted that removing of the ovaries caused a significant reduction in 
endogenous oestrogen level and a regression in breast cancer growth (Stockwell, 1983).
A meta-analysis of 51 epidemiologic studies enrolling 161,116 women to investigate the 
relationship between the risk of breast cancer and the use of hormone replacement therapy 
(HRT) showed that breast cancer diagnosed increased by 2.3% per year among women who 
use HRT (Calvo-Romero, 2001). These results clarify that hormone use increases the risk of 
developing breast cancer and support the crucial role of oestrogen in the pathogenesis and the 
development of breast cancer (Cheung, 2007).
Allen and Doisy observed the fact that double-oophorectomy abolishes the cyclic changes 
that normally occur in the genital tract of female manunals and hypothesised that these 
changes were due to some influence from the ovaries (Allen and Doisy, 1983). Oestrogen 
discovery brought lots of questions regarding the mechanism by which oestrogen exerts its 
tissue-specificity and the possibility of blocking oestrogen action.lt was identified that
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oestrogen mediates its effect through specific receptors without changes to the hormone 
itself. This discovery opened the door to a molecular approach for targeting breast cancer to 
provide treatment and prevention (Jensen and Jordan, 2003). Two thirds of breast cancer 
tumours express ER; therefore, ER-targeted therapy is widely applied in clinics to inhibit 
signalling through ER and reduce cell growth (Massarweh and Schiff, 2007).
1.8.3.2.Therapeutic approaches to target oestrogen activity
Since the link between breast cancer and oestrogen was discovered over a century ago, 
attempts have been made to antagonise the biological effects of oestrogen as a therapeutic 
strategy for women with breast cancer. Functional oestrogen antagonism may have huge 
benefits on a woman’s health by interfering with normal oestrogen-regulated targets 
(Heldring et al., 2007).
A number of hormonal therapeutic agents that target oestrogen action are available. For more 
than three decades, anti-oestrogen hormonal therapy (Anti-endocrine therapy) has been a 
commonly used treatment for women with ER-positive breast cancer, i.e. women whose 
tumours express ER. At least 70% of breast cancers are classified as ER-positive. Several 
effective options for the treatment of breast tumours that express ER include: selective ER 
modulators (SERMs), such as tamoxifen; selective ER down-regulators (SERDs), such as 
fulvestrant; and aromatase inhibitors such as anastrazole(Lewis and Jordan, 2005)
Selective oestrogen receptor mediators (SERMs)
The SERMs represent a major therapeutic advance in the treatment of breast cancer and 
provide benefits for clinical practice. They are a chemically diverse group of compounds that 
lack the steroid structure of oestrogens. Though the primary structure of SERMs differs 
strikingly from that of oestrogens as shown in figure I -10, the tertiary structure permits
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binding to the LBD of the ER. SERMs exert selective agonist or antagonist effects on various 
oestrogen target tissues. Several of these therapeutic agents have been available for decades. 
The current clinically available SERMs are tamoxifen, toremifene, and raloxifene, which all 
differ slightly in their actions and side effects(Riggs and Hartmann, 2003). The specific 
mechanism of action of SERMs is described below, using tamoxifen as an example.
OH
CH,
HO
17p-Oestradiol Tamoxifen
OH
HO HO
Toremifene Raloxifene
Figure 1-lOChemical structures of 17p-Oestradiol and the three FDA-approved 
SERMs.
Tamoxifen
Tamoxifen has been used in the clinic for more than 30 years. It is the most widely used and 
gold-standard anti-oestrogen for the treatment of ER-positive tumours and advanced breast 
cancer in both pre- and post-menopausal women. On June 1, 1992, the National Surgical 
Adjuvant Breast and Bowel Project (NSABP) implemented a randomized clinical trial to 
value the worth of tamoxifen for the prevention of breast cancer in women considered to be at
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increased risk for the disease. The NSABP found that the incidence of breast cancer was 
reduced by 50% in women who were treated with tamoxifen versus placebo-treated controls 
(Fisher et al., 1998). In 1999,tamoxifen also became the first cancer chemopreventive 
approved by the FDA for the reduction of breast-cancer incidence in both pre- and post­
menopausal women at high risk. (Gail et al., 1999).
The World Health Organization (WHO) records tamoxifen as an essential drug with an 
important role in the treatment of breast cancer(Love and Koroltchouk, 1993). It is estimated 
that more than 400,000 women are alive today as a result of tamoxifen therapy, and millions 
more have benefited from palliation and extended disease-free survival. By acting as a weak 
ER agonist in the bone, tamoxifen also reduces bone loss(Jordan, 2003). In addition, 
treatment induces a beneficial serum lipid profile by decreasing low-density 
lipoprotein(LDL) levels(Filippatos et al., 2009;Morales et al., 1996). However, tamoxifen 
therapy is also associated with an increase in the risk of endometrial cancer, because of its 
actions as a partial agonist in the endometrium(Swerdlow and Jones, 2005). Nevertheless, 
there have been numerous studiesdemonstrating efficacy of tamoxifen for the treatment and 
prevention of ER-positive breast cancer(Swaby et al., 2007).
Tamoxifen acts by blocking the binding of oestrogen to its receptor and promotes corepressor 
interactions that prevent activation of general transcriptional factors, as shown in figure 
(l-ll)(Knowiden et al., 2003).Laboratory trials using human breast epithelial cells in vitro 
indicated that the anti-oestrogen mechanism of tamoxifen in breast cancer can lead to either a 
cytostatic or a cytotoxic response(Preis et al., 2006). The former is defined as a cell growth 
arrest, which is mediated by protein inhibitors of CDKs, especially and P27^'^\ while
the latter signifies cell death leading to tumour shrinkage and regression by a mechanism still 
under investigation (Litsas, 2008). These studies are consistent with the observed clinical 
efficacy of anti-oestrogen (tamoxifen) therapy to inhibit cell proliferation and prolong
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survival. Additionally, tamoxifen is used to prevent the process of carcinogenesis in 
premalignant cells, classifying it as a chemoprevention agent (Jones et al., 2008)
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Figure 1-llMechanism of action of tam oxifen.Tam oxifen leads to ER association with 
corepressor complexes (COR), thus turning off gene transcription.
Selective oestrogen receptor down regulators (SERDS)
The agonist effects of tamoxifen and the development of endocrine resistance have led to the 
development of new hormonal therapeutic known as selective oestrogen receptor 
downregulators (SERDs) also termed pure anti-oestrogens. These have no agonist activity 
and augmented antagonist potencycompared with tamoxifen(Johnston, 2010).
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Fulvestrant
Fulvestrant is a pure anti-oestrogen and has shown promising clinical activity (Johnston,
2005). It has a novel mechanism of action distinct from any other hormonal therapy and is 
used clinically for the treatment of ER-positive metastatic breast cancer. Fulvestrant is used 
mainly for post-menopausal women with disease progression or relapse following adjuvant 
anti-endocrine therapy with drugs such as tamoxifen (Howell et al., 2004).
Fulvestrant is a competitive inhibitor that supresses the binding of oestrogen to the BR with a 
binding affinity that is significantly greater than that of tamoxifen. The fulvestrant-BR 
complex impairs receptor dimerization and energy-dependent nucleo-cytoplasmic shuttling. 
Any fulvestrant-BR complex that enters the nucleus is therefore transcriptionally inactive 
(Figure 1-12). Finally, the fulvestrant-BR complex is also unstable, resulting in degradation 
of the BR protein and complete inhibition of oestrogen action mediated by the BR (Osborne 
et al., 2004).
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Figure l-12M echanism  of action of fulvestrant.Fulvestrant binds to oestrogen receptor 
response elements (EREs) competitively, leading to rapid degradation of ER and loss of target 
protein.
Aromatase inhibitors
This type of drug interferes with oestrogen synthesis by inhibiting the enzyme aromatase that 
converts androgen to oestrogen. Aromatase is the main source of oestrogen production in 
post-menopausal women. Therefore, aromatase inhibitors effectively reduce the level of 
oestrogen in the body of post-menopausal ER-positive breast cancer patients as shown in 
(Figure 1-13) (Mokbel, 2002). Clinical trials have indicated that aromatase inhibitors, such 
as anastrazole, should be considered as a first-line treatment and adjuvant therapy in post­
menopausal ER-positive breast cancer (Osborne et al., 2002). Furthermore, investigations
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have confirmed that anastrazole has superior efficacy to tamoxifen in post-menopausal breast 
cancer patients (Nabholtz^f al 2000).
H,C
Aromatase inhibitor 
( Anastrazoie)
H3C
Androgen Aromatase Oestrogen
Figure l-13M echanism  of action of an aromatase inhibitor such as anastrazole.Aromatase
inhibitors stop the production of oestrogen by blocking the enzyme aromatase, which turns the 
hormone androgen into small amounts of oestrogen in the body. This means that less oestrogen is 
exacting to stimulate the growth of hormone-receptor-positive breast cancer cells.
1.8.4. New targeted therapies
1.8.4.1.The concept of new targeted therapy
Targeted therapies are classified as agents that block the growth of cancer cells by interfering 
with specific pathways in carcinogenesis and tumour growth. This is more sophisticated than 
simply interfering with rapidly dividing cells, like conventional chemotherapy does, which 
affects both malignant and normal tissues including hair follicles, the lining of the bowel, and 
bone marrow. Therefore, conventional chemotherapeutic agents are usually characterized by
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low specificity and considerable side effects. By contrast, targeted therapy allows for a 
specific target inhibition with an acceptable side-effect profile. In addition, when used in 
combination with conventional chemotherapy, they are more effective at blocking growth 
signals for cancer cells and improve the response to treatment without notably increasing side 
effects (Muss, 2006).
New targeted therapies hold particular promise for the treatment of breast cancer. For 
instance, HER2 is overexpressed in about 30% of breast caneers, and therapies targeting 
aetivity of this protein, such as the monoelonal antibodies trastuzumab (Herceptin®) and 
bevacizumab (Avastin®) are used in cIinics(BiekneIl, 2006). Additionally, small-molecule 
tyrosine kinase inhibitors (TKIs) are currently in clinical use for advaneed and metastatie 
HER2 positive breast cancer patients such as lapatinib, gefitinib, and afatinib.
The HER2 proto-oneogene is amplified in 20%-25% of human primary breast cancers and 
this alteration is associated with poor elinical patient prognosis in breast cancer (Weiner and 
Zagzag, 2000). It has been shown in several studies that both EGER and HER2 are linked 
with increased cell proliferation, decreased apoptosis, metastasis, and development of 
resistance to chemotherapy and radiotherapy (Repetto et al., 2005)Thus, small molecule 
inhibitors that inhibit both HER land HER2 would be therapeutieally advantageous in the 
treatment of breast cancers (Zlobec et al., 2007).
EDER/ERBB-targeted therapeutics
The potent role of HER 1/EGER and HER2/ERBB2 in promoting tumour growth and survival 
make them attractive therapeutic targets. Drugs that are used clinically comprise monoclonal 
antibodies and other drugs including the tyrosine kinase inhibitors (TKl) (see Table 1-5).
Both strategies ultimately lead to inhibition of the signal transduction cascade and thereby
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decrease cell proliferation, stop cancer progression and metastasis, and enhance several 
molecular consequences that promote apoptosis as shown in (Figure 1-14).
Table l-5ExampIes of new-targeted therapies for breast cancer used clinically.
Trastuzumab (Herceptin®) HER2
Pertuzumab (Omnitarg®) HER2
Cetuximab (ERBitux®) HERl
Gefitinib (Iressa®) HERl
Erlotinib (Tarceva®) HERl
Lapatinib (TykeRB®) HERl /HER2
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Figure l-140verview of the mechanisms of action of new targeted therapy drugs.There
are multiple strategies for interfering with HER1/HER2 signalling. These include monoclonal 
antibodies such as trastuzumab (Herceptin®) that bind to HER2. This prevents the receptor from 
activating the pathways that promote proliferation and survival and small molecule inhibitors that 
inhibit tyrosine kinases that responsible for the activation of many proteins by signal transduction 
cascades.. For instance lapatinib is known as a dual kinase inhibitor because it targets both HER2 and 
HERl receptors, whereas gefitinib is anHER 1 inhibitor.
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Monoclonal antibodies
Several companies have developed monoclonal antibodies for selective breast cancer 
treatment. These usually cannot penetrate the cell membrane, but are directed against targets 
on the cell surface. Amongst these, the drug trastuzumab (Herceptin®) has been the focus of 
many clinical studies(Amould et al., 2006). Trastuzumab is a monoclonal antibody (as shown 
inFigure 1-15) that binds to the extracellular domain of HER2 with high affinity.
Trastuzumab was approved by the U.S. FDA for the treatment of metastatic breast cancer in 
1998.Two clinical trials were conducted to compare the efficacy of adjuvant chemotherapy 
with or without concurrent trastuzumab. Trastuzumab combined therapy resulted in 50% 
reduction in recurrence rate, and also a 33% reduction in the mortality rate(Piccart-Gebhart et 
al., 2005). However, because a number of women with HER2-positive breast cancer 
experience disease progression while on trastuzumab treatment(Bartseh et al., 2007), and not 
all patients with HER2 overexpression benefit from trastuzumab, investigators were led to 
develop alternative mechanisms for disturbing receptor tyrosine kinase signalling.Such an 
alternative mechanism is demonstrated by tyrosine kinases inhibitors (TKIs)(Figueroa- 
Magalhaes et al., 2013).
Figure l-15Structure of trastuzumab.Taken from (Novel & Potent Kinase Inhibitors, 2005).
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Tyrosine kinase inhibitors (TKIs)
TKIs are effective and potent in the targeted treatment of various malignancies. Imatinib was 
the first to be introduced into clinical oncology, and was followed by other medications such 
as gefitinib, erlotinib, sorafenib, sunitinib, and dasatinib (Hartmann et al., 2009). Even though 
they share the same mechanism of action, namely competitive ATP inhibition at the catalytic 
binding site of tyrosine kinase, they behave differentily from each other in the spectrum of 
targeted kinases(Muss, 2006). Among the TKIs that are commercially available, the agents 
such as erlotinib, afatinib and gefitinibtarget only EGFR, whereas lapatinib and afatinib are 
typically able to diffuse into cells and act on intracellular targets to inhibit both EGFR and 
HER2 (McArthur, 2009)With variations from drug to drug, TKIsgenerally cause skin 
toxicity, including folliculitis, in more than 50% of patients(Hartmann et al., 2009).
Periorbital edema is a common adverse effect of imatinib. Besides, the haematological side 
effects of most of TKIs like anaemia, thrombopenia and neutropenia, TKIs often 
causenausea, hypothyroidism, vomiting and diarrhoea(Moy and Goss, 2007). However, these 
observationsare probably related to patient-selection. Overall, TKIs seem to be a very well- 
tolerated drug class compared with other chemotherapeutics (Moy and Goss, 2007). 
Clinically, it has demonstrated that patients with breast cancer get benefit from lapatinib, 
gefitinib and afatinib(0'Neill et al., 2013). The mechanism of each drug is discussed further 
in chapter 4.
PI3K inhibitors and mTOR inhibitors
The PI3K/Akt/mT0Rpathway plays a major role in breast cancer cell proliferation and 
progression.The mammalian target of rapamycin (mTOR) is a downstream effector of the 
PI3K/Akt signalling pathway (Schmelzle and Hall, 2000). Mechanisms involved in the 
activation of this pathway include: constitutive receptor tyrosine kinase activation of PI3K 
(IGF/IGFR, ERBB, FGF/FGFR systems). These alterations may trigger a cascade of events,
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regulating cell growth, proliferation, cell survival and migration, which ultimately contribute 
to tumour growth (Gingras et al., 1999). Approaches to targeting these pathways include 
either PI3K inhibitors, such as LY294002, or mTOR inhibitors, such as temsirolimus (CCI- 
779) and everolimus (RAD-001) (Morgan et al., 2009). The PI3K/ mTORsignalling pathway 
is frequently deregulated in breast cancer and it has reported that breast cancer cell lines are 
sensitive to mTOR antagonism (Miller et al., 2010).
In addition, promising preclinical data suggest a possible synergistic effect when mTOR 
inhibitors are combined with hormonal therapy and clinical trials are still ongoing(Yardley,
2013).The first phase II study assessing the combination of temsirolimus,the mTOR inhibitor 
and letrozole, ananti-oestrogen agent in MBC patients found a longer median progression- 
free survival (13.2 months ver^M l^ 1.6 months), in comparison with letrozole alone (Fedele 
et al., 2012).
Poly (ADP-ribose) Polymerase (PARP) inhibitors
Poly (ADP-ribose) Polymerase (PARP) has a well-recognised role in DNA repair processes, 
and small molecule inhibitors of PARP have been developed as chemotherapeutic sensitisers 
for the treatment of cancer (Lee et al., 2014). It has been demonstrated that PARP inhibition 
is selective for BRCA-1 or BRCA-2 deficiency, which suggests that PARP inhibitors may be 
particularly valuable for the treatment of breast cancer with BRCA mutations.This has been 
proven by Edwards et al., who reported that cells with loss of BRCA-2 functions are highly 
sensitive to PARP inhibitorsand that by deleting a mutation in BRCA2, resistance to PARP 
inhibition can be acquired (Edwards etal., 2008). However, there are still unanswered queries 
surrounding the use of PARP inhibitors; to be exact the levels of specificity and potency that 
are essential to provoke BRCA selectivity (Rosen and Pishvaian, 2014).
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1.9. Drug resistance and cancer
All effective cancer therapies are limited by the development of drug resistance (Garraway 
and Janne, 2012). In the clinic, resistance to anticancer therapy is a significant obstacle in the 
management of patients with breast cancer (Coley, 2008). Resistance to treatment with 
anticancer drugs is caused by a variety of factors and sophisticated mechanisms that reduce 
the sensitivity of treatments in patients. Increased understanding of the molecular and 
biochemical basis of drug efficacy has facilitated studies elucidating the mechanism(s) of 
drug resistance (Gottesman, 2002). Experimental approaches can help predict eventual 
clinical drug resistance and aim to identify novel resistance mechanisms behind drug 
resistance in order to develop more effective treatments (Garraway and Janne, 2012). In this 
study, we provide a historical background on drug resistance and a framework for 
understanding the common ways by which cancers develop resistance to anticancer 
therapeutic agents.
1.9.1. Mechanisms underlying drug resistance in cancer
There are numerous biological factors that influence the ability of drugs to kill cells. These 
include poor patient tolerance to anticancer drugs and poordrug pharmacokinetics and 
metabolism. For instance,rapid metabolism or excretion of the anticancer drug and limited 
absorption of the drug (common in elderly patients), can lead to reduced levels of drug dose 
below the optimum (Pluen et al. 2001).There might also be a failure to distribute the drug to 
the tumour location, particularly in solid tumours. Genetic changes within the cancer cell can 
also induce drug resistance. These may involve changes in the molecular components of the 
cell, for example lack of cell surface receptors, or drug efflux transporters, changes in the 
extracellular microenvironment, alteration of the drug target, changes in ability to repair 
DNA following drug-induced damage, disruptions in apoptotic-response
81
Chapter 1 Introduction
pathways,oralterations in the expression of protein and enzymes associated with tumour 
resistance. A summary of these mechanisms is shown in figure l-16(Coley, 2008).
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Figure l-16Representation of different Cellular mechanisms contributing to drug 
resistance. Decrease or increase in the expression or activity of theactive transporters responsible for 
both the uptake and the efflux of drugsrespectively, can reduce cellular drug concentrations. Low 
cytochrome p450 activity could result in a poor therapeutic outcome of the drug if  it requires 
bioactivation. On the other hand,theoverexpression of GSTs can detoxify the chemotherapeutic agent 
and causedecreased sensitivity to the drugs. Increasedexpression of anti-oxidant enzymes such as 
SOD that protect cells against ROS stress can contribute to drug resistance. Increased repair of drug- 
induced DNA damages can protect cells against the damage caused by chemotherapeutics. Decrease 
in topoisomerase 11 alpha expression is related to drug resistance. Evasion of apoptotic signalling 
pathways such as mutation of p53 function or changes in the expression of pro and anti-apoptotic 
proteins reduces cellular sensitivity to anticancer drugs. Microtubule alterations (for instance 
overexpression of the b-tubulin lllisotypeand mutations in b-tubulin) induceresistance to antimitotic 
tubulin-binding agents. BCRP:breast cancer resistance protein;MRP: multidrug resistance protein;
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OATP: organic anion-transporting polypeptide; OCT: organic cation transporter; Pgp: P-glycoprotein; 
CYP: cytochrome p-450; ROS: reactive oxygen species; SOD: superoxide dismutase; GST: 
glutathione S-transferase; MAPK: mitogen activated protein kinase.
1.9.1.1.Drug transporters and cancer resistance
To date, the most widely documented cellular mechanisms of tumour resistance are those 
correlated with drug efflux mechanisms mediated by members of the adenosine triphosphate 
(ATP)-binding cassette (ABC) membrane transporter family.These include P-glycoprotein 
(P-gp), multidrug-resistant protein 1 (MRPl), and breast cancer resistance protein (BCRP) 
(Leonard et al., 2003). These drug transporters are found in normal mammalian cells, where 
their role has been recognised as one of protection against, and also clearance of, extracellular 
and intracellular xenobiotics and toxins (Borst et al., 2000). It is important to study these 
transporters because a principle feature ABC- transporter over-expressing tumour cells is 
diminished ability to accumulate certain cytotoxic agents such as doxorubicin intracellularly 
resulting in ineffective cellular drug levels that fail to elicit cell death (Coley, 2008). This is 
established to be one of the main mechanisms contributing to the multiple drug resistance 
(MDR) phenotypes. These transporters are predominantly located on the plasma membrane 
of the cell. Nevertheless, there are other different mechanisms that are also regarded to be 
important, such as changes in the intracellular environment of MDR cells (Coley, 2008). 
These are explained in the next paragraphs.
The classical drug efflux transporter P-gp is a 170 kDa membrane protein encoded by the 
MDRl gene (Chen etal. 1986; Sauna et al. 2001; Gottesman et al. 2002), and consists of 12 
transmembrane domains attached to an ATPase domain (Chen et al.l986). ATP is hydrolysed 
when a substrate binds to the transporter with a high affinity, resulting in a conformational 
change that shifts the substrate to the lower affinity binding site and subsequently releases the
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substrate into the extracellular space from the outer leaflet of the membrane(Gottesman et al.,
2002).
Based on an immunohistochemistry-based assay designed to assess the expression of 
MDRl/gpl70 expression prior to and after the exposure to the chemotherapy i has been noted 
that treatment with either chemotherapy or hormonal agents was associated with an increased 
proportion of tumours that expressed P-gp, by approximately 1.8-fold. The same study noted 
that patients whose tumours over-expressed p-pg were three times more likely to fail to 
respond to chemotherapy compared with individuals whose tumours were P-gp- 
overexpression negative (Trock et al., 1997). These findings suggested that increased 
expression of P-gp may be implicated in the development of resistance during exposure to 
chemotherapeutic agents (Coley, 2008;Trock et al., 1997).
In addition to P-gp, other transporter proteins important to mention are those such as the 
multi drug resistance protein (MRP) family, which are also involved in the development of 
drug resistance by increasing efflux and decreasing intracellular accumulation of anticancer 
agents (Zhou et al., 2008). The MRP family comprises of 9 members (MRP1-MRP9). It has 
been shown that MRPl and MRP6 are the best characterized with regard to protein 
localization and substrate selectivity (Konig et al., 2005). This study will discuss MRP 
proteins that predominantly play a role in breast cancer resistance.
MRPl (ABCCl) is a 190 kDa protein consisting of 17 transmembrane domains, including a 
P-gp-like core (Gottesman et al., 2002). It has been reported that MRPl expression is 
correlated with the development of resistance to a spectrum of chemotherapies such as 
anthracyclines, antifolates, and vinca alkaloids (Hooijberg et al., 1999). Conversely, MRPl 
has not been seen to confer resistance to taxanes, mitoxantrone and cisplatin (Cole et al., 
1994). In the literature, it has been demonstrated that early expression of MRPl is correlated
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with a worse prognosis. Rudas and colleagues conducted a study to compare the expression 
of MRPl in breast carcinoma patients prior to and post chemotherapy. The study found that 
expression of MRPl was significantly lower in pre-chemotherapy breast cancer samples 
compared with those specimens exposed to chemotherapy (62% vs. 88%P < 0.001). The 
other observation was that over-expression of MRPl was more frequently found in patients 
with distant métastasés than in those without (50% vs. 8%, P = 0.02) (Rudas et al., 2003).
Another member of the MRP, MRP2 also contributes to the development of resistance to a 
different of chemotherapeutic agents such as polyglutamatable antifolates and methotrexate 
(Hooijberg et al., 1999). Furthermore, overexpression of human MRP2 is associated with 
enhanced the resistance to cytotoxic drugs such as etoposide, cisplatin, doxorubicin, and 
epirubicin (Cui et al., 1999). Recently, it has been found that MRP3 is frequently amplified 
and overexpressed in HER2-positive breast tumours, and this is correlated poor 
outcomes(Partanen et al., 2012).
Some multidrug resistant cells lines do not exhibit over-expression of P-gp or MRP family 
members, which suggests the existence of another ABC transporter that is able to cause drug 
resistance. In the laboratory, it was found that MCF7 human breast carcinoma cells over­
expressed a novel member of the G subfamily of ABC transporters, termed the breast cancer 
resistance protein (BCRP), due to its identification in MCF7 human breast cells (Doyle and 
Ross, 2003). BCRP (ABCG2) is also known as the mitoxantrone resistance gene (MXR). The 
protein is a 655-amino acid, 72 kDa half-transporter with six trans-membrane domains and an 
N-terminal ATP binding site (Coley, 2008).
The data generated from Doyle and coworkers strongly support the conclusion that the novel 
BCRP transporter plays a major role in the drug-resistance phenotype of MCF-7 cells. These 
findings also suggested that overexpression of BCRP can lead to resistance to cytotoxic
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agents such as mitoxantrone, anthracyclines, methotrexate, and topoisomerase I inhibitors, 
which is particularly relevant to the main obstacle of drug-resistance among patients in the 
metastatic stage (Doyle and Ross, 2003;Doyle et al., 1998).
1.9.1.2.MicrotubuIe alterations
The P-subunit of tubulin in microtubules is the binding site for paclitaxel, which has the 
ability to suppresses microtubule dynamics and ultimately inhibit cell proliferation causeing 
mitotic arrest and cell death (Matesanz et al., 2008). In vitro results showed that 
overexpression of p-tubulin III has been correlated with paclitaxelresistance (Kamath et al.,
2005). Clinical investigations indicate thatincreased expression of P-tubulin III is a 
potentialbiomarker for paclitaxel resistance in patients with advanced breast cancer (Paradiso 
et al., 2005).Additionally, high expression of class I and class III P -tubulin types may be 
associated with resistance to docetaxel therapy in breast cancer tissues (Hasegawa et al., 
2003).
1.9.1.3.Altered enzymes
Enzymic changes in cancer have been documented to be associated with anticancer drug 
resistance.The best example is topoisomerase, which is a key enzyme in DNA replication and 
so is essential for genomic stability (Coley, 2008). The antineoplastic agents used clinically in 
patients with breast cancer to target topoisomerase II are etoposide and the anthraquinone 
mitoxantrone.However, after a while, patients develop resistance to these treatments 
(Onyenadum et al., 2007). Extensive studies have been carried out to assess the resistance the 
mechanisms that result in resistance to topoisomerase Il-directed therapies (Lothstein et al., 
2001;0nyenadum et al., 2007). An in vitro study by Lewis et al, found that the MDA-MB- 
231 breast cancer cell line with acquired resistance to etoposide expressed a marked
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decreased in both topoisomerase II alpha and beta forms while not over-expressing P-gp and 
MRP(Lewis et al., 2007).
Another enzyme that causes drug resistance in breast cancer is aldehyde dehydrogenase, with 
the two isoforms ALDHlAl and ALDH3A1. It has been shown that breast adenocarcinoma 
cells express several fold higher levels of ALDH3A1 in comparison with normal tissues 
(Sladek, 1999).
1.9.1.4.p53 tumour suppressor gene
The p53 gene plays a pivotal role in inducing apoptosis in response to DNA damage. 
Mutation in p53 (TP53) is one of the most commonly described genetic events in human 
cancer; p53 is mutated in 31% of all tumours (Li et al., 2012). In a study designed to assess 
the National Cancer Institute (NCI) panel of 60 human cancer cell lines, it was found that the 
majority of breast cancer cell lines had a mutated p53 gene (O'Connor et al., 1997).
The manifestation of p53 mutations is less common in sporadic breast carcinomas than in 
other cancers, with a frequency of about 20%. However, evidence of mutated p53 status is 
significantly higher in breast carcinomas arising in carriers of germ-line BRCAl and BRCA2 
mutations (Gasco et al., 2003).
In vitro investigations have shown intact p53 to play a critical role fulfilling cell death in 
response to treatment with cytotoxic drugs like etoposide, 5-fluorouracil and doxorubicin 
(Boulikas and Vougiouka, 2004). Recently, it has been found that mutations in the P53 gene 
confer resistance to anthracyclines in a mouse sarcoma tumour model, and overexpression of 
the p53 protein, which is due to a mutated gene was revealed to be associated with lack of 
response to cisplatin-based chemotherapy in non-small cell lung cancer (Fan et al., 1995).
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Previous studies have reported that mutations in the P53 gene or overexpression of the p53 
protein can predict a poor prognosis in breast cancer tumours (Aas et al., 1996).
1.9.1.5.AIteration of DNA repair processes
Alterations of DNA repair processes have been known be important in mediating drug 
resistance. Acquired knowledge has provided insight into the molecular mechanisms of DNA 
repair pathways and their effect on response to anticancer agents (Martin et al., 2008b). For 
instance, mutations in BRCA-1 result in reduction in homologous recombinational repair of 
DNA double-strand breaks and crosslinks, which eventually lead to genomic instability 
(Bernstein et al., 2002).
An additional factor that is relevant to tumour resistance in breast carcinomas is mismatch 
repair (MMR). It has been observed that the MMR gene plays a vital role in the correction of 
DNA damage, and the loss of MMR has been associated in the development of resistance to a 
variety of chemotherapeutic drugs (Son et al., 2004). Also it has been observed that reduced 
expression of hMLHl and/or hMSH2 involved in MMR reduce the responsiveness to 
cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapeutic regimens in 
patients with sporadic invasive ductal carcinoma (Son et al., 2004).
1.9.1.6.CelI death responses
The cell death response is also implicated with anticancer drug resistance. A huge number of 
studies using mouse models and cultured cell as well as descriptive analyses from biopsies of 
different stages have demonstrated that acquired resistance from apoptosis is the principle 
factor in tumourigenesis (Coley 2008). Mutations in apoptotic pathways that help to 
circumvent cell death may cause drug resistance. Such mutations could serve as predictors of 
chemoresistance and most importantly, as new treatment targets (Simstein et al., 2003).
88
Chapter 1 Introduction
Understanding the molecular events that regulate apoptosis in response to anticancer 
therapies, and how cancer cells evade apoptotic death, provides novel opportunities for a 
more rational approach to develop molecular targeted therapeutic approach for combating 
cancer.
As discussed previously in section 1.6.1., the two main routes leading to programmed cell 
death are the mitochondrial (intrinsic pathway) and cell surface receptor (Fas)-mediated 
(extrinsic pathway)(Simstein et al., 2003). The MCFTbreast cancer cell line is well cited for 
its lack expression of executioner caspase-3, even though MCF7 cells still undergoapoptosis 
by the sequential activation of caspases-9 (associated with mitochondrial-mediated 
apoptosis), -7 and -6 (Mooney et al., 2002). It has been shown that the overexpression of the 
caspase-3 splice variant could promote cell survival and chemoresistance in locally advanced 
breast tumour cells (Vegran et al., 2006).
When considering anticancer drug resistance,data are more often related to the intrinsic 
pathway than the extrinsic pathway. The Fas receptor has been reported to be down-regulated 
in breast carcinoma in vitro, and many breast cancer cell lines are Fas-resistant (Keane et al., 
1996). In the intrinsic pathway, the Bcl-2 family of proteins are pivotal. Hence, the relative 
concentrations of proapoptotic versus anti-apoptotic Bcl-2 protein family members defines 
whether cells survive or undergo apoptosis and may form the basis for anticancer drug 
resistance in some instances (Coley 2008).Earlier studies showed that overexpression of Bcl- 
2inhibited drug induced apoptosis in MCF7 cells (Davis et al., 2003) and that down- 
regulation of Bcl-2 in MCF7 cells resulted in the sensitisation of the cells to 
chemotherapeutic treatment with etoposide and doxorubicin (Lima et al., 2004).Afurther 
study examining the cisplatin-response of five human breast cancer cell lines found a 
correlation between expression of Bcl-2 protein with drug sensitivity(cell death and growth 
arrest)(Yde and Issinger, 2006). In 2012, Larsen et al., found that low Bcl-2 expression levels
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have potential value as a marker for increased carboplatin sensitivity in breast cancer cells 
resistant to the hormonal treatments such as tamoxifen.They also revealed that tamoxifen- 
resistant breast cancer cells were more sensitive to carboplatin treatment compared with 
parental MCF7 cells. Finally, this study indicated that carboplatin may be an advantageous 
treatment in anti-oestrogen resistant breast cancer cells(Larsen et al., 2012).
The survivin gene is a member of the lAP (inhibition of apoptosis) gene group and is 
expressed at high levels in a number of cancers including breast tumours. 
Immunohistochemical analysis showed that survivin expression was positive in 70.7% of 
breast carcinomas,where it has been shown to be associated with a poor prognosis. In 
contrast, there was no survivin expression detectable in normal tissue (Tanaka et al., 2000).
The MCF7 cell line has also emerged as an important model of autophagy (Ogier-Denis and 
Codogno, 2003).The relevance of autophagic cell death in cancer chemotherapeutic tumour 
resistance has not yet been fully elucidated, but is an interesting area of research. Recently, it 
has been reported that autophagic cell death is a process that is very relevant to resistance to 
chemotherapy drugs such as paclitaxel (Ajabnoor et al., 2012).
1.9.2. Anti-endocrine resistance
As described earlier (section 1.8.3) anti-endocrine therapies target oestrogen actionto 
decrease the mortality rate from breast cancer. However, the efficacy of treatment is limited 
by intrinsic and acquired therapeutic resistance (Musgrove and Sutherland, 2009). 
Antioestrogen agents have been the basis of anti-endocrine therapy in both early and 
advanced breast cancer patients. This is important becauseanti-endocrine resistance may 
represent up to one-quarter of breast cancer patients(Musgrove and Sutherland, 2009). 
Clinical cases with advanced disease that do not respond to first-time treatment are referred
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as de novo resistance cases. In addition, patients who initially respond to the treatment and 
then have recurrent disease are known as acquired resistance cases (Zilli et al., 2009).
Tamoxifen resistance in breast cancer patients is the major obstacle limitingtreatment 
efficacy. One-third of women treated with tamoxifen for five years will relapse within fifteen 
years(Morimoto et al., 2013). Therapy witharomatase inhibitors (AIs) given as initial 
treatment or sequentially after tamoxifen seems to be more beneficial than the use of 
tamoxifen alone. Combination therapy might also be effective in tamoxifen resistant patients, 
as for tamoxifen treatment, both de novo and acquired resistance to AIs also occurs (Nabholtz 
et al., 2000). Despite the clinical benefits of incorporating a more potent approach for anti- 
endocrine agents, resistance to all forms of anti-endocrine therapy exist and remain a major 
problem(Ma and Lu, 2011). The mechanisms of anti-endocrine resistance in breast cancer are 
the focus of this study and are considered in more detail in the following chapters.
1.9.3. New targeted therapy resistance
More recently, the idea of new targeted therapy has been considered for breast cancer 
patients. In particular, the use of Herceptin has significantly changed the way some breast 
cancer patients are managed and has been shown to prolong survival in some breast cancer 
patients (Pinto et al., 2013). Typically, patients develop resistance to herceptin therapy over 
time(Valabrega et al., 2011). Similarly, the therapeutic efficacy of lapatinib is limited by 
primary (intrinsic) and acquired resistance.Chapter 6 discusses the possible mechanism of 
lapatinib resistance in breast cancer cells.
1.10. Working hypothesis
This study hypothesised that the use of tyrosine kinase inhibitors that target the molecular 
mechanisms of survival signalling through growth factor receptors such as EGFR and HER2
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would reverse the resistance to anti-oestrogens. We also hypothesised that targeting the 
survival pathway of autophagy using autophagy inhibitors could re-sensitise cells to anti­
oestrogen therapy for breast cancer.
1.11. Aims
This study aimed to identify the molecular mechanisms underlying anti-endocrine resistance 
in breast cancer; a secondary aim was to explore the use of novel therapeutic strategies to 
overcome the identified resistance mechanisms. It is hoped that the identification of 
molecular changes in anti-endocrine resistance can be used to develop predictive biomarkers 
to monitor disease progression and treatment responses. Undoubtedly, circumventing anti- 
endocrine resistance will facilitate improvement in therapeutic outcomes for the benefit of 
breast cancer sufferers.
1.12. Objectives
Using an approach of cultured human breast cancer cell lines with acquired resistance to 
tamoxifen, fulvestrant and lapatinib, this project set out to characterise molecular processes 
that are implicated in the attenuated response to those drugs. The path of scientific enquiry 
that was followed is described:
• Characterisation of cell line models by assessment of relative drug sensitivity using 
the MTT assay and clonogenic assay for assessment of drug-induced loss of viability.
• Assessment of molecular changes associated with acquired tamoxifen or fulvestrant 
resistanceThis includes:
o The determination of ER-a status.
92
Chapter 1 Introduction
o Assessment of key elements of cell-cycle deregulation.
o Measurementof signal transduction molecules such as PI3K/Akt, involved in 
survival pathways; and extracellular signal-regulated kinase (ERK), critical for 
uncontrolled cellular proliferation and survival.
• Expression profiling of members of the growth factor receptor signalling family 
(HERl, HER2 and HER3) in conjunction with ERa status with assessment of 
targeted therapy responses as evidence of pathway crosstalk.
• Investigation of whether the tyrosine kinase inhibitors (HER1/HER2 inhibitors) such 
as lapatinib show collateral sensitivity in anti-endocrine resistant cells, with the 
possibility of restoring anti-endocrine responsiveness in cell models of acquiredanti- 
endocrine resistance.
• Assessment of cell death responses by measuringthe expression of pro- and anti- 
apoptotic factors.
o Examination of any evidence suggestive of autophagy as a prosurvival 
mechanism involved in the development of anti-endocrine resistance.
• Demonstration of a therapeutic approach using autophagic inhibitors to target the 
survival mode of autophagy, with the objective of reversingtargeted therapy 
resistance.
• Identification of novel mechanisms of resistance to HER-directed therapy using a 
variety of molecular approaches.
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2. Materials and Methods
2.1 Chemicals and reagents
2.1.1 Cell culture reagents:
Foetal bovine serum (FBS) (heat inactivated at 55 °C for 30min), dextran coated charcoal 
stripped FBS (product code 12676029) and Glutamax® were obtained from Life 
Technologies (Paisley, UK); porcine trypsin-EDTA, Dulbecco’s Modified Eagles’ Medium 
(DMEM) HEPES modified cell culture medium, phenol red free/ MEM HEPES modified 
were obtained from Sigma Aldrich (Poole, UK).
2.1.2 Drugs and solvents
Drugs were made up to stock solutions as detailed in table 2.1. All drug stocks were stored at 
-20 °C and thawed prior to use.
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Table 2-lList of drug stock solutions
Materials and Methods
Oestradiol Sigma-Aldrich, Poole, UK Absolute ethanol lOOpM
4-
hydroxytamoxifen
Sigma-Aldrich, Poole, UK Absolute ethanol 10 mM
Cisplatin Sigma-Aldrich, Poole, UK Sterile 0.9% saline 
solution
10 mM
Fulvestrant Sigma-Aldrich, Poole, UK DMSO 1 mM
Lapatinib Selleck Chemicals (Houston, 
TX, USA; distributed by 
Stratech, Newmarket UK)
DMSO 20 mM
Gefitinib Selleck Chemicals (Houston, 
TX, USA; distributed by 
Stratech, Newmarket UK)
DMSO 10 mM
LY-294002 Biochemicals, Beeston,UK DMSO 10 mM
Z-VAD Bachem® Weil am Rhein, 
FRO.
DMSO 10 mM
Mefloquine Sigma-Aldrich, Poole, UK Sterile, distilled 
water
10 mM
Z-VAD = Z-Val-Ala-DL-Asp-fluoromethylketone
2.1.3 RNA isolation for qPCR
TRlzol® for RNA extraction was purchased from Invitrogen™ Life Technologies (Paisley, 
UK).SYBR® Green- based quantitative real-time PGR assay for gene expression analysis 
Human ESRl and GAPDH were purchased from Qiagen, (SABiosciences, Crawley, UK)
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2.1.4 Western blotting
All reagents for western immunoblotting were obtained from Invitrogen’r^ Life Technologies 
(Paisley, UK) unless stated otherwise. NuPAGE® NovexBis-Tris gels, MOPS, MES and 
Tris-Acetate electrophoresis running buffers, NuPAGE® PVDF 0.2 pm membranes. Western 
blotting transfer buffer, HiMark^^ PreStained high molecular weight protein standards 
(product code LC5699), Novex® sharp protein standards. Western Breeze® 
chemiluminescent Western blot immunodetection kit. Kodak BioMax XR Light Film 
(Eastman Kodak Company, distributed by Sigma Aldrich, Poole, U.K), Secondary antibody 
solutions (alkaline phosphatase conjugated anti-mouse and anti-rabbit) are pre-diluted, and 
ready to use formulations.
The suppliers and conditions of use for all primary antibodies is shown in table 2.1.
Table 2-2List of primary antibodies.
Akt Cell Signalling Technology® 11E7 Rabbit polyclonal 1 : 1 0 0
Bax Santa Cruz Biotechnology Inc 6D150 Mouse monoclonal 1 : 2 0 0
Bel-2 Santa Cruz Biotechnology Inc C-2 Mouse monoclonal 1 : 2 0 0
BECNl Santa Cruz Biotechnology Inc E- 8 Mouse monoclonal 1:50
Cyclin E Insight Biotechnology Inc Dallas HE12 Mouse monoclonal 1 : 1 0 0
E-cadherin Santa Cmz Biotechnology Inc Not stated Mouse monoclonal 1 : 1 0 0
EGER Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
ER a Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
ERK Santa Cruz Biotechnology Inc K-23 Rabbit polyclonal 1 : 1 0 0
GAPDH Santa Cruz Biotechnology Inc 7B Mouse monoclonal 1 : 1 0 0 0 0
HER2, Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
LC3B Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 2 0 0
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Mdr Santa Cruz Biotechnology Inc H-241 Rabbit polyclonal 1 : 1 0 0
Met Cell Signalling Technology® 25H2 Mouse monoclonal 1 : 1 0 0
P53 Santa Cruz Biotechnology Inc DO-1 Mouse monoclonal 1 : 1 0 0
P-Akt Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
P-EGFR Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
P ER a Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
P-ERK Santa Cruz Biotechnology Inc E-4 Mouse monoclonal 1 : 1 0 0
P-HER2 Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
P-HER3 Cell Signalling Technology® Not stated Rabbit polyclonal 1 : 1 0 0
P-Met Cell Signalling Technology® 130H2 Rabbit polyclonal 1 : 1 0 0
PI3- kinase Santa Cruz Biotechnology Inc Not stated Rabbit polyclonal 1 : 1 0 0
P-PI3- Santa Cruz Biotechnology Inc Z- 8 Rabbit polyclonal 1 : 1 0 0
Skp2 Santa Cruz Biotechnology Inc A-2 Mouse monoclonal 1:50
Survivin Santa Cruz Biotechnology Inc FL-142 Rabbit polyclonal 1 : 1 0 0
Twist Santa Cruz Biotechnology Inc Not stated Rabbit polyclonal 1 : 2 0 0
p-actin Sigma Aldrich St AC-15 Mouse monoclonal 1 : 1 0 0 0 0
P- Indicates phosphorylated form.
2.2 Buffers and Solutions
2.2.1 Phosphate buffer saline (PBS)
One PBS tablet (OXOID, Producr code: BR0014G) was dissolved in 100ml RO water. PBS 
was autoclaved in order to make it sterile if necessary. The typical formulation of PBS is as 
follows: Sodium chloride 8g/L, potassium chloride 0.2g, Di-sodium hydrogen phosphate 1.15 
g/L, potassium dihydrogen phosphate 0.2g/L with pH of 7.3 ± 0.2 at 25 °C.
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2.2.2 MTT solution
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from 
Sigma (Poole, Dorset, UK). 5 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide was dissolved in a sterile PBS solution and then sterile filtered prior to usage and 
kept in the dark at 4 °C. It is a water soluble tétrazolium salt yielding a yellowish solution 
when prepared in media lacking phenol red. Dissolved MTT is converted to an insoluble 
purple formazan by cleavage of the tétrazolium ring by dehydrogenase enzymes.
2.2.3 Cell lysis buffer
50mM Tris-HCl (C4H 11NO3 HCI) and 150 mM NaCl, adjusted to pH 7.5. The buffer was 
supplemented with Nonidet® P-40 detergent (1%), SDS (0.2%), PMSF (ImM), aprotinin 
(lOng/ml), leupeptin (lOng/ml), and Na3V0 4  (ImM). Lysis buffer must kept on ice, prepared 
freshly each time and used within approximately half an hour, as the half-life for PMSF is 20 
min at room temperature.
2.2.4 70% ethanol in PBS
In order to prepare 1 L of 70% ethanol (absolute ethanol, AR, Fisher Scientific, 
Loughborough, UK) in PBS, 700 mL 96% ethanol was mixed with 300 mL PBS solution and 
agitated thoroughly. The solution was kept at 4 °C.
2.2.5 NuPAGE® running buffer
Add 50 mL running buffer 20x (MES SDS, MOPS SDS, or TA) prepared in 1 L of RO water 
and use immediately.
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2.2.6 NuPAGE® transfer buffer
Add 50 mL transfer buffer 20x and 100 ml methanol in 1 L of RO water for inunediately use.
2.2.7 lOXTris-buffered saline (TBS)
To prepare 1 L of lOx TBS solution, 24.2 g Tris base and 80 g NACL were weighed and 
dissolved in RO water, PH adjusted to 7.6 with HCL. In order to make 1 L of lOx TBS 
working solution, 100 mL of stock solution was diluted in 900 mL RO water. The working 
solution was stored at room temperature.
2.2.8 PBS-/TBS-Tween20
To make 500 ml of either PBS- or TBS-Tween20, 500 pL Tween20 (0.1% V/V) was 
dissolved in 500ml PBS/TBS and kept at room temperature.
2.2.9. Blocking/primary antibody buffer
In order to prepare lOmL blocking/primary antibody buffer, 0.5 g of either powdered 
skimmed milk (supermarket brand/Marvel) or BSA (bovine serum albumin; Sigma Aldrich, 
Poole, UK) or 0.25 g dry milk mixed together with 0.25 g BSA weighed and dissolved in 
IXPBS/IXTBS based on the recommendation from the datasheet. 10 pL Tween20 was added 
and mixed thoroughly. Depending on the concentration of the primary antibody solution, the 
primary antibody was diluted in the buffer at a range from 1 : 1 0 0 0  to 1 :1 0 0 .
2.2.10. BSA protein standard
BSA stock solution was prepared by dissolving 25 mg of BSA in 5 mL sterile water. To make 
a set of BSA protein standards, stock solution (5 mg/ml) was diluted using sterile PO water.
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The range used was 0.2, 0.5, 0.7, 1.0, 1.2 and 1.5 mg/ml BSA. Standards were stored at -20 
°C. BSA standards were tested by performing Bio-Rad DC Protein Assay (Bio-Rad 
Laboratories Ltd, Herts, UK) in duplicate and plotting standard graph of A690 against BSA 
concentration.
2.3. Cultured human breast cancer cell line models and
establishment of tamoxifen-, fulvestrant- and lapatinib- 
resistant sublines
This work was based on human breast cancer cell lines derived from a pleural effusion of a 
patient, of which some are hormone-responsive cells (MCF7 and T47D), some HERl and/or 
HER2 expressing cells (SKBR3) and some triple-negative cells (MDA-MB-231) (Table 2-3). 
MCF-7 and MDA-MB-231 were obtained from American Type Culture Collection(ATCC) 
(LGC Promochem, Twickenham, UK) and T47D and SKBR3 were purchased fromEuropean 
Collection of Cell Cultures(ECACC) (Porton Down, Salisbury, UK).
Table 2-3List of parental cell lines.
M CF7 Luminal epithelial-like 
phenotype
Adenocarcinoma ER+, FR+
T47D Luminal epithelial-like 
phenotype
Metastatic Ductal 
carcinoma
ER+, PR+
MDA-MB-231 Mesenchymal-like or 
stromal-like phenotype
Invasive
Adenocarcinoma
ER-, PR-, HER2- and 
HERl-r
SKBR3 Weakly luminal epithelial- 
like phenotype
Adenocarcinoma HER2-H
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Novel drug-resistant cell lines were developed by Dr Helen Coley (University of Surrey) by 
culturing them in increasing doses of the appropriate selecting drug on successive passage 
until a stable resistance phenotype was acquired. Tamoxifen-resistant MCF7 breast cancer 
cells (henceforth designated as MCF7-TR) were derived from MCF7 by stepwise incubation 
with tamoxifen over a period of several weeks, as deseribed by Samaddar et al 
2008(Samaddar et al., 2008).
Similarly, fulvestrant-resistant T47D cells were created (henceforth designated as T47D-FR). 
In addition, two different lapatinib-resistant cell lines were generated for this study; one 
derived from MDA-MB-231 (MDA-MB-231-LapR) and one from SKBR3 (SKBR3-LapR) 
by step-wise incubation with lapatinib. Table 2-4 lists all resistant cell lines developed and 
the maintenance doses of drug required to maintain the phenotype.
Table 2-4List of drug resistant cell lines.
Acquired resistance MCF7 Tamoxifen 5 pM MCF7-TR
to hormone-targeted 
therapy
T47D Fulvestrant 0.4 pM T47D-FR
Acquired resistance SKBR3 Lapatinib 0.03 pM SKBR3-LapR
to a dual HERl/ 
HER2 inhibitor
MDA-MB-
231
Lapatinib 3 pM MDA-MB-231-LapR
All eell lines with the exception of oestrogen receptor -positive eell lines were cultured in 
DMEM Hepes-modified medium with 2 mM Glutamax® and supplemented with 10% heat- 
inactivated foetal bovine serum (FBS) and penicillin/ streptomycin (100 units/mL penicillin 
and 100 pg/mL streptomycin in the final formulation). Cells were cultured at 37 °C. Once the
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cells reach approximately 60% confluency they were passaged. First, the medium was 
aspirated off and the cells washed with PBS. Then trypsin was added and the flask incubated 
at 37°C until cells were detached. Next, medium was added to inactivate the trypsin and a 
small aliquot of cell suspension was transferred to a new flask containing fresh medium.
Oestrogen receptor-positive cell lines, such as MCF7 and T47D, were cultured in 
DMEM/F12 medium containing 5% dextran-coated charcoal stripped FBS (Invitrogen, 
Paisley, UK), which lacks endogenous steroid hormones for processing the experiment.
MCF7 and T47D cells were routinely treated with oestrogen (E2) 1 nM after each passage to 
mimic the in vivo scenario. In the literature, it has been established that oestradiol markedly 
increases the ability of the cells to grow in suspension, as well as the growth rate by 
stimulating cell division and the final saturation density of the cells (Darbre et al., 1983).
2.4. Cell cryopreservation and resuscitation
Cell lines in continuous culture are prone to genetic instability and also susceptible to 
microbial contamination. Therefore, cells were expanded to a contaminant-free working cell 
bank, which was then frozen down and preserved for long-term storage. Cells from the 
working cell bank are then used for no more than 15 passages. Cryopreservation is aehieved 
by seeding cells in a T25 flask until near confluence, trypsinizing and culturing in complete 
medium. Then cells were pelleted and a cryoprotective agent, such as dimethylsulfoxide 
(DMSO), added to reduee the freezing point of the medium and also allow a slower cooling 
rate, thereby greatly reducing the risk of ice crystal formation, which can damage cells and 
cause cell death. Cells were slowly resuspended and aliquoted into cryopreservation vials and 
placed into a container filled with isopropyl alcohol, allowing for a cooling rate of 1 °C/min.
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The container is then stored at -80 °C for at least 24 hours before transfer in to long-term 
liquid nitrogen storage.
In order to resuscitate cells from liquid nitrogen storage, vials were thawed by heating at 
room temperature in a water bath, then the thawed cells were pipetted into a T25 flask 
containing complete medium and placed inside an incubator for cell attachment. It is 
necessary to change the medium every two days for cells to aid recovery of the cells.
2.5. Counting cells using a haemocytometer
The haemocytometer and cover slip were cleaned and disinfected using 70% ethanol. The 
coverslip was then fixed on the haemocytometer using gentle pressure and small circular 
motions. The cell suspension to be counted was well-mixed and applied by filling a pipette 
and gently resting the end of the pipette against the edge of the chambers, upon which cells 
are sucked into the void between the haemocytometer and the cover slip by capillary forces. 
The void has a volume of exactly 0.1 mm^ or lO'"^  mL, respectively. Take care not to overfill 
the chamber. The haemocytometer is then placed under an optical microscope at lOx 
magnification and cells counted in all 4 quadrants (each consisting of 16 squares). The 
haemoeytometer is designed so that the number of cells in one quadrant is equivalent to the 
number of cells x 1 0 ^/ ml.
2.6. Cell Viability Assays
2.6.1. MTT assay
The MTT assay is widely used to determine cell viability. This assay is based on the ability of 
cells to metabolise 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium
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bromide(MTT)(Figure 2-1), to a yellow tétrazolium salt, into a water-insoluble, purple 
formazan product by intracellular NAD(P)H-oxidoreductases (Mosmann, 1983;van Meerloo 
et ah, 2011). This product can be dissolved in organic solvent such as dimethylsulfoxide 
(DMSO)(Vistica et al., 1991). The MTT solution was prepared by diluting 5 mg/ml MTT dye 
in sterile PBS followed by sterile filtration, and stored at 4 °C. In a typical MTT assay, 
cultured cell in single cell suspension were seeded into a 96-well plate at seeding densities 
shown in table 2-5. Seeding dencities were selected based on the doubling time of the cell 
line.
Table 2-5 Seeding densities for each cell line.
MCF7 4x10^
MCF7-TR 6x10"^
T47D 5x10"^
T47D-FR 7x10"^
MDA-MB-231 4x10^
MDA-MB-231-LapR 5x10"^
SKBR3 6x10"^
SKBR3-LapR 8x10"^
Cells were allowed to grow and attach in a humidified incubator for 24 hours at 37 °C and 
5% CO2 . On the next day, serial dilutions of the drugs in medium were prepared and 
appropriate amounts of the drug dilutions were added to the wells as described in table
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2-6. Untreated wells were used as positive controls. Cells were incubated with the drugs for 
72 hours or 96 hours depending on the doubling time. To evaluate cell viability, 25 pi MTT 
dye was added to each well. After an incubation period of 4-6 h, the medium was carefully 
aspirated from the wells to not disturb the formazan crystals and cells on the plastic surface. 
Next, 200 pi DMSO was added to each well and the plates agitated on a plate shaker for 5 
min. The absorbance of the coloured product was detected at 540 nm using a 
spectrophotometer (Labsystems Multiskan RC Plate Reader). Dose-responses were created in 
GraphPad and I C 5 0  values calculated by fitting with the 4-parameter model.
mitochondrial
reductase
Formazan (Dark blue)
Figure 2-lThereduction of MTT to formazan.
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Table 2-6Dose ranges of cytotoxic drugs in relation to cell line (MTT assay)
Materials and Methods
MCF7 and MCF7-TR
Tamoxifen
1 pM -  50 pM
T47D and T47D-FR
MCF7 and MCF7-TR
Fulvestrant
5 pM -  200 pM
T47D and T47D-FR
MCF7 and MCF7-TR
Lapatinib
0.5pM -  50 pM
T47D and T47D-FR
SKBR3 and SKBR3-LapR 0.01 pM - 0.5 pM
MDA-MB-231 and MDA-MB-231-LapR Ip M - 50 pM
MCF7 and MCF7-TR
Cisplatin
0.5 pM -  200 pM
T47D and T47D-FR
MCF7 and MCF7-TR
Mefloquine
0.5 pM -  100 pM
T47D and T47D-FR
In the case of the oestrogen-positive breast cancer cell lines MCF7 and T47D phenol red-free 
medium (DMEM F-12) was used during the MTT assay, containing 5% dextran-coated 
charcoal stripped FBS, because phenol red mimics endogenous oestrogen hormones. The 
medium was exchanged to standard medium before addition of the MTT dye, as this resulted 
in improved colour production and increased absorption readings.
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2.6.2. Clonogenic Assay
The clonogenic assay has been established in 1956 by Puck and Marcus, who described a cell 
culture technique for the assessment of the ability of single mammalian cells to form colonies 
(Puck and Marcus, 1956). The clonogenic assay, or colony formation assay, is regarded as the 
gold standard cellular viability assay to measure the ability of cells to proliferate after 
treatment with cytotoxic drugs (Franken et al., 2006), as shown in figure 2-2.
Cells were plated out into a 6 -well plate at a density of 1000 cells per well for the oestrogen- 
positive parental breast cancer cells (MCF7 and T47D), and at a density of 2000 cells per 
well for the resistant cell lines. After overnight ineubation, cells were exposed to the anti­
cancer agents at a different range of concentrations (Table 2-7) and placed in an incubator for 
48 h. Thereafter, the drug was removed by replaeing the medium with fresh growth medium 
and cells were kept in culture undisturbed for 12-14 days. After about 8  days colonies should 
be elearly visible under an optical microscope at lOx magnification. About a week later, cells 
were washed twice with PBS and incubated with 2 ml methanol for 5 min. After aspirating 
the methanol, 2  ml of a crystal violet solution ( 1 % in water) was added to each well and left 
for 10 min. Subsequently, the dye solution is aspirated, the plate rinsed under running tap 
water to remove excess dye and leave to dry. The numbers of colonies as well as the number 
of cells per colony were counted in each well. Only colonies consisting of about 50 cells or 
more are taken into consideration. The mean value of the number of colonies per well (colony 
count) for each drug-treated well of was divided by the mean colony count for the control 
wells.
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Table 2-7 Dose ranges of cytotoxic drugs in relation to cell line (clonogenic assay)
MCF7 and MCF7-TR Fulvestrant 1 pM -  10 pM
T47D and T47D-FR
MCF7 and MCF7-TR Mefloquine IpM  -  20 pM
T47D and T47D-FR
MCF7 and MCF7-TR LY294002 IpM  -  20 pM
Figure 2-2Example of colony formation from a single cell suspension in 6-well plate.
2.7. Preparation of whole cell lysate
This method can be used to harvest protein from cells in order to study their molecular 
characteristics. Breast cancer cell lines were grown in tissue culture T25 or T75 flasks until 
70% confluent, but generally a T75 flask was used to have a higher number of cells. In the 
case of drug-treated cells, floating cells in the medium were collected by pipetting into a 
universal tube. The remaining cells were trypsinized and centrifuged at lOOOg for 3 minutes 
in order to pellet the cells. The cell pellet was washed twice with ice cold PBS. Cell lysis
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buffer was added to the aspirated pellet, which was then disaggregated by mixing with a 
pipette and left on the ice for 10 min. Cell lysis buffer should be made up fresh each time.
The lysed cells were transferred to an eppendorf tube and further lysed using a 23 gauge 
needle before being left on ice for 20 to 30 min. A centrifugation step at 500g for 10 minutes 
at 4 °C removes the nuclei and unbroken cells. The supernatant or “whole cell lysate” 
containing the proteins was pipetted off into a fresh tube and labelled. Whole cell lysate is 
stored at -70 °C for western blotting analysis.
2.8. Protein quantification
The cell protein concentration was assessed by using the Biorad DC Protein Assay (BioRad 
Laboratories Ltd, Hemel Hemstead, UK). This assay is a dye binding assay based on the 
differential colour change of the dye occurring in response to different protein concentrations. 
By following the manufacturer’s instruction, 1:10 dilutions of the cell lysate samples were 
prepared by adding 5 pi of the sample to 45 pi of RO water. A range concentration of BSA 
standards (0.2-1.5 mg/ml) was prepared to obtain a standard curve. 50 pi of protein samples 
and BSA standards were added into the wells of a 96-well plate in duplicate. 25 pL of 
working reagent (20 pi of reagent S per 1 ml of reagent A) was added into each well, 
followed by adding 200 pi of reagent B. The plate was gently agitated to mix the reagents, 
left for 5 minutes, and the absorbance was measured at 690 nm. Using the standard curve, the 
protein concentration of the cell lysate was determined.
2.9. SDS-PAGE and Western Blotting
SDS-PAGE is a widely used technique to separate proteins according to their molecular 
weight by means of an electric current. In a typical experiment, the cell lysate sample was
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mixed with the loading dye and reducing agent and water was added to top up to the final 
volume. The mixture is heated at 70 °C for 10 min and then loaded into a NuPAGE® 
NovexBis-Tris Gels (7%, 8 %, 10%, 12% or 4-12% gradient gels), depending on the size of 
the protein of interest. NuPAGE® MOPS SDS, MES SDS or TA are used as running buffers 
(depending on the requirement of the gel type). A protein ladder was run alongside the 
sample to monitor the migration of the protein sample through the gel. The separation was 
carried out at 200 V until the dye reached the edge of the gel.
2 Protein transfer
1 Run SDS-PAGE 3 Blocking agent
4 Primary antibody
C o rre sp o n d in g  b a n d
5 Secondary antibody 
(HRP-conjugated)H yperfilm
6 Substrate 
+ 00 .
Chemiliminescent Signal
P ro te in  o f  in te r e s t
Figure 2-3Schematic diagram of SDS-PAGE and western blotting principles. 1- Samples 
are separated using SDS-PAGE with a marker. 2- Proteins are transferred to the membrane with an 
aid of electrical current. 3- The membrane is blocked using blocking solution in order to prevent the 
non-specific binging. 4- The membrane is incubated with the primary antibody. 5- The membrane is 
subjected to incubation with the secondary antibody (tagged with the enzyme). 6- The substrated is 
added and reacts with the enzyme to produce the chemiluminescent signal that is captured on the 
hyperfilm, the signal on the film corresponds with the position of the target protein on the membrane.
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Western blotting analysis (see schematic diagram in figure 2-3) was performed next in order 
to transfer the protein from the gel onto a PVDF or nitrocellulose membrane in an apparatus 
made by NOVEX Systems (Invitrogen). After the transfer was done successfully, the 
membrane was incubated with blocking solution, containing 2.5% milk and 2.5% BSA, to 
block non-specific binding sites on the membrane. Primary antibody was prepared in 
antibody diluent in order to probe the membrane. The membrane was incubated with the 
primary antibody solution at 4 °C overnight under gentle shaking. The membrane was 
washed and a suitable secondary antibody solution (tagged with the enzyme horseradish 
peroxidase) was used to probe the membrane for 2 hours with gentle shaking. Following the 
incubation the membranes were washed three times with PBS-Tween.To produce a 
luminescence signal, a substrate for horseradish peroxidase (“chemiluminescent substrate”) 
was added to the membrane. Oxidation of the substrate by horseradish peroxidase generates a 
photoluminescent signal, which was visualised on film. To detect equivalent protein loading, 
the membrane was stripped to remove an antibody’s signal attached to the protein on the 
membrane, which enables reprobing with different antibodies. This was done by incubating 
the membrane at room temperature for 2 h in 1 mM sodium azide in PBS and gentle shaking. 
The membrane was then exposed to an anti-mouse p-actin antibody or GAPDH antibody, 
which served as a loading control.
2.9.1. Densitometry
The chemiluminescent signals on the hyperfilm obtained from western blotting were scanned 
and analysed by densitometry (the quantitative measurement of band density) using 
QuantiScan software (Version 3.0, BioSoft, Cambridge, UK).
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2.10. RNA isolation for qPCR
RNA was extracted using Trizol® reagent (Invitrogen) and a phase separation technique 
according to the manufacturer’s instructions, which were as follows: ER-positive breast 
cancer cells (MCF7 and T47D) and tamoxifen- and fulvestrant-resistant cells (MCF7-TR and 
T47D-FR) were grown in T25 flasks. When the cells reached 80% confluence the sufficient 
amount of Trizol reagent was added to disassociate nucleoprotein complexes 
(homogenization step). The lysate was suspended through a pipette several times before 
being transferred into 2 ml microfuge tube. Next, phase separation was carried out by adding 
0.2 ml of chloroform per 1 ml of trizol and vortexing vigorously for 15 s, followed by 
incubation at room temperature for 2-3 minutes. Subsequently, samples were centrifuged at 
lO.OOOg (phase separation step). If done correctly, this will result in two phases. The lower, 
organic phase will contain proteins, whereas the upper, aqueous phase contains nucleic acids.
The aqueous phase containing RNA was transferred to a fresh tube and incubated with 0.5 ml 
isopropanol for 10 min to precipitate RNA. The mixture was centrifuged at 12,000g and the 
supernatant removed, leaving an RNA pellet behind. The RNA pellet was washed with 75% 
ethanol by adding at least 1 ml of 75% ethanol per 1ml of Trizol reagent, mixed by vortexing 
and centrifuged at 10.000 x g for 5 minutes. Finally, the RNA pellet was dried out either by 
gently pipetting off the supernatant and the RNA dissolved in RNAse-free water by passing 
the solutions few timed gently through a pipette tip and incubating at 55-60 °C for 10 
minutes. The purity and quantity of total RNAwas checked by using a Nanodrop NP-lOO 
spectrophotometer (Labtech International Ltd., East Sussex,UK) and the ratio of 260/280 nm 
calculated to assess the purity of RNA. A ratio of 2.0 is generally accepted as adequate for 
RNA purity. The RNA samples were stored at -80 °C.
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2.11. Reverse Transcriptase (RT) reaction
RNA extracted from cell samples can be analysed for the expression of a particular gene 
expression by converting RNA into cDNA and analyse the cDNA by real-time quantitative 
PCR (RT qPCR). The RT reaction was done by using the ImProm-II™ Reverse transcription 
system (Promega, Southampton, U K ). Following the manufacturer’s instructions, the 
reaction mixture was prepared by combined the experimental RNA (up to 1 pg) and the 
random primer (0.5 pg/reaction) in nuclease-free water for a final volume 5 pi per RT 
reaction. The tubes are then placed into a preheated 70°C heat block for 5 minutes and 
immediately chilled in ice for at least 5 minutes. The tubes are kept on ice until the reverse 
transcription mix is added. The reverse transcription mix was prepared by combining the 
components of the Impro-II™ Reverse transcription system as following: 5xImProm-IF^ 
reaction buffer, 0.5 mM dNTPs, 1.5 mM MgCl2 , 20 u recombinant ribonuclease inhibitor and 
1 pi ImProm-IF^ Reverse Transcriptase are added to each sample. Then, tubes are placed in 
the heat block at 25 °C for 5 minutes incubation and then at 42 °C for up to one hour. In order 
to proceed with PCR, the reverse trancriptase must be inactivated thermally prior to 
amplification by incubating the reaction tubes at 70 °C for 15 minutes. The generated cDNAs 
were used in quantitative real-time PCR for measurement of gene expression level.
2.12. microRNAanalysis
RNA was extracted from the SKBR3 and SKBR3-7LapR cell lines as described in section 
2.10. After the quantity and quality of RNA samples were checked using the Nano-drop 
spectrophotometer RNA samples were sent on dry ice to create pathways maps profiling of 
the expression of micro RNAs by commercial service (Thompson Reuters, London, UK).
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2.13. Quantitative real-time (qPCR) assay
Real time quantitative RT-PCR was performed using the QuantiTect® Green PCR kit andan 
ABI Prism 7700 Sequence detection system (Applied Biosystems, Nieuwerkerk a/d IJssel, 
The Netherlands) and Assay-on-Demand kits from Applied Biosystems. The reaction was 
prepared in a 96-well plate, each sample in duplicate; one set for the gene of interest (GOI) 
and the other set for the set for the housekeeping gene (HKG), which is either GAPDH or B- 
actin. The master mix for each reaction was 2x QuantiTect® SYBR® Green PCR master mix 
(use as Ix) plus gene-specific RT^q PCR primer for human Estrogen receptor 1 (ESRl) . The 
reaction mixture was prepared by combining the following reagents: 1 pi of each primer 
(provided by SA Biosciences, UK), 1 pi cDNA template, 12.5pi SYBR Green reagent and 
RNase-free water for a final reaction volume of 25pl. The plate was centrifuged at 3000g for 
3 minutes to remove air bubbles before being placed into the thermal cycler. The programme 
applied as recommended by the primers’ manufacturer was as follows: 10 min at 95 °C PCR 
for initial activation, 40 cycles for dénaturation for 15 seconds at 95 °C, and annealing for 60 
seconds at 60 °C. Data analysis has been done by using AACt method. In this type of 
analysis, the expression levels of GOI were normalised to the HKG by calculating the 
differences in threshold cycle (C t) between GOI and HKG, known as ACt, and then the 
differences of ACt values of the control and the samples, known as AACt. Finally the fold 
change in gene expression was determined by using the formula where AACt is the
A C t ( g e n e  o f  i n t e r e s t ) -  ACt(GAPDH) and Ctis the threshold cycle at which the fluorescence passes the 
threshold.
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2.14. Optical and fluorescence confocal microscopy (Confocol 
Laser Scanning Microscopy) (CLSM)
The advantage of using confocal fluorescence microscopy is to minimise the light detected 
that comes from outside the focal plane of the microscope by a pinhole located in front of the 
detector. In this thesis, confocal microscopy was carried out to visualise morphological 
changes of therapy-resistant breast cancer cell lines. For a typical experiment, cells were 
grown in T25 flasks and treated with the drug of interest for 48 hours. After harvesting, cells 
were either processed using a Cytospin 4 (Thermo Electron Corporation, Basingstoke, UK) to 
obtain a cell monolayer on glass slides, or grown on a cover slip in a 6 -well plate at a density 
of 3x10^ per wellfor the parent and 4x10^ for the resistant sub-lines. Next, cells were 
incubated overnight at 37 °C to allow for attachment and treated with the respective drugs (5 
pM for tamoxifen, 2 pM for fulvestrant, and 5pM for lapatinib) for 48 h. In later 
experiments, cells were additionally treated with a dose of IpM mefloquine, either on its own 
or in combination with tamoxifen. Cells were then covered with methanol for 20 min to fix 
cells and, r washing twice with PBS, incubated with 0.1% Triton X-100 to permeabilise cell 
membranes. Following rinsing with PBS, slides were incubated in 0.1% BSA in PBS/Triton 
for 1 h to block non-specific binding. This was then followed by overnight incubation with 
the respective primary antibody (LC-3, HFRl or HFR2) at a dilution of 1:200 in PBS-Triton 
at 4°C. Slides or cover slips were then washed with PBS and incubated with the secondary 
antibody conjugated to Alexa-Fluor488 (Molecular Probes, Invitrogen) for 2 h. After rinsing 
three times with PBS the nuclear dye T0PR03 (Nuclear Probes, Invitrogen) was applied for 
approximately 10-20 mins with two final washing using PBS. Slides were left to air-dry and 
then mounted onto a glass slide using VFCTASHIFLD® mounting medium. The edges of 
the slides were sealed with standard commercially available nail lacquer to prevent samples
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from drying out. Confocal microscopy was performed using a Zeiss LSM 510 confocal 
microscope. TO-PRO-3 nuclear stain was excited at 633 nm using an Argon/2 laser and 
emission detected between 650-710 nm. Alexa Fluor® was excited at 488 nm and detected at 
500-550 nm.
2.15. Annexin V with propidium iodide (PI) methodology for 
apoptosis with flow Cytometry
The Annexin V-FITC conjugated apoptosis detection kit incorporating PI was used as 
described by the manufacturer (Calbiochem® Oncogene™, UK) to aid cell death analysis. 
This experiment used two different fluorescent probes, Annexin V-FITC and PI and works on 
the principle that in the early stages of apoptosis, phosphatidyl serine (PS) molecules 
normally located on the cytosolic face of the plasma membrane of viable cells are flipped 
onto the cell surface which then leads to their removal by phagocytes (Sreejalekshmi et ah, 
2011). In the Annexin V Apoptosis Detection Kit (Calbiochem®; supplied by Merck 
Chemicals, Beeston,, UK), a fluorescein isothiocyanate (FITC) conjugate of Annexin V binds 
to these PS molecules, generating a fluorescent signal which can be detected by flow 
cytometry. Cells in late-stage apoptosis additionally have disrupted membranes, allowing 
propidium iodide (PI) to bind to the DNA. Therefore, cells in late apoptosis will be both 
FITC and PI positive, distinguishing them from early apoptotic cells (which will have FITC 
staining only) and necrotic cells (which will have PI staining only). Viable cells are 
negativefor both Annexin and PI. The data generated are presented as a cytogram composed 
of four quadrants, FI, F2, F3 and F4. FI contains cells that are dead or in end-stage 
apoptosis/necrosis (Annexin negative, PI positive), F2 contains cells in mid-phase and late- 
phase apoptosis (positive for both Annexin and PI), F3 contains viable cells (negative forboth
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Annexin and PI), and E4 contains cells in early apoptotic phase (Annexin positive, PI 
negative) as shown in figure 2-4.
E l( U ppe r  right qu ad ran t )  E2(Upper right quadran t )
Necrosis Late apoptosis
9.8%
85.7% ' . ' 0 1.0%
E3 (Lower left quadran t )  
Viable
FL3 (PI) »  FL1 (FITC)
E4 (Lower right quadran t )  
E arly/m id-phase apop tosis
Figure 2-4Cytogram readout generated by a flow cytometer.The cytogram consists of: 
bottom left; living cells (PI and FITC negative) bottom right; early apoptotic population (FITC 
positive) top right; mid-late stage apoptosis (PI and FITC positive) top left; necrotic/end stage 
apoptotic cells (PI positive, FITC negative).
Human breast cancer cells were seeded into 6 -well plates at approximately 50% confluence, 
allowed to attach and treated with the caspase inhibitor Z-VAD (lOOpM) prior to drug 
treatment for 1 hour to see if the cell death pathway is caspase-dependent or independent. A 
concentration of 100 pM Z-VAD was used referred to the previous studies which involved 
MCF-7 cell line (Mooney et al., 2002, Ajabnoor et al., 2012). Next, cells were treated for a 
period of 48 h with either tamoxifen (10 pM) or fulvestrant (1 pM) and harvested in the same 
way than described earlier. Cells were washed twice in cold PBS followed by resuspension in 
ice cold binding buffer and incubation with Annexin V -FITC for 30 min at room 
temperature. Cells were then centrifuged at lOOOg for 5 minutes, the medium removed, the
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cell gently resuspended in cold Ix binding buffer and propidium iodide (PI) added for 20 
minutes. Samples were analysed using a Beckman Coulter Epics XL flow cytometer used the 
ELI (FITC) and FL3 (PI) laser lines and each samples was assessed using a collection of 
1 0 , 0 0 0  events.
2.16. Flow cytometric analysis of cell cycle alterations
The alternative application for using flow cytometry is to determine the DNA content of cells 
and thereby determine what proportions of a cell population are at various stages of the cell 
cycle as shown in figure 2-5. The cell cycle consists of four stages: G l, S phase (synthesis 
phase), in which DNA is replicated, 02, and M phase (mitotic phase), during which mitosis 
occurs. Gl and G2 are gaps preceding the S and M phases (Darzynkiewicz et al., 1992). Cells 
are usually arrested in Gl following treatment with a cytostatic drug and it is therefore 
expected that the proportion of cells in Gl phase increases, resulting in a high G l peak in 
flow cytometry.
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Relative amount of DNA per cell (PI staining)
Gi Gg and M-phase
(ü)
Figure 2-5Flow Cytometry analysis of cell cycle phase.PI intercalates DNA strands so that the 
amount of DNA per cell can be determined, which is used to deduce the proportion of cells in each 
stage of the cell cycle. Also shown are the events occurring at each phase of the cell cycle represented 
by the graph, i.e. growth (Gl), DNA synthesis (S-phase), growth or mitosis (G2 and M-phase).
Breast cancer cells were treated with predetermined concentration of respective 
antioestrogens for a set of time 24 hours. Following drug treatment cells were trypsinised and 
and gently centrifuged at 500g. The cell pellet was washed with PBS before being 
resuspended in 2 mL ice cold 70% ethanol (in PBS) and incubated at 4°C for at least 24 hours 
for fixation and permeabilisation of the cell membrane. The ethanol was added slowly whilst 
mixing continuously using a vortex mixer. The cells were then washed with PBS before 
incubation with 5 pg/ml PI and 1 mg/ml Ribonuclease A (both from Sigma Aldrich, Poole, 
UK) for 30 minutes in the dark. During this time PI enters the cells and intercalates 
betweenDNA strands so that the amount of DNA present within the cell can be quantified by 
measuring the amount of fluorescence emitted by the dye. Ribonuclease A is used to break
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down RNA in the cells so that it cannot interfere with DNA detection (Arpino et ah, 2008). 
Samples are then analysed using an Epics XL TM flow cytometry (Beckman Coulter, 
Buckinghamshire, UK) by measuring the fluorescence at >575nm at an excitation wavelength 
of 488nm.
2.17. Statistical analysis
Summary data were presented as mean ± standard deviation, calculated by using GraphPad 
PRISM® (GraphPad Software, Inc, USA) and Microsoft Excel Software. Student’s Paired t- 
test was performed when making comparisons between parental and resistant cell lines. In 
addition, two-way ANOVA was performed for more than two groups and post-hoc tests were 
applied to correct for multiple comparisons. The specific statistical tests and corrections used 
are detailed in the figure legends of each figure. An alpha value of 0.05 was selected as the 
cut-off for significance (p<0.05).
121
Chapter 3 Characterisation of anti-endocrine-resistant breast cancer cells
Chapter 3
Characterisation of anti-endocrine-resistant
breast cancer cells
122
Chapter 3 Characterisation of anti-endocrine-resistant breast cancer cells
3. Characterisation of anti-endocrine-resistant breast 
cancer cells
3.1. Introduction
3.1.1. Overview of anti-endocrine therapy resistance
Despite the significant anti-neoplastic and chemopreventive activities of anti-endocrine 
therapy, most initially responsive breast tumours develop resistance (Lewis and Jordan, 
2005). Drug resistance remains a major obstacle in the struggle for the treatment and 
prevention of breast cancer. There is a huge body of research focused on the mechanism 
behind tamoxifen resistance in breast cancer, but little data exist on its interaction with 
oestrogen deprivation and even less is known about fulvestrant resistance. Approximately 
one-third of women treated with tamoxifen for five years will relapse and recurrent disease 
will occur within 15 years (Johnston and Dowsett, 2003).
Currently, three possible mechanisms of drug resistance to tamoxifen have been 
acknowledged: metabolic resistance, intrinsic (or de novo) resistance, and acquired 
resistance. Metabolic resistance is based on the levels of certain GYP enzymes, which 
activate prodrugs into more active compounds or vice versa, with evidence for inter­
individual variation in expression levels in the population. Intrinsic or de novo resistance is 
exemplified by tumours that fail to respond to initial therapy, while acquired resistance 
develops over the time course of long exposure to anti-oestrogen therapy.
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A prominent example of metabolic resistance is associated with the use of tamoxifen,a 
prodrug that is metabolically activated by CYP3A4/5 and CYP2D6 (Figure 3- 
1 ) .Hydroxytamoxifen and especially endoxifen are important active metabolites of tamoxifen 
that are necessary to achieve the maximum potent anti-oestrogenic and antitumour effects. 
These metabolites have been shown to possess a 100-fold greater affinity for ER and 30- to 
100- fold greater potency in suppressing ER-dependent proliferation and gene expression 
(Zilli et al., 2009). Wide variations in both of theenzymes responsible for tamoxifen 
metabolism exist in the population. Thus, the clinical response to tamoxifen therapy is likely 
to depend on the cumulative effect of these metabolites, giving rise to metabolic resistance 
(Johnson et al., 2004).
CYP3A4/5
N-desmethyltamoxifentamoxifen
CYP2D6CYP2D6
CYP3A4/5
HO HO
Endoxifen4-hydroxytamoxifen
Figure 3-lTamoxifen and its active metabolites.
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Intrinsic resistance is exemplified by tumours that fail to respond to initial therapy.lt has been 
observed when conducting a study on Caucasian women, which were found to be carrying 
inactive alleles of cytochrome P450 2D6 (CYP2D6) thatthey are unable to transform 
tamoxifen to its active metabolite endoxifen, rendering the treatment less effective (Hoskins 
et al., 2009).
This chapter focusses on acquired resistance of breast cancer cell lines against tamoxifen and 
fulvestrant. Here we investigate the mechanisms behind modifications of ERa status and the 
alterations in the intracellular environment via changed expression of cell cycle co-regulators 
and the influence of kinase downstream signalling. A huge body of research has been 
undertaken to elucidate the mechanism of tamoxifen resistance, but little has been published 
related to fulvestrant resistance. For the purpose of this study, we focus on two different anti- 
endocrine-resistant cell lines; one resistant to tamoxifen (MCF7-TR) and one resistant to 
fulvestrant (T47D-FR).
3.1.2. Molecular mechanisms for acquired resistance to anti-oestrogens
Acquired resistance to anti-endocrine therapy may develop after excessive exposure to the 
treatment. Research has suggested a variety of mechanisms that confer resistance to 
tamoxifen, such as 1) modifications of ER status, 2) changes in the intracellular environment 
due to altered expression of co-regulators and 3) the influence of kinase and growth factor 
signalling; all leading to the deregulation of cell survival and cell cycle progression. In the 
following, this chapter will describe the main proposed mechanisms responsible for anti- 
endocrine resistance.
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3.1.21. ERa Status
Loss of ERa expression
The effect of anti-endocrine therapies is mediated via the ER, and therefore the degree of 
expression of ER is a strong predictor of response to anti-oestrogen therapies. As mentioned 
earlier in chapter 1,tamoxifen acts as an antagonist of ERa, but it also has an agonistic 
activity, whereas fulvestrant is a pure antio-estrogen with no agonistic effect. Loss of 
expression, mutation, or change in activity of ERa, as well as an alteration in the expression 
of ERp are potential mechanisms by which ER status may change, thus affecting tamoxifen’s 
and fulvestrant’s actions, resulting in the development of clinical resistance. Anti-oestrogen 
therapies are only effective in cancers that are ER-positive and dependent on ER signalling 
for growth and proliferation and so ERa expression is the principal biomarker of response to 
anti-endocrine treatment (Zilli et al., 2009).
It has been hypothesised that loss of ERa expression is a potential mechanism of acquired 
resistance. However, loss of ERa expression occurs in only 17%-28% patients with acquired 
resistance(Musgrove and Sutherland, 2009). It has been observed that patients who develop 
tamoxifen-resistance will still responding to second-line anti-oestrogen agents with either 
fulvestrant and aromatase inhibitors, indicating a continuing role of oestrogen in the 
progression of breast cancer and also that patients with acquired resistance to tamoxifen still 
partially express ERa (Howell et al., 2005;0sbome et al., 2002).However, in the case of 
acquired fulvestrant-resistance, it was found for a range of different cell lines including 
MCF7, T47D, and ZR-75, that the ERa receptor was completely lacking and only minimal 
mRNA was detectable (90% decrease). This was accompanied by significant changes in 
oestrogen-induced expression of ERa target genes (Fan et al., 2006).
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Epigenetic mechanisms
Several epigenetic mechanisms have been proposed to explain the regulation of ERa 
expression, potentially enabling the discovery of new biomarkers to predict and diagnosis the 
development of acquired resistance in response to anti-oestrogens therapies (Trimarchi et ah,
2011).
The role of DNA méthylation in remodelling gene expression patterns associated with 
acquired anti-endocrine resistance is not fully understood. It has been reported that 
interrupting ERa function with anti-oestrogens can result in epigenetic modification of 
chromatin and altered gene expression. DNA méthylation occurred in CpG dinucleotides, 
which are concentrated to form CpG islands in the promoter region of 70% of human genes 
(Saxonov et al., 2006). Hypermethylation of CpG islands in gene promoters often leads to 
inactivation of transcription, and an inverse relationship between promoter méthylation levels 
and transcriptional activity has been well documented (Saxonov et al., 2006). Recent studies 
show that ERa depletion with small interfering RNA (siRNA) in breast cancer cells triggered 
repressive chromatin modifications and DNA méthylation in a set of ERa target promoters, 
resulting in transcriptional silencing of the corresponding genes (Garcia-Becerra et al., 2013). 
Molecular changes of the ERa associated with acquired tamoxifen and fulvestrant resistance 
were investigated by Fan et al. using genome-wide promoter méthylation analysis of 
oestrogen-responsive MCF7 breast cancer cells with acquired resistance to either tamoxifen 
or fulvestrant(Fan et al., 2006). They showed that tamoxifen and fulvestrant can cause either 
hypermethylation or hypomethylation of particular CpG-rich loci, resulting in a distinct 
promoter méthylation pattern. Surprisingly, promoter hypomethylation was found to be more 
prevalent than promoter hypermethylation in the anti-oestrogen-resistant breast cancer 
sublines. A possible explanation for this phenomenon is that oestrogen-responsive genes are
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also involved in cell growth and their inactivation therefore causes growth arrest or cell 
death. Consequently, breast cancer cells with acquired tamoxifen-resistance continue to use 
ERa to support cell growth and survival but through an altered ERa target gene network. In 
contrast, acquired resistance to fulvestrant was found to be an ERa-independent 
phenomenon(Fan et al., 2006).
ERa mutation
There is evidence that mutant ERs play a role in hormonal therapy resistance. By 
usingtheT47D human breast cancer cell line as a model system, three mutant ERa cDNAs 
have been identified in a tamoxifen-resistant variant that influenced the oestrogen- and DNA- 
binding domain of ERa. These findings suggest that genetic instability and mutant ERs 
mayplay a vital role in this breast cancer cell line modelling hormone-resistant Stage IV 
breast cancer (Graham et al., 1990). Herynk and Fuqua have reviewed the connection 
between ERa mutations and human diseases, of which several are linked to tamoxifen- 
resistance and response. For example, duplication of exons 6 and 7 of a tamoxifen-resistant 
variant of the MCF7 cell line leads to the production of an ERa that can no longer bind to 
tamoxifen (Herynk and Fuqua, 2004). In addition, short insertions in exon 6 have been 
identified in breast tumours that developed a resistance to tamoxifen (Pink et al., 1996). Wolf 
and Jordan reported that a point mutation at amino acid D351Y in the ligand-binding domain 
of ERacan confer resistance to tamoxifen, by using tamoxifen-resistant MCF7 xenografts 
(Wolf and Jordan, 1994). Similarly, co-expression of wild type ERa along with an ERa 
variant that lacked exon 5 within the ligand-binding domain rendered it unable to bind 
oestrogen, thereby causing resistance to tamoxifen(MacGregor Schafer et al., 2000).
However, it is important to consider that mutations in ERa occur only in less than 1% of
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breast tumours, and therefore they do not significantly contribute to anti-endocrine resistance 
(Zilli et al., 2009).
ERa phosphorylation
ERa is a target of serine, threonine and tyrosine kinase phosphorylation. ERa 
phosphorylation is a key player in non-genomic actions in response to oestrogen, but has also 
been shown to influence genomic transcription-mediated events (Riggins et al., 2007). 
Mutations at these sites of phosphorylation often cause an enhancement of ERa 
transcriptional activity. The kinases that contribute to these phosphorylations include 
Src,PAKl, PKA, cyclin A, Akt and ERKl/2. Many of the potential mechanisms altering the 
phosphorylation and thereby the activity of ERa, thereby contributing to the resistant 
phenotype, are discussed below.
3.1.2.1.AItered Expression of ERp
The role of ERp in anti-endocrine resistance is conflicting. As discussed previously, ERp has 
the ability to repress the activity of ERa (Pettersson et al., 2000). To date, few researchers 
have reported that low levels of ERp are associated with tamoxifen-resistance, but the 
number of studies assessing this is low(Zilli et al., 2009). The expression of ERp in breast 
cancer is associated with a better prognosis. However, there is currently no consensus 
regarding the mechanism of ERp in tamoxifen-resistance and more work is required to 
establish whether the role of ERp expression is important in anti-endocrine resistance in 
general.
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3.1.2.2.Altered expression of co-regulators
It is well known that co-regulators play an important role in mediating ERa transcriptional 
activity. Since many of these may exist at rate-limiting levels in the nucleus, changes in their 
level of expression or activity can cause an alteration of ERa signalling(Normanno et al., 
2005). In particular, an imbalance caused by over-expression of co-activators and down- 
regulation of co-repressors can abrogate the effects of anti-oestrogens either by abolishing the 
anti-oestrogenic effects or by switching the effect from anti-oestrogenic to oestrogenic 
(Girault et al., 2006).
In vitro studies have demonstrated that high levels of ERa co-activators can enhance the 
agonistic activity of tamoxifen. A lB l (also known as SRC-3) is an ERa co-activator and is 
considered a proto-oncogene. It is phosphorylated and activated by mitogen-activated protein 
kinase (MAPK) and high levels of activated A lB l may potentially decrease the antagonist 
effects of tamoxifen (Cho and Lee, 2003). Clinically, it has been observed that A lB l is 
overexpressed in more than 30% and gene amplified in 5%-10% of breast malignancies 
(Shahi et al., 2011).
Likewise, resistance is seen when cells express low levels of ERa co-repressors. It is 
established that decreased expression of the nuclear receptor co-repressor (NCoR) can result 
in a change in tamoxifen activity and potentially contribute to resistance (Cottone et al.,
2001).Girault et al. (2003) analysed the mRNA expression of NCoR by applying real- 
timeqPCR in a well-defined series of ER-positive breast cancer patients who exclusively 
received adjuvant tamoxifen therapy after surgery. They demonstrated that low expression of 
NCoR is correlated with notably shorter relapse-free survival in patients who were treated 
with tamoxifen (Girault et al., 2003). Therefore, evaluation of NCol expression may be
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considered as an important marker to predict the development of resistance to tamoxifen in 
patients with breast cancer(Zhou et al., 2007).
3.1.2.3.Growth factor signalling pathways
ERa signalling does not exist in isolation within the intracellular environment; many other 
elements, specifically those comprising growth factor transduction cascades, can influence 
ERa signalling (Nicholson et al., 2005). As described earlier, in addition to the genomic 
actions, ERa may initiate rapid cellular signalling via direct interaction with components of 
growth factor signalling pathways. Activation of ERa via the non-genomic pathway that 
occurs outside the nucleus results in phosphorylation and activation of cell surface tyrosine 
kinase receptors, such as IGF-IR, EGFR (HERl) and HER2 (Massarweh and Schiff, 2007). 
Many of these interactions lead to the activation of key downstream signalling kinases such 
as MAPK and Akt, which also have the potential to phosphorylate and thereby activate ERa 
itself. Alternatively, ERa co-activator proteins can potentially stimulate growth and 
proliferation of breast cancer cells independently of ERa or by cross-talk with 
ERa(Nicholson et al., 2007). In addition, alterations in these signalling cascades have the 
ability to reduce the therapeutic responses to anti-oestrogenic drugs such as tamoxifen and 
fulvestrant and potentially lead to the development of drug resistance (Garcia-Becerra et al.,
2012).
Recent evidence demonstrates that growth factor networks are highly interactive with the 
ERa in the control of breast cancer growth and development. As such, tumour responses to 
anti-oestrogens are likely to be a composite of both ERa and growth factor inhibitory activity 
of these agents, with alterations and aberrations in growth factor signalling providing a 
mechanism for the development of anti-oestrogen resistance (Musgrove and Sutherland, 
2009;Nicholson et al., 2004). In this light, chapter 4 focuses on illustrating the relationship or
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cross-talk between growth factor signalling and anti-hormone failure in our anti-endocrine- 
resistant breast cancer cell models. There, we also describe how we target their actions 
therapeutically in order to improve the effects of anti-oestrogen drugs and to block aggressive 
disease progression and proliferation.
3.1.2.4.Cell cycle regulators
Data from experimental model systems supported by clinical correlations, indicate that 
oestrogen accelerates cell cycle transition from G1 to S phase, while anti-oestrogen 
therapeutic agents have both cytostatic and cytotoxic effects, antagonising the action of 
oestrogen (Nair and Vadlamudi, 2008). It has also been observed that anti-endocrine therapy 
leads to a G1 phase-specific cell cycle arrest and consequently, a reduction in cell 
proliferation and growth rate (Doisneau-Sixou et al., 2003). Several studies have addressed 
deregulation of the activity of cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors 
as regulators of the cell cycle. Their crosstalk with ERa is considered as an underlying 
mechanism by which tumour cells use the cell cycle machinery to develop resistance to 
hormonal therapy(Riggins et al., 2007). The following paragraphs discuss examples of how 
the deregulation of cell cycle elements impact drug resistance.
Cyclin E
The contribution of cyclin E to tamoxifen resistance is unclear, but over-expression of cyclin 
E in MCF7-cells has been shown to partially counteract the growth arrest mediated by 
tamoxifen (Caldon et al., 2012). It was also found that low-molecular weight forms of cyclin 
E induced genomic instability and resistance to CDKI and failure to
respond to anti-oestrogens in breast cancer. These findings suggest that high levels of these 
isoforms of cyclin E are not only linked to resistance to anti-endocrine therapy, but also can
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be applied as prognostic indicators due to their influence on cell proliferation, progression 
and genetic instability (Akli and Keyomarsi, 2004).
In an attempt to understand more clearly the molecular mechanisms involved in tamoxifen- 
resistant breast tumours, an integrative bioinformatics approach to analyse gene expression 
profile data sets from ER-positive breast tumours was undertaken.This analysis showed that 
down regulation of cyclin E2 when using drugs of the phenothiazine family (trifluoperazine, 
thioridazine, and prochlorperazine) inhibited the growth of tamoxifen-resistant breast cancer 
cells (Huang et al., 2011). Expression levels of cyclin E are investigated within this chapter in 
the established parental and anti-oestrogen-resistant cell lines to assess its contribution to 
resistance.
Cyclin D1
Cyclin D1 is essential for early progression through the G1 phase and is also often 
deregulated in breast cancer(Alao, 2007). Cyclin D1 overexpression causes an increased 
abundance of cyclinDl-CDK4 complexes, which indirectly stimulate the activity of 
cyclinEl-CDK2 by sequestering the CDK inhibitors p21'^ ^^  ^and p27^^^\Stendahl et al.,
2004). The molecular pathways linking cyclin D1 to the development of tamoxifen-resistance 
have not been well established. One study showed that cyclin D1 interacts with several 
transcription factors including ERa and STAT3 inresponse to tamoxifen treatment.In this 
study, when of STATS by cyclin Dlled to the inhibition of cell growth. These findings breast 
tumours of patients were treated with tamoxifen, repression support the concept that the 
levels of cyclin Dland STAT3 expression are important markers to predict response to 
tamoxifen treatment in the clinic (Coqueret, 2002;Ishii et al., 2008). The down-regulation of 
cyclin D1 with siRNA restored the sensitivity breast cancer cells to tamoxifen (Kilker and 
Planas-Silva, 2006). Clinical studies also support the role of cyclin D1 in tamoxifen-
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resistance and revealed that patients with cyclin D1-negative tumours show better relapse- 
free survival, while in contrast, cyclin D1 expression is correlated with a poorer outcome of 
tamoxifen treatment (Jirstrom et al., 2005;Rudas et al., 2008).
p21’'""andp27“>’‘
p21™^'and p27*“'’’ are CDKIs and negative regulators of cell cycle progression. These 
proteins counteract the activities of cyclin D1 and cyclin E. Reduced expression ofthe CDKIs 
p2 jwafi resulted in decreased anti-oestrogensensitivity in viïro(Wang et al., 2008).
MYC overexpressionand the consequent development of tamoxifen resistance is 
accompanied bytranscriptional repression of CDKAiA, which encodesp21 '^^^^Mukherjee and 
Conrad, 2005), relieving the inhibitory effect of p21^^^  ^on cyclinEl-CDK2 complexes.
Cyclin D1 overexpression furthermore leads to an increased abundance of cyclin D1-CDK4 
complexeswhich can activate cyclin E1-CDK2 indirectly (Hui et al., 2002) by sequestering 
p2 iwafi p27^^\This can lead to the activation of cyclinE2-CDK2 by enhancing the 
transcriptionof CCNE2 whichencodes cyclin E2 (Caldon et al., 2009).
Tamoxifen increases the expression of p21'^ ^^  ^and p27^^^ proteins during cell cycle arrest, 
but their down-regulation prevents the growth inhibitory effects(Doisneau-Sixou et al., 2003). 
Somatic deletion of the p21^^^  ^gene in human breast cancer cells caused a hyper­
phosphorylation of ERa, leading to an increased gene expression of ERa-regulated genes. 
Clinical data also supports the critical role of these CDKIs in response to hormonal treatment. 
It has also been reported that increases in p27™’^  expression can better predict relapse-free 
survival upon tamoxifen combination treatment in premenopausal women with early breast 
cancer(Pohl et al., 2003). A multivariate analysis of their data revealed decreased 
p27kipiexpression to be associated with a poor therapeutic outcome upon combination anti- 
endocrine therapy (Pohl et al., 2003). The expression of p27 '^^  ^ in the parental and
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establishedanti-endocrine-resistant cell lines and their effect on anti-endocrine resistance has 
been evaluated as part of this chapter.
P53
P53 is a well-known tumour suppressor and is of profound importance in the regulation of the 
cell cycle. A cohort study was conducted to look at the relationship between the efficacy of 
anti-endocrine therapy of breast cancer and p53(Yamashita et al., 2006). The expression of 
p53 and other biological factors were measured via immunostaining in primary breast cancer 
tumours from patients suffering from recurrent or advanced disease who were previously 
treated with endocrine therapy. A number of clinical factors were also analysed and the 
significance of these was evaluated by measuring the time to anti-endocrine therapy failure 
(TTEF). The analysis generated showed that reduced TTEF was correlated with high 
expression of p53, thereby suggesting that p53 status is extensively important for the outcome 
of anti-endocrine therapy and could be used as a predictive marker for response to the 
treatment (Kai et al., 2006).
FOXMl
The role of the cell cycle regulator FOXMl in anti-endocrine resistance has been also been 
the focus of many studies (Gomes et al., 2013;Leung et al., 2001). The regulation of FOXMl 
expression by ERa and its role in hormonal therapy and anti-endocrine resistance has been 
investigated in breast carcinoma cell lines treated with tamoxifen and fulvestrant(Elkak and 
Mokbel, 2001). The study showed that depletion of ERa by RNA interference (RNAi) in 
MCF7 cells lead to down-regulation of FOXMl expression.By conducting reporter gene 
assays, the same study found that ERa activates FOXMl transcription through an ERE 
located within the proximal promoter region. Data from the study also revealed that upon
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treatment with tamoxifen, ERa recruits histone deacetylases to the ERE site of the FOXMl 
promoter, which is associated with a decrease in histone acétylation and transcription activity, 
thereby conferring resistance. Importantly, this acquired resistance could be overcome 
through silencing of FOXMl by RNAi(Millour et al., 2010). In addition, a strong and 
significant positive correlation was found betweenERa and FOXMl mRNA expression after 
qRT-PCR analysis with breast cancer patient samples (McGovern et al., 2009). Collectively, 
these results indicate that FOXMl is a key player in mediating the mitogenic functions of 
ERa and oestrogen in breast cancer cells and suggest that its deregulation may contribute to 
the insensitivity toward anti-endocrine therapy (Millour et al., 2010).
3.1.2.5.Cell survival via the PI3K /AKT signalling pathway
The PI3K/Akt downstream signalling pathway has been extensively investigated for its role 
in oncogenic transformation. This pathway plays an important role in cell proliferation, 
survival, and anti-endocrine resistance (Chang et al., 2003). Akt is one of the downstream 
targets of PI3K, stimulating cellular proliferation and promoting anti-apoptotic responses 
(Datta et al., 1999). Recent studies have observed that oestrogen stimulates the association of 
ERa with the IGF-1 receptor and the p85 regulatory subunit of PI3K in the plasma membrane 
(Clark et al., 2002), which leads to Akt activation and its subsequent downstream effects. In 
turn, Akt phosphorylates nuclear ERa at serinel67, resulting in ligand-independent activation 
(Martin et al., 2000).
In experimental models, it has been demonstrated that PI3K pathway activation confers anti­
oestrogen resistance and that knockdown of the suppressor phosphatase and tensin homolog 
(PTEN, considered a negative regulator of Akt) leads to increased PI3K and Akt 
phosphorylation in oestrogen-positive breast cancer cell lines.This ultimately leads
136
Chapter 3 Characterisation of anti-endocrine-resistant breast cancer cells
tohormone-independent growth and the development of resistance to tamoxifen and 
fulvestrant (Li et al., 1997;Miller et al., 2009).
Although much is still unknown about the mechanisms ofanti-endocrine therapy resistance in 
breast cancer, different forms of resistance are outlined in figure 3-2.
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Figure 3-2MolecuIar mechanisms of anti-endocrine resistance; model depicting 
molecules implicated in anti-endocrine resistance. l)Degredationof ERa. 2) The bidirectional
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crosstalk between ERa and growth factor receptor (GFR) signalling; many of these interactions lead 
to the activation of key downstream signalling kinases such as PI3K-mediated Akt activation, which 
is linked to rapid phosphorylation of ERa and ligand-independent receptor activation. 3) p21waf and 
p27 functions can be regulated in part by Akt, leading to sequestration of p27 and p21 ^  in the 
cytoplasm, where they are unable to interact with cyclin E and cyclin D, causing stimulation of cell 
cycle proliferation.
3.2. Aims
The aim of this chapter was to describe how novel drug-resistant cell lines were developed 
and used to study the mechanisms behind their resistance to the anti-oestrogens tamoxifen 
and fulvestrant.
The objectives designed to meet this aim were to:
• Measure the expression of ERa
• Measure the expression of the cell cycle elements p27, p53, cyclin B, and Skp2
• Assess the downstream signalling pathways of PI3K and Akt using Western blotting 
analysis.
3.3. Methods
Cell lines used in this work were the breast cancer cell lines MCF7 and T47D, and their drug- 
resistant variants MCF-TR (tamoxifen-resistant) and T47D-FR (fulvestrant resistant). All 
parental cells were routinely cultured with oestradiol (F2 at 1 nM). Techniques applied were 
the MTT cell viability assay (section 2.6.1), clonogenic assay (section 2.6.2), whole cell 
lysate preparation (section 2.7), Western blotting (section 2.9), RT-qPCR analysis (section 
2.13), and Annexin V-FITC with PI assay (section 2.15). All methods carried out in this 
chapter are described in full detail in Chapter 2.
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3.4. Results
3.4.1. Protocol for use of ERa-positive breast cancer cell lines in 
experiments
Oestrogens play an important role in the pathogenesis of breast cancer through the oestrogen 
ERa (Garcia-Becerra et al., 2013).This is because fat cells in breast tissue contain the enzyme 
aromatase which converts androgens into oestrogens (Travis and Key, 2003). Adding a 
physiological concentration of oestradiol (1 nM) to the cell culture medium has therefore 
been widely reported (Leary et al., 2010;Samaddar et al., 2008) as a means to increase 
ERaexpression and thereby promote cell proliferation and sensitivity to anti-oestrogens. In 
order to test if this also the case for the cell lines developed in this thesis, we treated 1) MCF7 
cells cultured with 1 nM oestradiol (E2) and 2) MCF7 cells cultured without oestradiol with 5 
pM tamoxifen or 2 pM fulvestrant for 48 hours. Morphological changes were analysed by 
optical microscopy (Figure3-3). There were more detached cells in the sample cultured with 
oestradiol and treated with fulvestrant/tamoxifen than in the sample cultured without 
oestradiol. This indicates that routinely culturing MCF7 cells with oestradiol could lead to an 
increased sensitivity to anti-oestrogens such as tamoxifen and fulvestrant.
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Figure 3-3 Morphological changes of parental MCF7 cells cultured with and without 
oestradiol (E2).0ptical microscopy of MCF7 cells to observe morphological changes of parental 
MCF7 cells cultured with InM oestradiol (E2) for 24 h and without oestradiol (E2) upon treatment 
with 5pM of tamoxifen and 2pM fulvestrant. Magnification x20, using Nikon Eclipse TSIOO inverted 
microscope.
The cell viability of the same samples was measured by flow cytometry after staining with 
Annexin V-FITC/PL The data showed decreased cell viability with anti-oestrogen treatment 
following pre-treatment with oestradiol (E2) (Figure 3-4 A). The data obtained from the 
cytograms generated from the Annexin-V FITC/PI assay are summarised as the viable 
population (PI negative and FITC negative; parts B). A significantly higher percentage of 
viable cells was seen for tamoxifen-treated cells in the absence of E2 versus the presence of
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E2 (92.56% (±3.81) versus 74.40% (±2.94) respectively; p<0.001; Figure 3-4 B). In similar 
experiments using fulvestrant in MCF7 cells, the population of viable cells was found to be 
94.73% (±2.61) in the absence and 78.13% (±2.20) in the presence of E2, respectively 
(p<0.001; Figure 3-4 B).
Based on these findings, we adopted the routine addition of 1 nM oestradiol to the culture 
medium for all future experiments.
MCF7-Control MCF7-Tamoxifen MCF7-Fuhestrant
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Figure 3-4Cell viability of parental MCF7 cells cultured with and without oestradiol
(E2).(A) Cytograms obtained from Annexin V assays of MCF7 cells treated with tamoxifen 5pM and 
fulvestrant 1.5 pM cultured with and without oestradiol InM. Each cytogram consists of, bottom left; 
living cells (PI and FITC negative) bottom right; early apoptotic population (FITC positive) top right; 
mid-late stage apoptosis (PI and FITC positive) top left; necrotic/end stage apoptotic cells (PI 
positive, FITC negative). The live cell population (i.e. PI negative, FITC negative) is indicated for 
each sample.(B) Bar graphs (derived from A) showing the cell viability of MCF7 cells cultured with 
oestradiol and treated with tamoxifen/fulvestrant compared with samples cultured without oestradiol. 
Data shown are representative of three independent repeat experiments (n = 3). Data are mean and 
standard deviation. Comparisons were made by paired t-test (***p<0.001).
3.4.2. Characterisation of tamoxifen-resistance in MCF7 breast cancer cells
MCF7 and MCF7-TR cells were treated with equal dose ranges of tamoxifen (1-500 pM) and 
cell viability was assessed by MTT assay. The dose response curves for both cell lines in 
Figure 3.5 (A) show that MCF7-TR cells are relatively resistant to tamoxifen, compared with 
the parental cell line. The tamoxifen IC5 0  values for parental and resistant cell lines were 
calculated using non-linear regression to be 11.91± 1.86pM and 38.56± 1.26 pM, 
respectively; the ratio of these values gives a resistance factor of 3.24-fold (calculated by 
dividing resistant IC5 0  by parent IC5 0 .), confirming that the MCF7-TR cell line is more 
resistant to tamoxifen-induced cell death. The difference between the responses is statistically 
significant (p<0.001; Figure 3-5 B).
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Figure 3-5Cell viability dose-response curves of MCF7 and MCF7-TR cells treated with 
tam oxifen.C ells were exposed to 1-500 pM tamoxifen for 96 h and cell viability was assessed by 
MTT assay.(A) Shows dose-response curve, each data point is the mean of the three independent 
experiments (performed in triplicate). (B) The IC50 values for MCF7 and MCF7-TR were calculated 
in Prism v .6  using a log drug concentration versus response slope and found to be 11.91 ± 1.86 pM 
and 38.56 ± 1.26 pM, respectively. The difference in response to this drug was highly statistically 
significant by paired t-Test (****p<0.0001).
3.4.3. Characterisation of fulvestrantresistance in T47D breast cancer cells
T47D and T47D-FR cells were treated with equal dose ranges of fulvestrant (1-200 pM) and 
cell viability was assessed by MTT assay. The dose response curves for bo»th cell lines in 
Figure 3.6 show those T47D-FR cells are resistant to fulvestrant. It is important to note that 
fulvestrant is growth-inhibiting rather than cytotoxic and hence the dose-response curve 
levels out at about 50%. The shape of the dose-response curves did not allow for obtaining a 
good fit using the 4-parameter model and hence IC5 0  values could not be calculated (Figure 
3-6). For this reason, a clonogenic assay was conducted to confirm the results, and also to 
allow the choosing of a suitable dose for future experiments.
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Figure 3-6Cell viability dose-response curves for T47D and T47D-FR cells treated with 
fulvestrant.Cells were exposed to 1-500 \iM fulvestrant for 96 hours and cell viability was assessed 
by MTT assay (n=3).
The clonogenic assay has been used in this study as an alternative to the M TT assay for 
treatm ents w ith fulvestrant, because fulvestrant has a cytostatic (grow th-inhibiting) rather 
than a cytotoxic effect. This m eans that in order to obtain an IC 50 value for fulvestrant with 
the M TT assay, large doses have to be used. The clonogenic assay, in contrast to the M TT 
assay is perform ed over a m uch longer tim e period (14 days ve rsu s  4 days) and therefore, an 
effect can be observed for m uch sm aller doses.
Cells were treated with the indicated concentrations o f fulvestrant for 48 h and, after a 
com plete culture m edium  change, cultured for another 14 days. Colonies consisting o f m ore 
than 50 cells were counted and norm alised to the untreated control. From  the bar graphs 
(Figure 3-7) generated from  the clonogenic assay, it was estim ated that a fulvestrant 
concentration o f 2^M  reduced colony form ation to 10% and 50%  in T47D and T47D -FR
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cells, respectively (p<0.05 versus T47D; Figure 3-7). In addition, at concentrations of 0.1 
\iM, 0.2 i^M, 0.5 pM, 1 pM, 2 pM and 5 pM the T47D-FR cells are significantly more 
resistant than the parental T47D cells (All p<0.05; Figure 3-7). This method confirmed that 
T47D-FR cells are more resistant to fulvestrant than the parent cell line.
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Figure 3-7 Antl-proliferative effects of fulvestrant (colony formation).T47D and T47D-FR 
cells were exposed to 0.1-5pM fulvestrant for 48h and colony formation was determined by 
clonogenic after an additional 14 days in culture without drug. Percent colony-forming units as a 
percentage derived from untreated cells, which were set to 100%. Data are representative of repeat 
experiments (n = 3). Comparisons were made by two-way ANOVA with Bonferroni correction 
(*p<0.05).
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3.4.4. Establishment of cross-resistance to anti-oestrogens
In the clinic, it has been observed that patients who are resistant to tamoxifen initially 
respond to fulvestrant as a second line treatment, but eventually develop a resistance to 
fulvestrant over time(Ring and Dowsett, 2004). Consequently, this study investigated if the 
tamoxifen-resistant cell lines used in this thesis show cross-resistance to fulvestrant.
3.4.4.I. Investigating cross-resistance to fulvestrant in tamoxifen-resistant MCF7-TR 
cells
MCF7 and MCF7-TR cells were treated with equal dose ranges (1-200 pM) of fulvestrant 
and cell viability was assessed by MTT. As cell viability never dropped below 50% using this 
dose-range (data not shown), it was increased to 500 pM (Figure 3-8), which did cause 
viability to drop below 50%, but still did not allow for obtaining a good fit with the four- 
parameter model.
150n
MCF7
MCF7-TR
so­
lo 100
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Figure 3-8Cell viability dose-response curves for MCF7 and MCF7-TR cells treated 
with fulvestrant.MCF7 and MCF7-TR cells were treated with fulvestrant at dose range 1-500 pM.
146
Chapter 3 Characterisation of anti-endocrine-resistant breast cancer cells
Cell viability was assessed by MTT assay. An IC50 could not be calculated using a four parameter 
model in Prism v6.
As seen previously, fulvestrant has a growth-inhibiting effect and thus we once more used the 
colonogenic assay as an alternative method to investigate the effect of fulvestrant on 
tamoxifen-resistant MCF7-TR cells. Cells were treated with the indicated concentrations of 
fulvestrant for 48 h and, after a complete culture medium change, cultured for another 14 
days. Colonies consisting of more than 50 cells were counted and normalised to the untreated 
control.
A dose-dependent reduction in colony formation was more apparent for parental MCF7 cells 
compared to the tamoxifen-resistant MCF-TR (Figure 3-9). From the bar graphs generated 
from the clonogenic assay, it was estimated that fulvestrant concentrations of 2pM reduced 
colony formation to 16% and 43% in MCF7 and MCF7-TR, respectively (p<0.01; versus 
MCF7 Figure 3-9). Additionally, at all other concentrations tested MCF7-TR cells formed 
significantly more colonies than MCF7 cells (all p<0.05; Figure 3-9). These results confirm 
that cells resistant to tamoxifen have developed cross-resistance to a drug with the same 
target, but with a different activity (mixed agonist/antagonist versus pure anti-oestrogen). The 
next section investigates the inverse relationship; the effect of tamoxifen on fulvestrant- 
resistant cells.
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Figure 3-9Anti-proliferative effects of fulvestrant: M C F 7 and M C F7-T R .C ells were 
exposed to 0.1-5pM fulvestrant for 48h and percent colony formation was determined by clonogenic 
assay after an additional 14 days in culture without drug. Percent colony formation is presented, 
where the number of colonies derived from untreated cells was set to 100%.Data are representative of 
repeat experiments (n = 3). Comparisons were made by two-way ANOVA with Bonferroni correction 
(*p<0.05; **p<0.01; ****p<0.0001).
3.4.4.2. Investigating cross-resistance to tamoxifen in fulvestrant-resistant T47D-FR 
cells
T47D and T47D -FR  cells were treated with tam oxifen. A resistance factor was calculated 
from  the IC 50 value o f tam oxifen in the resistant cell line (22.01 ± 1 . 1 5  pM ) divided by ICsoof 
the parent cell line (12.3 ± 0.68 pM ) and was found to be 1.78. The difference betw een the 
responses was statistically significant (p < 0.001; Figure 3-10) indicative o f a m oderate level 
o f cross-resistance.
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Figure 3-lOCell viability dose-response curves for T47D and T47D-FR cells to 
tamoxifen.Cells were exposed to 1, 2, 5, 10, 20, 50 and 100 pM tamoxifen for 96 hours and cell 
death was assessed by MTT assay. (A) Shows the dose-response curves for each cell line, each data 
point is the mean of the three independent experiments (performed in triplicate). (B) The IC50 values 
for T47D and T47D-FR cells were calculated in Prism v.6 using a log inhibitor versus response slope 
and found to be 21.4 ± 0.84 pM and 11 ± 0.70 pM, respectively. IC50 values are the averages of three 
MTT assays; error bars are ± SD. The difference in response to this drug was highly statistically 
significant by paired t-Test (***p<0.001).
3.4.5. Collateral sensitivity of tamoxifen- and fulvestrant-resistant cells to 
cisplatin
An MTT assay was performed to determine the response of MCF7/MCF7-TR cells, as well 
as T47D/T47D-FR cells to cisplatin. The dose response curves for both pairs of cell lines 
show that the respective resistant cell lines are more sensitive to cisplatin than the parent cell 
lines (Figure 3-11). In the case of the MCF7/MCF7-TR cells, ICsovalues were 41.15 ± 1.06 
pM (parental) vs. 14.28 ±1.4 pM (resistant) as shown in figure 3-11 (A). In the case of the
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T47D/T47D-FR cells, ICsovalues were 32.5 ± 2.07 \iM  (parental) vs. 15.4 ± 0.70 [xM 
(resistant), as shown in figure 3-11 (B). The differences in response between parental and 
anti-endocrine-resistant cells were statistically significant for both cell line pairs (both 
p<0.001; Figure 5.7B; Figure 3-11 A, B).The molecular mechanisms behind this effect of 
collateral sensitivity are studied in more detail in chapter 5.
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Figure 3-11 Cell viability dose-response curves of MCF7/MCF7-TR and T47D/T47D-FR 
cells treated with cisplatin.Cells were exposed to 0.5, 1, 2, 5, 10,20, 50, 100 and 200 gM cisplatin 
for 96 hours and cell viability was assessed by MTT assay. (A, B) Shows dose-response curves, each 
data point is the mean of the three independent experiments (performed in triplicate). The IC50 values 
for MCF7 and MCF7-TR were calculated in Prism v.6 using a log inhibitor versus response slope and 
found to be 41.15 ± 1.06 gM and 14.28 ±1.4 gM, respectively. The IC50 values for T47D and T47D- 
FR were 32.5 ± 2.07 gM and 15.4 ± 0.70 gM respectively. The differences in response between 
parental and anti-endocrine-resistant cells were statistically significant by paired t-Test (***p<0.001).
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3.4.6. Molecular characterisation of anti-endocrine-resistant cell lines
3.4.6.I. Down-regulation of ER-a
ERa expression is considered as the principal biomarker of response to anti- endocrine 
therapy. Various studies have implicated that loss of ERa expression is a potential 
mechanism of acquired resistance(Fan et ah, 2006;Musgrove and Sutherland, 2009). Thus, 
we now elucidate the role of ERa status in our established tamoxifen- and fulvestrant- 
resistant breast cancer cells in comparison to the parental cells. The protein expression levels 
of ERa in MCF7 parental- and resistant-cell lines wasdetermined by Western blotting (Figure 
3-12) and the bands semi-quantified by densitometry (b). Additionally, we examined the 
expression level of ERa mRNA of by extracting mRNA from the respective cell lines and 
performing a RT-qPCR analysis.
The expression of ERa in parent- and resistant-MCF7 cell lines was measured by Western 
blotting using a primary ERa antibody and GAPDH as a loading control (Figure 3-12 A) We 
measured both forms of ERa protein (total and phosphorylated) (parts A). Bands were semi­
quantified by densitometry (parts B). The blots revealed that total ERaexpression was down- 
regulated in tamoxifen-resistant cells compared with the parental MCF7 cell line (p<0.05; 
Figure 3-12 B). In addition, the expression of phosphorylated- ERawas significantly reduced 
in MCF7-TR cells compared with parental cells (p<0.01; Figure 3-12 B).
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Figure 3-12Changes in ERaexpression in parent- and resistant-MCF7 cell lines.(A) 40 gg
of each extract was separated by SDS-PAGE and transferred to PVDF membrane and then exposed to 
ERa antibodyusing a 1:100 dilution for 12 h before being exposed to anti-rabbit alkaline phosphatase. 
GAPDH expression was used as a loading control. Bands were detected using a chemiluminescent 
substrate. BRaand GAPDH were detected at 66kDa and 37kDa, respectively against a protein 
standard. (B) Bands were quantified by densitometry and normalised to GAPDH expression. 
Expression of total and phosphorylated ERa in parental control cells were set to one for ease of 
comparison.Data are representative of repeat experiments (n = 3). Comparisons were made by paired 
t-test (*p<0.05; **p<0.01).
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To confirm this observation, we performedRT-qPCR analysis for MCF7 and MCF7-TR cells. 
RNA was extracted from both cell lines with Trizol reagent as described in Chapter 2. The 
À ct values were calculated as the relative differences between expression levels of 
ERamRNA and a house keeping gene {GAPDH). The fold change was equal to 
Figure 3-13 shows that there is 70% lessERa mRNA in the tamoxifen-resistant cells 
compared with the parental cell line. (p<0.01; Figure 3.13).
0 1.0
Figure 3-13Expression of ERa in parent- and tamoxifen-resistant MCF7 cell lines 
determined using qPC R.Real time quantitative RT-PCR was performed using the QuantiTect® 
Green PCR kit. Each sample was prepared in duplicate; one set for the gene of interest and the other 
set for the set for the housekeeping gene, GAPDH. The master mix for each reaction contained 2x 
QuantiTect® SYBR® Green PCR master mix (used as Ix) plus gene-specific RT2 q PCR primer for 
human oestrogen receptor 1. The reaction mixture was prepared by combining the following reagents: 
1 gl of eaeh primer (provided by SA Biosciences, UK), 1 gl cDNA template, 12.5gl SYBR Green 
reagent and RNase-free water for a final reaction volume of 25gl. Data analysis has been done by 
using AACt method. Results represent the mean ± SD of three independent experiments. MCF7 
(parent) results were normalised to 1. Statistical analysis was performed using a two-tailed paired t- 
test (**P<0.01).
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The same study was performed using Western blotting analysis to detect the expression of 
ERain parental- and fulvestrant-resistant T47D cell lines. It was demonstrated that total and 
phosphorylated ERaexpression in the resistant cell lines was lower than the parental for this 
cell line model. The difference between total and phosphorylated forms of ERa expression in 
T47D parental and resistant cell lines was statistically significant (p<0.001 and p<0.0001, 
respectively; Figure 3-14 B).
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Figure 3-14The expression level of ERa in parent- and resistant-T47D cell lines.(A) 40
micrograms of each extract was separated by SDS-PAGE and transferred to PVDF membrane and
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then exposed to ERa antibodyusing a 1:100 dilution for 12 h before being exposed to anti-rabbit 
alkaline phosphatase. GAPDH expression was used as a loading control. Bands were detected using a 
chemiluminescent substrate. ERaand GAPDH were detected at 66kDa and 37kDa, respectively 
against a protein standard. (B) Bands were quantified by densitometry and normalised to GAPDH 
expression.Expression of total and phosphorylated ERa in parental control cells were set to one for 
ease of comparison. Data are representative of repeat experiments (n = 3). Comparisons were made by 
paired t-test (***p<0.001; ****p<0.0001).
Next, ER-amRNA levels were measured the parental and resistant T47D cells by RT-qPCR. 
As figure 3.15 shows, ERa mRNA was expressed at significantly lower levels in fulvestrant- 
resistant cells (p<0.0001. Figure 3-15).
****
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Figure 3-15Expression of ERa in parent- and parent and fulvestrant-resistant T47D cell 
lines determined using qPC R.Real time quantitative RT-PCR was performed using the 
QuantiTect® Green PCR kit. Each sample was prepared in duplicate; one set for the gene of interest 
and the other set for the set for the housekeeping gene, GAPDH. The master mix for each reaction 
contained 2x QuantiTect® SYBR® Green PCR master mix (used as Ix) plus gene-specific RT2 q 
PCR primer for human oestrogen receptor 1. The reaction mixture was prepared by combining the 
following reagents: 1 gl of each primer (provided by SA Biosciences, UK), 1 gl cDNA template.
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12.5gl SYBR Green reagent and RNase-free water for a final reaction volume o f 25gl. Data analysis 
has been done by using AACt method. Results represent the mean ± SD of three independent 
experiments. T47D (parent) results were normalised to 1. Statistical analysis was performed using a 
two-tailed paired t-test (****P<0.0001).
In the following sections, the contribution of drug transporters as another mechanism for 
acquired anti-endocrine resistance was elucidated using the example of P-gp (MDRl).
3.4.6.2. P-gp (MDRl) expression
One of the major obstaclesfor the success of chemotherapeutic treatment is the development 
of multi-drug resistance (MDR), which can cause a development of drug resistance (Coley,
2008)).This is often associated with over-expression of a transporter protein called P- 
glycoprotein (P-gp) (Gottesman et a l 2002; Coley 2008).
This experiment examined the expression levels of the drug transporter P-gp in the anti- 
endocrine-resistant human breast cancer cell lines by immunoblotting analysis (described in 
section 2, Chapter 2). It was found that there was a significant increase in P-gp in fulvestrant- 
resistant cells (T47D-FR) compared with the parental cell line, but only a slight increase in 
the tamoxifen-resistant MCF7-TR cells compared with the parental MCF7 cells as shown in 
Figure 3-16.
MDR (P-gp) 
p-Actin
0 0 Ê 0  Approx 170kDa
Approx 42kDa
Figure 3-16P-gp (MDRl) expression in parental- and anti-endocrine-resistant cells.
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Samples (60 gg protein) were electrophoresed on a 7% SDS-polyacrylamide gel, transferred to a 
PVDF membrane, and then exposed to MDRl antibody at a 1:100 dilution for 12 h before being 
exposed to anti-rabbit alkaline phosphatase. P-Actin expression was used as a loading control. Bands 
were detected using a chemiluminescent substrate. MDRl and P-Actin were detected at 170kDa and 
42kDa, respectively against a protein standard. Bands were detected using a chemiluminescent 
substrate (Invitrogen™). Data are representative of repeat experiments (n = 3).
3.4.6.3. Cell cycle regulation
As a third contributor to acquired anti-endocrine resistance we studied the change of 
regulatory cell cycle processes in the resistant vs. parental cells; in particular p53, p27 
Cyclin E, and Skp2.
p53status and responsiveness in anti-endocrine-resistant breast cancer cells
As a third contributor to acquired anti-endocrine resistance, we studied the role of p53 in the 
resistant vgr^wjparental cells.p53 is a transcription factor and plays a central role in regulation 
cell cycle process (Liang et al., 2011). It is a tumour suppressor protein and arguably the most 
commonly deregulated gene in human cancer.
Parental- and tamoxifen-resistant MCF7 cells were treated for 48 h with tamoxifen 5pM or 
fulvestrant 1.5 gM. Cell lysates were prepared from harvested cells following drug treatments 
in order to detect the p53 expression levels (Figure 3-17). The data showed that p53 protein 
expression could be induced in parental MCF7 cells (consistent with wild-type p53), whereas 
for tamoxifen-resistant cells (MCF7-TR), there was no induction following drug treatment 
(consistent with mutant p53).The intensity of the constitutive expression of p53 in the MCF7- 
TR cells is also indicative of a change in the protein half-life, as the levels are elevated 
compared with those for parental MCF7 cells. These factors point to a change in the p53 from 
wild type to mutant as a consequence of acquired tamoxifen-resistance.
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Figure 3-17 p53 protein level in parental M C F 7 cells and tamoxifen-resistant cells 
(M C F7-TR ).C ells were treated with tamoxifen 5 gM or fulvestrant 2 gM for 48hr before lysing. 
Protein extract (50 gg) was separated by SDS-PAGE and transferred to PVDF membrane. 
Immunodetection of p53 using a 1:100 antibody dilution (DO-1, Santa Cruz) produced a band at 53 
kDa, determined by use of a protein standard and (3-actin expression was determined as a loading 
control. Data represents n=3.
The protein expression levels of p53 in T47D parental and resistant cell lines were 
determined by Western blotting (Figure 3-18). T47D is known to harbour a point mutation in 
p53; however, expression levels appear to rise with drug induced stress in a wild-type 
manner. Again, p53 was induced in parental T47D cells in response to anti-oestrogen 
treatments, but not in the fulvestrant-resistant cell line (T47D-FR).
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Figure 3-18The expression of p53 in parent- and resistant-T47D cell lines.Cells were
treated with tamoxifen 5gM or fulvestrant 2 gM for 48hr before lysing. 50 gg of each extract was 
separated by SDS-PAGE and transferred to PVDF membrane. Immunodetection of p53 using a 1:100 
antibody dilution yielded a band at 53 kDa, determined by use of a protein standard and p-actin 
expression was determined as a loading control. Data represents n=3.
Measuring the level of p27 ^ ^hn anti-endocrine-resistant cells
p27 '^"Hs a CDKI that acts as a negative regulator of cell cycle progression. It has been 
revealed that reduced expression ofp27 results in reduced sensitivity to anti-oestrogen 
therapiesm vitroÇWmg et al., 2008). Western blotting analysis showed induction of the CDKI 
p27 in drug-sensitive MCF7 cells when treated with 5gM tamoxifen or2 gM fulvestrant. In 
contrast, this response was abolished in the drug-resistant counterparts (Figure 3-19).
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Figure 3-19The expression level of in tamoxifen-resistant MCF7 cells assessed
by Western blotting.Whole cell lysates were made following 48 h treatment with tamoxifen (5gM) 
or fulvestrant (2gM). Samples (50 gg protein) were electrophoresed on a 10% gel. After transfer of 
the proteins to a PVDF membrane, the membrane was probed with a monoclonal anti-mouse p27^^^  ^
antibody at a dilution of 1:100. Then, the blot was exposed to an anti-mouse alkaline phosphatase 
antibody (Invitrogen™). Bands were detected using a chemiluminescent substrate (Invitrogen™). 
Data are representative of repeat experiments (n = 3).
We compared fulvestrant-resistant and -sensitive breast cancer cells by measuring the 
expression level of p27^^\ revealing a noticeable induction of p27^^^ in the parent cell line 
when treated with 5gM tamoxifen or2 gM fulvestrant. In contrast,expression levels were 
either unchanged or reduced in fulvestrant-resistant cells under the same experimental 
conditions(Figure 3-20).
160
Chapter 3 Characterisation of anti-endocrine-resistant breast cancer cells
P27KIPI
/% /  y y y
Approx 27kDa
GAPDH Approx 37kDa
Figure 3-20The expression level of P27^ ^^  ^ in fulvestrant-resistant T47D cells assessed 
by Western blotting.Cells were treated with tamoxifen 5 gM or fulvestrant 2 gM for 48hr before 
lysing. 50 gg of each cell lysate was separated by SDS-PAGE and transferred to PVDF membrane. 
Immunodetection of p27^*^ using a 1:100 antibody dilution yielded a band at 27kDa, determined by 
use of a protein standard. Then, the blot was exposed to an anti-mouse alkaline phosphatase antibody 
(Invitrogen™). Bands were detected using a chemiluminescent substrate (Invitrogen™). Data are 
representative of repeat experiments (n = 3).
Alteration of the Gl-arrest phase of the cell cycle
D ata from  experim ental m odel system s supported by clinical correlations ind icate that anti- 
oestrogens are both cytostatic and cytotoxic and lead to decreased cell proliferation. In cell 
culture, anti-oestrogen therapeutic agents lead to a G l phase cell cycle arrest and a 
consequent reduction in growth rate (M usgrove and Sutherland, 2009).
This study exam ined the effect o f tam oxifen (10 gM , single dose) on cell cycle perturbation 
in tam oxifen-resistant M CF7-TR cells in com parison w ith parental M CF7 cells, using flow 
cytom etry. D N A  cytogram s of M CF7 cells show that 10 gM  tam oxifen caused  a com plete G l 
arrest (p<0.0001; Figure 3.20 A), w hereas there was no significant change in the cell cycle 
seen in M CF7-TR cells treated with the sam e dose o f tam oxifen (Figure 3-21 B). This is in
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accordance with the other data shown above showing a lack of inducibility of p2V'^ ‘^ ^by anti- 
oestrogens in the resistant variant and abolishment of Gl arrest.
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G l«  70.S3=:.S) 
S -  9 06=1.90 
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Figure 3-21DNA cytograms showing cell cycle analysis using propidium iodide staining 
of MCF7 and tamoxifen-resistant cells (MCF7-TR).MCF7 (A) and MCF7-TR (B) cells at 
70% confluence were treated with lOpM tamoxifen for 48 h and stained with propidium iodide for 10 
min. Bar charts represent the average of three repeated experiments. Comparisons of the size of the 
Gl arrest were made by paired t-test (****p<0.0001).
Cyclin E expression levels in anti-endocrine-resistant cells
Cyclin E is a key mediator of transition during the G 1/S cellular division phase. It has been 
shown that cyclin-B is deregulated in different types of cancer (Akli and Keyomarsi, 2004). 
The current study assessed the role of cyclin-E in breast cancer by measuring the expression 
level of cyclin-E in parental and endocrine-resistant breast cancer cell lines using Western
blotting analysis. The cells were treated for 48 h with 5pM tamoxifen or 2 pM fulvestrant.
The expression level of cyclin E was slightly increased in tamoxifen- and fulvestrant-resistant
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cells in comparison with their parental counterparts (Figure 3.22 A, B).
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Figure 3-22The expression of cyclin  E in parent- and resistant-MCF7 (A) and T247D 
(B) cell lines.W hole cell lysates were made following 48 h treatment with tamoxifen (5pM) or 
fulvestrant (2pM). 60 pgof each extract was separated by SDS-PAGE and transferred to PVDF 
membrane. Immunodetection of cyclin E using a 1:100 antibody dilution yielded a band at 45 kDa. 
The PVDF membrane was stripped of antibody using sodium azide and re-probed for the protein 
GAPDH which was used as a loading control. Data are representative of repeat experiments (n = 3).
Skp2expression inanti-endocrine-resistant cells
The S-phase kinase-associated protein (Skp2)isrequired for the ubiquitination and consequent 
degradation of p27"^'^\Ravaioli et al., 2008). The present study examined the role of Skp2 in 
anti-endocrine-resistant cells in comparison with the respective parental cell lines by Western
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blotting (Figure 3.23), in the hght of the changes in p27 '^^  ^ expression seen in these cell lines. 
Cells were treated for 48 h with 5[xM tamoxifen or 2 pM fulvestrant.The significant findings 
of the current study was a total absence of Skp2 expression levels in the parental MCF7 and 
T47D cells, while levels were remarkably up-regulated in tamoxifen- and fulvestrant-resistant 
breast cancer cells.
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Figure 3-23The expression of Skp2 in parent- and resistant- MCF7 (A) and T47D (B) 
cell lines. 100 pg of each extract was separated by SDS-PAGE and transferred to PVDF membrane. 
Immunodetection of using a 1:100 antibody dilution yielded a band at 48kDa, determined by use of a 
protein standard and GAPDH expression was determined as a loading control. Data are representative 
of repeat experiments (n = 3).
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3.4.6.4. The PI3K/Akt survival signalling pathway and anti-endocrine resistance in 
breast cancer cells
The PI3K/Akt signalling pathway is involved in the regulation of cell survival, cell cycle 
progression and cellular growth. Recent studies have indicated that PI3K/Akt signalling 
pathway components are frequently altered in breast cancer (Miller et al., 201 l;Van Tine et 
ah, 2011). This study evaluated the activity of the P13K/Akt pathway in anti-endocrine- 
resistant cells in comparison with parental cells by measuring the protein expression of P13K 
and Akt using Western blotting analysis.
Cell lysates were prepared in order to detect the expression of P13K/Akt proteins by using 
Western blotting analysis.Our findings indicated the Phosphorylated P13K (P-P13K), and 
phosphorylated Akt (P-Akt) were expressed at higher levels in tamoxifen-resistant cells 
(MCF7-TR) in comparison with their parental counterparts (Figure 3-24 A and B, 
respectively).
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Figure 3-24PI3K/Akt signalling molecules in parental MCF7 and tamoxifen-resistant 
cells (MCF7-TR) cells were harvested for immunoblot analysis.50 ggof protein was 
separated by SDS-PAGE and transferred to PVDF membrane. (A) Immunodetection of PI3K using a 
1:100 antibody dilution yielded a band at 85 kDa, (B) Immunodetection of Akt using a 1:100 antibody 
dilution yielded a band at 60 kDa.p-actin expression was determined as a loading control for both 
blots. Data represents n=3.
165
Chapter 3 Characterisation of anti-endocrine-resistant breast cancer cells
Western blotting was also performed to detect the expression levels of PI3K and Akt in T47D 
parental and resistant cell lines. The constitutive expression of phosphorylated Akt and PI3K 
was up-regulated in T47D-FR cells in comparison with parental T47D cells (Figure 3-25 A 
and B, respectively).
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Figure 3-25PI3K/Akt signalling pathways in parental T47D and fulvestrant-resistant 
cells (T47D-FR) cellswere harvested for immunoblot analysis.60 g g of protein was separated 
by SDS-PAGE and transferred to PVDF membrane. (A) Immunodetection of PI3K using a 1:100 
antibody dilution yielded a band at 85 kDa, (B) Immunodetection of Akt using a 1:100 antibody 
dilution yielded a band at 60 kDa.(3-actin expression was determined as a loading control for both 
blots. Data represents n=3.
The ERK survival signalling pathway and anti-endocrine resistance breast cancer cells
The ERK pathway is a key mediator of cell proliferation.Increased activity of this signal has 
also been associated with a poor prognosis among breast cancer patients(Frogne et al.,
2009).The current study investigated the role of extracellular signal-regulated kinase 1/2 
(ERK 1/2) signalling in tamoxifen- and fulvestrant-resistant human breast cancer cells in 
comparison with ER-positive human breast cells (MCF7 and T47D). An increase in total 
andphosphorylated ERK in fulvestrant-resistant cells compared with the parental cells was 
observed (Figure 3-26B). This increase was not so apparent for the MCF7-TR cell line 
(Figure 3-26 A).
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Figure 3-26The expression of ERK in parent- and resistant-MCF7 (A) and T47D (B) 
cell lines.60 ggof each extract was separated by SDS-PAGE and transferred to PVDF membrane. 
Immunodetection of ERK using a 1:100 antibody dilution yielded a band at 42kDa, determined by use 
of a protein standard and p-actin expression was determined as a loading control. Data represents n=3.
3.5. Discussion
Anti-endocrine therapy is the most commonly used treatment for patients with ER-positive 
breast cancer (Knowlden et al., 2003).However,tumourresistance to this approach remains the 
main obstacle for treatment efficacy in breast cancer patients and plays a crucial role in 
disease progression (Musgrove and Sutherland, 2009). The biological mechanisms 
underlying anti-endocrine resistance are, therefore, of considerable clinical significance. 
While tamoxifen resistance has been widely reseached (>2,000 citations, PubMed), there are 
few studies in the literature elucidating the molecular mechanisms behind fulvestrant 
resistance (approximately 24 citations, PubMed).
This study hypothesised that two anti-oestrogens (tamoxifen and fulvestrant) would induce 
adaptive distinct responses in breast cancer cells,thus promoting the emergence of drug 
resistance. To test this possibility, we generated human breast cancer cell lines with acquired 
resistance to tamoxifen and fulvestrant, known as MCF-TR and T47D-FR, respectively.
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The initial part of this chapter involved the characterisation of the developed cell line models 
(MCF7-TR and T47D-FR) by assessment of drug sensitivity and acquired resistance to 
tamoxifen and fulvestrant. The MCF7-TR cell line was found to be3.23-foldmore resistant to 
tamoxifen than the MCF7 parent cell line. When conducting a similar experiment for in the 
T47D-FR cell line using fulvestrant treatment, it became apparent that the MTT assay is not 
an ideal method to determine potency in this case. This is because fulvestrant has a growth- 
inhibiting rather than cytotoxic effect and therefore, the dose-response curve plateaus at 
around 50% cell viability instead of reaching 0%. Instead, the clonogenic assay was used to 
verify the resistance of fulvestrant resistant cells. Using this method, it was demonstrated 
again that T47D-FR cells are more resistant to fulvestrant than the parent cell line.Based on 
these results, the developed cell lines were deemed adequate to be used for further studies in 
this thesis.
We also investigated the phenomenon of “cross resistance” to anti-endoerine therapy (i.e. 
tamoxifen-resistant cells being cross resistant to fulvestrant and vice versa). The results 
confirmed what has already been observed in the clinic; that patients who develop acquired 
tamoxifen resistance also develop resistance to adjuvant fulvestrant over time (Ring and 
Dowsett, 2004). In fact, only 20% of patients who have relapsed on tamoxifen have 
responded to other aromatase inhibitors or ER-down-regulators, such as fulvestrant (Howell 
et al., 2002). Similarly, fulvestrant-resistant cells have been found to be cross-resistant to 
tamoxifen (Ring and Dowsett, 2004). This is despite the fact that fulvestrant is a pure ER 
antagonist, which completely abrogates oestrogen-sensitive gene transcription (Dowsett et al., 
2005). This led us to study the underlying molecular mechanisms of acquired drug resistance 
in more detail.
168
Chapter 3 Characterisation of anti-endoerine-resistant breast cancer cells
Better understanding of the mechanisms underlying resistance to anti-oestrogen therapies, 
such as tamoxifen and fulvestrant, may suggest novel strategies to overcome resistance and 
make further improvements to breast cancer survival (Zilli et al., 2009).As discussed 
previously, breast cancer patients who have relapsed on antiestrogen treatment have been 
found to be good responders to platinum compounds(Yde et al., 2007), and an increased 
sensitivity -  collateral sensitivity- to platinum compounds in vitro has been detected for 
tamoxifen- and fulvestant-resistant MCF7 breast cancer cells(Larsen et al., 2012). We were 
able to recapitulate these findings with our own anti-endocrine-resistant cell lines. Indeed, we 
found that both tamoxifen- and fulvestrant-resistant cells showed collateral sensitivity to 
cisplatin; indicating that platinum compounds may be an advantageous treatment in anti­
oestrogen resistant breast cancers. Although the basis of the collateral sensitivity hasnot yet 
been clarified, it may have important implications in clinical therapy with cisplatin. However, 
the role of p53 in cisplatin sensitivity is a considerable area of interest. Fan et al (1995) 
showed that disruption in p53 sensitised breast cancer cells to cisplatin (Fan et al., 1995). A 
different study identified the association between p53 expression and platinum sensitivity in 
human ovarian cancer cells. The findings generated from the their work showed that the loss 
of p53 leads to enhanced cisplatin chemosensitivity due to the loss of Gl/S checkpoint 
control, DNA repair, and the involvement of cell death pathways additional to apoptosis 
(Pestell et ak, 2000). According to our findings, anti-endocrine- resistant cells with p53 
mutation also have increased sensitivity to cisplatin, possibly via a similar mechanism. This 
suggests the pharmacological interest of cisplatin in the treatment of p5 3-mutated breast 
tumours. The molecular mechanisms behind this effect of cisplatin sensitisation in anti- 
endocrine resistant cells are studied in more detail in chapter 5.
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The effects of anti-oestrogens such as tamoxifen and fulvestrant are primarily mediated 
through the ERa and the degree of ERa expression is a strong predictor of response to these 
agents. This study measured the ERa status in parental and anti-endocrine-resistant cells. 
Immunoblotting analysis showed that expression levels of ERa were reduced in the 
tamoxifen-resistant cell line (MCF-TR), as were the levels of ERa mRNA. These findings are 
in agreement with the work of others (Fan et ak, 2006;Whisler et ak, 1995). The same 
analysis was performed for the fulvestrant-resistant T47D-FR cell line. The profound 
decrease in ERa protein and mRNA expression levels in T47D-FR cells versus parental 
T47D is in agreement with a study by Fan et ak(2006), who also observed a complete loss of 
ERa mRNA levels and ERa expression in MCF7 cells with resistance to fulvestrant. More 
recently, a study by Kirkegaard et al (2014) showed loss of ERa expression in a fulvestrant- 
resistant T47D cell line. Taken together, these findings demonstrate that reduction/loss of the 
ERa target is a good marker of resistance to anti-endocrine therapy (Kirkegaard et ak, 2014).
One of the major obstacles that faces breast cancer patients undergoing chemotherapeutic 
treatment is the development of multi-drug resistance, which can cause a failure to cure the 
disease (Gottesman and Ling 2006;Higgins 2007; Coley 2008; McGrogan et al, 2008). A 
common mechanism of drug resistance is reduced intracellular drug concentrations as a result 
of decreased influx or increased efflux. The latter is oftenmediated by the transporter P- 
glycoprotein (P-gp). To our best knowledge, there are only previous two studies evaluating 
the role of P-gp in tamoxifen resistance, but none that identify the role of P-gp in the 
development of fulvestrant resistance(Clarke et ak, 1992;Pavlik et ak, 1992).
Due to the prominent role of drug resistance in cancer, we considered the possible 
contribution of the ABC transporters in anti-endocrine resistance and measured the 
expression of P-gp in the anti-endocrine-resistant MCF7-TR and T47D-FR breast cancer
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celllines. We found that there was a very slight increase in the expression of P-gp in 
tamoxifen-resistant cells and a more profound increase in the fulvestrant-resistant cells 
compared with the parental cells. It has been previously reported that acquired, but not de 
novo resistance to tamoxifen may be associated with reduced intra-tumoural 
concentrations(Ring and Dowsett, 2004). Tamoxifen has also been shown to reverse 
multidrug resistance in P-gp-expressing cells (Callaghan and Higgins, 1995). The 
mechanisms responsible for altered tamoxifen accumulation are still poorly understood. 
However, it has been reported that P-gp is probably not responsible for the development of 
tamoxifen resistance (Clarke et ak, 1992), which is in accordance with our findings. Our 
resultsdid however show an association between overexpression of P-gp and resistance to the 
anti-oestrogen therapeutic agent fulvestrant. This has thus far not been reported in the 
literature.
p53 alterations are common in breast cancer, which may partly be due to the fact that p53 
plays a role in the antiproliferative and apoptotic activities of chemotherapy regimens used to 
treat breast tumours(Donehower and Lozano, 2009;Femandez-Cuesta et ak, 2011). The study 
conducted as part of this chapter evaluated the function of p53 in anti-endocrine-resistant 
cells and found that p53 was induced in response to anti-oestrogens in the parental cells, 
whereas there was evidence of mutated p53 in the anti-endocrine-resistant counterparts. It is 
well established that p53 plays an important role in inducing apoptosis by anticancer agents, 
such as anti-endocrine therapy (Elledge et ak, 1995;Zhivotovsky and Orrenius, 2003). Once 
p53 becomes mutated, it is possible that this then modulates the response to anti-endocrine 
therapy so that there is no cell cycle arrest, and cells continue to grow and survive in the 
presence of tamoxifen and fulvestrant. This is supported by a previous study whichalso
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showed that p53 mutated cells were more resistant to tamoxifen compared with p53 wild-type 
cells (Femandez-Cuesta et al., 2011).
In cell culture,it is known that anti-oestrogens lead to G1 phase-specific cell cycle arrest and 
a consequent reduction in growth rate (Doisneau-Sixou et ah, 2003). Unsurprisingly, the 
molecular events pivotal to anti-oestrogen effects on cell cycle progression playa huge role in 
the control of G1 progression.Increased Cyclin E expression has been associated with a 
poorertherapeutic outcome in ER-positive breast cancer and Cyclin E is included in several 
gene signatures that predict disease progression in either tamoxifen-resistant or metastatic 
breast cancer (Desmedt et ah, 2006). We, therefore examined the role of cyclin E in anti­
oestrogen resistance in viYroand found an increased cyclin E expression in the tamoxifen and 
fulvestrant resistant cells;when untreated or treated with tamoxifen and fulvestrant. These 
findingscorrelate well with previous literature showingthat Cyclin E overexpression is a 
potential mechanism of resistance to tamoxifen (Caldon et ah, 2012). However, to our best 
knowledge, the role of cyclin-E in fulvestrant resistancehas not been published before.
P2?Kipi is also an essential mediator of cell cycle arrest by anti-oestrogens. We therefore 
measured the protein expression of P27^^^after treatment with tamoxifen and fulvestrant and 
observed an induction of P27^^^ in theparental MCF7 and T47D cells, causing a complete 
G1 arrest. In contrast, we saw decreased expression in the resistant cells, leading in turn to an 
abrogation of cell cycle arrest and thereby to decreased sensitivity to anti-oestrogens in the 
tamoxifen- and fulvestrant-resistant cells. This is in accordance with a study by Chu et ah 
(2008) who also reported that decreased P27^‘^  ^ levels resulted in a diminished sensitivity to 
anti-oestrogens(Chu et ah, 2008). No published studies have so far been found regarding the 
impact of P27^^^ on development of fulvestrant resistance.
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Skp2, as key modulator of p27^^^ levels, was evaluated in the parental and anti-endocrine- 
resistant cells. The S-phase kinase-associated proteins Skp2 are required for the 
ubiquitination and consequent degradation of p27^^^ which allows cells to enter the S-phase 
(Ravaioli et al., 2008). It has been reported that deregulated expression of Skp2 in breast 
cancer cells might have a relevant role in the development of drug resistance (Foster et al.,
2003). The present study observed undetectable levels of Skp2 in the parental MCF7 and 
T47D cells (both in the control and after treatment with anti-oestrogens). In contrast, the 
expression of Skp2 was signifcantly upregulated in tamoxifen- and fulvestrant-resistant cells; 
this response was more profound when the cells were treated with tamoxifen. An explanation 
of this significant upregulation of Skp2 in the resistant cells could be that it offers a 
mechanism to keep levels of the p27^^^ CDKI at sub-optimal levels, thus allowing the cell 
cycle to progress. A previous study has also shown that low p27 and high Skp2 are more 
frequently associated with poor prognosis in breast cancer patients (Ravaioli et al., 2008). In 
addition, it has been reported that overexpression of Skp2 is associated with resistance to 
doxorubicin-based chemotherapy in breast cancer (Davidovich et al., 2008). The present 
study can be considered the only work identifying the role of Skp2 in acquired resistance to 
fulvestrant.
The last part of this study investigated the role of survival signalling pathways, such as 
PI3K/Akt and ERK, in acquired anti-endocrine resistance. There is a considerable body of 
evidence suggesting that there are multiple regulatory interactions between the ERa and other 
kinase signalling pathways (Arpino et al., 2008). In this chapter, the expression of PI3K, Akt 
and ERK proteins in the parental and anti-endocrine-resistant cells was measured. It was 
found that PI3K was upregulated in tamoxifen- and fulvestrant-resistant cells compared with 
the parental cells. These findings are in agreement with clinical evidence suggesting that
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hyperactivation of the PI3K pathway, the most frequentlymutated pathway among breast 
cancer patients, promotes anti-oestrogen resistance (Van Tine et ah, 2011).
PI3K is considered as a major signalling hub for downstream receptor tyrosine kinases such 
as HER2 and EGER. PI3K activates several elements involved in cell-cycle progression and 
survival and consequently promotes oestrogen-dependent and -independent ERa 
transcriptional activityin ER-positive breast cancer cells(Miller et al., 2011). In a consequent 
study conducted as part of this chapter, an increase in the expression of the Akt target was 
detected in tamoxifen-resistant cells. Both preclinical and clinical investigations have 
demonstrated a clear association between Akt signalling and the development of tamoxifen 
resistance (Jordan et al., 2004;Tokunaga et al., 2006), which supports our findings. Other in 
vitro studies reported in the literature have also shown that an increased constitutive activity 
of Akt in MCF-7 cells caused these normally hormone-dependent breast cancer cells to be 
more resistant to the inhibitory effects of tamoxifen (DeGraffenried et al., 2003). However, 
few studies have explored the direct effects of Akt signalling on breast cancer response to 
anti-endocrine agents other than tamoxifen(Miller et al., 2011). We investigated the effects of 
Akt signalling in fulvestrant-resistant breast cancer cells and detected an increase of the 
survival signalling of Akt. These findings support the data obtained by Beeram and co­
workers (2007) who reported that Akt plays a pivotal role in mediating acquiredfulvestrant 
resistance (Beeram et al., 2007). The third signalling pathway investigated within this chapter 
was that of ERK. Previous studies have reported increased levels of the downstream kinases 
of ERK in anti-endocrine resistant cells (Frogne et al., 2009) in support of our data.
Taken together, these findings highlight the role of an intimate crosstalk between the ERa 
and the HER family signalling pathways involving EGER andHER2, which canincrease the 
role of the non-nuclear fraction of ERa. The interaction between membrane/cytoplasmic
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ERaand tyrosine kinase receptors turns on the tyrosine kinase pathways and theirdownstream 
kinases, for instance PI3K, Akt and ERK. The cross-talk between these two signalling 
pathwaysemerges as a fundamental contributor to the development of resistance to anti- 
endocrine therapies. These observations open the door for this thesis to conduct a detailed 
study on the mechanisms of cross-talk and its implication in the development of the anti- 
endocrine resistance, as will be discussed in the next chapter.
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4. The bidirectional crosstalk between ERa and receptor 
tyrosine kinase signalling and implications in the 
development of anti-endocrine resistance
4.1 Introduction
The ERa signalling pathways and their associated ligands have been shown to be key players 
in breast cancer progression. The ERa is a nuclear ligand-dependent transcriptional factor 
that cancommunicate most mitogenic and survival stimuli in cancerous breast tissue through 
two pathways. One such pathway is the direct modulation of gene expression known as 
genomic action (nuclear-initiated steroid signalling (NISS) and the other is by acting as a 
component of membrane and cytoplasmic signalling cascades (non-genomic actions) (Zilli et 
al., 2009). Substantial evidence for non-genomic action of ER is established (Levin and 
Pietras, 2008). This non-genomic action of ER; also known as membrane initiated steroid 
signalling (MISS), begins outside the nucleus and is initially independent of gene 
transcription. It has been shown that this activity is mediated by the interaction between a 
small fraction of ER and various components of growth factor receptor tyrosine kinase 
signalling pathways (Zilli et al., 2009).
4.1.1. Growth factor receptor signalling pathways
Homeostasis of non-cancerous cells requires an equilibrium between cell survival, cell cycle 
arrest and cell death; this balance is disrupted during cancer progression. The ability of cells 
to sense their environment and decide to die or survive is fundamentally dependent on the 
presence of growth factors. Growth factors are key players in regulating cell survival, binding
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to the cell surface human epidermal growth factor receptor family HER, also known as ErbB, 
consisting of four receptors: HERl (EGER or ErbB-1), HER2 (ErbB-2), HER3 (ErbB-3) and 
HER4 (ErbB-4). The first receptor tyrosine kinase to be discovered was the HERl or EGER 
(Carpenter et al., 1978). HER2 and HER3 are not autonomous because of the fact that HER2 
has no known ligand and HER3 lacks intrinsic kinase activity(Lee-Hoeflich et al., 2008).
The signal from an extracellular growth factor can be transduced through the cell, regulate 
gene transcription and trigger cell progression through different steps. The first step which is 
the binding of the growth factor to its receptor causes a conformational change that reveals an 
extracellular receptor dimerization domain (Camarena et al., 2010). HER dimerization 
stimulates intrinsic intracellular protein-tyrosine kinase activity. As a result, auto­
phosphorylation of intracellular kinase domains of HER occurs. This autophosphorylation 
initiates a cascade of an extensive network of signal transduction pathways that include 
activation of the PI3K/Akt, RAS/ERK and JAK/STAT pathways. These pathways 
predominantly lead to inhibition and activation of transcription factors that regulate 
expression of both pro- and anti-apoptotic proteins respectively, effectively blocking the 
apoptotic pathway.
The consequences of HER activation are multiple and lead to cell proliferation, cell cycle 
progression and enhanced cellular survival. Growth factor receptor signalling pathways are 
often altered in cancer(Ueda et al., 2006). Cumulative clinical data suggest that aberrant 
EGER and HER2 signalling has been causally correlated with increased breast cancer cell 
progression and shorter survival in patients with breast carcinomas and is associated with a 
poor outcome (Arpino et al., 2004). The membrane tyrosine kinase HER2 is gene amplified 
in 20-25% of oestrogen receptor-positive breast cancers(Moulder et al., 2001;Wolff et al., 
2007).
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4.1.2. The bi-directional crosstalk between ERa and growth factor receptor 
signalling pathways as a cause for anti-endocrine therapy resistance 
in breast cancer
In the breast cancer field, it is becoming evident that evolution and tumour progression are 
intensely governed by the complex interactions between a steroid receptor (ERa) and growth 
factor receptor signalling. Growth factor signalling pathways, in particular EGER (HERl) 
and HER2, play a significant role in the development of both intrinsic and acquired resistance 
to anti-endocrine manipulation (Arpino et al., 2008;Rexer and Arteaga, 2012). However the 
molecular mechanisms underlying this aspect of anti-endocrine resistance are incompletely 
understood.
As mentioned previously, ERa signalling does not exist in isolation within the intracellular 
environment, and many other elements, most notably those consisting of growth factor 
transduction cascades, can influence breast cancer cell proliferation (Nicholson et al., 2007). 
In the literature, there are different proposed mechanisms by which growth factor receptors 
are involved in mediating of tamoxifen resistance. The first mechanism, by which breast 
cancer cells overcome the oestrogen antagonist effect of tamoxifen, initially occurs in a 
ligand-dependent manner, whereas the second mechanism is ligand-independent as will be 
explained later. In the first mechanism of anti-endocrine resistance, both oestrogen and 
tamoxifen activate the cytoplasmic ERa. Activation of ERa results in phosphorylation and 
activation of surface tyrosine kinase receptors (EGER and HER2)(Massarweh and Schiff, 
2007). Many of these interactions lead to the activation of key downstream signalling kinases 
such as PI3K, MAPK and Akt, which also have the potential to phosphorylate and thereby 
activate ERa itself or its co-activator proteins rather than corepressors. These actions result in 
enhanced expression of oestrogen-regulated genes (Shou et al., 2004), as shown in figure 4-
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1 .Alterations in these signalling cascades have the ability to alter therapeutic responses to 
anti-estrogenie drugs and potentially lead to the development of resistance.
Key
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ERE Oestrogen receptor element
Tam Tamoxifen 
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Figure 4-1A molecular mechanism of tamoxifen resistance through a ligand-dependent
m anner.Cytoplasm ic ERa activity may interact directly with tyrosine kinase receptors (EGER, and 
HER2) via the non-genomic pathway. This results in activation of coactivators (CoA), which prevent 
the inhibitory effect of tamoxifen (Tam) and causes anti-endocrine resistance through a ligand- 
dependent manner.
The plausibility for this mechanism of resistance was demonstrated in an experimental model 
system using ERa -positive breast cancer cells that also overexpress both AIB1
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(ERacoactivator) and HER2 (Shou et ah, 2004). The clinical data alsostrongly suggest that 
both HER2 and AIBl are considered necessary for the resistant phenotype (Bouras et al., 
2001). By addressing the mechanism experimentally, gene expression and cell proliferation 
was strongly increased in a tamoxifen-resistant derivative cell line(MCF-7/HER2- 
18)engineered to overexpress HER2 and AIBl resulting in stimulation of cell growth. These 
effects are in stark contrast to parental MCF7 cells, which do not express HER2(Shou et al.,
2004). In vitro investigations found that activation of ERa, EGFR/HER2 receptors, and 
MAPK and Akt signalling pathways, and recruitment of the AIB 1 coactivator were all up­
regulated in tamoxifen-resistant cells compared with wild-type MCF7 breast cancer cells, and 
can elicit tamoxifen resistance (Arpino et al., 2008). These findings were in agreement with 
the clinical observation that tumours that co-express HER2, EGFR and AIB 1 are associated 
with poor outcomes and treatment failure to tamoxifen (Fuchs et al., 2007).
The second mechanism of resistance is caused by the inappropriate activation of growth 
factor signalling cascades. This can potentially occur through an enhanced supply of growth 
factor ligands, via up-regulation, or through increased activation of the receptors or their 
downstream signalling cascades (e.g. MAPK, PI3K and Akt)(Nicholson et al., 2004). Such 
changes can potentially stimulate growth and proliferation of breast cancer cells via crosstalk 
with ER and growth factor receptors, and thereby contribute to resistance as shown in figure 
4-2.
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Figure 4-2A molecular mechanism of tamoxifen resistance in the absence of ERa
ligand.Overexpression of growth factor signalling pathways, which initially activate ER in the 
absence of ligand (oestrogen or tamoxifen) and enhance gene transcriptional activity and tumour 
progression.
One of the first indications of the crosstalk between ER and growth factor receptors was 
discovered by assessing the anti-endocrine sensitivity of MCF7 cells transfected with full 
length HER2 cDNA. This resulted in down-regulation of ER and development of resistance 
to tamoxifen(Benz et ah, 1992). Subsequently, several further studies have supported the role 
of growth factor receptors in resistance to anti-endocrine therapy (Arpino et al., 2004;Arpino 
et al., 2008).
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The crosstalk between ERa and growth factor receptors can influence the sensitivity of cells 
to tamoxifen(Faridi et al., 2003). Knowledge of this has caused researchers to focus on the 
particular receptor tyrosine kinases involved in this mechanism of tamoxifen resistance 
(Arpino et al., 2008;Musgrove and Sutherland, 2009). Increases in expression of EGFR and 
HER2 receptors and activation of downstream signalling pathwayscan be a result of genetic 
or epigenetic modifications or alterations in upstream regulators(Miller et al., 2011;Musgrove 
and Sutherland, 2009). However, the exact mechanism is not completely understood, despite 
the existence of different hypotheses discussed in the available literature. For example: 1) 
decreased expression of the receptor ERa; 2) activation of mitogenic signalling cascades due 
to loss of repression of growth factor receptors by ERa; 3) up-regulation of key cell cycle 
regulators, such as MYC, D-type and E-type cyclins, through induction of mitogenic 
signalling pathways; and finally 4) suppression of apoptosis, enhancing cell survival 
(Musgrove and Sutherland, 2009).
There is evidence supporting the role of IGF-IR (Insulin-like Growth Factor-1 receptor) in 
emerging anti-endocrine resistance, but it is less clear than the role of EGFR and HER2. IGF- 
IR is also a member of the receptor tyrosine kinase family, which is activated after ligand 
binding of insulin to IGF-I or IGF-II, resulting in activation of downstream signalling 
pathways including Akt, MAPK and PI3K cascades (Knowlden et al., 2003). IGF-IR is an 
ERa-dependent gene and tamoxifen, which effectively inhibits classical ER-dependent 
transcription, can effectively reduce its expression (Massarweh et al., 2008). Data regarding 
the levels of IGF-IR in tamoxifen-resistant breast cancer lines is variabledue to the 
synergistic interactions between IGF-IR, ERa and EGFR. Oestrogen results in an increased 
expression of IGF-IR and epidermal growth factor, predominantly EGFR, which in turn
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leadsto the activation of several kinases that are able to phosphorylate ERa and initiate 
oestrogen-mediated gene expression (Knowlden et ak, 2005).
Campbell and co-workers identified the mechanism by which IGF-1-treated breast cancer 
cells may eseape tamoxifen-induced apoptosis; namely via the IGF-mediated activation of 
Akt and subsequent phosphorylation of ER, leading to ligand-independent activation of 
ER(Campbell et al., 2001). Recently, in vitro studies have been aimed at elucidating the role 
of IGF-IR in drug resistant breast. Massarweh et al. discovered that p-IGF-IR, although 
initially reduced in the tamoxifen-sensitive tumours, is increased at the time of resistance, 
suggesting that IGF-IR becomes activated at that point and then augments important cell 
survival pathways (Massarweh et al., 2008). Data also suggest that bi-directional crosstalk 
pathways between the epidermal growth factor family of receptors (HER) and IGF-IR exist, 
and that these interactions are evoked in part to mediate the development of acquired 
resistance to tamoxifen (Cohen et al., 2005).
There is very limited work reporting the role of receptor tyrosine kinases in the development 
of fulvestrant resistanee. One study indicated that breast cancer cells resistant to fulvestrant 
demonstrated increased activation of epidermal growth factor receptor family members, such 
as EGFR and HER2 (Zhang et al., 2013).
4.1.3. Therapeutic strategies to overcome HER/ER cross-talk signalling 
pathways and anti-endocrine resistance
Anti-endocrine therapy is the most important systemic therapy for patients with ERa-positive 
breast cancer. Unfortunately, after the initial response, most patients ultimately relapse with 
acquired anti-endocrine resistance that leads to disease progression (Riggins et al., 2007). 
Preclinical models have indicated that an adaptive up-regulation of growth factor signalling
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islinked with acquired resistance to anti-endocrine therapies (Arpino et ak, 2008). For 
instance, HER2 is significantly overexpressed in 10% of ERa -positive breast cancers and has 
been assoeiated with poor prognosis and development of resistanee to both anti-endocrine 
therapeutic agents, such as tamoxifen, and aromatase inhibitors (Wong and Chen, 2012).
Recent studies on ER biology have emphasised the fundamental role of the intimate cross­
talk between the ER and growth faetor signalling pathways on the development of endocrine 
resistance. It has been indieated that the increased activity of growth factor signalling through 
multiple intracellular pathways may lead to the evolution of an anti-endocrine resistance 
phenotype. Consequently, targeting of growth factor signalling networks has emerged as an 
attractive strategy to overcome the resistance to anti-endocrine therapies among breast cancer 
patients. Clinically, restoring or modulating anti-endoerine resistance remains an important 
priority.
Considerable attention has been directed to the development of therapies that specifically 
target growth factor pathways in breast cancer; with the HER2 monoclonal antibody 
trastuzumab (Herceptin) being a prominent example. Successful clinical usage of 
trastuzumab has been verified in HER2-positive breast caneer and a significant benefit has 
been reported when used as first-line monotherapy, with up to a 48% clinical benefit rate in 
HER2-positive tumours and a 34% objective response rate in tumours identified as positive 
for HER2 amplification by fluorescence in situ hybridization (Vogel et ak, 2001). This 
indicated that other small molecule tyrosine kinase inhibitors (TKIs) might also prove potent 
strategies to target breast cancer cell proliferation and reverse drug resistance in the 
appropriate setting. The present study has used three different tyrosine kinase inhibitors, 
gefitinib, afatinib and labatinib (Figure 4-3) to investigate overcoming drug resistance. These 
are described in the following sections.
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Figure 4-3Chemical structure and main inhibition targets of three targeted therapy
agents.Lapatinib and afatinib are known as a dual kinase inhibitor because it targets both HER2 and 
HERl receptors. Gefitinib is an EGFR-inhibitor. The inhibition of growth factor receptor activity 
results in a blockade of the activation of the signal transduction pathways such as the PI3K/Akt and 
the Ras/Raf/ERK/MAPK pathways.
4.1.3.1. Gefitinib
Gefitinib (Iressa®) was the first drug developed as an inhibitor of the EGFR tyrosine kinase 
domain. Gefitinib reversibly competes with adenosine triphosphate (ATP) for binding to the
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intracellular domain of EGFR tyrosine kinase and prevents EGFR phosphorylation and 
downstream signalling. This has been shown to reduce production of pro-angiogenic factors 
and induce apoptosis in numerous in vitro and xenograft models (Mahipal et al., 2014). 
Gefitinib was evaluated in a phase II trial that cited evidence of the drug’s activity in 
Japanese patients with advanced non-small-cell lung cancer (NSCLC) (Paez et al., 2004). 
Gefitinib was initially approved by the US Food and Drug Administration (FDA) in 2003 
(Pao et al., 2004). Ithas since been approved for the treatment of advanced colorectal 
cancer, squamous cell carcinoma of the head and neck, NSCLC, as well as pancreatic and 
breast cancer (Lurje and Lenz, 2009).
EGFR is commonly expressed in epithelial tumours. In breast cancer, EGFR plays a major 
role in promoting cell proliferation and malignant growth associated with decreased 
sensitivity to anti-endocrine therapy and poorer prognosis (Knowlden et al., 2003).
Preclinical studies have offered evidence that gefitinibimproves tamoxifen sensitivity and 
delays acquired resistance in MCF-7 cells (Massarweh et al., 2008). Two randomised placebo 
controlled phase II trials showed efficacy and tolerability of anti-endocrine 
therapy(anastrozole or tamoxifen) combined with gefitinib in postmenopausal women with 
metastatic breast cancer. Studies reported that metastatic breast cancer patients who received 
a combination of anastrozole and gefitinib showed a longer progression-free survivalin 
comparison with those receiving anastrozole plus placebo (Polychronis et al., 2005).
4.1.32. Lapatinib
Lapatinib (Tykerb®) is an orally active small-molecule TKI. These types of molecules are 
typically able to diffuse into cells and act on intracellular targets to inhibit both EGFR and 
HER2 signalling. Several clinical trials have been conducted to study the effectiveness and 
safety of the drug. For example, in a phase I clinical study, oral lapatinib monotherapy was
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tolerated in 67 patients with ER/HER2-positive breast cancer patients at daily doses ranging 
from 500 to 1600 mg (McArthur, 2009). The most commonly reported side effects were 
diarrhoea in 42% of treated patents and rash reported in 31%. In a phase II clinical trial, 
lapatinib was effective in the treatment of 78 patients with HER2-positive metastatic breast 
cancer and a history of disease progression on trastuzumab (Bilancia et al., 2007). In a phase 
III clinical study, lapatinib had a positive effect in the treatment of women with HER2- 
positive metastatic breast cancer, but no effect on HER2-negative breast cancer (Press et al., 
2008). Lapatinib combined with capecitabine was approved by the US FDA in 2007 for the 
treatment of metastatic breast cancer, in which HER2 is overexpressed (Kaufman et al.,
2008).
To elucidate the mechanism of action of lapatinib, Fabian et al. (2005) screened the binding 
affinity of 20 kinase inhibitors against 100 different protein kinasess (Fabian et al., 2005). 
They found that lapatinib has the greatest binding affinity to EGFR and HER2 compared with 
other TKIs. Additionally, lapatinib has a slower dissociation rate compared with other ErbB 
TKIs, consequently prolonging inhibition of the receptor (Fabian et al., 2005)More precisely, 
lapatinib exerts its antitumor activity by binding to the intracellular domains of EGFR and 
HER2, resulting in inhibition of phosphorylation. This inhibition leads to downstream 
blocking of MAPK and PI3K(McArthur, 2009). Another in vitro study observed that breast 
cancer cells treated with lapatinib undergo G1 cell cycle arrest (Tang et al., 2013).
In addition to the actions listed above, it has been observed that lapatinib in conjunction with 
conventional chemotherapy regimens slightly decreases toxicity and reduces the risk of 
relapse in a clinically significant way (Liao et al., 2010). Consequently, improving disease- 
free survival and cancer management can be achieved among women with advanced breast 
cancer. Clinical trials have demonstrated significant benefits of lapatinib over trastuzumab in
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terms of overall survival (Wu et al., 2011). Apart from its greater affinity for EGFR and 
HER2, lapatinib has the ability to induce apoptosis in trastuzumab-resistant SkBr3 breast 
cancer cells (Nahta et al., 2006). A study by Konecny et al. (2009) demonstrated the 
synergistic effect of lapatinib combined with trastuzumab alone on breast cancer cell lines 
such as MCF-7 and SkBr3(Konecny et al., 2006). The antitumor activity of lapatinib 
observed in vitro was also confirmed in women with HER2-positive advanced breast cancer 
who experienced disease progression on trastuzumab therapy (Mohd Sharial et al., 2012). A 
study by Gril et al. (2008) found that lapatinib inhibited the formation of brain métastasés in a 
metastatic breast cancer xenograft model (Gril et al., 2008).
In the literature, only one study has so far explored the effectiveness of lapatinib to limit the 
occurrence of anti-endocrine resistance. In this study, MCF7 models of acquired resistance to 
tamoxifen were established and it was found that lapatinib and tamoxifen co-treatment led to 
a more profound cell cycle arrest (Leary et al., 2010). It was also highlighted that the 
therapeutic efficacy of lapatinib in combination with tamoxifen may be beneficial to patients 
with ER-positive breast cancer irrespective of HER2/EGFR expression (Leary et al., 2010).
4.I.3.3. Afatinib
More recently the small molecule TKI therapeutic approach has seen the addition of newer 
agents such as afatinib. Afatinib (Gilotrif®)irreversibly and selectively targets the HER 
family of receptors; EGFR/HERl and HER2(Lin et al., 2012).On July 12, 2013, the U. S. 
FDA approved afatinib as the first-line treatment for patients with metastatic NSCLC. The 
approval of afatinib was based on the demonstration of improved progression-free survival 
rate in patients with metastatic NSCLC, whose tumors previously progressed on 
gefitinib(0'Neill et al., 2013).
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In vitro studies have indicated that afatinib treatment inhibits the growth of trastuzumab- 
resistant breast cancer cells (SUM 190 cell line) which had progressed following treatment. 
These cells expressed high levels of HER2 and afatinib showed an effective antitumor 
activity in human xenograft models (Narayan et al., 2009). Furthermore, a Phase II study was 
conducted to assess the efficacy and safety of afatinib monotherapy in patients with HER2- 
positive metastatic breast cancer(Lin et al., 2012). Afatinib demonstrated a potent efficiency 
to inhibit cell proliferation and showed promising clinical activity in HER2-positive breast 
cancer cells(Lin et al., 2012). Further clinical trials of afatinib in breast cancer patients are 
ongoing.
4.2. Aims
This chapter focuses on the cross-talk between growth factor receptor signalling and ERa 
signalling in our anti-endocrine-resistant models of breast cancer cells. In addition, we aim to 
illustrate how cross-talk actions can be targeted therapeutically in order to improve the 
sensitivity of the cells to anti-hormonal drugs, inhibit survival signalling, and eventually 
block cell proliferation.
The aim above will be met by:
• Measuring the sensitivity of anti-endocrine-resistant breast cancer cells using the new 
targeted agents gefitinib (targeting HERl), and lapatinib and afatinib (targeting HERl 
and HER2) by MTT assay.
• Assessing ERagene expression by quantitative PCR after exposure of tamoxifen- and 
fulvestrant-resistant breast cancer cells (MCF7-TR & T47D-FR) to lapatinib.
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• Co-administering lapatinib andanti-endocrine therapies(tamoxifen and fulvestrant) to 
determine the effect on cell deathusing flow cytometry.
• Determining TKI signalling of HERl and HER2 by confocal microscopy in anti- 
endocrine-resistant breast cancer cells when treated with lapatinib and gefitinib.
• Establishing the molecular mechanism behind endocrine therapy sensitisation using 
lapatinib by Western blotting for PI3K and ERK.
4.3. Methods
Cell lines used in this chapter were the breast cancer cell lines MCF7 and T47D and their 
drug-resistant variants MCF7-TR (tamoxifen-resistant) and T47D-FR (fulvestrant-resistant). 
All parental cells were routinely cultured with oestradiol. Techniques applied were viability 
assay (MTT) (section 2.6.1), whole cell lysate preparation (section 2.7),Westemblotting 
analysis (section 2.9), RT-qPCR analysis (section 2.13), Annexin V-FITC with PI assay 
(section 2.15).and confocal microscopy (section 2.14). All methods carried out in this chapter 
are described in Chapter 2.
4.4. Results
4.4.1. Evaluating the sensitivity of anti-endocrine resistant cells to new 
targeted therapies (lapatinib, gefitinib, afatinib)
The MTT assay was carried out to determine the response of parental MCF7 cells and 
tamoxifen-resistant MCF7-TR cells to lapatinib, gefitinib and afatinib. Dose response curves 
from this experiment confirm that MCF7-TR cells were more sensitive to lapatinib (IC5 0  =
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3.5± 0.50 [xM), gefitinib (IC5 0 = 18.25 ± 3.18pM) and afatinib (IC5 o= 0.50 ± 2.88pM), in 
comparison with the parent MCF7 cell line (IC5 0  = 7.00 ± 0.25pM for lapatinib, IC50 = 34.20 
± 1.69[xM for gefitinib, IC5 0  = 7.09 ± 2.12pM for afatinib; Figure 4.6 A, B and C 
respectively). The difference in response to these drugs was highly statistically significant by 
t-test (p <0.05, p < 0.05, p < 0.001 respectively; Figure 4-4).
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Figure 4-4Dose response curve of MCF7 and MCF-TR cells treated with lapatinib (A), 
gefitinib (B) and afatinib (C) generated from the MTT assay.Fach data point represents the 
mean of three independent experiments per cell line. Dose response curves were fitted in Prism v.6
192
Chapter 4 Bidirectional crosstalk between ER and receptor tyrosine kinase signalling
and an IC50 was calculated; A) MCE7 and MCF-TR cells were treated with lapatinib and the IC50 
found to be = 7 ± 0.25pM and 3.5 ± 0.50 pM respectively. The difference in response to this drug was 
highly statistically significant by t-test (p < 0.05). B) MCF7 and MCF-TR cells were treated with 
gefitinib and the IC50 found to be = 34.20 ± 1.69pM and 18.25 ± 3.18pM respectively, the difference 
between the two curves was assessed by T-test (p <0.05). C) MCF7 and MCF-TR cells were treated 
with afatinib and the IC50 found to be = 7.09 ± 2.12pM and 0.50 ± 2.88pM respectively, the 
difference between the two curves was assessed by T-test (p <0.001). Each data point represents the 
mean of three independent experiments per cell line. Dose response curves were fitted in Prism v.6 
using an IC50 equation.
The MTT assay was also performed to determine the response of parental T47D cells and 
fulvestrant-resistant T47D-FR cells to lapatinib, gefitinib, and afatinib. Results from figure 
4.7 (A, B, C) show that the resistant T47D-FR cell line was more sensitive than the parental 
cell line to lapatinib (IC50 = 3.32±1.3|iMv^r5M5lC5o = 8.4±0.84|4M), gefitinib (IC5o=  
925± l.l6\)Mversus IC50 = 29±1.41pM), and afatinib (IC50 =  8.5±3.3iiMver5M5lC5o =  
53.75±4.7|xM).The difference in response to lapatinib, gefitinib, and afatinib was highly 
statistically significant by t-test (p <0.05, p < 0.01, p < 0.01 respectively; Figure 4-5).
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Figure 4-5Dose response curve of T47D and T47D-FR treated with lapatinib (A) and 
gefitinib (B) generated from the MTT assay.Each data point represents the mean of three 
independent experiments per cell line. Dose response curves were fitted in Prism v.6 and an IC50 was 
calculated; A) T47D and T47D-FR cells were treated with lapatinib and IC50 found to be = 
8.4±0.84pM and 3.32±1.3pM respectively, the difference in response to this drug was highly 
statistically significant by t-Test (p < 0.01).B) T47D and T47D-FR cells were treated with gefitinib 
and IC50 found to be = 29±1.41pM and 9.25±1.76pM respectively, the difference between the two 
curves was assessed by T-test (p <0.01). ). C) T47D and T47D-FR cells were treated with afatinib and 
the IC50 found to be = 53.75±4.7pM and 8.5±3.3pM respectively, the difference between the two 
curves was assessed by T-test (p <0.01). Each data point represents the mean of three independent 
experiments per cell line. Dose response curves were fitted in Prism v.6 using an IC50 equation.
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4.4.2. Changes in EGFR and HER2 receptor expression levels in anti- 
endocrine-resistant breast cancer cells
In order to evaluate the underlying mechanism of collateral sensitivity in endocrine-resistant 
cell lines, we measured the expression levels of EGFR and HER2 in MCF7/MCF7-TR and 
T47D/T47-FR cells by Western blotting and confocal microscopy.
4.4.2.I. Determination of the expression of EGFR (BDERl) in anti-endocrine-resistant 
cell lines
In this thesis, EGFR expression was determined since it plays a major role in promoting cell 
proliferation and malignant growth in breast cancer by stimulating tyrosine kinase activity 
(Fedele et ak, 2012). Figure 4-6 shows the expression levels of EGFR in parental and anti- 
endocrine-resistant MCF7 by Western blotting and the corresponding confocal images in 
which the EGFR receptor, as well as phosphorylated EGFR (pEGFR) were stained using a 
fluorescent antibody. The strongly EGFR-expressing cell line HN5 was used as a positive 
control.
Both methods revealed that EGFR was detected at low levels in the parental cells, while there 
were markedly higher levels of EGFR and its activated form pEGFR in the resistant MCF7- 
TR cells. However, upon treatment with 5pM lapatinib or 7 pM gefitinib, which both target 
EGFR, phosphorylated EGFR expression was not detected in the resistant cells. Regarding 
the parental cells, pEGFR expression was also not detected after treatment with lapatinib, but 
significant pEGFR expression was observed after treatment with gefitinib.
Figure 4-7 shows the expression levels of EGFR in parental and anti-endocrine-resistant 
T47D cellsvisualised by Western blotting and confocal microscopy (Figure 4-7) in the same 
way as described above. Again, the results showed significantly up-regulated levels of EGFR
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and pEGFR in the resistant T47D-FR cells compared with parental cells for both methods, 
while levels of pEGFR decreased in the resistant cells upon treatment with 5pM lapatinib or 
7 pM gefitinib, as shown in the confocal micrographs.
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Figure 4-6The expression of EGFR in parent and resistant MCF7 cells using Western
blotting and confocal microscopy.(A) Western blotting analysis measure the protein 
expression of total and phosphorylated EGFR in parent and resistant MCF-7, Total protein
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was extracted from MCF7 parent/resistant cells and quantified by DC protein assay (Biorad). 
50 micrograms of each extract was separated by SDS-PAGE and transferred to PVDF 
membrane. After probing with polyclonal anti-rabbit pEGFR/EGFR antibodies at a dilution 
1:100, the blot was exposed to an anti-rabbit alkaline phosphatase antibody, p-actin 
expression was used as a loading control. Bands were detected using a chemiluminescent 
substrate. pEGFR/EGFR and p-actin were detected at 185kDa and 42kDa, respectively 
against a protein standard. Data shown are representative of repeat experiments (n = 3). (B) 
Confocal fluorescence microscopy imaging for EGFR detection in MCF7 and MCF7-TR cell 
lines. Cells were treated with 5pM lapatinib or 7 pM gefetinib and incubated for 48 h. 
Confocal images, nuclei were labelled with TO-PRO-3® (blue) and the EGFR receptor with 
a fluorescein-labelled EGFR antibody (green). HN5 cells were used as a positive control.
Data are representative of repeat experiments (n = 3). HN5, a head and neck cancer cell line 
overexpressing EGFR, provided by Dr H Modjtahedi (Institute of Cancer Research, Sutton), 
was used as a positive control.
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Figure 4-7The expression of EGFR in parent and resistant T47D cells using W estern 
blotting and confocal microscopy.(A) Changes in total and phosphorylated EGFR 1/2 expression 
in fulvestrant-resistant T47D cell lines using Western blotting; Samples (50 pg protein) were
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electrophoresed on a 10% SDS-polyacrylamide gel, and the proteins were transferred to a PVDF 
membrane. After probing with polyclonal anti-rabbit pEGFR/EGFR antibodies at a dilution 1:100, the 
blot was exposed to an anti-rabbit alkaline phosphatase antibody. P-actin expression was used as a 
loading control. Bands were detected using a chemiluminescent substrate. pEGFR/EGFR and p-actin 
were detected at 175kDa and 42kDa, respectively against a protein standard. Data shown are 
representative of repeat experiments (n = 3). (B) Confocal fluorescence microscopy imaging for 
EGFR detection in T47D and T47D-FR cell lines. Cells were treated with 5pM lapatinib or 7 pM 
gefetinib and incubated for 48 h. Cells were co-stained with EGFR and TO-PRO-3® (blue)). MDA- 
MB-231 cells were used as a positive control. Data are representative of repeat experiments (n = 3).
4.4.2.2. HER2 expression in anti-endocrine-resistant cell lines
As with EGFR, this study examined the expression of HER2, in parental and anti-endocrine- 
resistant MCF7 (Figure 4-8) and T47D cells (Figure 4.9) using Western blotting analysis and 
confocal microscopy. SKBR3 cells, which are HFR2-positive, were used as positive control. 
Both methods show that HFR2 and pHFR2 levels in the parental MCF7 cells were negligible, 
before and after treatment, while, in the resistant phenotype, there was a higher amout of the 
phosphorylated active form for HFR2. Upon treatment with lapatinib, pHFR2 levels 
decreased in MCF7-TR cells to an extent where no fluorescence of pHFR2 could be 
observed.
Figure 4.9 shows the expression levels of HFR2 in parental and anti-endocrine-resistant 
T47D cellsvisualised by Western blotting and confocal microscopy. Both methods revealed 
significantly up-regulated levels of total and p-HFR2 in the resistant T47D-FR cells 
compared with parental cells for both methods, while levels of pHFR2 decreased in the 
resistant cells upon treatment with 5pM lapatinib, as shown in the confocal micrographs.
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Figure 4-8The expression of H E R 2 in parent and resistant MCF-7 cells using Western 
blotting and confocal Microscopy.(A) Western blotting analysis measure the protein expression 
of total and phosphorylated HER2 in parent and resistant MCF7, 50 micrograms of each extract was
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separated by SDS-PAGE and transferred to PVDF membrane. Immunodetection of HER2using a 1:00 
antibody dilution yielded a band at 175 kDa, determined by use of a protein standard. The PVDF 
membrane was stripped of antibody using sodium azide and re-probed for the protein actin, which 
was used as a loading control. Bands were detected using a chemiluminescent substrate. 
pHER2/HER2 and p-actin were detected at 185kDa and 42kDa, respectively against a protein 
standard. Data shown are representative of repeat experiments (n = 3). (B) Confocal fluorescence 
microscopy imaging for EGFR detection in MCF7 and MCF7-TR cell lines. Cells were treated with 
5pM lapatinib or 7 pM gefitinib and incubated for 48 h. For the confocal images, nuclei were labelled 
with TO-PRO-B® (blue) and the HER2 receptor with a fluorescein-labelled HER2 antibody. SKBR3 
cell were used as a positive control. Data are representative of repeat experiments (n = 3).
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Figure 4-9The expression of HER2 in parent and resistant T47D cells using Western 
blotting and confocal microscop.(A) Changes in total and phosphorylated HER2 expression in 
fulvestrant-resistant T47D cell lines using Western blotting; Samples (50 pg protein) were 
electrophoresed on a 10% SDS-polyacrylamide gel, and the proteins were transferred to a PVDF
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membrane. After probing with polyclonal anti-rabbit pHER2/HER2 antibodies at a dilution 1:100, the 
blot was exposed to an anti-rabbit alkaline phosphatase antibody, p-actin expression was used as a 
loading control. Bands were detected using a chemiluminescent substrate. pHER2/HER2 and p-actin 
were detected at 185kDa and 42kDa, respectively against a protein standard. Data shown are 
representative of repeat experiments (n = 3). (B) Confocal fluorescence microscopy imaging for 
HER2 detection in T47D and T47D-FR cell lines. Cells were treated with 5pM lapatinib or 7 pM 
gefitinib and incubated for 48 h, nuclei were labelled with TO-PRO-3® (blue) and the HER2 receptor 
with a fluorescein-labelled HER2 antibody.
4.4.2.3. HER3 expression in parent and resistant MCFTand T47D cell lines
HER2, which was found to be up-regulated in both resistant cell lines (MCF7-TR and T47D- 
FR), has no known extracellular ligand. This means that for activation, it likely forms a 
heterodimer with another member of the ErbB family, which can either be EGFR or HER3. 
We therefore measured the expression levels of HER3 by Western blotting to assess if more 
HER3 was available to form a possible heterodimer with HER2.The results in Figure 4-10 
show that there is no statistical difference in HER3 expression in either cell \me,versus 
parental cells, regardless of their resistance status, but there is a possible trend towards higher 
expression in resistant-cells.
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Figure 4-lOThe expression of HER3 in parent and resistant MCF7 and T47D cell 
lines.(A) 100 micrograms of each cellular total protein extract was separated by SDS-PAGE and 
transferred to PVDF membrane. Separated proteins were then exposed to a HER 3 antibody at a 1:100 
dilution for 12h before being exposed to anti-rabbit alkaline phosphatase, p-actin expression was used 
as a loading control. Bands were detected using a chemiluminescent substrate. HER3 and P-actin were 
detected at 185kDa and 42kDa, respectively against a protein standard. (B) Bands were quantified by 
densitometry and normalised to p-actin expression. Data represent n=3 for each cell type.
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4.4.3. The impact of lapatinib treatment on ERa expression in drug 
resistant cells
It is known that overexpression of growth factor receptors can stimulate signalling pathways 
which activate ERa in the absence of ligand (oestrogen) and thereby enhance gene 
transcriptional activity and tumour progression. We have already demonstrated in chapter 3 
that ERa expression is down-regulated inanti- endocrine-resistant cells. In this set of 
experiments, we investigated the effect of lapatinib treatment on ERa status to assess if there 
is any cross-talk between growth factor receptors and the ERa receptor in parental and anti- 
endocrine resistant MCF7 and T47D cells using Western blotting analysis. Additionally, we 
examined the mRNA expression of ERa by extraeting the respective mRNA and performing 
RT-qPCR analysis.
Cells were treated with 5[xM lapatinib at different time points up to 72 h (Figure 4-11). 
Western blotting analysis (Figure 4-11) revealed that phosphorylated ERa expression was 
gradually reactivated in tamoxifen-resistant cells following treatment with lapatinib, whereas 
in parental cells, phosphorylated ERa levels were lost after 72 h exposure to lapatinib.
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Figure 4-llThe expression of ERa in parent and resistant MCF7 cell lines treated with 
5 pM lapatinib at different time points up to 72h.40 pg of each extract was separated by SDS- 
PAGE and transferred to PVDF membrane. Separated proteins were then exposed to ERa antibody at 
1:100 dilution for 12h before being exposed to anti-rabbit alkaline phosphatase. GAPDH expression 
was used as a loading control. Bands were detected using a chemiluminescent substrate. ERa and 
GAPDH were detected at 66kDa and 37kDa, respectively against a protein standard. Data are 
representative for a set of three independent experiments.
We also performed qPCR analysis to quantify ERa at the mRNA level in MCF7 and MCF7- 
TR cells after 72 h treatment with lapatinib. The Act values were ealculated as the relative 
differences between expression levels of ERa mRNA and a house keeping gene {GAPDH). 
The fold change was equal to Treatment with 5pM lapatinib caused a 2.5 fold
increase in the mRNA level of ERa in the tamoxifen-resistant cells compared with the 
untreated control (p<0.01; Figure 4-12). In contrast, the ERa mRNA level was reduced in 
lapatinib-treated MCF7 cells compared with the untreated control (p<0.05; Figure 4-12).
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Figure 4-12Real time quantitative RT-PCR analysis of ERa mRNA level in parent and 
resistant MCF7 cell lines treated with 5 pM lapatinib.Each sample was prepared in triplicate; 
one set for the gene of interest and the other set for the set for the housekeeping gene, GAPDH. The 
master mix for each reaction contained 2x QuantiTect® SYBR® Green PCR master mix (used as Ix, 
12.5 pi per reaction) plus 1 pi each gene-specific RT2 q PCR primers for human oestrogen receptor 1 
(provided by SA Biosciences, UK) and 1 pi cDNA template. , Data were analysed using the AACt 
method. Results represent the mean ± SD of three independent experiments. Expression in MCF7 and 
MCF7-TR cells (untreated controls) was normalised to 1. Statistical analysis was performed using a 
two-tailed paired t-test (*p<0.05; **p<0.01).
Western blotting was also performed to detect the expression level of ERain fulvestrant- 
resistant T47D-FR cells when treated with 5pM lapatinib at different time points. No 
significant change inpERaexpression was observed in fulvestrant-resistant cells treated with
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lapatinib (Figure 4-13), possibly because expression was already low, but pERaexpression 
gradually reduced over time in parental T47D cells treated with lapatinib (Figure 4-13).
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Figure 4-13The expression of ERain parent and resistant T47D cell lines treated with 
5pM lapatinib at different time points up to 72 h.40 pgof each extract was separated by SDS- 
PAGE and transferred to PVDF membrane. Separated proteins were then exposed to ERaantibody at 
1:100 dilution for 12h before being exposed to anti-rabbit alkaline phosphatase. GAPDH expression 
was used as a loading control. Bands were detected using a chemiluminescent substrate. ERaand 
GAPDH were detected at 66kDa and 37kDa, respectively against a protein standard. Data are 
representative of a set of three independent experiments.
Next, ERamRNA levels were measured by RT-qPCR the parental and resistant T47D cells 
treated with 5^iM lapatinib. Although this was not observed at the protein level, there was a 
significant increase of mRNA in fulvestrant-resistant cells treated with lapatinib compared 
with untreated resistant cells (p<0.001; Figure 4.14). Treatment with lapatinib had no 
significant effect in parental T47D cells compared to the untreated control (Figure 4.14).
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Figure 4-14Real time quantitative RT-PCR analysis of ERa mRNA level in parent and 
resistant T47D cell lines treated with 5 \ iM  lapatinib.Each sample was prepared in triplicate; 
one set for the gene of interest and the other set for the set for the housekeeping gene, GAPDH. The 
master mix for each reaction contained 2x QuantiTect® SYBR® Green PCR master mix (used as Ix, 
12.5 pi per reaction) plus 1 pi each gene-specific RT2 q PCR primers for human oestrogen receptor 1 
(provided by SA Biosciences, UK) and 1 pi cDNA template. , Data were analysed using the AACt 
method. Results represent the mean ± SD of three independent experiments. Expression in T47D and 
T47D-FR cells (untreated controls) was normalised to 1. Statistical analysis was performed using a 
two-tailed paired t-test (***p<0.001).
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4.4.4. The effects of lapatinib and tamoxifen on in anti-endocrine-
resistant cells
Chapter 3 discussed the effect of anti-oestrogen treatment as well as development of 
resistance on the cell cycle regulator p27^^\ It was found that p27^^^ was inducible by anti­
oestrogen treatment in both MCF7 and T47D parental cell lines, causing G1 arrest, while it 
was not inducible (MCF7-TR) or even reduced (T47D-FR) in the resistant counterparts. The 
following experiment investigates the effect of lapatinib treatment on p27^^^ expression by 
Western blotting (Figure 4-15,4-16 part A), as an indicator of cell proliferation. Subsequent 
densitometry analysis (Figure Figure 4-15,4-16 part B) was performed to normalise the 
target protein against the loading control (GADPH).
The results revealed thatp27^^^^expression was induced in parental MCF7 cells treated with 
5pM tamoxifen compared with the resistant cells treated with the same agent (p<0.001;
Figure 4-15 B). This is consistent with the results obtained in chapter 3. However, treatment 
with 5pM lapatinib had no effect on p27^^^ levels in the parental MCF7 cells and caused a 
significant induction in the MCF7-TR cell line (p<0.01; Figure 4-15B).
When comparing p27^^^ levels within the two variants (parent and resistant, respectively), 
expression was induced in MCF7 cells after tamoxifen treatment compared with the untreated 
control (p<0.05; statistics not shown in figure 4-15) and unaffected following lapatinib 
treatment. Expression was significantly reduced in MCF7-TR cells after tamoxifen treatment 
compared with the untreated control (p<0.05; statistics not shown in figure 4-15), but 
considerably induced after treatment with lapatinib (p<0.05; statistics not shown in figure 4- 
15).
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Figure 4-15The expression of in tamoxifen resistant cells assessed by Western
blotting.Whole cell lysates were made following 48 h treatment with tamoxifen (5^iM) and lapatinib 
(5^M). Samples (50 pg protein) were electrophoresed on a 10% gel. After transfer to a PVDF 
membrane, the membrane was probed with a monoclonal anti-mouse p27KlPl antibody at a dilution 
of 1:100. Then, the blot was exposed to an anti-mouse alkaline phosphatase antibody (Invitrogen™). 
Bands were detected using a chemiluminescent substrate (Invitrogen™). p27 KIPl and GAPDH were 
detected at 27kDa and 37kDa, respectively against a protein standard. Data are representative of 
repeat experiments (n = 3). Comparisons were made by two-way ANOVA with Bonferroni correction
(**p<0.01; ***p<0.0001).
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Figure 4.16 shows the results of the same analysis conducted with T47D and T47D-FR cells. 
The results showed that p27kipl expression upon treatment with 5pM tamoxifen was induced 
in parental T47D compared with the MCF7-TR cells treated with the same agent (p<0.001; 
Figure 4.16 B). Treatment with 5pM lapatinib had caused a significant induction in thep27 
kipl in T47D-FR cells compared with the parental cells treated with the same agent (p<0.01; 
Figure 4.16 B).
When comparing p27^^^ levels within the two variants (parent and resistant, respectively), 
expression was induced in T47D after tamoxifen treatment compared with the untreated 
control (p<0.01; statistics not shown in figure 4-16) and unaffected following lapatinib 
treatment. Expression was slightly reduced in T47D-FR cells after tamoxifen treatment 
compared to the untreated control, but considerably induced after treatment with lapatinib 
compared with untreated control cells (p<0.01; statistics not shown in figure 4-16).
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Figure 4-16The expression of in fulvestrant resistant cells assessed by Western
blotting.Whole cell lysates were made following 48 h treatment with tamoxifen (5pM) and lapatinib 
(5pM). Samples (50 pg protein) were electrophoresed on a 10% gel. After transfer to a PVDE 
membrane, the membrane was probed with a monoclonal anti-mouse p27KIPl antibody at dilutions 
of 1:100. Then, the blot was exposed to an anti-mouse alkaline phosphatase antibody (Invitrogen™). 
Bands were detected using a chemiluminescent substrate (Invitrogen™). P27 KIPl and GAPDH were 
detected at 27kDa and 37kDa, respectively against a protein standard. Data are representative of 
repeat experiments (n = 3). Comparisons were made by two-way ANOVA with Bonferroni correction
(**p<0.01; ***p<0.0001).
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4.4.5. The co-administration of lapatinib and tamoxifen to cause cell death 
inanti-endocrine-resistant breast cancer cells
This study investigated the effect of lapatinib administered concomitantly with tamoxifen on 
cell death in parental and anti-endocrine-resistant MCF7 cells (Figure 4-17) and T47D cells 
(Figure 4-18) using the Annexin V assay with PL Parental and tamoxifen resistant cells were 
treated with 5pM lapatinib, 5pM tamoxifen, or concomitant lapatinib and tamoxifen for a 48 
h period.
Cell viability in tamoxifen-resistant cells treated with tamoxifen was comparable to the 
MCF7-TR control, because MCF-TR cells are resistant to tamoxifen (Figure 4-17), whereas a 
reduction in the cell viability was observed when the resistant cells were treated with 
lapatinib compared to untreated resistant phenotype (p<0.0001). The combined treatment of 
MCF7-TR cells with lapatinib and tamoxifen caused a significant reduction in cell death 
compared with untreated MCF7-TRcells (p<0.0001), which was potentially additive.
Bar graphs generated from the cytograms (part B) demonstrated that tamoxifen resistant cells 
(MCF7-TR) were not as responsive to the tamoxifen treatment compared with parental 
MCF7 treated with the same agent (93.27% (±1.26) versus 80.00% (±1.51); p<0.001, average 
of three experiments; Figure 4-17 B). However, treatment of MCF7-TR cells with lapatinib 
alone or tamoxifen and lapatinib combined caused more profound cell death compared with 
the parental MCF7 cells treated with the same agents (p<0.0001 for both; Figure 4-17 B).
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Figure 4-17The effect of lapatinib witb tamoxifen on MCF7 and MCF7-TR cell 
viability, as measured by Annexin V-FITC/PI assay.Cells were treated with single agent 
tamoxifen, or lapatinb, or a combination of the two for 48 h and processed for Annexin V-FITC/PI 
staining analysis using flow cytometry. (A) The data are presented in a four quadrant format; each 
quadrant in a cytogram represents a different state of cell viability as a percentage. Lower left 
quadrant represents live cells, lower right represents cells in early apoptosis (Annexin V-FITC 
positive, PI negative), upper right represents cells in late mid-phase apoptosis (Annexin V-FITC and 
PI positive) and upper left represents represents cells in necrotic/end stage apoptosis (PI positive.
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FITC negative). The percentages displayed in (A) are representative of one experiment only. (B) Bar 
graph derived from A showing cell viability in MCF-TR cells treated with the combination of 
lapatinib and tamoxifen compared with the parental MCF7 cells. Data shown in (B) are of the average 
of repeat experiments (n=3). Comparisons were made by two-way ANOVA with Bonferroni 
correction (***p<0.001;****p<0.0001).
The Annexin-V FITC/PI experiment was also performed to test the apoptotic effect of co­
administering lapatinib and tamoxifen in parental T47D and fulvestrant-resistant T47D-FR 
cells. Parental and fulvestrant-resistant cells were treated with tamoxifen 5pM, lapatinib 
5pM, or combination of lapatinib and tamoxifen for a 48 h period and then subjected to 
AnnexinV-FITC analysis with PI (Figure 4-18 A, B).There was no reduction in the 
percentage of the viable fulvestrant-resistant cellsafter treatment with tamoxifen compared 
with the T47D-FR control (Figure 4-18 A), due to the fact that these cells are cross-resistant 
to tamoxifen (as established in chapter 3). Treatment of T47D-FR cells with either lapatinib 
as a single agent or in combination with tamoxifen resulted in a significant reduction in cell 
viability compared with untreated T47D-FR cells (p<0.0001). The co-administration of 
lapatinib and tamoxifen appeared to be more potent than the sum of the effects of either drug 
alone.
There was also a significant reduction in T47D-FR cell viability after treatment with either 
lapatinib or the combination of lapatinib and tamoxifen compared with parental T47D cells 
treated with the same agents (p<0.001 and p<0.0001, respectively; Figure 4-18 B).
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Figure 4-18The effect of lapatinib witb tamoxifenon T47D and T47D-FR cell viability, 
as measured by Annexin V-FITC/PI assay.The histograms are representative of typical data 
obtained. Control and resistant cells were treated with single agent of anti-oestrogen agent such as 
tamoxifen, and targeted therapy such as a lapatinib or in combination for 48. Cells were harvested and 
subjected to flow cytometry using the Annexin V assay with PL A) (A) The data are presented in a 
four quadrant format; each quadrant in a cytogram represents different state of apoptosis as a 
percentage. The percentage of live cells (expressed as a percentage of the untreated control) is 
indicated in the bottom left hand corner (PI and FITC negative cells). The percentages displayed in 
(A) are representative of one experiment only. (B) Bar graph derived from A showing cell viability in 
MCF-TR cells treated with the combination of lapatinib and tamoxifen compared with the
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parentalMCF? cells. Data shown in (B) are of the average of repeat experiments (n=3). Comparisons 
were made by Two-way ANOVA with Bonferroni correction ((**p<0.01; **p<0.01;****p<0.0001).
4.4.6. Molecular mechanisms of lapatinib sensitivity in tamoxifen-resistant 
cells
Experimental and clinical evidence suggests that PI3K is a major signallingmolecule 
downstream of HER2 and other receptor tyrosine kinases (Van Tine et al., 2011). Therefore, 
it was relevant to examine the expression of total and phosphorylated PI3K (P-PI3K) in 
MCF7 and MCF7-TR cells using Western blotting analysis. Cells were treated with 5pM 
tamoxifen, 5[xM lapatinib and the combination of these two therapies. Phosphorylated-PI3K 
expression was considerably higher in untreated tamoxifen-resistant cells compared with 
untreated MCF7 parental cells (Figure 4-19). Following treatment of tamoxifen-resistant cells 
with combination treatment, total and P-PI3K were expressed at much lower levels compared 
with parental cells treated with the same agents. In drug resistant cells treated with lapatinib 
alone, total and pPI3K expression were also reduced compared to the parental MCF7 cells 
treated with the same agent, but to a lesser extent than with combination treatment (Figure 4-
19).
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Figure 4-19Expression of PI3K in M CF7 and M CF7-TR cells following treatment with 
lapatinib in combination witb tamoxifen.Cells were treated with 5pM  lapatinib, 5pM 
tamoxifen, or a combination with two therapeutic agents for 48 h before lysing. Samples (60 pg 
protein) were electrophoresed on a 10% SDS-polyacrylamide gel. After transfer to a PVDF membrane, 
the proteins were probed with polyclonal anti-rabbit PI3K/pPI3K anti-rabbit antibodies at a dilution of 
1:100. The membrane was then exposed to an anti-rabbit alkaline phosphatase antibody. P-actin 
expression was used as a loading control. Bands were detected using a chemiluminescent substrate. P- 
PI3K/PI3K and p-actin were detected at 85kDa and 42kDa, respectively against a protein standard. 
Data shown are representative of repeat experiments (n = 3).
The cumulative data from clinical studies support the hypothesis that high levels of 
phosphorylated ERK (P-ERK), contributes to tamoxifen resistance (Gee et al.,
2001;Gutierrez et al., 2005). Therefore, it was important to assess the expression of P-ERK in 
MCF7 and MCF-TR cells. Cells were treated with 5pM tamoxifen, 5pM lapatinib and in 
combination of these two therapies.
It was found that total and pERK were expressed at higher levels in untreated resistant 
cells(MCF7-TR) compared with the untreated parental MCF-7 cells (Figure 4-20). Upon
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treatment with 5pM tamoxifen, total and P-ERK was expressed at lower levels in tamoxifen- 
treated parental MCF7 compared with resistant cells treated with the same agents (Figure 4-
20). However, following treatment of tamoxifen-resistant cells with combination treatment, 
expression of total and P-FRK could barely be detected compared with the parental cells 
treated with the same therapeutic agents (Figure 4-20).
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Figure 4-20Changes in total and phosphorylated ERK (pERK) expression in tamoxifen- 
resistant MCF7 cell lines following combination treatment of lapatinib and 
tamoxifen.Cells were treated with 5pM lapatinib, 5[xM tamoxifen, or acombination of the two 
therapeutic agents for 48 h. Samples (50 pg protein) were electrophoresed on a 10% SDS- 
polyacrylamide gel, and the proteins were transferred to a PVDF membrane. After probing with 
polyclonal anti-mouse ERK/pERK antibodies at a dilution of 1:100, the blot was exposed to an anti­
mouse alkaline phosphatase antibody, p-actin expression was used as a loading control. Bands were 
detected using a chemiluminescent substrate. pErk/Erk and P-actin were detected at 42kDa and 
42kDa, respectively against a protein standard. Data shown are representative o f repeat experiments 
(n = 3).
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4.5. Discussion
Compelling clinical evidence suggests that HER tyrosine kinase receptor family plays a role 
in the mediating anti-endocrine resistance(Arpino et al., 2008). It has been postulated that up- 
regulation of HER growth factor receptor signalling pathways leads to the modulation of ERa 
activity by causing ligand-independent receptor activation, resulting in enhanced ERa 
transcriptional activity(Levin and Pietras, 2008). From the data provided by the current 
study, there is evidence for substantial crosstalk between these two receptor signalling 
pathways, providing a basis for a complex resistance mechanism, supported by 
others(Morrison et al., 2014).
In this research, protein expression analysis revealed that EGFR and HER2 were 
overexpressed in the MCF7-TR cell line compared with parental cells. More importantly, the 
phosphorylated active form was increased, which is indicative of enhanced signalling. These 
Western blot data were supported by confocal microscopy indicating increased fluorescence 
levels of EGFR and HER2 in the resistant cells compared with the wild-type phenotype. This 
finding is in agreement with other published literature showing that in vïïroanti-endocrine- 
resistant breast cancer cells is often associated with increased expression of the EGFR family 
members, EGFR (HERl) and HER2 (Fan et al., 2006;Kong et al., 2008). The findings from 
the current study provide support of HER2 over-expression in breast cancer patients (Yeon 
and Pegram, 2005). HER3 expression on the other hand was comparable if not slightly higher 
in resistant MCF cell lines compared with parental cells. HER3 lacks tyrosine kinase activity 
and is considered a defective protein (Kong et al., 2008), however, its ability to form a 
heterodimer with HER2 could still implicate it in the resistance mechanism. Others have 
reported that tamoxifen treatment can induce HER3 and that HER3 expressing tumours are 
more prone to relapse, implicating it in the resistance mechanism (Chung et al., 2013).
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Next we examined the role of total and phosphorylated EGFR, HER2 and HER3 (total only) 
in the development of fulvestrant resistance. Western blotting analysis and 
immunofluorescence using confocal microscopy revealed that EGFR and HER2 were up- 
regulated in T47D-FR compared to the parental cells (T47D). HER2 overexpression is a well- 
established resistance mechanism in vivo. Only recently, T47D cell lines resistant to 
fulvestrant were established by Kirkegaard et al (2014) to explore whether a switch to EGFR 
signalling, as seen in fulvestrant-resistant T47D cell lines, can be considered as a resistance 
mechanism. They found that fulvestrant-resistant T47D cells do not express ERa but that 
EGFR and HER2 were over expressed (Kirkegaard et al., 2014). These outcomes are in 
agreement with our findings that ERa expression is low in fulvestrant-resistant cells as shown 
in chapter 3, and that cell survival was driven by HER receptors. This is important for breast 
cancer patients who develop fulvestrant resistance (Kirkegaard et al., 2014).
Increased expression of growth factor receptors, espeeially EGFR/HER2, has been associated 
with both experimental and clinical anti-endocrine therapy resistance (Osborne and Schiff, 
2011). Consequently targeting these pathways using TKls could be important in reducing 
cancer cell survival and in resistance reversal. Since EGFR and HER2 were over-expressed in 
both resistant cell lines, we used gefitinib and lapatinib to selectively target EGFR and 
EGFR/HER2, respectively.
Three different TKls were investigated herein. We demonstrated that tamoxifen- and 
fulvestrant-resistant cells developed collateral sensitivity to lapatinib,afatinib and gefitinib. 
Afatinib and then lapatinib were more potent at restoring sensitivity to tamoxifen in 
tamoxifen-resistant cells compared withgefitinibby MTT assay. Similarly, lapatinib was 
shown to more effectively reduce cell survival than the HER TKls gefitinib and afatinib in 
fulvestrant-resistant cells. For both resistant-cell lines TKls induced collateral sensitivity with
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greater potency than in the respective parental cell lines.To our knowledge the collateral 
sensitivity of anti-endocrine-resistant cells to afatinib is a novel finding and needs further 
investigation. Afatinib was the most potent of the three TKls in the tamoxifen-resistant cell 
line, suggesting that might be useful for targeting tamoxifen resistance specifically. However, 
it was decided to use lapatinib to design our experiments and identify the mechanisms behind 
this sensitivity because of its overall effectiveness in both cell lines and the greater volume of 
published data available. We also investigated the effect of gefitinib in these cell lines to 
distinguish between the effects of a selective EGFR inhibitor versus a dual inhibitor of 
EGFR/HER2.
This study observed that EGFR fluorescence levels were decreased dramatically when 
resistant-cells were treated with gefitinib and lapatinib. These outcomes are in agreement 
with findings from the clinical setting where EGFR protein expression was associated with 
tamoxifen-resistance in breast tumors from 205 patients with metastatic breast cancer (Arpino 
et al., 2004). A preclinical study supports our finding that targeting EGFR signalling using 
the EGFR TKI gefitinib can improve tamoxifen sensitivity and delay acquired resistance in 
MCF7 cells (Massarweh et al., 2008) but did not examine the mechanism of fulvestrant 
resistance. More recently, Zhang et al (2013) reported that EGFR signalling might play a role 
in the development of fulvestrant resistance. Fulvestrant effectively inhibits ERa-dependent 
cell growth and cell survival with important clinical activity, but also results in enhanced 
EGFR signalling and EGFR ligand expression (Zhang et al., 2013). As Sonne-Hansen et al. 
(2010) reported, breast cancer cells can switch between ERa and EGFR signalling(Sonne- 
Hansen et al., 2010).These findings suggested that blockade of EGFR might reverse acquired 
resistance, which could be explored as a direct therapeutic strategy in patients receiving 
fulvestrant.
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Targeting HER2 has been the main focus in breast cancer although increasingly, inhibition of 
EGFR in combination with HER2 blockage is seen to be important in breast cancer 
therapy.Our work demonstrated increased expression of phosphorylated HER2 in tamoxifen- 
and fulvestrant-resistant cells, which indicates greater signalling, but this expression was 
reduced sharply when these cells were treated with lapatinib. Fluorescence microscopy 
confirmed the role of HER2 signalling in the development of anti-endocrine resistance and 
the benefits of treating tamoxifen- and fulvestrant-resistance cells with lapatinib to inhibit 
HER2 signalling, as manifested in increase cell death. Cui et al supported a key role for 
HER2-mediated tamoxifen resistance and suggested its potential usage as a therapeutic target 
to block HER2 pathways for the treatment of this type of anti-endocrine-resistant breast 
cancer (Cui et al., 2012).
The current study showed that treating resistant-cells with lapatinib caused reactivation of 
ERa transcription. Increased mRNA levels were translated into increased protein expression, 
which indicates functional activation. Despite this agonist effect on ERa function, lapatinib 
alone did stimulate cell death in tamoxifen- and fulvestrant-resistant cells when used as 
monotherapy. A greater reduction in cell viability was observed when lapatinib was used 
concomitantly with tamoxifen in resistant-cells. It is therefore imperative that lapatinib be 
combined with tamoxifen to simultaneously inhibit ERa and EGFR/HER2 survival signalling 
pathways. Combination treatment was also more effective in resistant cells than in parental 
cell treated with the same agents.
These findings suggested that lapatinib treatment might restore anti-oestrogens 
responsiveness by reactivating ERa function. Combination therapy could be investigated as a 
potential strategy in patients with acquired resistance. In the literature, only one previous 
study explored the relationship between ERa status and lapatinib treatment to reverseanti-
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endocrine resistance when using tamoxifen-resistant MCF7 cells with long term oestrogen 
depletion (Leary et al., 2010). This published study found that treatment of the resistant cells 
with lapatinib and tamoxifen could restore responsiveness to anti-endocrine treatment by 
increasing ERa expression (Leary et al., 2010). The same study also showed that lapatinib 
reactivated ERa genomic function observed by increased ERa transcriptional activity in 
tamoxifen resistance models (Leary et al., 2010).
In parallel with the investigation of crosstalk in tamoxifen-resistant cells, we also investigated 
if the same mechanism was involved in fulvestrant resistance. qPCR data showed increased 
ERa expression at the mRNA level but changes in the protein levels were not detected. This 
may be because the expression was already low and changes in expression might have been 
too small to detect in the resistant phenotype. The doubling time of fulvestrant-resistant cells 
is longer than that of tamoxifen-resistant cells (72 h versus 36 h), which means that changes 
in protein expression may not yet have occurred. The flow cytometry data indicated that a 
profound effect on the reduction of cell viability was observed in fulvestrant resistant cells 
when treated with the combination of lapatinb and tamoxifen versus the drugs administered 
alone. These findings indicated the importance of the combination of lapatinib with anti- 
endocrine therapy to interrupt EGFR/HER2 and ERa crosstalk. The current study is the first 
study highlighting the crosstalk among the two signalling pathways and also identifies the 
apoptotic effect of lapatinib in acquired fuvestrant resistance.
An important question is the mechanism underlying this sensitivity of anti-endocrine resistant 
cells to lapatinib. To answer this question, we measured the expression of CDKI p27^'^\ 
Significant induction of p27 was observed when both resistant cell lines were treated with 
lapatinib. In contrast, p27 expression was abolished when these cells underwent 
treatment with tamoxifen. Loss of p27 leads to abrogation of cell cycle arrest and
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mediates cell progression and drug resistance (as found in chapter 3). These findings might 
explain why lapatinib caused cell death, as a massive induction in p27 is required to 
oppose p27 proteolysis and cause cell cycle arrest in tamoxifen resistant cells (Chu et al., 
2005). To date, induction of p27 occurring in fulvestrant-resistant cells following 
treatment with lapatinib is a novel finding.
Another mechanism under investigation was disruption of downstream signalling pathways. 
Clinical data indicate that tamoxifen-resistant breast cancers often have an increased 
expression of the receptor tyrosine kinases, EGFR and HER2 and consequent increases in 
their downstream signalling cascades involving MARK, PI3K and Akt. This can lead to 
increased phosphorylation of the ERa and confer tamoxifen-resistance in breast cancer 
cells(Arpino et al., 2008;Morrison et al., 2014). Our findings indicated that PI3K was 
decreased in tamoxifen-resistant cells after treatment with lapatinib and tamoxifen. Increased 
protein expression of PI3K was established in chapter 3 as a mechanism implicated in 
tamoxifen resistance. Thus, down-regulation of PI3K by lapatinib might contribute to the re­
sensitisation of tamoxifen-resistant cells. To our knowledge, no other research group have 
measured the expression of PI3K in response to treatment with TKls nor investigated the 
consequences of reducing PI3K.
Activation of the ERK signalling pathways is associated with survival and proliferation of 
tamoxifen-resistant cells(Nicholson et al., 2007). Our study showed high expression of total 
and phosphorylated ERK in untreated tamoxifen-resistant cells compared with MCF7 
cells.These outcomes are consistent with previous findings of increased levels of pERK in the 
tamoxifen-resistant cell line (McCune et al., 2010). In our study we also observed that ERK 
expression is reduced to almost undetectable levels when tamoxifen-resistant cells were 
treated with the lapatinib and tamoxifen combination. These outcomes agree with Leary et al
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(2010) who found that lapatinib cooperates with tamoxifen to reduce the expression levels of 
ERK in tamoxifen-resistant cells (Leary et al., 2010). It has been shown that hyperactive 
signalling through EGFR, HER2 and downstream ERK and MAPK represses ERa in vitro 
and results in decreased ERa expression (Oh et al., 2001). Importantly, inhibition of EGFR or 
HER2 using gefitinib or trastuzumab has been shown to reinduce ERa expression and restore 
response to anti-endocrine therapy (Bayliss et al., 2007). Our report also showed that lapatinib 
reactivates ERa function in tamoxifen-resistant cells, potentially through reduced ERK 
signalling, explaining why combination therapy is more effective than monotherapy.
In conclusion, anti-endocrine resistance is associated with up-regulation of the EGFR/HER2 
signalling pathway. The crosstalk between the EGFR/HER2 and ERa signalling pathways as 
a mechanism for the development of anti-endocrine resistance suggested the importance of 
combination therapy. Interrupting this crosstalk with lapatinib can inhibit the survival 
signalling of EGFR and HER2 and enhance cell cycle arrest via induction of P27 Also 
this study highlights the importance of the co-administration of lapatinib with tamoxifen, to 
inhibit both signalling pathways in the event that lapatinib reactivates ERa function in 
resistant breast cancer and restores response to anti-endocrine therapy.Combination treatment 
is also required to circumvent survival signalling of PI3K and ERK and cause cell death. 
Thus, combination therapy with TKls and anti-oestrogens should be investigated further as a 
therapeutic strategy in patients with acquired anti-endocrine resistance.
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5. Cell death pathways involved in acquired drug 
resistance
5.1. Introduction
5.1.1. Overview of programmed cell death
Cell death is a fundamental process of life. Hence, not surprisingly various forms of cell 
death exist. The most important process that regulates the balance between cell growth and 
cell death is programmed cell death (PCD) (Kerr, 2002). Two forms of PCD exist; apoptosis 
(type I PCD) and autophagy (type II PCD) (Elmore, 2007). Although apoptosis and 
autophagy bear distinct morphological characteristics and a different physiological process, 
there still exists as a sophisticated alliance between these two processes (Liu et al., 2011). 
Occasionally, apoptosis and autophagy can have a synergetic effect, while sometimes 
autophagy is triggered when apoptosis is inhibited (Chaabane et al., 2013).
5.1.2. Apoptosis and cancer
Programmed cell death by apoptosis acts as a natural barrier to cancer development and this 
has been established by a number of functional studies conducted over the last twenty years 
(Adams and Cory, 2007).There is a fine balance between cell proliferation and cell death. 
Disruption of this balance by altered survival signalling of the apoptotic machinery can lead 
to tumour progression (Musgrove and Sutherland, 2009). The apoptotic machinery consists of 
both upstream regulators and downstream effector components (Adams and Cory, 2007). In 
turn, the regulators are divided into two major circuits, one receiving and processing
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extracellular death-inducing signals, which is known as the extrinsic apoptotic program, such 
as the Fas ligand/Fas receptor (Ricci and Zong, 2006).The other circuit senses and integrates 
signals of intracellular origin, and is known as the intrinsic program. Currently, the intrinsic 
apoptotic program is more extensively implicated in tumour progression(Hanahan and 
Weinberg, 2011).
The apoptotic trigger that mediates signals between the regulators and effectors is controlled 
by a counterbalancing of pro- and anti-apoptotic members of the Bcl-2 family of regulatory 
proteins (Cory and Adams, 2002). Bcl-2, along with its relatives such as Bcl-xL, Bcl-w, Mcl- 
1, A l are all anti-apoptotic proteins, acting in part by binding to and thereby inhibiting two 
pro-apoptotic triggering proteins (Bax and Bak); the latter are embedded in the mitochondrial 
outer membrane. When relieved of inhibition by their anti-apoptotic relatives, Bax and Bak 
cause disruption of the integrity of the outer mitochondrial membrane, and result in the 
release of pro-apoptotic signalling proteins, the most crucial of which is cytochrome c(Akhtar 
et al., 2006;Cory et al., 2003).
The released cytochrome c activates, consecutively, a cascade of caspases that act via their 
proteolytic activities to provoke the multiple cellular changes associated with the apoptotic 
program. The pro-apoptotic molecules such as Bax and Bak share protein-protein interaction 
domains, referred as BH3 motifs BH3-only proteins function by either inducing the function 
of the pro-apoptotic proteins or by binding and interfering with anti-apoptotic Bcl-2 proteins 
(Willis et al., 2005). In addition to the role of the Bcl-2 family in apoptosis, inhibitor-of- 
apoptosis (LAP) families have been identified. An example of a member of this family is 
survivin(Wei et al., 2008). It has been shown survivin inhibits apoptosis in cancer through 
direct inhibition of caspase-3 and caspase-7, which function as terminal effectors in the 
apoptotic protease cascade(Shin et al., 2001).
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Tumour cells evolve diverse strategies to circumvent apoptosis. The most common genetic 
abnormality established so far is the mutation in p53 function in human cancer(Hanahan and 
Weinberg, 2011). P53 mutation/alteration, which leads to elimination of this critical damage 
sensor from apoptosis-inducing circuitry, is found in up to 50% of breast carcinomas(Junttila 
and Evan, 2009). The most proposed mechanism by which cancer cell populations evade 
apoptosis is by increasing the expression of anti-apoptotic regulators such as Bcl-2 or Bcl-xL, 
or by down-regulating pro-apoptotic factors such as Bax, Bim and Puma(Adams and Cory, 
2007).
5.1.2.1.Defects of apoptosis in anti-endocrine resistance
Disruption of the apoptotic machinery has important influences on the clinical outcomes of 
anticancer therapy. In order for these treatments to trigger cell death successfully, these cells 
must be capable going through apoptotic cell death (Tardy et al., 2006). It has been reported 
that the majority of chemotherapeutic agents work by inducing stress signals that can activate 
the intrinsic pathway of apoptosis in cancer cells (Danial and Korsmeyer, 2004).
Nevertheless, some types of chemotherapy induce the extrinsic pathway by stimulating the 
immune system to produce TNF. It has also been found that the combination of TNF with 
chemotherapeutic agents such as melphalan is effective toward vascular localised tumours, 
such as sarcomas and melanomas (Ricci and Zong, 2006).
In the literature, it has been demonstrated that the dysregulation of anti-apoptotic and pro- 
apoptotic Bcl-2 proteins is one of the essential features of cancer cells in comparison to 
normal cells, and contributes considerably to the resistance of cancer cells to the therapeutic 
agents. Since resistance to anti-cancer treatments is a major clinical obstacle, elucidating the 
role of apoptosis in drug response is critically important for the development of more 
effective therapeutic strategies (Weyhenmeyer et al., 2012).
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The role of survivin as a member of the TAP family is also thought to be important in drug 
resistance. This is due to the observation that overexpression of survivin desensitizes breast 
cancer cells to anticancer agents and irradiation, both of which ultimately cause 
apoptosis(Shin et al., 2001;Tamm et al., 1998). Also, it has been found that increased 
expression of the survivin protein in MCF-7 cells lead to the attenuation of tamoxifen- 
induced apoptosis (Moriai et al., 2009).
The chemotherapeutic treatments used in the present work, were the anti-oestrogens 
tamoxifen and fulvestrant, and the cells used were oestrogen-positive breast cancer cells 
(MCF7 and T47D), which are resistant to tamoxifen and fulvestrant, respectively. It is 
therefore worthwhile to discuss how anti-oestrogens induce apoptosis in parental and anti- 
endocrine resistant breast cancer cells and explain the possible documented mechanisms of 
how these anti-endocrine resistant cells evade apoptosis and develop the resistance.
5.1.2.2.Anti-oestrogens - mechanism of apoptosis induction
In the published literature, there are very few papers explaining the mechanisms by which 
anti-oestrogens induce apoptosis. Anti-oestrogens as therapeutic agents primarily act by , 
either preventing or antagonising the secretion of endogenous oestrogen, which can 
ultimately lead to death of breast cancer cells. In vitro studies have revealed that anti- 
oestrogens used on breast cancer cells can induce growth arrest (cytostasis) via induction of 
the cyclin-dependent kinase inhibitors such as p21 and p27^^\ and cell death 
(cytotoxicity) by mechanisms still being defined (Caldon et al., 2006). For example, 
tamoxifen has been shown to inhibit the proliferation of breast tumours via a receptor- 
mediated cell-cycle arrest at low concentrations (0.1-lpM) or by a receptor-mediated 
induction of apoptosis at pharmacological concentrations above 5 pM. The observable effects 
of tamoxifen on breast cancer cells are associated with morphological changes that are
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consistent with apoptosis, such as cytoplasm condensation and DNA fragmentation (Zhang et 
al., 1999).
It has been found that tamoxifen induces down-regulation of Bcl-2 at both mRNA expression 
and protein levels (Marcsek et al., 2004;Zhang et al., 1999). Furthermore, tamoxifen results 
in a significant increase in the pro-apoptotic regulator Bax and a decrease in Bcl-2 mRNA 
expression in oestrogen-positive MCF7 cells (Darakhshan et al., 2013). On the other hand, 
there is also accumulating evidence suggesting that decreased expression of pro-apoptotic 
regulators such as Bax and Bak can attenuate the response to tamoxifen (Riggins et al., 2005). 
Furthermore, increased expression levels of anti-apoptotic molecules, for example Bcl-2 and 
Bcl-x leads to increased anti-oestrogen responsiveness to tamoxifen in MCF7 breast cancer 
cells(Riggins et al., 2005). Larsen and colleagues also observed that low Bcl-2 expression is 
associated with an increase in the sensitivity to carboplatin in the MCF7 tamoxifen-resistant 
cell line (Larsen et al., 2012).
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is involved in several 
crucial aspects of assessing the anti-endocrine responsiveness in breast cancer cells. It is a 
dimeric transcription factor made up of homo- or heterodimers of protein members in the NF- 
KBfamily. It has been reported that up-regulation of NF-KBis associated with tamoxifen 
resistance in MCF-7 cells. For example, Nehra et al. (2010) investigated whether NF-kB 
inhibition reverses resistance to tamoxifen in resistant cells and increases sensitivity to 
tamoxifen in highly responsive cells. Results showed that inhibition of NF-kBsynergistically 
restores sensitivity to tamoxifen in resistant cell and induces growth inhibition. This occurs 
via decreased expression of Bcl-2, increased mitochondrial membrane permeability and 
induced caspase-dependent apoptotic cell death in tamoxifen resistant cells (Nehra et al., 
2010).
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In the literature, the only documented paper describing how evasion of apoptosis can lead to 
fulvestrant resistance was published in 2010 by Ning and co-workers(Ning et al., 2010). This 
study demonstrated that IFNy, an inflammatory cytokine, stimulates the function of IFN 
regulatory factor 1 (IRFl). IRFl is a tumour suppressor gene that can increase anti-oestrogen 
responsiveness of fulvestrant in breast cancer cells and inhibit breast tumourigenesis. This 
occurs by suppressing the activity of NF-kB p65, inhibiting the expression of anti-apoptotic 
proteins such as Bcl-2 and Bcl-xL, and inducing the expression level of pro-apoptotic 
members such as Bak and mitochondrial Bax (Ning et al., 2010). This molecular signalling is 
associated with increased mitochondrial membrane permeability and activation of caspase-7, 
caspase-8, and caspase-9 (Pizzoferrato et al., 2004). It has been indicated that endogenous 
IRFl expression is significantly reduced in fulvestrant-resistant breast cancer cells (Ning et 
al., 2010). Similar work by Ning et al., (2010) has demonstrated that treatment with IFNy 
rescues and enhances IRFl expression in fulvestrant resistant breast cancer cells and restores 
their sensitivity to fulvestrant-mediated apoptosis (Ning et al., 2010). Thus, the restoration of 
fulvestrant sensitivity is driven by an IRFl-dependent mechanism that leads to activation of 
the intrinsic (mitochondrial) apoptotic pathway (Ning et al., 2010).
5.1.3. Autophagy mediates both cell survival and death
Autophagy is a controversial process as it appears to have conflicting roles. It may induce cell 
death and act as a powerful tumour-suppressing mechanism (Sridhar et al., 2012)but may also 
serve as a cell survival mechanism to generate nutrients in time of cellular stresses. The latter 
process may directly lead to survival of cells that have undergone treatments, and 
consequently reduce the effectiveness of therapy (White and DiPaola, 2009).
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Similar to apoptosis, the autophagy machinery works at low levels in virtually all cells to 
perform homeostatic functions such as protein and organelle turnover (Maiuri et al., 2007). 
However, it can be rapidly elevated when cells need to generate intracellular nutrients and 
energy in the case of cellular stressors such as metabolic starvation and growth factor 
withdrawal, or high bioenergetics demands. Also, autoghagy can be up-regulated when cells 
undergo structural remodelling in response to oxidative stress, infection, poor nutritional 
status, and hormonal factors (Klionsky, 2007). On the other hand, autophagic cell death may 
occur when apoptotic cell death (type I PCD) is inhibited (Moretti et al., 2007).
5.1.3.1.The autophagic pathway
The cellular events during autophagy follow distinct steps (Figure 5-1). The initial step 
includes vesicle nucléation, involving the formation of the isolation membrane. The second 
step involves elongation of the isolation membrane, which is also called a phagophore. The 
edges of the phagophore then fuse to form a double membrane vesicle (autophagosome) that 
is able to sequester cytoplasmic material. This is followed by third step called the fusion step, 
which leads to the fusion of the autophagosome with a lysosome to from an autolysosome. 
This causes lyses of the autophagosome inner membrane and breakdown of its contents 
(Levine and Kroemer, 2008).
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Figure 5-lThe cellular stages of autophagy: The process of autophagy follows distinct
stages.Stage 1: Vesicle nucléation includes the formation of isolation membrane; Stage 2: vesicle 
elongation, also known as growth and closure phase; Stage 3: fusion stage, includes fusion of the 
double membrane of the autophagosome with the lysosome to form an autolysosome, leading to the 
lysis of the autophagosome inner membrane and breakdown of its contents inside the autolysosome.
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One of the key molecular components regulating the autophagy pathway is mammalian target 
of rapamycin (mTOR) kinase signalling. mTOR negatively regulates autophagy by 
phosphorylation of Atgl3 and Unc51-like kinase (ULK, also known as Atgl), and inhibits 
the formation of a trimeric complex (ULK-Atgl3-FIP200), that is required for 
autophagosome formation (Chan et al., 2009).In addition, mTOR is also considered an 
inhibitory signal that switches off autophagy when growth factors and nutrients are present 
(Levine and Kroemer, 2008). The signalling molecules PI3K/Akt stimulate the binding of 
receptor tyrosine kinases to mTOR, causing activation and repressing autophagy in response 
to the presence of growth factor signals such as insulin-like growth factors (Lum et al., 2005).
Beclin l(Atg6)plays an important role in the nucléation phase of autophagy as elucidated in 
Figure 5-1. Autophagic proteins are localised to a pre-autophagosomal structure (PAS), based 
on interaction with the class III type phosphoinositide 3-kinase (PI3KC3)/Vps34. Together, 
they form the Beclin 1-Vps34-Vpsl5 core complex for the promotion of the cellular process 
of autophagy (Kang et al., 2011).
Beclin-1 is also an apoptotic regulatory protein containing a BH3 domain, which is necessary 
for binding to Bcl-2 and Bcl-xL proteins (Levine and Kroemer, 2008). Other proteins 
containing the BH3 domain can displace Beclin-1 bound to Bcl-2 and Bcl-xL, and the 
released Beclin-1 can then trigger autophagy(Apel et al., 2009). In a similar way, these 
proteins can also displace pro-apoptotic proteins, such as Bax and Bak, which trigger 
apoptosis upon their release (White and DiPaola, 2009). Consequently, stress-transducing 
BH3 proteins can either enhance apoptosis and/or autophagy depending onthe cell’s 
physiological state. It has been shown that inactivated alleles of the Beclin-1 gene or other 
autophagy regulators render mice prone to cancer (White and DiPaola, 2009). This indicates 
that induction of autophagy may act as an obstacle to tumourigenesis, which may function
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autonomously or in cooperation with apoptosis. These results support the hypothesis that 
autophagy is another hurdle that needs to be overcome for a tumour to develop (Qu et al., 
2003).
Importantly, microtubule-associated protein 1 A/lB-light chain 3 (LC3) is a soluble protein 
with a molecular mass of ~17 kDa that is considered a significant marker for the autophagic 
pathway (Mizushima et al., 2004). LC3 is distributed ubiquitously in mammalian tissues as 
well as in cultured cells. During autophagy in times of starvation, autophagosomes engulf 
cytoplasmic cellular components, including cytosolic proteins and organelles. Concomitantly, 
a cytosolic form of LC3 (LC3-I) is conjugated to phosphatidylethanolamine to form LC3- 
phosphatidylethanolamine conjugate (LC3-II), which is recruited for the formation of 
autophagosomal membranes (Pattingre et al., 2008). Thus, lysosomal turnover of the 
autophagosomal marker LC3-II reflects starvation-induced autophagic activity, and 
measuring the level of LC3-II by immunoblotting or immunofluorescence has become a 
reliable marker for monitoring autophagy machinery and autophagy-related processes(Tanida 
et al., 2008).
5.1.3.2.The role of autophagy in breast cancer
Autophagy has dual roles in the cancer field, performing as both a tumour suppressor by 
preventing the accumulation of damaged proteins and organelles and also acting as a 
mechanism of cell survival that can promote the growth and proliferation of established 
tumours (Yang et al., 2011). Tumour cells are able to activate autophagy under certain 
circumstances such as in response to cellular stress and or in the case of increased metabolic 
demands related to rapid cell proliferation (Karantza-Wadsworth and White, 2007).
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Autophagy-related stress tolerance can enhance cell survival by maintaining energy 
production that can lead to cancer cell growth and therapeutic resistance (Liu et al., 2011).
It has been found that the human heclinl gene is mono-allelicallydeleted in 40 to 75% of 
sporadic human breast, ovarian, and prostate cancers (Qu et al., 2003). Laboratory 
investigation showed that many breast cancer cell lines exhibit deletions of one or more 
beclinl alleles, and another observation was that human breast tumours had decreased 
expression of Beclinl compared to normal adjacent tissue(Aita et al., 1999;Liang et al.,
1999).
To investigate specifically the role of autophagy in tamoxifen-treated breast cancer cell lines, 
the siRNA approach has been used to target three different autophagy genes, Atg5, Beclin-1 
and Atg7. It was that inhibition of autophagy, in combination with tamoxifen treatment in 
MCF7 cells, results in reduction of cell viability concomitant with increased mitochondrial- 
mediated apoptosis(Cook et al., 2011).The same study observed that the combination of 
autophagy inhibition and tamoxifen treatment similarly resulted in reduced cell viability in 
T47D cells, and tamoxifen-resistant MCF7 cells. Together, these results indicate that 
autophagy has a primary pro-survival role following tamoxifen treatment, and suggest that 
inhibition of autophagy may be useful in a combination therapy setting to sensitise breast 
cancer cells to tamoxifen therapy (Cook et al., 2011).
Qadir et al. (2008)used siRNA with Atg5, Beclin-1 and Atg7 in order to inhibit autophagy in 
MCF-7, T47D and tamoxifen-resistant MCF7 cell lines. They reported that concurrent 
inhibition of autophagy and treatment with tamoxifen resulted in increased mitochondrial- 
mediated apoptotic cell death and overall reduced cell viability (Qadir et al., 2008).
Moreover, it has been speculated that inhibition of autophagy through Beclin-1 siRNA in 
tamoxifen-resistant MCF7 breast cancer cells restored the effectiveness of anti-oestrogen
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therapy (Crawford et ah, 2010).Previous studies indicated that autophagic cell death is a 
process that is very relevant to resistance to other classes of chemotherapy drugs such as 
paclitaxel, which is used to treat breast cancer (Ajabnoor et ah, 2012).
To date, the functional interaction between autophagy and breast cancer-promoting functions, 
in particular those involving gene amplification as a mechanism of tumour progression, 
remains unclear. This area requires further investigation and could have significant 
prognostic consequences and therapeutic implications for breast cancer.
5.1.3.3.The role of autophagy in anti-endocrine resistance
The main impediment to the successful treatment of ER-positive breast cancer is the 
development of acquired resistance to anti-oestrogen therapeutic agents. The molecular 
mechanisms of acquired anti-oestrogen resistance in breast cancer cells are being unravelled 
with in vitro studies (Musgrove and Sutherland, 2009). Very few studies have examined the 
role of autophagy in the development of anti-endocrine resistance; therefore the mechanism is 
not fully understood. The first study demonstrating a correlation was in 2008, by Samaddar 
and co-workers. They suggested that autophagy is critical to the survival of non-invasive, 
ER-positive breast cancer cells and the development of anti-oestrogen resistance(Samaddar et 
al., 2008). This pro-survival role for autophagy in tamoxifen-treated breast cancer cells is 
consistent with one function of the autophagosome vesicles, which is to recycle metabolites 
from degraded cellular constituents to support a basal level of cell maintenance under 
starvation conditions (Lum et al., 2005).
Initial studies by Bursch et al. established that ER-positive breast cancer cells treated with the 
anti-oestrogen tamoxifen died by PCD II. During PCD II, cells exhibited a cytosolic content 
of autophagosomes and a nucleus with irregular chromatin compaction, not consistent with
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the chromatin compaction at the nuclear membrane typically seen in cells dying by apoptosis 
(Bursch et ah, 1996). Nevertheless, these initial studies did not address the potential role for 
autophagy in the survival of the cancer cell population. Samaddar’s study demonstrates that 
tamoxifen treatment induces autophagy in MCF-7 breast cancer cells that do not undergo 
death; these surviving cells comprise approximately 70% of the cell population (Samaddar et 
al., 2008). Samaddar’s group also hypothesised that whether autophagy induces cell survival 
or cell death may be dependent on the number of autophagosomes in each cell, resulting in a 
threshold limit. Inhibiting autophagosome formation by using 3-methyladenine (3-MA) or 
Beclin-1 siRNA significantly enhanced anti-oestrogen-induced cell death in MCF-7 cells, 
further suggesting the role of pro-survival autophagy in the development of resistance to anti­
oestrogen therapy (Samaddar et al., 2008).
5.1.3.4.Pharmacological compounds and strategies to target autophagy
The role of autophagy in cancer is an area of active investigation. There are two different 
strategies to target autophagy. The first strategy is to stimulate autophagy using 
pharmacological inducers such as mTOR inhibitors and its analogues, in order to promote 
cell death. The other strategy is to supress the survival mechanism of autophagy using 
autophagy inhibitors such as anti-malarial agents (chloroquine (CQ) and mefloquine (MQ)), 
bafilomycin A^ andPDK inhibitors such as LY294002 and Methyladenine (3- MA). The 
mechanisms to differentiate between these two strategies are shown in Figure 5-2.
Autophagy inducers in cancer therapy
It has been shown that excessive or sustained autophagy has an important role in the 
induction of tumour cell death. These inducers may therefore be potential therapeutics for 
cancer treatment.
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mTOR inhibitors
It was mentioned previously that autophagy is closely regulated by the mTOR signalling 
pathway. That there are two distinct forms of mTOR signalling complexes known as 
mTORCl and mT0RC2 (Jung et al., 2010). mTOR inhibitors such as rapamycin and its 
analogues temsirolimus (CCI-779), everolimusm (RAD-001) and deforolimus (AP-23573), 
selectively target mTORCl to activate autophagy (Yang et al., 2011).
In the clinical setting, it has been shown that rapamycin and its analogues have had limited 
success in various tumour types with the exception of renal cell carcinomas(Wang and Sun, 
2009). In a multicentre phase III trial, it was revealed that patients who received temsirolimus 
had a progression-free survival and longer overall survival (Hudes et al., 2007).
The modest anti-tumour activity of rapamycin is due to inability to inhibit mT0RC2, and 
inability to abrogate the negative feed-loop to the PI3K-Akt pathway that results to the 
functional activation of Akt signalling in cancer cells (O'Reilly et al., 2006). The limited 
potency of mTOR inhibitors as monotherapy has led to the assessment of drug combinations. 
Clinical and laboratory investigations have found that when rapamycin is combined with 
chemotherapy, co-treatment can lead to enhancement of apoptosis in vitro and the promotion 
of antitumour activity in v/vo(Abraham and Gibbons, 2007;Meric-Bemstam and Gonzalez- 
Angulo, 2009). In preclinical models, it has been observed thatrapamycin and related 
compounds (rapalogs) increase the efficacy of tamoxifen, fulvestrant and letrosole in breast 
carcinomas (deGraffenried et al., 2004).
Sadler and co-workers demonstrated for the first time that the combination oftemsirolimus 
and an anti-oestrogen agent such as tamoxifen or fulvestrant has excellent anticancer activity 
in breast cancer MCF7 cells and therefore, may have clinical benefit in treating hormone- 
dependent tumours (Sadler et al., 2006).
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Autophagy inhibitors in cancer therapy
Targeting autophagy, particularly when acting in a survival mode to induce tumourigenesis, 
has significant potential to lead to the development of novel therapeutic agents that can 
considerably reduce both tumourigenesis and the emergence of anti-oestrogen-resistant breast 
cancer cells. Accumulating data suggest that it could be beneficial to combine inhibitors of 
autophagy with cytotoxic chemotherapy or with anti-endocrine therapy in breast cancer 
(Sharma et al., 2012). A few of these inhibitors are discussed below.
Anti-malarial agents
Chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) have been approved by the 
FDA as autophagy inhibitors; these agents suppress autophagy by blocking auophagosome 
fusion and degradation(Sui et al., 2013). A phase II clinical trial is currently investigating the 
effects of autophagy inhibition by applying HCQ therapy to breast cancer patients 
(Amaravadi et al., 2011). The current outcomes indicate that the combination of CQ or HCQ 
with chemotherapeutic drugs enhance the efficacy of breast cancer tumour cell killing via the 
inhibition of autophagy. However, their sensitizing effects can also occur independently of 
autophagy inhibition, which is a mechanism that should be considered in the ongoing clinical 
trials (Schoenlein et al., 2009).
Mefloquine (MQ) is approved by the FDA for the prophylaxis and treatment of malaria(Dow 
et al., 2005). Several studies have demonstrated the ability of MQ to inhibit P-gp and because 
of this effect, when used in combination with doxorubicin, MQ has been observed to reverse 
the resistance of cancer cells to doxorubicin (Fujita et al., 2000). Recently, MQ has also been 
demonstrated to have superior potency over CQ in the inhibition of autophagy and the 
triggering of cell death in both hormone receptor-positive cell lines such as T47D and 
hormone receptor-negative breast cancer cells such as MDA-MB-231 (Sharma et al., 2012).
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Bafilomycin Aj
In addition to antimalarial drugs, bafilomycin Ai is a specific inhibitor of the vacuolar type 
H^-ATPase (V-ATPase) in cells, and inhibits the acidification of organelles containing this 
enzyme, such as lysosomes and endosomes. Recently, it has been reported that bafilomycin 
Al can inhibit autophagy via blocking the fusion of autophagosomes with lysosomes (Yang et 
ah, 2011). Furthermore, it has been revealed that the combination of bafilomycin A l with 
tamoxifen effectively induces cell death in HER2- and ERa-positive breast cancer cells (Jin 
et ah, 2013).
P3K inhibitors
LY294002 is a potent, cell permeable inhibitor of PI3K that acts on the ATP binding site of 
the enzyme (Xing et ah, 2008). The PI3K pathway has been extensively studied for its role in 
inhibiting apoptosis and is also known to be involved in the initiation and expansion stages of 
autophagy (Kondo et ah, 2005). Inhibition of PI3K with LY294002 can inhibit autophagic 
sequestration and diminish the pro-survival pathway of autophagy (Zhao et ah, 2012).
Methyladenine (3- MA) is another inhibitor of PI3K. 3-MA prevents autophagy by blocking 
autophagosome formation via the inhibition of class III PI3K. The experimental evidence 
indicated that 3-MA could attenuate the inhibitory role of HER2/Akt/mT0R survival 
pathway and induces apoptosis in the HER2-overexpressing BT474 and AU565 breast cancer 
cells (Liu et ah, 2013).
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Figure 5-2The two therapeutic strategies to target autophagy in cancer.Strategy 1:
inhibition of mTOR to induce autophagy. In certain cellular contexts, excessive or sustained 
autophagy may stimulate cell death using mTOR inhibitors such as rapamycin or its analoguescan 
block the formation of the ULK-Atg 13-FIP200 trimeric complex and thereby induce autophagy. 
Strategy 2: Inhibition of cytoprotective autophagy using LY294002, 3-MA, or CQ/HCQ/Bafilomycin 
A l.
5.2. Aims
The role of apoptosis in cancer has been a well elucidated and there is accumulated evidence 
demonstrating the disruption of apoptosis in breast cancer and in the development of 
resistance. To date, only a few studies have attempted to elucidate the role of the survival 
pathway of autophagy in the development of tamoxifen-resistance and none have been related 
to fulvestrant resistance. Due to this lack of knowledge, this research focusses on the 
molecular basis of autophagy to provide better understanding of its role in cell survival in 
breast cancer and the development of anti-oestrogen resistance. In addition, this work
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proposes some therapeutic strategies to target the survival pathway of autophagy and improve 
the efficacy of hormonal treatments in breast cancer.
The aims above will be met by:
• Measuring the expression of the pro-apoptotic factor Bax and the inhibitors of 
apoptosis, Bcl-2 and survivin in parental and anti-endocrine-resistant cells resistant by 
Western blotting analysis.
• Flow cytometry analysis to investigate the role of autophagy in anti-endocrine- 
resistant cells by treating parental and resistant breast cancer cells with tamoxifen or 
fulvestrant in the presence of the pan-caspase inhibitor Z-VAD-fmk, to block 
apoptosis.
• Assessment of the expression of autophagy-related markers such as LC3 in anti- 
endocrine-resistant breast cancer cells by using Western blotting analysis. The 
localisation of LC3 was also examined by detection the LC3 fluorescence using 
confocal microscopy. An alternative autophagy-related marker (Beclin-1) was also 
assessed using Western blotting analysis.
• Measuring the cytotoxicity of MQ by MTT assay and clonogenic assay in resistant- 
cells compared with parental cells.
• Demonstrating the therapeutic effect of MQ and LY294002 at targeting the survival 
mode of autophagy, in combination with anti-oestrogens using flow cytometry.
• Measuring PI3K, Akt and ERK protein expression by Western blotting to establish 
the molecular mechanism behind anti-oestrogen sensitisation by MQ.
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5.3. Methods
All methods used in this chapter are described in Chapter 2 (Materials and Methods): cell 
viability assay MTT assay (section 2.6.1), clonogenic assay (section 2.6.2), whole cell lysate 
preparation (section 2.7), Western immuno-blotting analysis (section 2.9), confocal 
microscopy (section 2.14) and Annexin V-FITC with PI assay (section 2.15).
5.4. Results
5.4.1. The effect of apoptosis in anti-endocrine resistant breast cancer cells
5.4.1.x. Changes in pro-apoptotic protein expression
This study examined the expression of the pro-apoptotic protein Bax, in parental and anti- 
endocrine resistant MCF7 (Figure 5-3) and T47D cells (Figure 5-4) using Western blotting 
analysis (parts A). Subsequent densitometry analysis (parts B) revealed that Bax was 
expressed at similar levels in both untreated MCF7 and MCF-TR cells (Figure 5-3 B). Upon 
treatment with 5fiM tamoxifen and 2 \iM fulvestrant, Bax was expressed at lower levels in 
tamoxifen-resistant cells compared with parental cells treated with the same agents (p<0.001 
and p<0.01, respectively; Figure 5-3 B). Within the MCF7 parental cell line, tamoxifen and 
fulvestrant treatment did not significantly change Bax expression, whereas in resistant cells, 
Bax levels were decreased considerably upon treatment.
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Figure 5-3Changes in Bax expression in tamoxifen-resistant MCF7 cell lines following 
treatment with anti-oestrogens.(A) Cells were treated with tamoxifen 5pM  or fulvestrant 2pM 
for 48hr before lysing. Samples (50 pg protein) were electrophoresed on a 10% SDS-polyacrylamide 
gel, transferred to a PVDF membrane and then exposed to a Bax antibody at a 1:100 dilution for 12hr 
before being exposed to anti-mouse alkaline phosphatase. GAPDH expression was used as a loading 
control. Bands were detected using a chemiluminescent substrate. Bax and GAPDH were detected at 
23kDa and 37kDa, respectively against a protein standard. (B) Bands were quantified by densitometry 
and normalised to GAPDH expression. Data are representative of repeat experiments (n = 3). 
Comparisons were made by two-way ANOVA with Bonferroni correction (**p<0.01; ***p<0.001).
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Furthermore, Western blotting was performed to detect the expression of Bax in fulvestrant- 
resistant cells when treated with anti-oestrogens (Figure 5-4). The findings were similar to 
those observed with tamoxifen resistance; Bax protein expression was reduced in fulvestrant 
resistant cells when treated with tamoxifen and fulvestrant compared with parental T47D 
cells treated with the same therapeutic agents (p<0.01 and p<0.05, respectively; Figure 5-4 
B). Following treatment of T47D cells with tamoxifen and fulvestrant, Bax expression was 
increased compared with the control (p<0.01 and p<0.05, respectively; statistics not shown 
on figure), whereas in resistant cells, Bax expression was comparable to the control following 
t r e a t m e n t .
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Figure 5-4Changes in Bax expression in tamoxifen-resistant T47D cell lines following 
treatment with anti-oestrogens.(A) Cells were treated with tamoxifen 5pM  or fulvestrant 2 pM 
for 48hr before lysing. Samples (50 pg protein) were electrophoresed on a 10% SDS-polyacrylamide 
gel, transferred to a PVDF membrane and then exposed to a Bax antibody at a 1:100 dilution for 12hr 
before being exposed to anti-mouse alkaline phosphatase. GAPDH expression was used as a loading 
control. Bands were detected using a chemiluminescent substrate. Bax and GAPDH were detected at 
23kDa and 37kDa, respectively against a protein standard. (B) Bands were quantified by densitometry 
and normalised to GAPDH expression. Data are representative of repeat experiments (n = 3). 
Comparisons were made by two-way ANOVA with Bonferroni correction (*p<0.05; **p<0.01).
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5.4.I.2. Changes in anti-apoptotic protein expression
As with Bax, this study examined the expression of the anti-apoptotic protein Bcl-2, in 
parental and anti-endocrine-resistant MCF7 (Figure 5-5) and T47D cells (Figure 5-6) using 
Western blotting analysis (parts A). Subsequent densitometry analysis (parts B) was 
performed to normalise the target protein against the loading control (GADPH). There was a 
six-fold lower expression of Bcl-2 in untreated tamoxifen-resistant cells(MCF7-TR-Control) 
compared with parental MCF-7 cells (p<0.0001; Figure 5-5 B). In addition, the expression 
level of Bcl-2 was significantly reduced in MCF7-TR cells following treatment with 5pM 
tamoxifen and 1.5 pM fulvestrant compared with parental cells treated with the same agents 
(p<0.0001 and p<0.0001, respectively; Figure 5-5 B). Following treatment of MCF7 cells 
with tamoxifen and fulvestrant, Bcl-2 expression was reduced significantly versus control 
(p<0.01 and p<0.0001, respectively; statistics not shown on figure). After treatment of 
MCF7-TR cells with tamoxifen and fulvestrant, Bcl-2 expression was comparable to the 
control.
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Figure 5-5Changes in anti-apoptotic Bcl-2 protein expression in MCF-7 and MCF-TR 
lines following treatment with anti-oestrogens.(A) Cells were treated with tamoxifen 5pM or 
fulvestrant 2 pM for 48hr before lysing. Samples (50 pgprotein) were electrophoresed on a 10% SDS- 
polyacrylamide gel, transferred to a PVDF membrane and then exposed to a Bcl-2 antibody at a 1:100 
dilution for 12hr before being exposed to anti-mouse alkaline phosphatase. GAPDH expression was 
used as a loading control. Bands were detected using a chemiluminescent substrate. Bcl-2 and 
GAPDH were detected at 26kDa and 37kDa, respectively against a protein standard. (B) Bands were 
quantified by densitometry and normalised to GAPDH expression. Data are representative of repeat 
experiments (n = 3). Comparisons were made by two-way ANOVA with Bonferroni correction 
(****p<O.QOQl).
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Furthermore, Western blotting was performed to detect the constitutive expression level of 
Bcl-2 in parent and resistant T47D cells and in T47D-resistant cells when treated with the 
two anti-oestrogens (Figure 5-6). Constitutive expression was lower in T47D-FR cells 
compared with parental T47D cells (p<0.05; Figure 5-6 B) .It was found that there was 
decreased Bcl-2 protein expression in fulvestrant-resistant cells when treated with tamoxifen 
and fulvestrant compared with parental T47D cells treated with the same therapeutic 
agents(p<0.01 and p<0.05, respectively; Figure 5-6B). Following treatment of T47D cells 
with tamoxifen, Bcl-2 expression was increased compared with the control (p<0.05; statistics 
not shown on figure). Bcl-2 expression level was also increased in fulvestrabt-treated T47D 
but the difference was not significant compared with the T47D control. Bcl-2 expression 
levels in tamoxifen- and fulvestrant-treated resistant cells remained comparable to control 
resistant cells.
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Figure 5-6Changes in anti-apoptotic Bcl-2 protein expression in T47D and T47D- FR 
lines following treatment with anti-oestrogens.(A) Cells were treated with tamoxifen 5pM or 
fulvestrant 2 pM for 48hr before lysing. Samples (50 pg proteins) were electrophoresed on a 10% 
SDS-polyacrylamide gel, transferred to a PVDF membrane and then exposed to a Bcl-2 antibody at a 
1:100 dilution for 12hr before being exposed to anti-mouse alkaline phosphatase. GAPDH expression 
was used as a loading control. Bands were detected using a chemiluminescent substrate. Bcl-2 and 
GAPDH were detected at 26kDa and 37kDa, respectively against a protein standard. (B) Bands were 
quantified by densitometry and normalised to GAPDH expression. Data represents n=3. Comparisons 
were made by two-way ANOVA with Bonferroni correction (*p<0.05; **p<0.01).
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5.4.I.3. Changes in inhibitor of apoptosis (lAP) protein expression
The protein expression of the inhibitor of apoptosis (lAP) survivin was determined in 
parental and anti-endocrine resistant MCF7 (Figure 5-7) and T47D cells (Figure 5-8) using 
Western blotting analysis (parts A). Subsequent densitometry analysis (parts B) revealed that 
survivin was expressedat higher levels in untreated, tamoxifen treated, and fulvestrant treated 
MCF-TR cells in comparison to the parental cell lines treated with the same agents 
(p<0.0001, p<0.001 and p<0.01 respectively; Figure 5-7 B). Following treatment of MCF7 
cells with tamoxifen and fulvestrant, survivin expression was comparable to the wild- 
typecontroLSimilarly, survivin expression levels in tamoxifen- and fulvestrant-treated 
resistant cells remained comparable to levels in control resistant cells.
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Figure 5-7Changes in inhibitor of apoptosis survivin protein expression in tamoxifen- 
resistant MCF7 cell lines following treatment with anti-oestrogens.(A) Cells were treated 
with tamoxifen 5pM or fulvestrant 2 pM for 48hr before lysing. Samples (50 pg proteins) were 
electrophoresed on a 10% SDS-polyacrylamide gel, transferred to a PVDF membrane and then 
exposed to a survivin antibody at a 1:100 dilution for 12hr before being exposed to anti-mouse 
alkaline phosphatase. GAPDH expression was used as a loading control. Bands were detected using a 
chemiluminescent substrate. Survivin and GAPDH were detected at 16.5 kDa and 37kDa, respectively 
against a protein standard. (B) Bands were quantified by densitometry and normalised to GAPDH 
expression. Data are representative of repeat experiments (n = 3). Comparisons were made by Two- 
way ANOVA with Bonferroni correction (**p<0.01; ***p<0.001; ****p<0.0001 ).
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Additionally, Western blotting was performed to detect the expression level of survivin in 
fulvestrant-resistant cells when treated with anti-oestrogens (Figure 5-8).Constitutive 
expression of survivin protein was significantlyhigher in T47D-FR cells compared with 
parental T47D cells (p<0.05; Figure 5-8B)
Additionally, survivin protein expression was higher in fulvestrant-resistant cells when 
treated with tamoxifen and fulvestrant compared with parental T47D cells treated with the 
same therapeutic agents(both p<0.05; Figure 5-8 B). Following treatment of T47D and 
T47D-FR cell lines with anti-oestrogens, survivin expression levels was comparable to the 
corresponded control.
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Figure 5-8Changes in inhibitor of apoptosis survivin protein expression in fulvestrant- 
resistant T47D cell lines following treatment with anti-oestrogens.(A) Cells were treated 
with tamoxifen 5pM or fulvestrant 2 pM for 48hr before lysing. Samples (50 pg proteins) were 
electrophoresed on a 10% SDS-polyacrylamide gel, transferred to a PVDF membrane and then 
exposed to a survivin antibody at a 1:100 dilution for 12hr before being exposed to anti-mouse 
alkaline phosphatase. GAPDH expression was used as a loading control. Bands were detected using a 
chemiluminescent substrate. Survivin and GAPDH were detected at 16.5 kDa and 37kDa, respectively 
against a protein standard. (B) Bands were quantified by densitometry and normalised to GAPDH 
expression. Data are representative of repeat experiments (n = 3). Comparisons were made by Two- 
way ANOVA with Bonferroni correction (*p<0.05).
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5.4.2. The role of autophagy in anti-endocrine-resistant cells
5.4.2.I. Investigating the induction of non-apoptotic cell death pathways in anti- 
endocrine-resistance
The main focus of this research was to establish if autophagy is a key mechanism of cell 
survival in tamoxifen- and fulvestrant-resistant MCF7-TR and T47D-FR breast cancer cells, 
respectively. This was achieved by pre-incubating cells with the pan-caspase inhibitor Z- 
VADlOOpM, for 1 h prior to treatment with tamoxifen 5[xM or fulvestrant 2 pM for 48hr and 
subjecting them to flow cytometry using the Annexin-V FITCwith PI assay, to establish the 
amount of cell death occurring whilst eliminiating the effects of caspasesapoptosis.
The data obtained from the cytograms generated from the Annexin-V FITC/PI assay (Figure 
5-9 A,B) demonstrated the differences in the apoptotic response between tamoxifen and 
fulvestrant (Figure 5-9A; a,c,e) versus the apoptotic effect of these agents in the presence of 
Z-VAD (Figure 5-9 A; b,d,f) in parental cells. Following treatment of MCF7 cells with 
tamoxifen 5pM and fulvestrant 2 pM ,reduction of cell viability was approximately 35.7% 
and 12.9% respectively, compared with untreated MCF7 cells (p<0.0001 and p<0.001, 
respectively).
Following treatment of MCF7 cells with tamoxifen and fulvestrant in the presence of Z- 
VAD, reduction in cell viability was attenuated compared with cells treated with the same 
agents but without Z-VAD (Figure 5.8A; b,d,f). Subsequent bar graphs generated from the 
cytograms (parts B) demonstrated a significant difference in the percentage of viable cells 
between tamoxifen-treated cells in the absence of Z-VAD versus treatment with Z-VAD 
(64.73% (±2.61) versus 84.96% (±4.55); p<0.0001; Figure 5-9B). Following treatment of 
MCF7 cells with fulvestrant in the absence of T^-WPiDversus treatment with Z-VAD, the
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population of viable cells was found to be 84.4% (±1.30) and 93.8% (±0.85) respectively 
(p<0.05; Figure 5-9 B). These observations confirmtheprotective effect of Z-VAD against 
apoptotic cell death in these cell lines. Moreover, these data provide information on the 
contribution of caspases in anti-endocrine agent responsiveness in breast cancer cells with 
varying levels of drug sensitivity.
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Figure 5-9Determination of apoptotic response in parental MCF7 cells treated with 
tamoxifen and fulvestrant in the absence or presence of Z-VAD.(A) Cytograms obtained 
from Annexin-V FITCwith PI assay assays of MCF7 cells treated with tamoxifen 5pM or fulvestrant 2 
pM in the absent and present of Z-VAD 100 pM. Each cytogram consists of: bottom left; living cells 
(PI and FITC negative) bottom right; early apoptotic population (FITC positive) top right; mid-late 
stage apoptosis (PI and FITC positive) top left; necrotic/end stage apoptotic cells (PI positive, FITC
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negative). In a) control untreated cells; b) Z-VAD-treated control cells; c) tamoxifen-treated cells; d) 
tamoxifen and Z-VAD combination treatment; e) fulvestrant-treated cells; f) fulvestrant and Z-VAD 
combination treatment. The live cell population is indicated for each sample and is representative of 
data obtained. (B) Bar graphs (derived from A) showing the extent of protection of tamoxifen 5pM- 
and fulvestrant 2 pM-treated cells following Z-VAD treatment. Data (mean and standard deviation 
(SD)) shown are representative of three independent repeat experiments (n = 3). Comparisons were 
made by paired t-test (*p<0.05; ***p<0.001).
The Annexin V assay with PI was also performed to detect alternative cell death pathways in 
tamoxifen-resistant cells (MCF-TR) aftertreatment with tamoxifen5pM and fulvestrant 2 
pM in the absence (Figure 5-lOA and B; a, c, e)and presence of Z-VAD (Figure 5-10 A and 
B; b,d,f).The cell viability in tamoxifen-resistant cells treated with anti-oestrogen agents was 
comparable to the control (Figure 5.9 A), consistent with MCF-TR cellsbeing resistant to 
tamoxifen and cross-resistant to fulvestrant. As no cell death occurred at these concentrations, 
it was impossible to examine the effect of Z-VAD on cell death pathways.
To overcome this obstacle, we treated the MCF-TR cells with higher doses of tamoxifen 
(lOpM) and fulvestrant (4 pM) to cause detectable levels of cell death (Figure 5-10 B). The 
bar graphs (Figure 5-10 C) generated from the cytograms (Figure 5-10 B) revealed there was 
no change in cell viability of untreated, tamoxifen-treated, and fulvestrant-treated MCF-TR 
cellsin the presence of Z-VAD compared with the MCF-TR cells treated with the same anti­
oestrogen agents without adding the Z-VAD (p= 0.6, p=0.8 and p=0.9 respectively; Figure 5- 
10 C).These observations indicate that caspases were not involved in the cell death mediated 
by treatment with either agent in tamoxifen-resistant MCF7-R cells.
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Figure 5-lODetermination of apoptotic response in parental and tamoxifen- resistant 
MCF7-TR cells treated with tamoxifen and fulvestrant in the absence or presence of Z- 
VAD.(A) Cytograms obtained for MCF7-TR cells following 48 h continuous exposure to tamoxifen 
5pM and fulvestrant 2 pM in the absence or presence of Z-VAD. (B) Cytograms obtained for MCF7- 
TR cells following 48 h continuous exposure to tamoxifen lOpM and fulvestrant 3 pM in the absence 
or presence of Z-VAD 100 pM. Each cytogram consists of: bottom left; living cells (PI and FITC
264
Chapter 5 Cell death pathways involved in acquired drug resistance
negative) bottom right; early apoptotic population (FITC positive) top right; mid-late stage apoptosis 
(PI and FITC positive) top left; necrotic/end stage apoptotic cells (PI positive, FITC negative). In a) 
control untreated cells; b) Z-VAD-treated control cells; c) tamoxifen-treated cells; d) tamoxifen and 
Z-VAD combination treatment; e) fulvestrant-treated cells; f) fulvestrant and Z-VAD combination 
treatment. The live cell population is indicated for each sample and is representative of data obtained. 
(C) Bar graph (derived from A, B) showing lack of protection of tamoxifen- and fulvestrant-treated 
cells following Z-VAD treatment. Data (mean and standard deviation (SD)) are representative of 
repeat experiments (n = 3). No comparisons were found to be statistically significant by paired t-test.
The current study also investigated the induction of non-apoptotic cell death in fulvestrant- 
resistant cells (T47D-FR) compared with their parental counterparts. Parental T47D cells 
were pre-incubated with Z-VAD lOOfxM for 1 h prior to treatment with tamoxifenSpiM or 
fulvestrant! for 48hr and subjected to the flow cytometry using the Annexin V assay with 
PI. The data obtained from cytograms generated from the Annexin- V FITC/PI assay (Figure 
5-11 A, B) showed the differences in the apoptotic response between tamoxifen and 
fulvestrant (Figure 5-11 A; a, c, e) versus the apoptotic effect of these anti-oestrogen agents 
in the presence of Z-VAD (Figure 5-11 A; b, d, f) in parental T47D cells. There was a 
significant reduction in viability in tamoxifen-treated T47D cells compared with the control 
(71.70% (±1.62) versus 96.00% (±2.30); p<0.0001; Figure 5-11 A) (Average f  three 
experiment). Reduced cell viability was also observed in fulvestrant-treated T47D cells 
compared with the control (82.00% (±3.37) versus 96.00 (±2.30); p<0.001; Figure 5-11 A) 
(Average of three experiment).
After treatment of T47D cells with tamoxifen and fulvestrant in the presence of Z-VAD, a 
smaller reduction in the viable cell population was observed (Figure 5-11 A; b,d,f).Subsequent 
bar graphs generated from the cytograms (parts B) demonstrated a significant increase in the 
percentage of viable cells between tamoxifen and fulvestrant-treated T47D cells in the 
absence of Z-VAD versus treatments in the presence of Z-VAD (p<0.0001 and p<0.001.
265
Chapter 5 Cell death pathways involved in acquired drug resistance
respectively; Figure 5-11 B). As with MCF7 cells, these observations indicated a protective 
effect of Z-VAD against apoptotic cell death machinery in parental T47D cell lines.
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Figure 5-llDetermination of apoptotic response in parental T47D cells treated with 
tamoxifen and fulvestrant in the absence or presence of Z-VAD.(A) Cytograms obtained 
from Annexin V assays of T47D cells treated with tamoxifen 5pM or fulvestrant 2 pM in the absence
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or presence of Z-VAD 100 pM . Each cytogram consists of: bottom left; living cells (PI and FITC 
negative) bottom right; early apoptotic population (FITC positive) top right; mid-late stage apoptosis 
(PI and FITC positive) top left; necrotic/end stage apoptotic cells (PI positive, FITC negative). In a) 
control untreated cells; b) Z-VAD-treated control cells; c) tamoxifen-treated cells; d) tamoxifen and 
Z-VAD combination treatment; e) fulvestrant-treated cells; f) fulvestrant and Z-VAD combination 
treatment. The live cell population is indicated for each sample and is representative of data obtained. 
Percentage displayed is representative of one experiment. (B) Bar graphs (derived from A) showing 
the extent of protection of tamoxifen and fulvestrant-treated cells following Z-VAD treatment 
lOOpM. Data (mean and standard deviation (SD)) are representative of three independent repeat 
experiments (n = 3). Comparisons were made by paired t-test (****p<0.0001; ***p<0.001).
The same experiment wasalso conducted to investigate the alternative cell death pathways in 
fulvestrant-resistant cells (T47D-FR) aftertreatment with higher doses of tamoxifen lOpM and 
fulvestrant 4pMin the absence (Figure 5-12 A; a, c, e)and presence of Z-VAD (Figure 5.12 
A;b,d,f).The bar graphs (Figure 5-12 B) generated from the cytograms (Figure 5-12 A) 
indicated no change in cell viability of tamoxifen-treated and fulvestrant-treated fulvestrant- 
resistant cells in the presence of Z-VAD compared with T47D-FR cells treated with the same 
anti-oestrogen agents without adding Z-VAD (p= 0.2, p=0.9 and p=0.7 respectively; Figure 
5-12 B).
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Figure 5-12Determination of apoptotic response in parental and fulvestrant- resistant 
T47D-FR cells treated with tamoxifen and fulvestrant in the absence or presence of Z- 
VAD.(A) Cytograms obtained for T47D-FR cells following 48 h continuous exposure to tamoxifen 
lOpM or fulvestrant 4 pM in the absence or presence of Z-VAD lOOpM. Each cytogram consists of:
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bottom left; living cells (PI and FITC negative) bottom right; early apoptotic population (FITC 
positive) top right; mid-late stage apoptosis (PI and FITC positive) top left; necrotic/end stage 
apoptotic cells (PI positive, FITC negative). In a) control untreated cells; b) Z-VAD-treated control 
cells; c) tamoxifen-treated cells; d) tamoxifen and Z-VAD combination treatment; e) fulvestrant- 
treated cells; f) fulvestrant and Z-VAD combination treatment. The live cell population is indicated 
for each sample and is representative of data obtained. (B) Bar graph (derived from A) showing lack 
of protection of tamoxifen- and fulvestrant-treated cells following Z-VAD treatment. Data (mean and 
standard deviation (SD)) are representative of repeat experiments (n = 3). No comparisons were found 
to be statistically significant by paired t-test.
S.4.2.2. Detection of markers of autophagy in anti-endocrine-resistant breast cancer
cells
We investigated the expression of the autophagy-related markers,beclin-1 and LC3. We also 
assessed LC3 localisationin parental and anti-endocrine-resistant breast cancer cell lines.
Detection of beclin-1 expression in anti-endocrine-resistant breast cancer cells
This study examined the expression of the autophagy-related marker beclin-1 in parental and 
anti-endocrine resistant breast cancer MCF-7 cells (Figure 5-13) and T47D cells (Figure 5- 
14) using Western blotting analysis (parts A). Subsequent densitometry analysis (parts B) 
revealed that beclin-1 was expressed at higher levels in untreated tamoxifen-resistant cells 
compared withuntreated parental MCF7 cells (p<0.01; Figure 5-13B).
Within the MCF7 parental and resistant cell lines, tamoxifen and fulvestrant treatment had no 
effect on beclin-1 expression compared with their corresponding controls.
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Figure 5-13Changes in beclin-1 expression in tamoxifen-resistant MCF7 cell lines 
following treatment with anti-oestrogens.(A) Cells were treated with tamoxifen 5 pM or 
fulvestrant 2 pM for 48hr before lysing. Samples (lOOpg protein) were electrophoresed on a 10% 
SDS-polyacrylamide gel, transferred to a PVDF membrane and then exposed to a beclin-1 antibody at 
a 1:50 dilution for 24 h before being exposed to anti-mouse alkaline phosphatase. (3-actin expression 
was used as a loading control. Bands were detected using a chemiluminescent substrate. Beclin-1 
(upper band) and p-actin were detected at 60kDa and 42kDa, respectively against a protein standard. 
(B) Bands were quantified by densitometry and normalised to P-actin expression. Data are 
representative of repeat experiments (n = 3). Comparisons were made by Two-way ANOVA with 
Bonferroni correction (**p<0.01).
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Western blotting was also performed to detect the expression of beclin-1 in fulvestrant- 
resistant cells when treated with anti-oestrogens (Figure 5-14). Beclin-1 protein expression in 
untreated and fulvestrant-treated resistant cells was higher thanfor the parental and 
fulvestrant-treated T47D cells, respectively (p<0.05 and p<0.0001, respectively; Figure 5-14 
B), whereas the expression level of beclin-1 was reduced in tamoxifen-treated T47D-FR cells 
compared to parental T47D cells treated with the same agent (p<0.01; Figure 5-14 B).
Following treatment of T47D cells with tamoxifen and fulvestrant, beclin-1 expression was 
significantly reduced compared with expression in the parental control cells (p<0.0001 and 
p<0.0001, respectively). Beclin-1 expression was also significantly reduced in tamoxifen- 
treated and fulvestrant-treated T47D-FR cells compared with resistant-control cells 
(p<0.0001 and p<0.01; statistics not shown on figure).
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Figure 5-14Beclin-l protein expression in T47D and T47D- FR lines following treatment 
with anti-oestrogens.(A) Cells were treated with tamoxifen 5 pM or fulvestrant 2 pM for 48hr 
before lysing. Samples (lOOpg proteins) were electrophoresed on a 10% SDS-polyacrylamide gel, 
transferred to a PVDF membrane and then exposed to a beclin-1 antibody at a 1:50 dilution for 24hr 
before being exposed to anti-mouse alkaline phosphatase, p-actin expression was used as a loading 
control. Bands were detected using a chemiluminescent substrate. Beclin 1 and P-actin were detected 
at 60kDa and 42kDa, respectively against a protein standard. (B) Bands were quantified by 
densitometry and normalised to p-actin expression. Data are representative of repeat experiments (n = 
3). Comparisons were made by Two-way ANOVA with Bonferroni correction (*p<0.05; **p<0.01;
***p<0.001).
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Detection of LC3 expression in anti-endocrine resistant breast cancer cells
Autophagy can be measured by the presence of LC3 in autophagosomes as well as by 
tracking the level of conversion of LC3-I to LC3-ILBoth methods have been used as reliable 
indicators of autophagic activity .In particular, levels of LC3-II correlate with autophagosome 
formation, due to its association with the autophagosome membrane (Levine and Kroemer, 
2008).
This study examined the expression of autophagy-related marker LC3, in parental and anti- 
endocrine-resistant MCF7 (Figure 5-15) and T47D cells (Figure 5-16) using Western blotting 
analysis (parts A). Subsequent densitometry analysis was used to calculate the ratios of LC3- 
II with respect to LC3-I (parts B). This analysis revealed that the ratio of LC3-II/LC3-Iwas 
higher in tamoxifen-resistant cells following treatment with tamoxifen 5pM in the absence 
and presence of Z-VAD 100 pM, compared with parental cells treated with the same agents 
(p<0.05 and p<0.01, respectively; Figure 5-15 B). Following treatment of MCF7 cells with 
tamoxifen with and without Z-VAD, the ratio of LC3-II/LC3-I was decreased compared 
with the untreated MCF7, whereas in resistant cells when treated with tamoxifen in the 
absence and present of Z-VAD, the ratio was increased considerably compared to the MCF7- 
TR control ((p<0.05 and p<0.05, respectively).
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Figure 5-15Changes in LC-3I/II expression in parent and tamoxifen-resistant MCF7 
cell lines following treatment with anti-oestrogens in the presence or absence of Z- 
VAD.(A) Total protein was extracted from parent- and tamoxifen-resistant MCF7 cells treated with 
5pM tamoxifen with or without Z-VAD lOOpM. 60pg of each extract was separated by SDS-PAGE 
and transferred to PVDF membrane. Immunodetection of LC3-I/-11 using a 1:100 antibody dilution, 
incubated for 12 h yielded two bands at 16 kDa (LC3-1) and 14 kDa (LC3-II). GAPDH expression 
was used as a loading control. Bands were detected at 37kDa against a protein standard. (B) The 
densitometric ratios of LC3-11 were calculated with respect to LC3-1. Data are representative of repeat 
experiments (n =3). Comparisons were made by two-way ANOVA with Bonferroni correction 
(*p<0.05; **p<0.01).
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The same experiment was conducted in fulvestrant-resistant cells (Figure 5-16). The analysis 
demonstrated that the ratio of LC-3II/LC-3Iwas increased significantly in fulvestrant-resistant 
cells when treated with tamoxifen in the presence of Z-VAD compared with parental T47D 
cells treated with the same therapeutic agents(p<0.05; Figure 5.16 B). Following treatment of 
T47D cells with tamoxifen in the absence or presence of Z-VAD, the ratio of LC3-II/LC3-I 
was increased compared with the control (p<0.05 and p<0.05, respectively; statistics not 
shown on figure), whereas in drug resistant cells, the ratio of LC3-II to LC3-I was 
comparable to the control following treatment with tamoxifen. However, the ratio was 
increased significantly in resistant cells following treatment with tamoxifen in the presence of 
Z-VAD compared with untreated resistant cells (p<0.0001; statisties not shown on figure).
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Figure 5-16Changes in LC3-I/II expression in T47D and T47D- FR lines following 
treatment with anti-oestrogens in the presence or absence of Z-VAD.(A) Total protein was 
extracted from parent- and tamoxifen- resistant MCF7 cells treated with 5pM tamoxifen with or 
without lOOpM Z-VAD. 60pg of each extract was separated by SDS-PAGE and transferred to PVDF 
membrane. Immunodetection of LC3-E-I1 using a 1:100 antibody dilution, incubated for 12h yielded 
two bands at 16 kDa (LC3-1) and 14 kDa (LC3-II). GAPDH expression was used as a loading control. 
Bands were detected at 37 kDa against a protein standard. (B) The densitometric ratios of LC3-I1 were 
calculated with respect to LC3-1. Data are representative of repeat experiments (n = 3). Comparisons 
were made by two-way ANOVA with Bonferroni correction (*p<0.05).
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The localisation of LC3 to cellular autophagic vacuoles has been used in previous studies as 
an indicator of autophagy. This study detected the localisation of LC3 in parental and anti- 
endocrine resistant MCF7 (Figure 5-17) and T47D cells (Figure 5-18) by 
immunofluorescence using confocal microscopy. MCF7 and MCF-TR cells were treated with 
tamoxifen 5pM and fulvestrant 1.5pM. Cells were loaded with LC3 antibody conjugated with 
Alexa-Fluor488, the nuclear stain TOPRO-3 and also co-stained with LC3 and TOPRO-3 
(Figure 5-17; a, b, c). Heavy green staining corresponding to LC3 expression indicated more 
LC3 vacuole localisation in untreated tamoxifen-resistant (MCF-TR) cells compared with 
untreated parental MCF7 cells (Figure 5-17 A). Following treatment with tamoxifen, LC3 
staining was detected with greater intensity in tamoxifen-resistant cells compared with the 
parental MCF7 cells treated with the same agent (Figure 5-17 B). The increase in LC3 
fluorescence occurred in both cell lines in parallel when exposed to fulvestrant treatment.
MCF7-Control
a
MCF7-TR-Control
a
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Figure 5-17Confocal fluorescence microscopy imaging for LC3 detection in MCF7 and 
M CF7-TR cell lines.Cells were treated with tamoxifen 5pM and fulvestrant 1.5pM and incubated 
for 48 h. Images (a) cells were stained for LC3 alone (Alexa-Fluor 488 associated fluorescence), and 
images (b) cells were stained with the nuclear dye TOPRO-3, images (c) cells were co-stained with
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LC3 and TOPRO-3. Images (B, C) showed the deposition of LC3 granules in vacuoles in MCF7 
parental and MCF7-TR cell lines when treated with tamoxifen and fulvestrant. Data are representative 
of repeat experiments (n = 3).
The same experiment was performed in fulvestrant-resistant cells (Figure 5-18). The analysis 
demonstrated thatLCS stainingwas increased in untreated fulvestrant-resistant cells compared 
with untreated parental T47D cells Figure (5-18 A). High fluorescence of LC3-II was clearly 
detected in tamoxifen-treated fulvestrant-resistant cells compared with lowere levels seen in 
parental cells in the same experiments (Figure 5-18 B). It was found that fulvestrant induces 
LC3 fluorescence in both parental and resistant cells, but the staining more pronounced in 
fulvestrant-resistant cells (T47D-FR).
T47D-Control
T47D-FR-Control
a
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Figure 5-18Confocal fluorescence microscopy imaging for LC3 detection in T47D and 
T47D-FR cell lines.Cells were treated with tamoxifen 5pM and fulvestrant 2pM and incubated for
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48 h. Images (a) cells were stained for LC3 alone (Alexa-Fluor 488 associated fluorescence), and 
images (b) cells were stained with the nuclear dye TOPRO-3, images (c) cells were co-stained with 
LC3 and TOPRO-3. Images (B, C) showed the deposition of LC3 granules in vacuoles in T47D 
parental and T47D-FR fulvestrant-resistant cell lines when treated with tamoxifen and fulvestrant. 
Data are representative of repeat experiments (n = 3).
S.4.2.3. Therapeutic strategies to inhibit autophagy 
The use of antimalarial agent (mefloquine MQ)
Due to the previous Western blotting and confocal findings showing that autophagy is up- 
regulated in anti-oestrogen-treated resistant cells, this work explored the role of autophagy 
further by exploiting the ability of antimalarial agents to inhibit autophagy (Sharma et al., 
2012).Theeffect of the antimalarial agent MQ on parental and anti-endocrine-resistant MCF7 
(Figure 5-19) and T47D cells (Figure 5-20) was investigated.
Cell viability after treatment with increasing concentrations of MQ (0.5-100 pM) was 
assessed after 96 h using the MTT assay. The dose-response curves for MCF-7 and MCFTR 
cell lines (Figure 5-19 A) gave IC5 0  8.69 ± 0.80 pM and 10.06 ± 0.65 pM, respectively 
(Figure 5-19). The difference between the responses was not statistically significant (p=0.32).
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Figure 5-19Dose-response curves of cell viability of MCF7 and MCF-TR cells treated 
with mefloquine (M Q).Cells were treated with increasing concentrations M Q (0.5-100 pM) and 
cell viability was analysed by MTT assay. Each data point is the mean of 3 independent experiments 
(performed in triplicate). Percent cell viability (mean ± SD) is displayed, where the viability of 
untreated control cells was set to 100%. The difference between the two curves was assessed by 
paired T-test (p=0.32).
The MTT assay was also performed to determine the sensitivity of T47D and T47D-FR cells 
to MQ (Figure 5-20). The dose response curves for both cell lines demonstrated that MQ had 
a cytotoxic effect. The I C 5 0  values were estimated to be 7.54 ± 0.26 pM (parental) versus 
6.53 ± 0.34 pM (resistant) (Figure 5-20). The difference between the responses was not 
statistically significant (p=0.08)
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Figure 5-20Dose-response curves of T47D and T47D-FR cells to Mefloquine (M Q).Cells
were treated with increasing concentrations of MQ for 96 h, and cell survival was determined by MTT 
assay. Each data point is the mean of 3 independent experiments (performed in triplicate). Percent cell 
viability (mean ± SD) is displayed, where the viability of untreated control cells was set to 100%. The 
difference in response to this drug was not statistically significant by t-Test (p < 0.08).
The above short-term (96 h) cytotoxicity MTT assays were complemented by long-term (14 
days) clonogenic assays based on the ability of the cells to proliferate and form colonies in 
response to treatment.Specifically, we assessed the ability of individual cells to survive 48 h 
of drug treatment and spawn a colony of descendants within the following 14 days. Parental 
and tamoxifen-resistant MCF7 cells were treated with equal dose ranges of MQ (1-20 pM). 
Dose-dependent reduction in colony formation was observed for both parental and resistant 
MCF7 cell lines (Figure 5-21 A) .The bar graphs (Figure 5-21 B) generated from the 
clonogenic assay (Figure 5-21 A) estimated that MQ concentration of 5pM reduced colony 
formation to 43% and 30% in MCF7 and MCF7-TR cells, respectively (p<0.01; Figure 5- 
21). At the concentrations 1 pM and 2 pM, the MCF7 cells were significantly more
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responsive to MQ treatment that the resistant variant (p<0.001, p<0.01 respectively; Figure 5-
21), but as concentrations increased the difference in response was lost.
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MCF7
5 mM 10pM 2 0 |jMControl IjjM 2 [jM
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mi
B
150
o 100
MCF7 
MCF7 -TR
Mefloquine (pM)
Figure 5-21 Cytotoxic and anti-proliferative effects of mefloquine (M Q ).Cells were treated 
with 0-20 pM MQ for 48 h and cell survival was determined by clonogenic assay after an additional 
14 days in culture without drug:. (A) An example of the ability of MQ to reduce colony formation in 
both MCF7 and MCF7-TR cells. (B) Bar chart (derived from A) depicting summarised clonogenic 
assay results for MCF7 and MCF7-TR cells. Data are representative of repeat experiments (n = 3).
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Data shown are percent colony formation (mean ± SD), where the number of colonies derived from 
untreated cells was set to 100%. Comparisons were made by two-way ANOVA with Bonferroni 
correction (**p<0.01; ***p<0.001).
The co-administration ofMQ and tamoxifen to cause cell death inanti- endocrine-resistant 
breast cancer cells
This study investigated the combined cytotoxic effect of MQ when administered 
concomitantly with tamoxifen in parental and anti-endocrine resistant MCF7 cells (Figure 5-
22) and T47D cells (Figure 5-23). Parental and tamoxifen-resistant cells were treated with 
tamoxifen5pM, MQ 2 pM, and combined MQ and tamoxifen for a 48 h period and then 
subjected to AnnexinV-FITC analysis (Figure 5-22 A, B).The co-administration of MQ and 
tamoxifen showed a synergistic effect on cell death in MCF-TR cells compared with the 
effect ofeither MQ or tamoxifen alone (both comparisons p<0.0001)
Subsequent bar graphs generated from the cytograms (parts B) revealed a three-fold reduction 
in MCF7-TR cell viability aftercombination treatment withMQ and tamoxifen comparedwith 
the parental MCF7 cells treated with the same therapeutic agents (p<0.0001; Figure 5-22
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Figure 5-22 Determination of apoptotic response in MCF7 and MCF7-TR cells treated 
with mefloquine and tamoxifen.Cells were treated with single-agent tamoxifen 5^iM, or 
mefloquine 2 pM, or a of both for 48 h. Cells were harvested and processed for Annexin V-FITC/PI 
staining analysis using flow cytometry. (A) The data are presented in a four quadrant format; each 
quadrant in a cytogram represents a different state of cell viability as a percentage. Lower left
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quadrant represents live cells, lower right represents cells in early apoptosis (Annexin V-FITC 
positive, PI negative), upper right represents cells in late mid- phase apoptosis (Annexin V-FITC and 
PI positive) and upper left represents cells in necrotic/end stage apoptosis (PI positive, FITC 
negative). (B) Bar graph derived from (A) showing cell viability in MCF-TR cells treated with the 
combination of mefloquine and tamoxifen compared with parental MCF7 cells. Data are 
representative of repeat experiments (n = 3). Comparisons were made by two-way ANOVA with 
Bonferroni correction (**p<0.01; ****p<0.0001).
The Annexin-V FITC/PI experiment was also performed to test the apoptotic effect of co­
administering MQ and tamoxifen in parental T47D and fulvestrant-resistant cells (T47D-FR). 
Parental and fulvestrant-resistant cells were treated with tamoxifen 5pM, MQ 2 pM, or 
combination of MQ and tamoxifen for a 48 h period (Figure 5-23 A, B). The findings were 
similar to those observed with tamoxifen resistance. Treatment of T47D-FR cells with the 
combination of MQ and tamoxifen resulted a significant reduction in the viable cell 
population compared with T47D-FR cells treated with either MQ or tamoxifen alone that 
demonstrated the synergism (both p<0.0001). The bar graphs generated from the 
cytogramsalso showed a significant reduction in T47D-FR cell viability after treatment with 
the combination of MQ and tamoxifen compared with parental T47D cells treated with the 
same agents (p<0.0001; Figure 5-23B).
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Figure 5-23Determination of apoptotic response in T47D and T47D-FR cells treated 
withmefloquine and tam oxifen.Parental and resistant cells were treated with single agent 
mefloquine2 pM or tamoxifen 5pM, or the combination for 48 h. Cells were harvested and subjected 
to flow cytometry using the Annexin V assay with PI. The percentage of live cells (expressed as a 
percentage of the untreated control) is indicated in the bottom left hand corner (PI and FITC negative
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cells) of the quadrant cytogram; bottom right, early apoptotic population (FITC positive); top right, 
mid-late stage apoptosis (PI and FITC positive); top left, necrotic/end stage apoptotic cells (PI 
positive, FITC negative). (B) Bar graph derived from (A) showing the cell viability in T47D-FR cells 
treated with the combination of mefloquine and tamoxifen compared with parental T47D cells. Data 
shown are representative of repeat data (n=3). Comparisons were made by two-way ANOVA with 
Bonferroni correction (*p<0.05; ***p<0.001).
S.4.2.4. Molecular mechanisms of the MQ sensitivity in tamoxifen-resistant cells
This study examined the expression of members of the PI3K/Akt pathway in parental and 
anti-endocrine resistant MCF7 cells using Western blotting analysis (Figure 5-24). 
Constitutive activation of the PI3K/Akt pathway is considered a survival mechanism 
commonly encountered in human cancer. Parental and tamoxifen-resistant cells were treated 
with 5pM tamoxifen, 2 pM MQ or with a combination of the two for a 48 h period. 
Phosphorylated PI3K (P-PI3K), and phosphorylated Akt (P-Akt) were expressed at higher 
levels in untreated MCF7-TR cells compared with the parental cells (Figure 5-24 A). 
Subsequent densitometry analysis was conducted to calculate the ratios P-PI3K and P-Akt 
with respect to total PI3K and total Akt, respectively. This revealed that the constitutive 
expression as judged by P-PI3K/PI3K and P-Akt/Akt ratios was significantly increased in 
tamoxifen resistant cells (MCF-TR) compared with the parental cell lines (p<0.0001 and 
p<0.01, respectively; Figure 5-24 B).
Following treatment of tamoxifen-resistant cells with combination treatment, P-P13K 
expression was decreased compared with parental MCF7 cells (Figure5-24 A). Densitometry 
analysis revealed that ratio of P-P13K/P13K was reduced significantly in MCF7-TR cells that 
had undergone treatment with the combination of MQ and tamoxifen compared with parental 
cells treated with the same agents (p<0.0001 Figure 5-24B). In contrast, in resistant cells
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treated with MQ and tamoxifen concomitantly, the ratio of P-Akt/Akt was comparable to 
parental cells treated with the same agents (Figure5-24 C).
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Figure 5-24Changes in PI3K and Akt expression in tamoxifen-resistant MCF7 cell lines 
following combination treatment with mefloquine and tamoxifen.(A) Whole cell lysates 
were made following 48 h treatment with 5[xM tamoxifen and 2 gM mefloquine. Samples (50 pg
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protein) were separated by SDS-PAGE. After transfer to a PVDF membrane, the proteins were probed 
with polyclonal anti-rabbit pPI3K/PI3K antibodies or pAkt/Akt polyclonal anti-rabbit antibodies at a 
dilution of 1:100 for 12 h before being exposed to anti-rabbit alkaline phosphatase. P-Actin expression 
was used as a loading control. Bands were detected using a chemiluminescent substrate. pP13K/P13K, 
pAkt/Akt, and P-Actin were detected at 85kDa, 60kDa, and 42 kDa respectively against a protein 
standard. (B) The densitometric ratios of pP13K and pAkt were calculated with respect to P13K and 
Akt, respectively. Data shown are representative of repeat experiments (n = 3). Comparisons were 
made by two-way ANOVA with Bonferroni correction (**p<0.01; ***p<0.0001).
Western blotting was performed to detect the expression of phosphorylated and total P13K in 
fulvestrant-resistant cells when treated with 5pM tamoxifen, 2 pM MQ, and combination 
treatment with MQ and tamoxifen (Figure 5-25). P-P13K was higherin untreated T47D-FR 
cells compared with parental cells. Subsequent densitometry analysis revealed an increase in 
the ratios of P-P13K, with respect to total P13K in untreated fulvestrant-resistant 
cellscompared with the parental cell line (p<0.0001; Figure 5-25 B). Following treatment of 
fulvestrant-resistant cells with combination treatment, the ratio of P-P13K/P13K was reduced 
significantly in T47D-FR cells that had undergone combination treatment compared with 
parental cells treated with the same agents (p<0.05; Figure 5-25B).
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Figure 5-25Changes in PI3K expression in fulvestrant-resistant T47D cell lines 
following combination treatment with mefloquine and tamoxifen.(A) Whole cell lysates 
were made following 48 h treatment with 5pM tamoxifen and 2pM mefloquine. Samples (50 pg 
protein) were separated by SDS-PAGE. After transfer to a PVDF membrane, the proteins were probed 
with polyclonal anti-rabbit P-P13K/PI3K antibodies at a dilution of 1:100 for 12 h before being 
exposed to anti-rabbit alkaline phosphatase. (3-Actin expression was used as a loading control. Bands 
were detected using a chemiluminescent substrate. P-PI3K/PI3K and P-Actin were detected at 85kDa
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and 42 kDa respectively against a protein standard. (B) The densitometric ratios of P-PI3K were 
calculated with respect to PI3K. Data shown are representative of repeat experiments (n = 3). 
Comparisons were made by two-way ANOVA with Bonferroni correction (**p<0.01; ***p<0.0001).
This study examined extracellular signal-regulated kinase 1/2 (ERKl/2) signalling in parental 
and tamoxifen-resistant cells by measuring the expression of total and phosphorylated 
ERKl/2 with Western blotting analysis (Figure 5-26). The cells were treated with 5pM 
tamoxifen, 2pM MQ and the combination ofMQ and tamoxifen. It was found that total and P- 
ERKl/2 in was expressed at higher levels in untreated resistant cells(MCFV-TR) compared 
with the parental MCF-7 cells and remained higher when both cell lines were treated with 
tamoxifen(Figure 5-26). The expression of total and P-ERKl/2 in resistant cells treated with 
MQ and combination treatment was comparable to the parental cells treated with the same 
therapeutic agents (Figure 5-26). Following treatment of MCF7-TR cells with MQ and the 
combination of mefloquine and tamoxifen, P-ERKl/2 expression levelswere reduced 
compared with untreated MCF7-TR expression (Figure 5-26). Within parentalMCF7 cells 
treated with tamoxifen, MQ and the MQ-tamoxifen combination, the total and pERKl/2 
expression was slightly higher compared with the MCF7 untreated control (Figure 5.25).
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Figure 5-26Changes in total and phosphorylated Erkl/2 expression in tamoxifen- 
resistant MCF7 cell lines following combination treatment with mefloquine and 
tamoxifen.Cells were treated with tamoxifen 5|iM or mefloquine 2[xM and a combination of the two 
treatments for 48 h before lysing. Samples (50 pg protein) were electrophoresed on a 10% SDS- 
polyacrylamide gel, and the proteins were transferred to a PVDF membrane. After probing with 
polyclonal anti-mouse pERK/ERK antibodies at a dilution 1:100, the blot was exposed to an anti­
mouse alkaline phosphatase antibody. P-actin expression was used as a loading control. Bands were 
detected using a chemiluminescent substrate. P-Erk/Erk and P-actin were detected at 42kDa and 
42kDa, respectively against a protein standard. Data shown are representative o f repeat experiments 
(n = 3).
The expression of total and P-ERKl/2 under the same dosing conditions was also 
investigated in T47D parental and resistant cells. Total and pERKl/2 protein expression 
washigher in untreated T47D-FR cells compared with T47D controls(Figure 5-27). Following 
treatment of T47D cells with tamoxifen and the MQ and tamoxifen combination, total and 
P-ERKl/2 protein expressionwas reduced compared with untreated T47D controlcells(Figure
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5-27).Total and phosphorylated ERK 1/2 expression was increased in MQ and tamoxifen 
combination in T47D-FR cells compared with T47D-FR untreated control.
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Figure 5-27Changes in total and phosphorylated ERKl/2 expression in fulvestrant- 
resistant T47D cell lines following combination treatment of mefloquine and 
tamoxifen.Cells were treated with tamoxifen S^iM or mefloquine 2pM, or a combination of the two 
treatments for 48hr before lysing. Samples (50 pg protein) were electrophoresed on a 10% SDS- 
polyacrylamide gel, and the proteins were transferred to a PVDF membrane. After probing with 
polyclonal anti-mouse pERK/ERK antibodies at a dilution 1:100, the blot was exposed to an anti­
mouse alkaline phosphatase antibody. P-actin expression was used as a loading control. Bands were 
detected using a chemiluminescent substrate. pErk/Erk and P-actin were detected at 42kDa and 
42kDa, respectively against a protein standard. Data shown are representative o f repeat experiments 
(n = 3).
The same drug combinations were used to assess changes in the localisation of LC3 in 
parental and tamoxifen-resistant MCF7 cells (Figure 5-28) by immunofluorescence using 
confocal microscopy (Figure 5-28 A, B). Cells were stained for LC3 as described in section
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2.10 (Figure 5-28 a, b, c). High fluorescence of LC3 was clearly detected in untreated MCF7- 
TR cells compared with untreated parental MCF7 cells (Figure 5-28 A, B).
Heavy green staining corresponding to LC3 expression indicated more LC3 vacuole 
localisation in untreated tamoxifen-resistant (MCF-TR) cells compared with untreated 
parental MCF7 cells (Figure 5-28A). Following treatment with tamoxifen, LC3 staining was 
detected with greater intensity in tamoxifen-resistant cells compared with the parental MCF7 
cells treated with the same agent (Figure 5-28 B).
No change in LC3 fluorescence level was observed in tamoxifen-treated, mefloquine-treated 
and combination-treated MCF7 cells compared with untreated parental MCF7 cells (Figure 5- 
28 A). However, it was observed that more LC3 was present in tamoxifen-treated tamoxifen- 
resistant cells (MCF7-TR) compared with untreated MCF7-TR cells (Figure 5-28 B). The 
level of LC3 fluorescence was unchanged versus MCF7-TR control cells when MCF-TR 
cells were treated with mefloquine, whereas a reduction apparent when these cells treated 
with the combination of tamoxifen and mefloquine compared with MCF7-TR control cells 
(Figure 5-28 B).
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Figure 5-28Confocal fluorescence microscopy imaging for LC3 detection in MCF7 and 
MCF7-TR cell lines.Cells were treated with 5pM tamoxifen, IpM mefloquine, or a combination of
298
Chapter 5 Cell death pathways involved in acquired drug resistance
these two therapeutic agents and incubated for 48 h. Images (a) cells were stained for LC3 alone 
(Alexa-Fluor 488 associated fluorescence), (b) cells were stained with the nuclear dye TOPRO-3, and 
(c) cells were co-stained with LC3 and TOPRO-3. Images (A) show the deposition of LC3 granules in 
vacuoles in MCF7 parental cell lines when treated with tamoxifen, mefloquine and combination- 
treatment. (B) shows the deposition of LC3 granules in vacuoles in untreated, tamoxifen-treated and 
combination-treated MCF7-TR cell lines. Data are representative of repeat experiments (n = 3).
Inhibition of autophagy by LY294002
This study also used analtemative inhibitor of autophagy;the PI3K inhibitor LY294002 (Chen 
and Karantza-Wadsworth, 2009). We examined the cytotoxic effect of LY294002 using the 
clonogenic assay (Figure 5-29 A). Parental and tamoxifen-resistant MCF7 cells were treated 
with increasing concentrations of LY294002 (1-20 pM). From the bar graphs (Figure 5-29 B) 
generated from the clonogenic assay (Figure 5-29 A), it was estimated that an LY294002 
concentration of 10 pM reduced colony formation to 46.00% and 9.70% in MCF7 and 
MCF7-TR cells respectively(p<0.01 versus MCF7; Figure 5-29 B). Also, tamoxifen-resistant 
cells were significantly more sensitive to LY294002 at all other concentrations (p<0.05; 
Figure 5-29 B), with the exception of 1 pM, where there was no significant difference. These 
data indicate that tamoxifen-resistant MCF7 breast cancer cells were more sensitive to 
LY294002 treatment than parental MCF7 cells.
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Figure 5-29Antiproliferative effects of LY294002 in M C F 7 and M C F-T R .C ells Cells were 
treated with lOpM LY294002 for 48 h and cell survival was determined by clonogenic assay after an 
additional 12 days in culture without treatment: (A) an example of colony formation in both MCF7 
and MCF7-TR cells. (B) Bar chart (derived from A) demonstrating % colony formation (mean ± SD) 
of each cell line following LY294002 treatment. Data are representative of repeat experiments (n = 3),
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where the number of colonies derived from untreated cells was set to 100%. Comparisons were made 
by two-way ANOVA with Bonferroni correction (*p<0.05; **p<0.01; ***p<0.001).
The ejfect o f co-administration ofLY294002 and anti-oestrogens on cell death:
This study investigated the effect of LY294002 administered concomitantly with anti- 
oestrogens on cell death in parental and tamoxifen-resistant MCF7 cells using the Annexin V 
assay with PI. Both cell lines were treated with LY29400210 pM, tamoxifenSpM, and 
fulvestrant2 pM separately. LY294002 was then also administered concomitantly with the 
same doses of either tamoxifen or fulvestrant for a 48 h period (Figure 5-30 A,B).Combined 
treatment of MCF7-TR cells withLY294002 and either anti-oestrogen had a synergistic effect 
on cell death compared with treatment with LY294002 with either anti-oestrogen agent(both
p<0.0001).
Subsequent bar graphs obtained from the cytograms (part B) demonstrated a significant 
reduction in the percentage of viable MCF-TR cells treated with the combination of 
LY294002 and tamoxifen versus parental MCF7 cells treated with the same therapeutic 
agents (46.13% (±3.32) versus 86.17% (±2.30); p<0.00001; Figure 5-30 B) (Average of three 
experiment). The same was true for MCF7-TR cells treated with combined LY294002 and 
fulvestrant, (56.07% (±2.12) versus 89.03% (±1.59); p<0.00001; Figure 5-30 B). These 
percentages are average of three experiments.
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Figure 5-30Determination of apoptotic response in MCF7 and MCF7-TR cells treated 
with LY294002 and anti-oestrogens.Cells were treated with LY294002 10 jiM, tamoxifen 5pM,
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or fulvestrant 2 pM. Cells were also treated with combined LY294002 and tamoxifen or fulvestrant at 
the same doses for a 48 h and processed for Annexin V-FITC/PI staining analysis using flow 
cytometry. (A) The data are presented in a four-quadrant format; each quadrant in a cytogram 
represents a different state of cell viability as a percentage. Lower left quadrant represents live cells, 
lower right represents cells in early apoptosis (Annexin V-FITC positive, PI negative), upper right 
represents cells in late mid-phase apoptosis (Annexin V-FITC and PI positive) and upper left 
represents cells in necrotic/end stage apoptosis (PI positive, FITC negative). Percentage displayed is 
representative of one experiment (B) Bar graph derived from (A) showing the cell viability in MCF- 
TR cells treated with the combination of LY294002 and either tamoxifen or fulvestrant compared 
with parental MCF7 cells.
5.5. Discussion
Understanding the mechanisms by which anti-oestrogens cause cell death is critical to our 
efforts to develop ways to circumvent resistance. This chapter focuses on changes in 
programmed cell death pathways namely apoptosis and autophagy that accompany anti- 
endocrine resistance by using parental (MCF7, T47D) and anti-endocrine resistant cell lines 
(MCF-TR and T47D-FR).
Our data show that there are significant changes in expression of key regulators of 
programmed cell death. Despite MCF7-TR cells expressing similar levels of Bax to parental 
MCF7 cells, upon treatment with anti-oestrogens, Bax was significantly reduced. This 
suggests that reduction in Bax attenuates the sensitivity of MCF7-TR cells to anti-oestrogens 
by decreasing the apoptotic response. This may significantly contribute to the resistance of 
breast cancer cells. Recently, it has been confirmed by others that Bax level was decreased in 
tamoxifen-resistant cells compared to MCF7 cells(Larsen et al., 2012). However, it is 
important to consider that other proapototic factors such as Bad, Bak and Bok could 
compensate for low Bax and overcome the anti-apoptotic effect(Dewson and Kluck, 2009).
303
Chapter 5 Cell death pathways involved in acquired drug resistance
In contrast to MCF7 cells, a significant induction of Bax expression in parental T47D cells 
was observed following treatment with tamoxifen and fulvestrant in comparison with 
untreated cells. This differential effect could be explained by the complement of caspases that 
these two cell lines express. Parental MCF7 cells lack caspase 3, whereas T47D cells express 
the full complement of caspases (Lamparska-Przybysz et al., 2006). This could enhance 
apoptotic response in T47D cells and help to explain the induction of Bax observed. T47D- 
FR cells did not demonstrate this inductive Bax response when challenged with anti- 
oestrogens, suggesting that down- regulation of Bax may be an important mechanism for the 
development of tamoxifen and fulvestrant-resistance in both cell lines. Whereas this has been 
supported in the literature for MCF7 cells, this hypothesis is yet to be confirmed by others in 
T47D cells. Even in clinical settings the role of apoptosis in fulvestrant resistance has been 
hard to establish (Musgrove and Sutherland, 2009). However, our Western blot findings are 
supported by our flow cytometry data, whereby MCF7 and T47D cells treated with tamoxifen 
or fulvestrant underwent cell death by apoptosis, but resistant cells did not appear to die via 
apoptosis at the same dose.
Unexpectedly, constitutive Bcl-2 expression was detected at significantly lower levels in 
MCF-TR cells in comparison to the parental cell lines. This would appear to be 
counterintuitive as the majority of published literature suggests that increased expression of 
anti-apoptotic molecules such as Bcl-2 leads to the therapeutic failure of MCF7 cells to 
tamoxifen and is correlated with the development of drug resistance (Cittelly et al., 
2010;Riggins et al., 2005). The only study reporting data consistent with our finding was by 
Yde and co-workers (2007). They indicated that low Bcl-2 expression was associated with 
the development of anti-oestrogen resistance in MCF7 cells, but was indicative of increased
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sensitivity to cell death induced by cisplatin (Yde et ah, 2007). We also demonstrated 
collateral sensitivity to cisplatin in chapter 3.
Similarly, Bcl-2 expression was reduced in fulvestrant resistant cells (control and treated) 
compared with parental T47D cells. This is in agreement with the study by Larsen et al 
(2012) who found that Bcl-2 level was lower in fulvestrant-resistant MCF7 cells (Larsen et 
al., 2012). No published studies currently report the expression of Bcl-2 in fulvestrant- 
resistant T47D cells.
Whether cells enter apoptosis is measured by the ratio of proapoptotic:antiapoptotic factors 
(Mooney et al., 2002). Our results demonstrate that these anti-oestrogens can induce 
apoptosis in parental MCF7 cells by down-regulation of Bcl-2, while Bax expression remains 
unchanged. Previous reports demonstrate that the expression of Bcl-2 at both the mRNA and 
protein levels was down-regulatedin MCF-7 cells after treatment with tamoxifen, while no 
changes in Bax expression were detected (Perry et al., 1995;Zhang et al., 1999). This might 
suggest that down-regulation of Bcl-2 protein alone is sufficient to alter the Bax:Bcl-2 ratio 
and promote the susceptibility to apoptosis. However, it is also possible that other members 
of the Bcl-2 family, for example BAG-1-land Bad, may enhance with anti-oestrogen-induced 
apoptosis rather than Bax. In drug resistant MCF-7TR cells, the balance of apoptotic 
regulators is less favourable for apoptosis. Following drug treatment, Bcl-2 expression 
remained low, but Bax expression also decreased. This shift could represent and important 
mechanism for resistance to anti-oestrogen treatment.
A different scenario was observed in T47D cells where the ratio was shifted the opposite 
way. Such an up-regulation of Bcl-2 with down-regulation of Bax would reduce apoptosis in 
this cell line. This would appear counter-intuitive, since we know that treatment with anti- 
oestrogens does induce apoptosis in human breast cancer cell lines such as MCF7
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(Darakhshan et ah, 2013). However, this result may indicate that cells die via a pathway 
independent of Bcl-2 or Bax signalling. Indeed, in drug resistant T47D cells, levels of Bcl-2 
and Bax were unchanged by treatment, further suggesting the absence of a role for these 
regulators in this cell line. Taken together, our findings may suggest that other regulators, 
other thanBcl-2, play a role in the development of resistance in these cell lines.
Herein, we demonstrated that the lAP survivin was up-regulated in tamoxifen- and 
fulvestrant-resistant breast cancer cells compared with their parental cell lines, but there was 
no significant effect of treatment on expression levels. This observation is supported by the 
fact that up-regulation of the anti-apoptotic protein survivin, which inhibits caspase-3 and 
caspase-7, may reduce apoptotic response and cause acquired resistance to tamoxifen (Moriai 
et al., 2009). Thus, survivin, in addition to Bcl-2 and Bax may be an important regulator in 
the development of drug resistance. However, there is no evidence in the literature clarifying 
the role of survivin in fulvestrant-resistance.
To examine whether caspases are involved in anti-oestrogen induced apoptosis, cells were 
incubated with a broad spectrum caspase inhibitor Z-VAD. This study found that Z-VAD 
abrogated the apoptotic effect of anti-oestrogens in both MCF7 and T47D cells. These 
findings indicated that caspases are involved in anti-oestrogens induced apoptosis in parental 
MCF7 and T47D cells. Despite the lack of caspase-3 expression, MCF-7 cells still undergo 
apoptosis in response to tamoxifen and fulvestrant. Some research has suggested that this 
may be due to the compensatory effect of caspase 7 (Mooney et al., 2002).
In contrast to the ER-positive breast cancer cells (parental variants), tamoxifen-resistant 
MCF7 cells evade death by apoptosis in response to tamoxifen and fulvestrant. The same 
scenario has been found in fulvestrant-resistant T47D cells.
306
Chapter 5 Cell death pathways involved in acquired drug resistance
Challenging the anti-endocrine-resistant cells with anti-oestrogens in the absence or presence 
of the pan-caspase inhibitor Z-VAD offered no protection against treatment in anti- 
endocrine-resistant cells. This suggests that development of endocrine resistance to anti- 
oestrogens is associated with lack of caspase activity and also suggests a switch from 
caspase-dependent cell death (apoptosis) to caspase-independent cell death such as 
autophagy. A study by Ajabnoor and colleagues suggested that paclitaxel-resistant MCF7 
cells is associated with a switch from apoptosis to autophagy as it was characterised by a 
complete absence of caspase-mediated apoptotic cell death (using the pan-Z-VAD) compared 
with parental MCF7 cells (Ajabnoor et al., 2012). Further analysis showed that this was due 
to lack of expression of caspase 7 and 9 (Ajabnoor et al., 2012). A study by Samaddar et al 
(2008) is the only work that provides compelling data that autophagy plays a critical role in 
cell survival and facilitates the development of acquired tamoxifen resistance (Samaddar et 
al., 2008).
The current study expands the knowledge around the role of the molecular basis of autophagy 
in the development of tamoxifen and fulvestrant resistance and lends to support to the work 
of Samaddar et al. (2008). This is due to the limited number of studies elucidating the role of 
the survival pathway of autophagy in the development of tamoxifen resistance and the 
complete lack of those related to fulvestrant resistance.
We demonstrated increased constitutive expression of LC3 (LC3-I and II) in both MCF-7 and 
MCF-7TR treated with antioestrogens with and without Z-VAD, suggesting increased 
autophagic response. The ratios of LC3-IItoLC-3I were increased compared with the parental 
MCF7 cell lines treated with the same therapeutic agents in line with increased vesicular 
acitivity. These data were further supported by confocal microscopy, which detected greater 
localisation and intensity of LC3 fluorescence in the cytoplasm of MCF-TR cells after
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treatment with ant-oestrogens compared with parental MCF7 cells. These findings are in 
agreement with evidence from Samaddar et al., who indicated a high level fluorescence of 
LC3 in tamoxifen-resistant cells treated with tamoxifen in comparison with parental MCF7 
cells (Samaddar et al., 2008).
This study is the first evidence indicating autophagic response in relation to fulvestrant 
resistance.Induction of LC3 conversion from LC3-I to II formwas seenn fulvestrant-resistant 
cells treated with tamoxifen folowingcaspase-inhibition by Z-VAD. These results suggest 
that once caspases are no longer active, autophagy may be increased to aid cell survival and 
contribute to the development of fulvestrant resistance. Another observation to support the 
role of autophagy in fulvestrant resistance was the heavy staining of the LC3 fluorescence in 
untreated, tamoxifen-treated and fulvestrant-treated fulvestrant resistant cells by confocal. 
Thus, autophagy might also be correlated with cell survival in the development of fulvestrant 
resistance.
Beclin-1 is an essential and major marker for autophagy, which is required for 
autophagosome formation. This study showed a constitutive up-regulation of beclin-1 
expression in untreated, tamoxifen-treated and fulvestrant-treated MCF7-TR cells compared 
to the parental cell line under the same treatment conditions. These findings are a 
confirmatory indication of the positive autophagy induction in tamoxifen-resistant cells.
This study explored two possible mechanisms to explain the increase of beclin-1 and the 
development of tamoxifen resistance. First, increased expression of beclin-1 triggers 
conversion of LC-3I to LC-3II and enhances the formation of autophagosomes (Kang et al., 
2011). Thus, the increased expression of LC3 discussed above could have been mediated by 
increased levels of beclin-1. Second, beclin-1 is a member of the BH3-only subfamily of 
apoptotic regulatoryproteins, and its BH3 domain allows it to bind and interact with Bcl-2
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protein, which results in the inhibition of autophagy (Cook et ah, 2011). Other proteins 
containing the BH3 domain can displace Beclin-1 bound to Bcl-2, enabling the stimulation of 
autophagy (Hanahan and Weinberg, 201 l;Kang et ah, 2011). As found previously in this 
research, the significant reduction of Bcl-2 level in MCF-TR cells could have led to the 
liberation of Beclin-1. These findings support the hypothesis that autophagy is another hurdle 
that needs to be overcome for breast cancer therapy to be successful. The present study is in 
agreementwith Samaddar et al (2008) who observed that inhibition of autophagy by targeting 
beclin-1 with RNAi induced cell death in MCF7 cells treated with tamoxifen (Samaddar et 
al., 2008). This means that beclin-1 is a key facilitator of tamoxifen-resistant cell survival.
This study also investigated the role of beclin-1 in fulvestrant-resistant cells and found an 
increase in beclin-1 level in untreated fulvestrant-resistant cells compared with the parental 
cells. In the present study, tamoxifen and fulvestrant treatments significantly reduced beclin-1 
level in fulvestrant-resistant cells.
The mechanism of reduced beclin-1 in fulvestrant resistance has not been identified yet, but it 
might be due to the fact that Bcl2 level is expressed at low levels in T47D cells in comparison 
with MCF7 cells and is further reduced when treated with anti-oestrogens. This would mean 
with respect to the Bcl-2-Beclin-l ratio, there is only slightly less Bcl-2 available for 
dimerization with beclin-1 in resistant cells than there is in parental cells. Thus, no significant 
difference in beclin-1 expression would be expected in untreated cells.
Overall, our data showed that beclin-lis key to cell survival in the development of tamoxifen 
resistance but not necessarily in fulvestrant resistance. Whether beclin-1 expression facilitates 
cell survival in human breast cancer cells during antiestrogen challenge is an important 
question and remains to be answered.
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The present study supports the idea that targeting autophagy would improve the efficacy of 
hormonal treatment in anti-endocrine resistant cells. The therapeutic agent used by this study 
to target autophagy was MQ. It is interesting to note that MQ was considerably more potent 
in the clonogenic assay than the MTT assay, which suggests the MQ is more cytostatic than 
cytotoxic. Low cytotoxicity at low doses suggests that MQ may be useful to sensitise the 
breast cancer cells to anti-oestrogens. The current study is the first to consider the cytotoxic 
effect of MQ in anti-endocrine-resistant cells.
The cytotoxicity assays were used to inform the dose to be used to study the co­
administration effect of MQ with tamoxifen on cell death in tamoxifen- and fulvestrant- 
resistant cells. The flow cytometry data indicated that a synergistic effect on the reduction of 
cell viability was observed in tamoxifen and fulvestrant resistant cells when treated with the 
combination of MQ and tamoxifen versus the drugs administered alone. The MQ and 
tamoxifen combination was also significantly more effective in resistant-cells than in parental 
cell treated with the same agents. It has been previously reported that MQ is a potent inhibitor 
of autophagy and can cause cell death in T47D and MCF7 cells (Sharma et al., 2012). Herein, 
for the first time, a synergistic effect was observed when anti-endocrine-resistant cells were 
concomitantly treated with tamoxifen and MQ.
An important question is the mechanism underlying this synergistic effect. To answer this 
question, molecular components of the PI3K/Akt survival signalling pathway in parental and 
anti-endocrine resistant MCF7 were assessed. Genetic and biochemical evidence suggests 
that activation of the PI3K/Akt pathway contributes to breast cancer tumourigenesis(Van 
Tine et al., 2011). It has been shown that PI3K and Akt are considered as a major survival 
signalling hub for downstream receptor tyrosine kinases such as HER2 and EGFR/HERl. 
These can activate several elements involved in cell-cycle progression and survival and
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consequently promote transcriptional activity in ER-positive breast cancer cells (Miller et al., 
2011). Our findings indicated that PI3K and Akt were decreased in tamoxifen-resistant and 
fulvestrant-resistant cells after treatment with MQ and tamoxifen. Increased protein 
expression of PI3K and Akt was established in chapter 3 as a mechanism implicated in anti- 
endocrine resistance.
It has been shown that MQ is able to arrest autophagy at the stage of autophagosome 
formation in MDA-MB-231 and T47D cells (Sharma et al., 2012). Heavy deposition of 
autophagosome formation was observed in tamoxifen-treated MCF7-TR cells, suggesting that 
tamoxifen induces autophagy in resistant-cells. However, the addition of MQ counteracted 
this and reduced LC3 to levels similar to the control. This mechanism could lead to increased 
sensitivity of tamoxifen-resistant cells to tamoxifen.
The second therapeutic agent used in this study to target autophagy was LY294002; a PI3K 
inhibitor. Our data generated from the clonogenic assay indicated that tamoxifen-resistant 
MCF7 cells are more sensitive to LY294002 than parental cells. Co-administration of 
LY294002 with anti-oestrogens had a synergistic effect on cell death than either agent alone. 
Tamoxifen-resistant cells were also significantly more sensitive to co-treatment with either 
anti-oestrogen than parental cells, which suggest that this strategy could be effective at 
overcoming resistance.
The only study demonstrating the combined effect of LY294002 with tamoxifen in ER- 
positive MCF7 cells revealed that LY294002 potentiates tamoxifen-induced apoptosis (Clark 
et al., 2002). The same study identified that induction in apoptosis was attributable to 
inhibition of Akt signalling in breast cancer cells. The current study provides preliminary data 
emphasising that LY294002 increased the sensitivity of tamoxifen-resistant cells to anti- 
oestrogens, but the mechanism behind this still needs to be elucidated.
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In conclusion, we show that anti-endocrine-resistance is associated with profound changes in 
key regulators of apoptosis, associated with up-regulation of the autophagic pathway, as a 
survival mechanism. Inhibition of autophagy either using the antimalarial drug MQ, or the 
PI3K inhibitor LY294002 has been indicated to promote cell death and increase the 
sensitivity ofanti- endocrine-resistant cells to anti-oestrogen. This combination treatment 
should be considered in future in vivo studies as a potential alternative tumour killing 
strategy.
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6. Understanding acquired resistance to lapatinib in 
breast cancer
6.1 Introduction
6.1.1. Overview of growth factor receptors and cancer therapy:
Growth factor receptors belong to the subfamily of receptor tyrosine kinases and include 
EGFR (HERl), HER2, HER3 and HER4. These have been identified as central players and 
key regulators of cancer cellproliferation and angiogenesis, and are therefore considered 
suitable potential targets for cancertherapies(Robertson et al., 2000). Several approaches for 
targeting growth factor receptors have been developed.The most successful and well-used 
strategy in the clinic comprises monoclonal antibodies, such as trastuzumab, which binds the 
extracellular domain of HER2 with high affinity and promotes receptor degradation, and 
small molecule tyrosine kinase inhibitors (TKIs) such as lapatinib, gefitinib, afatinib and 
imatinib.The mechanism of action of each TKI was discussed in chapter 4.
6.1.2. Mechanisms of resistance to TKIs
The therapeutic efficacy of TKIs is limited by primary (intrinsic) and acquired resistance. The 
latter is typically developed within a short time of starting therapy and is correlated with poor 
outcomes (Vazquez-Martin et al., 2009). Thus, resistance is taken as a vital issue in the 
clinics. There are several proposed mechanismsto explain resistance to TKIs. These are 
discussed below.
314
Chapter 6 Understanding acquired resistance to lapatinib in breast cancer
6.I.2 .I. The role of genetic modifications in resistance to TKIs
Clinical and in vitro evidence has indicated that cells treated with TKIs tend to acquire 
genetic modifications to overcome the inhibitory effects of these therapeutic agents. The 
common mechanisms related to the genetic modifications include point mutations, deletions, 
and amplifications of genomic areas (Sierra et al., 2010). The schematic diagram in figure 6-1 
summarises the main molecular mechanisms of acquired resistance to TKIs.
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Figure 6-1 The main genetic modification mechanisms related to resistance to tyrosine 
kinaseinhibitors (TKIs).l: Point mutation in receptor tyrosine kinase (RTK). 2: Gene 
amplification in the kinase domain. 3: Activation of an alternative RTK that can compensate the 
signals lost due to target inhibition. All of these mechanisms lead to the activation of the downstream 
survival signalling transduction cascades, principally the PI3K, Akt, ERK, and MARK pathways, 
leading to cell proliferation, cancer progression and drug resistance.
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Point mutations
Point mutationsarethe most frequent types of mutations that decrease the affinity of the drug 
for the target kinase domain while maintaining its catalytic activity(Sierra et al., 2010).0ther 
mutations include alteration of the amino acids that surround the drug binding site, which 
reduce the region availability of the target towards the TKIs withoutinterfering with ATP 
binding (Zhang et al., 2009). Some mutations can also cause an increase the affinity of the 
kinasefor ATP and ultimately decrease the potency of the ATP-competitive inhibitors 
(Tanaka and Kimura, 2008).
The strongest mutational evidence comes from the study of imatinib, a small TKI that binds 
with highaffinity to c-Abl kinase(Sierra et al., 2010). Imatinib is used in the clinic to treat 
patients with chronic myeloid leukemiawho express a constitutivelyactive c-Abl tyrosine 
kinase.Imatinibworks via abrogating the oncogenic function ofBCR-ABL through binding the 
protein in its inactive state, consequently preventing its autophosphorylation and 
thenblockingthe activation of downstream signal transducers(Hochhaus and La Rosee, 2004). 
Imatinib usage has improved the life expectancy of CMLpatients, but major problems have 
cited -  particularly the development of drug resistance. Approximately 50% of relapsed CML 
patients acquire pointmutations,witharound 90 distinct point mutations that cause 
conformation change of the c-Abl kinase discovered so far. These mutations reduce the 
ability of imatinib to bind the c-Abl kinase domain(Melo and Chuah, 2007).
Gefitinib and erlotinib are small molecule TKIs targeting EGFR (HERl). Intense research 
has identified two major mechanisms of resistance to gefitinib and erlotinib in patients with 
lung adenocarcinomas. The first appearance of a resistance was due to a point mutation in the 
kinase domain (T790M) that occurred in 50% of gefitinib-resistant patients (Nguyen et al., 
2009). This mutation caused increased affinity for ATP and reduced the affinity for ATP-
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competitive inhibitors (Sierra et ah, 2010). The second resistance mechanism was caused by 
activation of an alternative oncogene, which was able to compensate for inhibited signalling 
pathways (Pillay et al., 2009).
Lapatinib is another TKI designed to target EGFR and HER2. Trowe and co-workers were 
able to identify 12 mutations in the kinase domain of HER2 that could confer resistance to 
lapatinib in human breast and gastric carcinomas(Trowe et al., 2008).
Amplifications of genomic areas
Gene amplification has been shown to mediate resistance to cancer therapy via amplification 
of genes coding for critical transducers driving signalling pathways that can compensate for 
the signals lost due to target inhibition (Pillay et al., 2009). A notable example is the 
amplification of the mesenchymal-to-epithelial transition (METjgene.MET activation has a 
causal role in cell survival, growth, angiogenesis, migration and metastasis and is considered 
an essential hallmark of cancer (Smolen et al., 2006). Amplification of the MET oncogene is 
observed in 20% of non-small-cell lung cancer (NSCLC)casesin which patients develop 
resistance to gefitinib and erlotinib (Bean et al., 2007). These results agreed with those 
obtained in in vitro experiments after treating sensitive NSCLC cell lines with progressively 
increasing doses of gefitinib or erlotinib (Turke et al., 2010). Another study by Chen and 
colleagues found that lapatinib resistance in gastric cancer was mediated by MET through 
restoring downstream signalling pathways such as MAPK and Akt.Treatment with PHA- 
665752, a highly selective MET tyrosinekinase inhibitor, was able to resensitize NCI-N87 
gastric cancer cells to lapatinib by inhibiting MET phosphorylation and suppressing MAPK 
and Akt signal transduction (Chen et al., 2012).
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AXL is a membrane-bound receptor TK containing a kinase domain closely related to MET.
It has been reported that AXL plays an important role in resistance to imatinib as well as to 
chemotherapy (Mahadevan et al., 2007). Liu et al. provide definitive evidence that AXL can 
play an important role in acquired resistance to lapatinib in a BT474 lapatinib-resistant cell 
line. They observed an increased AXL expression in the BT474 lapatinib-resistant cell line, 
but not in BT474 lapatinib-sensitive cells. Another observation from the same study indicated 
that lapatinib sensitivity can be restored in BT474 lapatinib-resistant cells by treating cells 
with GSK1363089, which is a potent inhibitor of AXL, MET, andvascular epithelial growth 
factor receptor(VEGFR)(Liu et al., 2009).
Deletions
The other genomic alterations frequentlyfound upon treatment with TKIs are deletions. 
Khorashad and collaboratorsperformed a genome-wide study comparing DNA samplesfrom 
patients with CML prior to treatment with imatinib andafter relapse had occurred. 
Comparative genomic hybridizationanalyses generated from all patients indicated 
thatapproximately 28% of the copy number alterations were genomic deletions(Khorashad et 
al., 2008).
6.I.2.2. The role of EMT resistance to TKIs
Epithelial-to-mesenchymal transition (EMT) is a process characterised by the loss of 
epithelial markers such as E-cadherin, claudin, and occludin, and the gain of mesenchymal 
markers such as vimentin and N-cadherin (Uramoto et al., 2010). Induction of EMT allows 
cancer cells to disseminate from the primary tumour and invade the sounding tissues, 
eventually leading to metastasis (Lamouille et al., 2013). It was observed that EMT was 
induced in in tumour samples from lung adenocarcinoma patients who developed resistance
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to gefitinib (Uramoto et ah, 2010). The exact mechanism behind this induction hasyet to be 
clearly defined.
A recent paper by Garofalo et al. (2012) has found a link between overexpression of the MET 
receptor,resistance to TKIs, and EMT in NSCLC (Garofalo et al., 2012). They discovered 
that certain miRNAs (miR-30b, miR-30c, miR-221 and miR-222),which are modulated by 
either both EGF and MET receptors or MET only, played important roles in gefitinib-induced 
apoptosis and epithelial-mesenchymal transition of NSCLC cells. This suggests that miRNAs 
can be an important role in the pathways involved in TKI resistance, which will be discussed 
in more detail in the next section.
6.I.2.3. The role of microRNAs (miRNAs) in resistance to TKIs
Most studies have focused on genetic alterations occurring during tumour progression and 
drug resistance development. However, it has been revealed that other than genetic (point 
mutation, amplification, deletion) and epigenetic alterations occurring during drug resistance 
mechanisms, drugresistance might also be regulated by microRNAs (miRNAs)(Fojo, 2007).
miRNAs are small, endogenous non-coding RNA molecules that contribute to modulating the 
expression of specific proteins depending on sequence complementarities with their target 
mRNA molecules. Complimentary binding of miRNAs to their targets causes these mRNA 
molecules to be degraded, resulting in decreased levels of the protein encoded by the 
mRNA(Li et al., 2010). Several investigations have shown that the expression of miRNAs is 
altered; either up-regulated or down-regulated in several tumours, including endometrial, 
breast, ovarian, pancreatic, colon, oesophageal, and lung cancers compared with their normal 
variants (Boren et al., 2008;Giovannetti et al., 2012).
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In recent years, the role of miRNAs in the pathogenesis of malignancieshas become 
increasinglyappreciated, and they have been considered to be diagnostic and prognostic 
markers inleukaemia, lung cancer, and colon cancer (Marcucci et ah, 2011). It is also 
suggested that miRNAs can be identified as therapeutic targets in human cancers (Schetter et 
al., 2008).
Up- or down-regulation of the level of miRNA can influence the expression of multiple target 
mRNAs and, therefore, several proteins, leading to alterations in the sensitivity of cells to 
anti-cancer treatmentvia numerous cellular processes. Most of the miRNAshave been shown 
to alter cellular response to anti-canceragents via modulation of survival pathways, cell cycle 
proliferation, andapoptotic pathways (van Jaarsveld et al., 2010).
Weiss and colleagues examined the role of miRNAs to predict responseto TKIs in NSCLC 
and found that microRNA-128b directly regulates EGFR. They analysed miRNA-128b 
expression in 58 NSCLC tumour samples and found that loss of miRNA-128b expression 
was associated with increased sensitivity to gefitinib treatment (Weiss et al., 2008). MiRNAs 
have also been found to have a fundamental role in breast cancer tumourigenesis. The 
expression of miR-200 family members has been shown to be linked to regulation of tumor 
progression in a panel of breast cancer cell lines through a double-negative feedback loop 
which ultimately prevents EMT(Bracken et al., 2008).Similarly, miRNA-205 is a suppressor 
able to interfere with the PI3K/Akt survival pathwaymediated by the HER receptor 
family(lorio et al., 2008), suggesting that miRNA-205 can improve the responsiveness of 
breast tumours to anticancer therapies such as gefitinib and lapatinib(Iorio et al., 2009). 
MiRNA-205 will be investigated within this chapter for its role in acquired lapatinib 
resistance.
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6.1.2.4. Crosstalk between ERa and HER2
HER2 expression is currently the principal biomarker of response to lapatinib in breast 
tumours (Weiner and Zagzag, 2000). Early phase clinical trials reported that clinical 
responses to lapatinib in patients with HER2-positive breast cancer are short lived (Nahta et 
al., 2006). However, the mechanism of resistance has not been fully elucidated. A number of 
studies have addressed the proposed mechanism contributing to lapatinib resistance. In one in 
vitro study, a model of BT474 HER2+/ ER+ breast cancer cells with acquired lapatinib 
resistance was established.
It was found that lapatinib resistance in BT474 cells is mediated by increased ERa signalling 
by activation of faetorssueh as FOXOSa and eaveolin-1 that induce the transcriptional 
activity of ER (Chen et al., 2008). Consequently, these findings provided a rationale to 
abrogate the development of lapatinib resistance by combining a TKI (lapatinib) with an anti­
oestrogen, such as tamoxifen or fulvestrant, in order to block both ER and HER2 signalling 
(Chen et al., 2008).
6.1.2.5. Deregulation of cell death pathways
Up-regulation of the anti-apoptotie protein Bcl-2 was observed in lapatinib-resistant breast 
cancer cells (Chen et al., 2008). Acquired resistance to lapatinib in SKBR3 (SKBRSlapR) 
cells appears to be an oestrogen-independent process, as the source of resistance was due to 
increased expression of NF-Kb in the resistant SKBR3 cells (Dankort et al., 1997). Another 
mechanism associated with the development of acquired lapatinib resistance is the lack of 
inhibition of the lAP survivin(Colleoni et al., 2008). Martin et al.reported that resistant cells 
had decreased activation of apoptotie proteins Bax and Bak and overexpression of anti- 
apoptotie protein Bcl-xL, altogether leading to decreased apoptotie responses which protected 
the HCTl 16 cells from the anti-tumour effect of lapatinib (Martin et al., 2008).
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Chen et al. were the first to report a link between autophagy and the development of lapatinib 
resistance in HER2-positive breast cancer cells undergoing treatment with lapatinib. They 
noticed increasing levels of autophagosomes in breast cancer cells resistant to lapatinib and 
hypothesized that autophagy plays a critical role in inducing lapatinib resistance as a source 
of tumour recurrence and metastasis. Consequently, abolishing the formation of 
autophagosomes might be helpful to restore the sensitivity of lapatinib in resistant breast 
cancer cells (Chen et al., 2011).
6.2. Aims
The aim of this study was to identify the molecular mechanisms of TKI resistance in breast 
cancer using lapatinib. To date, there is a very limited number of publications elucidating the 
mechanisms of lapatinib resistance in breast cancer. As discussed in the introduction to this 
chapter, resistance to TKIs can be caused by a number of different mechanisms, such as 
genetic alteration of the target e.g. HER and more recently miRNA regulation has been 
described. In this chapter we used an approach of microRNA array as a discovery platform to 
investigate novel mechanisms of lapatinib resistance. This enabled the identification of a 
mechanism for lapatinib resistance other than changes in HER expression
This study consists of four specific objectives:
• Development and characterisation of lapatinib-resistant cell line models
o Assessment of drug-induced loss of viability as a measure of relative lapatinib 
sensitivity in the establishment of resistance using the MTT assay.
o Measuring the expression level of the HER family of proteins (EGER, HER2 
and HER3) using Western blotting.
323
Chapter 6 Understanding acquired resistance to lapatinib in breast cancer
• Assessment of microRNA (miRNA) regulation among parental and lapatinib-resistant 
SKBR3 breast cancer subtypes (by a service provider)
• Based on the results of the miRNA analysis, evaluating the role of the MET receptor 
in acquired lapatinib resistance in SKBR3 and analysis of the EMT/MET pathway in 
SKBR3LapR cells and verifying the expression of specific proteins, such as E- 
eadherin and twist, by Western blotting analysis.
6.3. Methods
Cell lines used in this work were the breast cancer cell lines MDA-MB-231, SKBR3 and their 
lapatinib-resistant variants MDA-MB-231 -LapR and SKBR3-LapR. Techniques applied were 
viability assay (MTT)(seetion 2.6.1), whole cell lysate preparation(section 2.7), Western 
blotting analysis(seetion 2.9), and microRNA analysis(seetion 2.12).All methods carried out 
in this chapter are described in full detail in Chapter 2 (Materials and Methods).
6.4. Results
6.4.1. Evaluation of resistance level among lapatinib-resistant cell lines
MDA-MB-231 and MDA-MB-231-LapR cells were treated with equal dose ranges of 
lapatinib (0.1-200pM), and cell viability was assessed by MTT assay. The dose response 
curves for both cell lines in Figure (Figure 6-2 A) show that MDA-MB-231-LapR cells are 
more resistant to lapatinib than the parent cell line. The lapatinib IC5 0  values for parental and 
resistant cell lines were calculated to be 10.55± 0.72 pM and 29.15 ± 2.34 pM, 
respeetivelyusing non-linear regression. The ratio of these values gives a resistance factor of 
2.77, confirming that the MDA-MB-231-LapR cell line is more resistant to lapatinib-induced
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cytotoxic action. The difference between the IC5 0 values was statistically significant (p<0.01; 
Figure 6-2 B).
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Figure 6-2Dose-response curves of cell viability of MDA-MB-231 and MDA-MB-23I- 
LapR cells treated with lapatinib.Cells were exposed to 1-200 pM lapatinib for 96 h and cell 
viability was assessed by MTT assay. (A) Shows the dose-response curves for each cell line; each 
data point is the mean of the three independent experiments (performed in triplicate). (B) The IC50 
values for MDA-MB-231 and MDA-MB-231-LapR cells were calculated in Prism v.6 using a log 
drug concentration versus response slope and found to be 9.00 ± 0.72 pM and 32.15 ± 1.76 pM, 
respectively. The difference in response to this drug was assessed by paired t-Test (**p<0.01).
The MTT assay was also performed to determine the response of parental SKBR3 and 
lapatinib-resistant SKBR3-LapR treated with lapatinib. The dose-response curves for both 
cell lines generated by the MTT assay in figure 6.3 A show that lapatinib-resistant SKBR3- 
LapR cells are more resistant to lapatinib than the parental cell lines. The I C 5 0  values for 
parental and resistant cell lines were calculated to be 0.22 ± 0.04pM and 13.66 ±1.02pM,
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respectively.The ratio of these values gives a resistance factor of 62.10. The difference 
between the IC5 0  values was statistically significant (p<0.01; Figure 6.3 B).
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Figure 6-3Dose-response curves of cell viability of SKBR3 and SKBR3-LapR cells 
treated w ith  lapatin ib .C ells were exposed to 0.05-20 pM lapatinib for 96 h and cell viability was 
assessed by MTT assay. (A) Typical dose response curves for each cell line; each data point is the 
mean of the three independent experiments (performed in triplicate). (B) The IC50 values for SKBR3 
and SKBR3-LapR cells were calculated in Prism v.6 using a log drug concentration versus response 
slope and found to be 0.22 ± 0.04 pM and 13.66 ±1.02 pM, respectively. The difference in response 
to this drug was assessed by paired t-Test (**p<0.01).
6.4.2. Changes in EGFR, HER2 and HER3 receptor expression levels in 
lapatinib-resistant breast cancer cells
The protein expression level of EGFR (HERl)in both the parental and resistant SKBR3 and 
MDA-MB-231 cell lines wasdetermined by Western blotting (Figure 6.4 A) and the bands 
semi-quantified by densitometry (Figure 6-4 B). The expression of EGFR was significantly
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higher in both the resistant SKBR3-LAPR and MDA-MB-231-LapR cell lines compared with 
their respective parental controls(p<0.01 and p<0.05, respectively; Figure 6.4B). HN5 cells 
were used as a positive control of EGFR expression.
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Figure 6-4The expression of EGFR in parent and resistant SKBR3 and MB231 cell 
lines.(A) 25 pg ofeach extract was separated by 10% SDS-polyacrylamide gel and transferred to 
PVDF membrane.Proteins were then exposed to an EGFR antibody at a 1:100 dilution for 12hr before 
being exposed to anti-rabbit alkaline phosphatase. P-actinexpression was used as a loading control. 
Bands were detected using a chemiluminescent substrate. EGFR and P-actin were detected at 175kDa 
and 42kDa, respectively against a protein standard. (B) Bands were quantified by densitometry and 
normalised to P-actin expression. Expression of EGFR in parental control cells were set to one for 
ease of comparison. Data are representative of repeat experiments (n = 3). Comparisons were made by 
t-Test (*p<0.05; **p<0.01).
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The expression levels of HER2 in SKBR3 and MDA-MB-231 parental and resistant cell lines 
were also examined by Western blotting (Figure 6-5 A).Theexpression of HER2 is up- 
regulated in both resistant SKBR3 and MDA-MB-231 compared with their respective 
parental cell lines (both p<0.05; Figure 6-5B).
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Figure 6-5The expression of HER2 in parent and resistant SKBR3 and MB231 cell 
lines.(A) 25 micrograms of each extract was separated by SDS-PAGE and transferred to PVDF 
membrane. Immunodetection of HER2 using a 1:1000 antibody dilution yielded a band at 185 kDa, 
determined by use of a protein standard and P-actin expression was determined as a loading control. 
(B) Bands were quantified by densitometry and normalised to P-actin expression.Expression of HER2 
in parental control cells were set to one for ease of comparison. Data are representative of repeat 
experiments (n = 3). Comparisons were made by t-Test (*p<0.05).
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The expression level of HER3 in SKBR3and MDA-MB-231 parental and resistant cell lines 
(Figure 6-6) was determined by Western blotting analysis (parts A). Subsequent densitometry 
analysis (parts B) revealed that the expression of HER3 was slightly lower in lapatinib 
resistant MDA-MB-231-LapR cells compared with the parental counterparts. There was no 
observable difference in the expression of HER3 in parental and resistant SKBR3 cells. 
Expression of HER3 in all cell lines was comparable regardless of resistance status (6-6 B).
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Figure 6-6The expression of H E R 3 in parent and resistant S K B R 3 and M B 231 cell 
lines.(A) 50 pg of each extract was separated by SDS-PAGE and transferred to PVDF membrane. 
Immunodetection of HER3 using a 1:100 antibody dilution yielded a band at 185 kDa. P-actin 
expression was determined as a loading control. (B) Bands were quantified by densitometry and 
normalised to P-actin expression.Expression of HER3 in parental control cells were set to one for ease
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of comparison. Data are representative of repeat experiments (n = 3). Comparisons were made by 
paired T-test; no significant differences were observed.
6.4.3. miRNA analysis
We conducted a broad microRNA analysis via a service provider to determine exactly which 
microRNAs are up- or downregulated in the resistant phenotype (refer to table A-1 in the 
appendix).
6.4.3.I. Top maps identified by micro-RNA pathway analysis
Figure 6.7 shows the top-rated outcome of the microRNA pathway analysis and shows two 
pathway maps and their components, which were discovered based on the significant up- 
regulation of miR-205in resistant cells (as indicated by the red thermometer). MiR-205 is 
known to be connected with inhibition of EMT when expressed at high levels. Members of 
the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429), however, 
which are also involved in the same process, were not differentially expressed in the two cell 
lines(Park et al., 2008).
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Figure 6-7GeneGo pathway analysis micro-RNA microarray of lapatinib-resistant 
SKBR3 cells (sorted according to statistical significance).The top map shows inhibition of 
EMT and the bottom map shows induction of EMT. The microRNAs involved are listed on the left 
(members of the miR-200 family (mlR-200a, miR-200b, miR-200c, miR-141 and miR-429) and miR- 
205) and their targets are shown on the right (TGFp and ZEB2/SIP1). The transforming growth 
factor-p (TGFp) induces the activity of transcriptional factor of ZEB2/SIP1 that have emerged a 
fundamental mechanisms for E-cadherin loss during EMT pathway.MiR-200 family members and 
miR-205 inhibit ZEB2/SIP 1 and inhibit TGFp causing inhibition of EMT.
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The schematic diagram below (Figure 6-8) outlines the underlying mechanisms between 
miR-205 and miR-200 family members and EMT regulation. Given that miR-205 was up- 
regulated in SKBR3-LapR cells, it would appear that EMT is inhibited in these cells (Figure 
6-8 scenario A).
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Figure 6-8Mechanism for EMT induction/inhibition through mR-205 and mR-200 
family members.Epithelial-like cells (A) generally express high levels of members of miR-200 
family and E-cadherin, whereas mesenchymal cell (B) express high levels of ZEB and vimentin. (A) 
Increased expression levels of miR-200 family members (miR-200a, miR-200b, miR-200c, miR-141 
and miR-429) and miR-205 repress the transcriptional factors ZEBl and ZEB 2/S IP 1, and also repress 
the signalling molecules (TGPP) and lead to inhibition of EMT. (B) High levels of ZEB transcription 
factors repress miR-200c and miR-141. As these ZEBs are targets of these miRNAs, their own levels 
are in turn less repressed, and results in induction of EMT.EMT, epithelial-to-mesenchymal transition; 
SIPl, Smad interacting protein 1; TGFp, transforming growth factor-P; ZEB, zinc-finger E-box- 
binding homeobox transcription factors. Adapted from (Ocana and Nieto, 2008).
Cells in an epithelial state express high levels of E-cadherin and miRNAs such as those 
belonging to the miR-200 family, but low levels of vimentin. Conversely, mesenchymal cells
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express low levels of E-cadherin, high levels of vimentin and have negligible expression of 
the miR-200 family (Ocana and Nieto, 2008). As indicated in figure 6-8, high levels of 
miRNAs down-regulate key transcription factors e.g. ZEBl and ZEB2 (SIPl), leading to 
inhibition of EMT. In contrast, in mesenchymal cells which have high levels of the 
transcription factors ZEBl and ZEB2 (SIPl). MiRNAs of the miR-200 family and miR-205 
are suppressed, which abolishes downregulation of ZEB 1/2 by these, leading to the induction 
of EMT.
6.4.3.2. Verifying EMT inhibition by measuring the expression of the epithelial 
marker E-cadherin and its regulator Twist
MiRNA analysis revealed that miR-205 was up-regulatedby approximately 48-fold in 
lapatinib-resistant SKBR3 cells (data not shown). E-cadherin expression was assessed to 
determine any changes associated with EMT/MET in parental versus lapatinib-resistant 
SKBR3 cells. The expression of E-cadherin appeared unchanged in SKBR3-LapR cells 
versus SKBR3 cells (Figure 6-9).
/
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E-cadherin
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Figure 6-9The expression of E-cadherin in parent and resistant SKBR3 and MB231 cell 
lines.80 pg of each extract was separated by SDS-PAGE and transferred to PVDF membrane, and
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then exposed to E-cadherin antibody at 1: 100 dilution for 12hr before being exposed to anti-mouse 
alkaline phosphatase. P-Actin expression was used as a loading control. Bands were detected using a 
chemiluminescent substrate. E-cadherin and P-Actin were detected at 135kDa and 42kDa, 
respectively against a protein standard. Bands were detected using a chemiluminescent substrate 
(Invitrogen™). Data are representative of repeat experiments (n = 3).
We next used Western blotting to measure the expression of Twist, a transcriptional repressor 
of E-cadherin gene expression in breast cancer (Figure 6-10). The data show that Twist 
wasmarkedly down-regulated in the lapatinib-resistant SKBR3 cells with the parental cells, 
thereby lowering the repression of E-cadherin and preventing EMT.
/ /
Twist  ^ f Approx 28kDa
G APDH • * * *  Approx 37KDa
Figure 6-lOTwist expression in parental and lapatinib-resistant eells.80 pg protein was 
electrophoresed by SDS-PAGE, transferred to a PVDF membrane, and then exposed to Twist 
antibody at a 1:100 dilution for 12hr before being exposed to anti-rabbit alkaline phosphatase. 
GAPDH expression was used as a loading control. Bands were detected using a chemiluminescent 
substrate. Twist and (3-actin were detected at 28kDa and 37kDa, respectively against a protein 
standard. Bands were detected using a chemiluminescent substrate (Invitrogen™). Data are 
representative of repeat experiments (n = 3).
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6.4.4. The role of the MET receptor in acquired lapatinib resistance
The expression of MET in parent- and resistant-SKBR3 cell lines was measured by Western 
blotting using a primary MET antibody and p-actin as a loading control (Figure 6-11 ).Both 
forms of METprotein (total and phosphorylated) were measured to assess functional activity. 
The blots revealed that total MET was slightly increased in lapatinib-resistant cells compared 
with the parental SKBR3 cell line (Figure 6-ll),whereasthe expression of phosphorylated 
METwas considerably up-regulated in SKBR3-LapR cells compared to the parental cells 
(Figure 6-11).
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Figure 6-11 Changes in MET expression in parent- and resistant-SKBR3 cell lines.80 pg
of each extract was separated by SDS-PAGE and transferred to PVDF membrane and then exposed to 
the total and phosphorylated MET antibodies using a 1:100 dilution for 12 h before being exposed to 
anti-mouse and anti-rabbit alkaline phosphatase respectively, p-actin expression was used as a loading 
control. Bands were detected using a chemiluminescent substrate. P-MET/METand P-actin were 
detected at 145kDa and 42kDa, respectively against a protein standard. Data are representative of 
repeat experiments (n = 3).
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6.5. Discussion
HER2 is overexpressed in approximately 25%-30% of metastatic breast cancers and is 
correlated with an aggressive clinical course resulting in reduced disease-free and overall 
survival compared with other breast cancer subtypes(Baselga, 2010;Wolff et al., 2007). Thus, 
HER2 is an important therapeutic target in the clinic for the treatment of breast cancer 
patients (Gayle et al., 2012). There are several therapeutic agents on the market targeting 
HER2; lapatinib being one of them. Lapatinib is a potent and dual tyrosine kinase inhibitor 
(TKI), which inhibits phosphorylation of both HER2 and EGFR, thereby interrupting the 
downstream survival signalling pathways such as MAPK and Akt.
Lapatinib has been approved to treat breast cancer patients with advanced or metastatic stage 
cancer, whose tumours overexpress HER2 (Ryan et al., 2008). However, many of the patients 
who initially responded eventually developed resistance to this therapeutic approach, which 
limits its efficacy and enhances tumour progression(Liu et al., 2009).
The initial part of this chapter involved the assessment of drug sensitivity and acquired 
resistance of the cell lines SKBR3/SKBR3-LapR and MDA-MB-231/MDA-MB-231-LapR to 
lapatinib. It was shown that parental SKBR3 cells are more sensitive towards lapatinib (IC5 0  
= 0.22 piM) than parental MDA-MB-231 cells (IC50 = 10.55 fxM), as the former overexpress 
HER2, whereas the latter are HER2-negative, as has also been confirmed by others(Hegde et 
al., 2007). The relationship between the level of HERl expression and sensitivity to lapatinib 
has been shown to be negligible in BT-474 and SKBR3 cells (Zhang et al., 2008).
We next measured EGFR, HER2, and HER3 expression by Western blotting to compare 
parental and resistant phenotypes. It was found that HER2 was overexpressed by 
approximately four-fold in resistant SKBR-3 and MDA-MB-231 cells, while HERl was
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approximately overexpressed by seven-fold in SfCBRS-LapR cells compared with SK-BR-3 
and by three-fold in MDA-MB-231-LapR compared with MDA-MB-231. These findings are 
in disagreement with the work of others who showed protein levels of EGFR (HERl), HER2, 
and HER3 were similar in lapatinib-resistant BT474 breast cancer cells (ER4-, PR+/-,
HER2+) compared with the parental BT474 cells (Liu et al., 2009). However, it is known that 
EGFR and HER2 overexpression leads to activation of downstream survival signalling 
events, ultimately resulting in enhanced tumour progression and resistance to apoptosis, 
which is correlated with poor prognosis and decreased survival rate(Hynes and Lane, 2005).
HER3 expression, on the other hand, was not significantly different in the lapatinib-resistant 
SKBR3 cells compared with parental cells. In the literature, HER3 phosphorylation has been 
reported to lead to gefitinib resistance in lung cancer through persistent activation of 
PI3K/Akt survival signalling (Engelman et al., 2007) and HER3 up-regulation has been found 
in lapatinib-resistant SKBR3 breast cancer cells (Garrett et al., 2011). These results indicate 
that molecular mechanisms behind lapatinib resistance still need to be better understood and 
suggest that combined targeting of HER2 and HER3 could act synergistically against 
resistant tumours to block the compensatory engagement of HER3.
We also assessed miRNA regulation differences between parental- and lapatinib-resistant 
SKBR3 breast cancer subtypes. It is known that selected miRNAs may influence the human 
biology of cancer, such as development, differentiation, proliferation, apoptosis, and drug 
resistance (Li et al., 2010). The study outcome (carried out by a service provider) returned a 
top map which indicated that EMT, a process in which epithelial cells acquire mesenchymal 
characteristics, was significantly inhibited in lapatinib-resistant SKBR3 cells due to up- 
regulated miR-205. EMT has considerable relevance to tumour progression: it is postulated to 
confer invasive properties to tumours and correlates with poor patient prognosis (Hugo et al..
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2007). More recently, miR-205 and miR-200 family members have been shown to regulate 
EMT by targeting key signalling transcription factors such as ZEBl and SIPl (Gregory et al.,
2008).
EMT is regulated by multiple signalling molecules that originate from the stroma of 
surrounding cancer cells. These can include TGFp, HGF, platelet-derived growth factor and 
EGF, which all converge at the level of key transcription factors such as ZEB, SNAIL and 
Twist (Bullock et al., 2012). In recent years it has been reported that the EMT inducers ZEBl 
and ZEB 2/SIP 1 are direct targets of miRNAs, suggesting that miRNAs can indirectly 
regulate E-cadherin expression and thereby EMT in tumour cell lines (Ocana and Nieto,
2008).In a study by Sempere et al. which analysed tumour tissues from more than 100 breast 
cancer patient cases, miR-205 expression was found reduced or lost compared to healthy 
tissue (Sempere et al., 2007). In an in vitro study by lorio et al., expression of miR-205 has 
been reported to inhibit invasion, proliferation and growth in breast cancer, which is in part 
mediated through direct targeting of HER3 and VEGF-A (lorio et al., 2009). A study by a 
different group reported that miR-205 can also target HER3 and interfere with the PI3K/Akt 
survival pathway. Re-introduction of miR-205 in SKBR3 cells inhibited their clonogenic 
potential and abrogated HER3-mediated resistance, restoring pro-apoptotic activity and 
increasing responsiveness to the tyrosine-kinase inhibitors gefitinib and lapatinib (lorio et al.,
2009).
MiR-205 can also act as a tumour suppressor by inducing p53 in triple-negative breast cancer 
and its re-expression can strongly reduce cell proliferation and cell cycle progression (Piovan 
et al., 2012). We found that in addition to overexpression of miR-205, SKBR3-LapR cells 
expressed similar levels of E-cadherin to parental cells and that the repressor of E-cadherin 
expression (Twist) was down-regulated. All of these findings suggest that EMT is inhibited in
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the lapatinib-resistant SKBR3 cells under study. Overall, this means that enhanced EMT is 
not responsible for acquired lapatinib resistance in our model. Rather, cells in the epithelial 
state have acquired resistance through other mechanisms, some of which may involve the 
MET receptor. There is some evidence in the literature that SKBR3 cells do not express wild 
type E-cadherin (Ji et al., 1997). It would appear that the antibody we used can detect this 
mutant form of E-cadherin. As the protein is mutant, it may then render it incapable of 
orchestrating MET. This is in contrast to a recent study by Kim et al. who found a link 
between EMT and lapatinib resistance in a HER2-positive gastric cancer cell line (SNU216) 
(Kim et al., 2014). This shows that resistance mechanisms to TKIs are likely to be diverse 
and require further research.
Many transcription factors which repress E-cadherin directly, such as ZEBl and ZEB2/SIP1, 
bind to the E-cadherin promoter and repress its transcription. In contrast, factors such as 
Twist repress E-cadherin indirectly and also transcriptionally repress other junctional 
proteins, including claudins and desmosomes, thus facilitating EMT and cancer metastasis 
(Park et al., 2008). A study by Wang and colleagues has reported up-regulation of Twist as a 
novel mechanism leading to paclitaxel resistance in a nasopharyngeal carcinoma cell line 
(Wang et al., 2004). However, the role of Twist in the development of lapatinib resistance has 
not been reported previously and is thus an entirely novel finding highlighted by this study.
We next investigated whether activated MET, another important TK receptor, can confer 
resistance of breast cancer cells to lapatinib. Western blotting analysis indicated that 
phosphorylated MET was strongly overexpressed in lapatinib-resistant SKBR3 cells. A 
number of clinical studies have described MET-receptor overexpression and hyperactivation 
in tissues derived from breast cancer patients and have found a strong relationship between 
MET signalling and tumour progression (Gastaldi et al., 2010;Jin et al., 1997). It has been
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shown that MET expression was negligible at the time of diagnosis but increased 
significantly in late recurrences and relapse (Camp et al., 1999;Welm et al., 2005).
However, no study to date has investigated the association between MET status and lapatinib- 
resistance in breast cancer. A study by Chen and colleagues reported MET-mediated 
resistance to lapatinib in gastric cancer cells. They found that activation of MET by its natural 
ligand HGF reversed lapatinib-induced growth inhibition. In addition,inhibiting MET by a 
small molecule inhibitor (PHA-665752) or down-regulating its expression with siRNA re­
sensitised the cells to lapatinib by suppressing MAPK and Akt signal transduction (Chen et 
al., 2012).
In conclusion, the molecular mechanisms that underlie lapatinib resistance still need to be 
better understood. The results described in this part of the study shed new light on the 
inhibition of EMT in lapatinib-resistant breast cancer cells, indicating that this process is 
involved in the acquisition of lapatinib resistance. We also found a role for the activation of 
MET. Identification of these components can potentially lead to the development of novel, 
targeted anticancer agents which could help overcome acquired resistance of breast cancer 
tumours to tyrosine kinase inhibitors (TKIs) such as lapatinib. It has commonly been found 
that the miR-200 family and miR-205 are reduced in metastaic breast cancer. In this scenario 
it might be possible to use micro-RNA mimetics to replace those lost and reverse the EMT 
process. In our case, miR-205 was up-regulated; suggesting that knock-down using small 
interfering RNA could be a useful therapeutic strategy to overcome lapatinib resistance in 
breast cancer.
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7. Discussion & Future work
7.1. General Summary
Anti-endocrine resistance is a major clinical problem in current breast cancer treatment, 
inspite of the availability of new treatment options. A better understanding of the molecular 
mechanisms ofanti-endocrine resistance can then inform clinicians as to possible alternative 
approaches such as the use of novel strategies for therapeutic intervention. The work 
described herein has identified some of the key mechanisms of anti-endocrine resistance and 
their therapeutic implications and has provided rationale for new treatment options for 
patients with acquired anti-endocrine resistance.
The first part of this chapter provides a concise summary of the most important findings of 
this thesis, including a table (7-1) summarising research results. The second part of this 
chapter discusses the treatment options developed in this work in the light of previous, related 
work in the literature, particularly clinical trials, and emphasise their novelty and potential.
To recapitulate, it is a well-known fact that homeostasis of non-cancerous cells requires an 
equilibrium between cell survival, cell cycle arrest and cell death, and this balance is 
disrupted during cancer progression. Acquired resistance to chemotherapeutic drugs is often 
linked to alterations to these processes besides other drug resistance mechanisms, such as 
alteration of the target, increased drug efflux, or crosstalk between signalling pathways. In 
hormone-responsive breast cancer, ERa is the key factor associated with cell proliferation 
and survival and can be activated in two different ways; by binding of a ligand to theERa 
(oestradiol classical genomic pathway) or through so-called “non-genomic” pathways, 
which can be mediated by a wide range of different tyrosine kinases. These two pathway
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types can interact with each other in crosstalk, which has been supported by findings describd 
in this thesis.
An in-depth characterisation of the anti-oestrogen-resistant cell lines established in this thesis 
has been presented. All comparisons were made against the parental cell lines as shown in 
table 7-1. ERa was consistently down-regulated in the resistant phenotypes (alternation of the 
target) and P-gp was higher (increased efflux). There was evidence of mutated p53 and 
p2 ?kipi trans-activation was abolished, while Skp2 expression was found to be increased 
(alteration of the cell cycle; table 7-1). The survival pathway signalling components PI3K,
Akt and ERK were significantly up-regulated (table 7-1). As was later demonstrated, this was 
due to ERa-independent activation of the PIK3/Akt pathway in response to the growth factor 
receptors EGFR and HER2, which were overexpressed in the tamoxifen and fulvestrant- 
resistant cell lines, suggesting crosstalk between the two signalling pathways in the 
development of drug resistance.
The PIK3/Akt pathway has been intensively studied for its role in carcinogenesis because of 
its involvement in regulating proteins which control cellular proliferation through cell cycle 
alteration and cell death mechanisms, such as apoptosis and autophagy (Steelman., 2011). We 
continued to investigate this crosstalk in more detail by inhibiting the tyrosine kinase 
pathway using the TKIs lapatinib, gefitinib and afatinib. This not only caused ERa to be 
reactivated, but also demonstrated that all three agents were very effective at reducing cell 
viability in the anti-oestrogen-resistant cells (collateral sensitivity). When used as a combined 
treatment, tamoxifen plus lapatinib was more effective at cell killing than the respective 
single treatments in the anti-endocrine resistant cells.
Of interest was the demonstration of collateral sensitivity of anti-endocrine-resistant breast 
cancer cells to cisplatin. This finding suggested that the platinum compound cisplatin would
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be effective on anti-oestrogen-resistant tumours and could be of great importance for future 
breast cancer treatment. Another observation was a lower expression of the anti-apoptotie 
protein Bcl-2 in these resistant breast cancer cells (Table 7-1), which has also been reported 
by a Danish research team as a marker of cisplatin sensitivity (Yde et al., 2007).This finding 
initially seemed somewhat counterintuitive, because low levels of Bcl-2 dictates a more pro- 
apoptotic status. This led us to study the different cell death pathways and their implications 
in anti-endocrine-resistance in greater detail.Use of the pan-caspase inhibitor ZVAD 
protected the parental cell lines from apoptotie cell death, howeverthis effect was not 
recapitulatedin the resistant phenotypes, indicating that non-caspase-mediated cell death was 
operating in those cells. This drew our attention to the alternative cell death mechanism of 
autophagy, which has been reported to have a dual role in breast cancer; i.e. suppressing 
tumour progression in early tumourigenesis, but promoting it at later stages.
Both autophagy markers LC3-II and Beclin-1 were up-regulated in the resistant cells after 
stressing with anti-oestrogens (Table 7-1), confirming the assumption that the pro-survival 
pathway of autophagy is activated in the development of the resistance. We therefore tested 
two anti-autophagic agents, mefloquine and LY294002, for their ability to act as sensitisers 
of anti-oestrogen-resistant cells. As hypothesised, the MCF7-TR and T47D-FRcells were 
preferentially sensitised to the effects of tamoxifen and/or fulvestrant when mefloquine or 
LY294002 were co-administered, compared with respective parental counterpart (Table 7-1).
Since its approval by the FDA in 2007, lapatinib has emerged as a valuable treatment option 
for many breast cancer patients. The literature cites many reports of acquired resistance to 
this agent in different types of cancer and consequently this remains an active research area 
for the management of breast cancer(Chen and Karantza-Wadsworth, 2009;Sierra et al.,
2010). Using a microRNA discovery platform, SKBR3 breast cancer cells with acquired
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lapatinib resistance were assessed. In addition to EGFR (HERl) and HER2 receptors up- 
regulation, a role for the EMT pathway was implicated in the development of lapatinib 
resistance. In the micro-RNA analysis, miR205 was up-regulated, causing inhibition of EMT 
in lapatinib resistance. The transcriptional factor twist, which promotes a more mesenchymal 
state (associated with EMT), was also down-regulated in lapatinib resistant cells. While only 
recently, a study reported that EMT was induced in the SNU216 gastric cancer cell line with 
acquired lapatinib resistance (Kim et al., 2014), our results show that this is not the case for 
our breast cancer model. While the lapatinib-resistant SKBR3 cell line may not show signs of 
active metastasis, the upregulation of the MET protein was indicative of increased 
proliferation and progression. This is an important and novel finding, which could facilitate 
greater understanding of the mechanism of lapatinib reistance.
Table 7-1 provides an overview of all alterations in protein expression (ERa, P-gp, cell cycle 
regulators, downstream survival signalling components etc.) measured in the experimental 
chapters of this thesis in the resistant vs. the parental phenotypes. The table includes 
constitutive expression, as well as expression levels after treatment with various anticancer 
agents as monotherapies or in combination.
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Table 7-lSum m ary of qualitative protein expression levels in tamoxifen- and 
fulvestrant-resistant breast cancer cells relative to parental cells; both constitutive and 
after treatment with antioestrogens.
■I
Constitutive expression:
ERa a
P-gp Î Î Î
Cell cycle regulators:
p53 mutated
p27kipi No difference
Cyclin E Î
Skp2 Î
Downstream survival signalling:
PI3K Î Î Î Î
Akt Î Î Î Î
ERK Î Î Î
Growth factor receptors:
pEGFR (HERl) Î Î Î Î
pHER2 Î Î Î Î Î Î
HER3 Î Î
Apoptotie pathways:
Bax No difference i
Bcl-2 li u
Survivin T T
Autophagy markers:
LC3-II T T
Beclin-1 Î Î
346
Chapter 7 Discussion & Future Work
Expression after treatment with antioestrogens 
p27^ ^^  i  (tamoxifen & fulvestrant)
p53 Repressed induction (tamoxifen & fulvestrant)
Cyclin E Î (tamoxifen & fulvestrant)
Skp2 Î (tamoxifen & fulvestrant)
Expression after treatment with tyrosine kinase inhibitors (monotherapy)
ER-a
P2?kipl
P-EGFR
P-HER2
P-PI3K
P-ERK
Î (lapatinib) not detectable
Î (lapatinib) 
i  (lapatinib or gefitinib) 
f (lapatinib) 
i  (lapatinib) 
i  (lapatinib)
Expression after treatment with antioestrogens + tyrosine kinase inhibitors (combination therapy) 
P-PI3K I  H i  n/a
I
P-ERK I  iU  n/a
Expression after treatment with anti-oestrogens + anti-autophagic agents (combination therapy) 
P-PI3K ! H i
P-Akt I H i
P-ERK Î
Î = slight increase, Î Î  = significant increase, Î Î Î  = dramatic increase, i  = slight decrease, i i  = 
significant decrease, i f f  = dramatic decrease/complete loss; p- indicates phosphorylated form;n/a= 
Not available.
Altogether, as we hypothesised, targetting survival signalling molecules such as the tyrosine 
kinases using lapatinib leads to increased sensitivity of resistant cells to anti-oestrogens. In 
addition and also in agreement with our hypothesis, targeting the survivlal pathway of
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autophagy with mefloquine and LY294002 in combination with tamoxifen also reversed drug 
resistance.
7.2. Discussion
We used our findings not only to understand the mechanisms of resistance to current anti- 
endocrine therapy, but also to suggest novel treatment strategies for drug resistant breast 
cancer patients. The current understanding of ERa and other cellular signalling pathways is 
increasingly expanded; especially the vital role of the intimate crosstalk between the ERa and 
growth factor signalling pathways in the development of drug resistance was highlighted in 
the work shown in the present study. Clinical evidence suggests that patients with breast 
tumoursoverexpressing HER2 and EGER have a poorer outcome when treated with 
tamoxifen and AIs. This indicates that up-regulation of these growth factor receptors is 
responsible for the development of acquired resistance by activating ERa in a ligand- 
independent manner, thereby inducing cell survival and proliferation(Arpino et al.,
2008).These findings are in agreement with our observations for a repeated treatment regime 
with tamoxifen or fulvestrant, which rendered the cells resistant.
It has also been shown that breast cancers with activation or over-expression of EGER and 
HER2 can showloss of ERa expression through increased MAPK activation (similar to ERa- 
negative tumours). These tumours have a worse prognosis and are associated with the 
development of resistance to anti-oestrogens (Creighton et al., 2006). This is accordance with 
our work, which showed that growth factor receptors EGFR and HER2 were up-regulated in 
cells with acquired anti-endocrine resistance, leading to increased expression of the 
downstream survival signalling components PI3K and Akt, and also significant reduction of 
ERa levels at the protein and mRNA level.
348
Chapter 7 Discussion & Future Work
Another factor known to contribute to loss of ERa and often found in ER-negative tumours is 
mutation of p53 (Angeloni et ah, 2004). p53 mutation is already used as an independent 
prognostic marker of breast cancer progression and survival for over two decades (Thor et al., 
1992). This thesis provides evidence of acquired p53 mutation in tamoxifen- resistant cells, 
suggesting that p53 mutations in breast tumours may not only contribute to breast cancer 
oncogenesis, but also to anti-oestrogen resistance, and can thus serve as molecular marker for 
acquired resistance to anti-oestrogens.
Taken together, these findings suggest that targeting both ER and HER pathways using 
combined therapy, for example anti-oestrogens plus specific inhibitors or blockers of growth 
factor receptors such as gefitinib and lapatinib, represents a promising therapeutic approach 
to increase therapeutic efficacy and resistance-reversal. We showed that treating tamoxifen- 
or fulvestrant-resistant breast cancer cells with gefitinib (EGFR inhibitor) or lapatinib (dual 
EGFR/HER2 inhibitor) can improve sensitivity to tamoxifen/fulvestrant. Evidence for 
reversal of cquired antiendocrine resistance can be shown byinduction of p27^^^ expression. 
This has also been observed by others for tamoxifen-resistant cells (Chu et al., 2005), but has 
not yet been reported for fulvestrant-resistant cells. In our hands, the effect was even more 
pronounced when treating with a combination of lapatinib and tamoxifen and supports the 
rationale of co-targeting the ERa and growth factor receptor pathways to overcome 
resistance.
Recently, this co-targeting strategy has become a major focus of clinical trials to evaluate 
strategies to overcome anti-endocrine resistance. For example, a Phase III clinical trial has 
been conducted to evaluate the efficacy of the antiestrogen anastrazole (an AI) monotherapy 
versus the combination of anastrazole plus trastuzumab (HER2 inhibitory antibody) in 
patients with metastatic breast cancer. There was a significant improvement in progression-
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free survival for the combination compared with anastrazole alone (Kaufman et ah, 2009). 
Another Phase II clinical trial compared the effect of tamoxifen versus tamoxifen plus 
gefitinib in metastatic breast cancer patients and also showed increased progression-free 
survival in patients who received the combination treatment (Osborne et al., 2011). The only 
trial to date comparing lapatinib in combination with an antioestrogen (letrozole, an AI), was 
a Phase III clinical study by Johnston et al (2009). The study demonstrated that the 
combination of letrozole and lapatinib significantly prolonged progression free survival 
compared with letrozole alone and showed a statistically significant reduction in the risk of 
disease progression (Johnston et al., 2009). The combination of tamoxifen plus lapatinib has 
thus far only been explored in preclinical studies, in which it was found that treatment of 
tamoxifen-resistant MCF7 cells with lapatinib plus tamoxifen restored responsiveness to anti- 
endocrine treatment (Leary et al., 2010). This has been reproduced in this thesis and led us to 
test the same combination in fulvestrant-resistant cells, with the same positive outcome.
We continued our study by investigating the mechanism behind this co-treatment 
phenomenon and observed an almost complete loss of ERK expression (pro-apoptotic) when 
tamoxifen-resistant cells were treated with the lapatinib and tamoxifen combination, which 
has been previously reported by others (Leary et al., 2010). Furthermore, we found that PI3K 
was decreased in tamoxifen-resistant cells after successful treatment with lapatinib and 
tamoxifen, which, to our best knowledge, has not been reported to date. However, the 
PI3K/Akt signalling pathway has been extensively investigated for its role in cancer 
progression and has been found to be the most frequently altered in breast cancer (Miller et 
al., 2011), mediating resistance to all forms of anti-endocrine therapy by its interaction with 
ERa. In addition, the PBK/Akt signalling pathway is well known to play a role in autophagy 
regulation, and is frequently dysregulated in human cancer (Lum et al., 2005).
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Autophagy plays a dual role as both a mechanism of tumour suppression and as an adaptive 
stress response that can facilitate tumour cell survival and progression. A growing body of 
evidence sees autophagy as a tumour promoter, which can enhance cell survival by 
maintaining energy production, leading to cancer cell growth and therapeutic resistance (Liu 
et al., 2011). We showed that both tamoxifen- and fulvestrant-resistant cells circumvented 
apoptotic cell death and switched to autophagy as a survival mechanism. This has previously 
been reported by a research group in tamoxifen-resistant MCF7 cells(Samaddar et al.,
2008)but had not been reported in fulvestrant-resistant cells.
Based on the above finding, we decided to test if targeting the autophagic pathway with either 
an early-stage autophagy inhibitor (LY294002, a PI3K inhibitor) or a late-stage autophagy 
inhibitor (mefloquine) in combination with anti-oestrogens could potentially improve the 
efficacy of hormonal treatment in anti-endocrine-resistant cells. The former targeting method 
has been demonstrated by Sanchez et al. (2011) using fulvestrant in combination with three 
different PI3K inhibitors (BGT226, BKM120 and RADOOl) in MCF7 cells (Sanchez et al.,
2011), but not in cells with acquired anti-endocrine resistance. More recently, a Phase lb 
clinical trial investigated the effectiveness of a combination treatment of the AI letrozol and 
the pan-PI3K inhibitor buparlisib in patients with metastatic ER-positive breast cancer 
refractory to anti-endocrine therapy. Phase III trials of buparlisib and antiendocrine therapy in 
patients with ER-positive breast cancer are ongoing (Mayer et al., 2014). In accordance with 
these studies, we observed a synergistic effect on apoptotic cell death in tamoxifen-resistant 
cells treated concomitantly with the PI3K inhibitor LY294002 and tamoxifen. Collectively, 
these data provide a strong rationale to evaluate the combination of PI3K inhibitors with anti­
estrogen therapy in hormone receptor-positive breast cancer in the clinic.
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Preclinical studies have furthermore shown that inhibition of cytoprotective autophagy by the 
antimalarial agent chloroquine, a late-stage autophagy inhibitor, can overcome treatment 
resistance in combination with saracatinib (a dual-specific inhibitor of Src and Abl) in 
prostate cancer xenografts and lead to significant growth inhibition (Wu et al., 2010). 
Recently, it was reported that mefloquine displayed substantially greater activity than 
chloroquine, which requires concentrations between 30 and 100 pM to be effective (Sharma 
et al., 2012). The same group showed that mefloquine displayed anticancer activity in breast 
cancer cell lines at lower concentrations, and their report is to our knowledge the first study 
reporting cytotoxic activity of mefloquine in oestrogen receptor-positive MCF7 and T47D 
breast cancer cells. The activity of mefloquine in breast cancer cells with acquired anti- 
endocrine resistance and when used in combination with another chemotherapeutic drug is a 
novel finding of this thesis.
To further advance the approach of using mefloquine as a potential treatment option, we 
investigated its effects as a sensitiser to reverse anti-endocrine resistance. We found that co­
administration of mefloquine or LY294002 and tamoxifen had a synergistic effect resulting in 
enhanced cell death preferentially in anti-endocrine resistant cells. To our best knowledge 
this is an entirely novel finding which has not yet been reported by others. The mechanism 
behind this sensitisation effect was identified as a repression of survival signalling through 
the PI3K/Akt pathway. In addition, it has been reported (but not validated by us) that 
mefloquine is an inhibitor of the drug efflux pump P-gp, and thereby increases intracellular 
drug concentrations and reverses P-gp efflux as a mechanism for drug resistance (Kim et al., 
2013). This could provide another mechanism by which mefloquine re-sensitises anti- 
endocrine-resistant breast cancer cells with increased P-gp expression.
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In conclusion, it can be seen that the mechanisms behind anti-endocrine resistance are as 
diverse as the heterogeneous pathology of breast cancer at both the clinical and the molecular 
level. Resistance can arise from alterations in any of the cell signalling pathways such as 
ERa signalling and growth factor signalling pathways, as well as crosstalk between these two 
signalling pathways. Dysregulation of cell death pathways is also an important component of 
drug resistance. These outcomes indicate that treatment of patients with anti- endocrine- 
resistant breast cancer is challenging; however a combination of anti-endocrine therapy with 
other drugs targeting key molecules involved in survival signalling pathways is a very 
promising therapeutic approach to overcome this resistance and benefit breast cancer patients.
7.3. Future Work
This thesis and all its findings are based on in vitro studies using standard 2D cell culture 
methods. However, it is well known that cells grown in 2D monolayers suffer from the lack 
of structural architecture and suffer overexposure to drugs, as 50% of cells are exposed to 
tissue culture medium. Overall, this can result in differences in cellular morphology, 
differentiation, proliferation, apoptosis, and gene expression. In recent years, an increasing 
body of research has investigated methods of culturing cells in 3D, as an intermediate, more 
physiologically relevant method between 2D cell culture and animal models potentially 
replacing these in the future. 3D cell culture models hold great promise to reduce the number 
of costly drug failures in clinical trials, which are often due to lack of efficacy, which was 
observed in vitro but not on the clinic, or toxicity issues which were not observed in vitro, but 
unexpectedly occurred in the clinic. Future work will replicate some of the work conducted in 
this thesis in a 3D environment using electrospun scaffolds (Mimetix®, The Electrospinning 
Company). Following this, we aim to explore our novel findings with regard to the use of 
mefloquine as a resensitiser of anti- endocrine-resistant cells in in vivo xenograft
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experiments. This will include hormone-positive, as well as triple-negative breast cancer cells 
and their resistant counterparts, which are associated with particularly poor prognosis and 
survival.
We have also presented preliminary data showing that tamoxifen- and fulvestrant-resistant 
cells developed collateral sensitivity to afatinib, which to the best of our knowledge is a novel 
finding that requires further research. This was beyond the scope of this thesis, but it is hoped 
that future work will include exploration of the mechanism behind this sensitisation.
Next, there is accumulating evidence for using endoxifen, the most potent active metabolite 
of tamoxifen, as an anticancer agent itself (Hawse et al., 2013). In a xenograft model of AI- 
resistant breast cancer, endoxifen has demonstrated superiority over tamoxifen, 4HT, and 
letrozole in inhibiting cell proliferation or tumour growth. Endoxifen blocks ERa 
transcriptional activity, but unlike tamoxifen or 4HT also works as an ERa downregulator, 
similar to fulvestrant (Wu et al., 2009). Therefore, we would like to investigate the sensitivity 
of ouranti- endocrine-resistant cells to endoxifen and test whether it can reverse this 
resistance in vitro, and perhaps later on in the clinic.
Finally, this study presented the novel finding that phosphorylated MET was significantly 
increased in lapatinib-resistant breast cancer cells. Future work could include a simultaneous 
treatment with both lapatinib and a MET inhibitor to re-sensitise cells to lapatinib and 
potentially overcome this resistance.
The ultimate goal of this research is to translate laboratory findings into effective treatment of 
strategies for the reversal of resistance as it manifests in the clinic. Such a multifaceted 
treatment approach could also be used prophylactically, to reduce the occurrence of 
resistance rather than treating it once established. For this to happen, the safety and efficacy
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of a two- or three-pronged approach targeting resistance would need to be investigated with 
randomized clinical trials. If successful, combined treatment regimens may increase patient- 
survival, reduce relapse rates, and reduce costs associated with oncology réadmissions.
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A-lMiR expression profiles in lapatinib-resistant breast cancer cells versus SKBR3 
parental cells.
miR-193a-5p 47.6988 up 4.378E-07 Tumour suppressor with a role in 
NSCLC metastasis
(Yu et al., 2014)
miR-205 47.7529 up 2.033E-16 Biomarker oftumour necrosis factor- 
receptor-associated periodic syndrome
(Lucherini et al., 
2013)
miR-196a-5p 66.43081 up 3.778E-06 Biomarker of Huntingtons’ disease (Hoss et al., 2014)
miR-937-5p 61.1884 up 5.569E-06 Role in the pathogenesis of latent 
tuberculosis infection
(Meng et al., 2014)
miR-361-5p 80.89861 up 1.478E-17 Tumour suppressor in prostate cancer (Liu et al., 2014)
miR-3656 112.4880 up 2.876E-12 Biomarker of colorectal carcinogenesis (HamQord et al., 
2012)
miR-1290 155.3422 up 1.097E-06 Regulation of cellular differentiation 
during brain development
(Yelamanchili et 
al., 2014)
miR-150-3p 273.8837 up 4.378E-07 Biomarker of NSCLC (Jiang et al., 2013)
miR-4430 310.5001 up 2.730E-08 Up-regulated in salivary adenoid cystic 
carcinoma-M cells during metastatic 
progression
(Chen et al., 2014)
miR-3934-5p 3897.0594 up 2.033E-05 Molecular function has not been 
identified
miR-574-3p -1068.5268 down 4.378E-07 Molecular function has not been 
identified
miR-4730 -539.3592 down 2.138E-06 Molecular function has not been 
identified
miR-6716-3p -483.2459 down 4.191E-06 Molecular function has not been 
identified
miR-451b -352.4897 down 2.965E-07 Molecular function has not been 
identified
miR-4254 -343.9184 down 1.321E-08 Molecular function has not been 
identified
miR-4455 -282.1442 down 4.079E-08 Molecular function has not been 
identified
miR-3162-3p -256.2314 down 9.659E-07 Molecular function has not identified.
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miR-3591-3p -215.4068 down 6.358E-11 Roles in cardiovascular disease (Morley-Smith et 
al., 2014)
miR-3132 -207.7114 down l.OOlE-04 Molecular function has not been 
identified
miR-3149 -190.2052 down 1.134E-18 Molecular function has not been 
identified
miR-5787 -186.0553 down 2.920E-06 Controls cellular growth by targeting 
eukaryotic translation initiation factor 5 
in fibroblasts
(Yoo et al., 2011)
miR-6514-3p -176.7112 down 3.778E-06 Molecular function has not been 
identified
miR-5194 -113.5081 down 2.001E-09 Molecular function has not been 
identified
miR-32-3p -129.3442 down 2.033E-16 Molecular function has not been 
identified
miR-4649-3p -128.9334 down 7.360E-07 Molecular function has not been 
identified
miR-4701-3p -127.9665 down 5.163E-07 Molecular function has not been 
identified
miR-5010-3p -126.408 down 2.138E-06 Molecular function has not been 
identified
miR-18a-5p -121.4994 down 1.294E-05 Molecular function has not been 
identified
miR-5194 -113.5081 down 2.001E-09 Molecular function has not been 
identified
Cut-off values of miR up-regulation (>10 fold higher) and down-regulation (< -100 fold lower) were 
employed to identify the largest fold changes.
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